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ABSTRACT  
   
Phenotypic and molecular profiling demonstrates a high degree of heterogeneity in the 
breast tumors. TP53 tumor suppressor is mutated in 30% of all breast tumors and the mutation 
frequency in basal-like subtype is as high as 80% and co-exists with several other somatic 
mutations in different genes. It was hypothesized that tumor heterogeneity is a result of a 
combination of neo-morphic functions of specific TP53 driver mutations and distinct co-mutations 
or the co-drivers for each type of TP53 mutation. The 10 most common p53 missense mutant 
proteins found in breast cancer patients were ectopically expressed in normal-like mammary 
epithelial cells and phenotypes associated with various hallmarks of cancer examined. Supporting 
the hypothesis, a wide spectrum of phenotypic changes in cell survival, resistance to apoptosis 
and anoikis, cell migration, invasion and polarity was observed in the mutants compared to 
wildtype p53 expressing cells. The missense mutants R248W, R273C and Y220C were most 
aggressive. Integrated analysis of ChIP and RNA seq showed distinct promoter binding profiles of 
the p53 mutant proteins different than wildtype p53, implying altered transcriptional activity of 
mutant p53 proteins and the phenotypic heterogeneity of tumors. Enrichment and model-based 
pathway analyses revealed dysregulated adherens junction and focal adhesion pathways 
associated with the aggressive p53 mutants. As several somatic mutations co-appear with mutant 
TP53, we performed a functional assay to fish out the relevant collaborating driver mutations, the 
co-drivers. When PTEN was deleted by CRISPR-Cas9 in non-invasive p53-Y234C mutant cell, 
an increase in cell invasion was observed justifying the concept of co-drivers. A genome wide 
CRISPR library-based screen on p53-Y234C and R273C cells identified separate candidate co-
driver mutations that promoted cell invasion. The top candidates included several mutated genes 
in breast cancer patients harboring TP53 mutations and were associated with cytoskeletal and 
apoptosis resistance pathways. Overall, the combined approach of molecular profiling and 
functional genomics screen highlighted distinct sets of co-driver mutations that can lead to 
heterogeneous phenotypes and promote aggressiveness in cells with different TP53 mutation 
background, which can guide development of novel targeted therapies. 
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CHAPTER 1 
IDENTIFYING GENE CANDIDATES FOR DEVELOPING ALTERNATE TARGETED THERAPIES 
FOR AGGRESSIVE BREAST CANCER HARBORING DIFFERENT TP53 MISSENSE 
MUTATIONS: BACKGROUND, HYPOTHESIS AND APPROACHES 
 
 
Introduction 
 
Overview of human breast cancer 
 
The breast cancer tumor evolves from a transformed normal cell via hyperplasia, premalignant 
tumor, in-situ carcinoma to invasive carcinoma by accumulation of various genetic alterations 
(Beckmann 1997). Consequently, breast cancer displays heterogeneity with inter and intra tumor 
diversity that influences breast cancer progression and therapy resistance (Polyak 2011). Gene 
expression analysis of breast tumors have identified the major subtypes- luminal, HER2 
overexpressing and basal-like. Each subtype has different genetic constitution, risk factor, 
response to treatment, disease progression and pattern of metastasis. Luminal tumors are 
hormone receptor positive (ER+ and PR+) and are treated with hormonal therapies. HER2 
amplified tumors respond well to anti-HER2 antibody trastuzumab. But there is no targeted 
therapy for basal-like subtype due to lack of the targetable receptors ER, PR and HER2 (Triple 
Negative Breast Cancer). Systemic chemotherapy is the only available option and unfortunately, 
only 20% of tumors respond to the standard chemotherapy.  
 
Triple negative breast cancer (TNBC) that includes the basal subtype is highly heterogeneous 
than was thought before and gene expression analysis identified six more of its subtypes, each 
with unique molecular markers. The six subtypes include basal-like (BL1 and BL2), 
immunomodulatory, mesenchymal (M), mesenchymal stem-like (MSL) and luminal androgen 
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receptor (LAR) subtype (Mayer 2014). Owing to this heterogeneity, no single targeted therapy 
has been approved for the treatment of TNBC.  
 
Luminal A subtype breast tumors are most common (70%) while the TNBC subtype tumors 
account for 15%. The TNBC and the HER2 overexpressing tumors have the worst prognosis. The 
metastatic disease is the cause for the estimated 90% deaths due to breast cancer and is not 
curable. De novo and acquired resistance are the major challenges and no targeted therapies 
have been approved for the most aggressive TNBCs. 
 
Single targeted therapies including platinum agents, PARP inhibitors, PI3K and MEK inhibitors 
did not bear favorable outcomes for TNBC treatment. No single targeted therapy has been 
approved for TNBC and the cytotoxic chemotherapy remains the standard treatment. Apart from 
the standard chemotherapy, immunotherapy targeting CTLA-4 and PD-L1 are investigated for 
treatment of TNBC. Combination of two or more agents may make a more rational approach to 
treat TNBC.  The most commonly used combination chemotherapies show only 7-11% 
improvement in survival for younger women and just 2-3% for women above 50 years.  
 
30% of all breast cancer tumor subtypes carry mutations in TP53.  The distribution of TP53 
mutations in the subtypes include 26% in luminal tumors (17% luminal A, 41% luminal B), 88% in 
basal-like or TNBC carcinomas, and almost 50% in HER2+ tumors. The high rate of TP53 
mutations in TNBC promotes survival and proliferation of the cancer cells, contributes to the 
heterogeneity and resistance to chemotherapy. The current therapeutic strategies aim at 
restoring the wildtype activities of the p53 tumor suppressor assuming that the different p53 
missense mutants are functionally equal. Thus, so far, no drug has been effective in abrogating 
the oncogenic effects of mutant p53. The non-specific chemotherapy benefits only a small 
fraction of patients as we do not know how the heterogeneity of each tumor affects response to 
therapy or the recurrence. The TNBC tumors contain more genetic mutations compared to 
luminal and HER2+ subtype due to high mutation rate and identification of the minor subclones 
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(infrequent but biologically important somatic mutations) and designing targeted therapies against 
them could be effective in treating the TNBC patients. 
 
 
Overarching goal 
 
The focus of the research is to gain a mechanistic understanding of the phenotypic heterogeneity 
observed in aggressive triple-negative breast cancer (TNBC) harboring different TP53 mutations 
and numerous other somatic mutations to discover novel therapeutic targets for personalized 
medicine. The phenotypic and transcriptomics data on 10 normal breast epithelial cell lines each 
expressing a distinct missense mutant p53 protein and systems-level analysis through ChIP Seq, 
RNA seq and CRISPR-based screening would enable identification of possible novel molecular 
targets for personalized treatment of TNBC patients with specific TP53 mutations. Such a broad-
spectrum molecular profiling and functional genomics screening could efficiently select and 
narrow down the targetable co-existing mutations of mutant p53 and their downstream targets 
and pathways as key candidates for personalized targeted therapies. 
 
This chapter provides a comprehensive overview on the tumor suppressor gene TP53 in humans.  
The first section covers the structure and function of the tumor suppressor protein. The initial 
discovery of TP53 is a fascinating story because of the prevailing view at the time that TP53 acts 
as an oncogene instead of a tumor suppressor gene.  The following sections describe the 
mutation repertoire of TP53 in cancer, its contribution to cancer initiation and progression in 
general and specific contribution towards breast cancer progression. TP53 remains the most 
frequently mutated gene in all cancer types and exists in a sea of other somatic mutations. 
Mutant TP53 is not effective in initiating cancer alone and interacts with the other co-mutations or 
the co-drivers. The last section of the chapter describes clonal evolution of cancer tumors, the 
interacting somatic mutations and the tumor heterogeneity they generate. Without a doubt, the 
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TP53 gene is the most extensively studied tumor suppressor gene. Yet, in the 40 years since its 
discovery, we still do not fully understand p53’s functional complexity. 
 
 
TP53: Tumor suppressor frequently mutated in all cancer types  
 
Function and regulation of the p53 tumor suppressor protein 
 
TP53 tumor suppressor gene controls multiple cellular programs that work towards suppressing 
cancer and that explains why this gene is mutated in multiple cancer types. A range of stresses 
activate p53, including DNA damage, hyperproliferative signals, nutrient deprivation, hypoxia, 
oxidative and replicative stress. p53 mediates tumor suppression by transient cell-cycle arrest, 
senescence and apoptosis that have been termed as the canonical p53 functions. But recently 
the focus has shifted to the non-canonical functions of p53 that include regulation of cell 
metabolism, stem cell maintenance, invasion and metastasis control to mediate tumor 
suppression (Fig 1.1). The loss of p53 influences cell motility and contributes to invasive and 
metastatic potential (Kaiser 2018). Wild-type p53 prevents epithelial to mesenchymal transition 
(EMT) by degrading Slug and enhancing E-cadherin expression strengthening cell-cell junction. 
Loss of p53 activity is accompanied by increased activity of RhoA/ROCK promoting cell motility 
and invasion during tumor progression. Mutant p53 suppresses E-cadherin while activating Slug 
or Twist inducing EMT (Muller 2011).  
 
The p53 is widely known as the ‘guardian of the genome’ by mediating tumor suppression via the 
classical function of inducing transient G1 cell-cycle arrest, DNA repair, apoptosis and 
senescence restricting the propagation of DNA damaged cells (Beiging 2014). Both the canonical 
and the non-canonical functions of p53 demonstrate the diverse phenotypes the protein controls 
and why TP53 is mutated in a wide variety of cancer types (Fig 1.2).  
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The action of tumor suppressor p53 is context dependent. The determinants of this context 
dependency include the cell type, genetic background, cell microenvironment and the nature of 
the stress that activates p53. The mechanism for context dependence may operate depending on 
amount of p53 protein induced, post translational modifications of p53 and other parallel signaling 
networks. Both canonical and non-canonical responses of p53 integrate to suppress tumor 
formation.  
  
 
Figure 1.1. Signaling pathways regulated by p53 in tumor suppression. Low dose 
DNA damage, nutrient starvation and oncogene activation are some of the stresses 
encountered in a tumor that activate p53. In response, p53 binds to the relevant 
response elements and regulates the gene expression coordinating different cellular 
processes contributing to tumor suppression. Image adapted from (Mello 2018).  
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TP53 is a transcription factor and binds to its DNA response elements in a sequence specific 
manner via the DNA binding domain and regulates transcription by the two N-terminus 
transactivation domains (TADs) and the regulatory C-terminal domain (CTD). Each TAD 
transactivates different target genes and effector pathways and makes p53 a robust transcription 
factor. The TADs are known to interact with diverse transcriptional cofactors and may contribute 
to p53 function in a context dependent manner. CTD is a positive regulator of p53 function and 
needed for transactivation of the target genes. The CTD is intrinsically disordered informing that it 
could bind to several different p53 transcription co-factors and other binding partners depending 
on the context thus, affecting the p53 function. The CTD also serves as a site for many post 
translational modifications (PTMs) (Sullivan 2018).  
 
 
Figure 1.2. The p53 target genes. A. The domains of the p53 protein. B. The key p53 target 
genes for tumor suppressive activity of p53. The canonical functions are in purple and non-
canonical in beige. Image adapted from (Beiging 2014). 
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Under cellular stress p53 protein is stabilized and the transcriptional output depends on the 
strength of p53 response element, PTMs, the available binding partners and epigenetic 
landscape of target gene promoters (Beckerman 2010). Hundreds of PTMs have been reported 
for p53 and are crucial for regulating p53 level and activity (Fig 1.3). Phosphorylation of p53 is 
essential for p53 stabilization. Polyubiquitination of p53 by Mdm2 controls p53 protein levels and 
phosphorylation of p53 at the N-terminal weakens this interaction and in turn stabilizes p53 in 
response to cellular stress signals. Specific PTMs occur in response to different stress signals 
and direct different p53 responses and cell fate. For example, phosphorylation at Ser15 by ATM 
and ATR kinases is required for cell cycle arrest whereas phosphorylation at Ser46 by HIPK2 
regulates apoptosis. Site-specific acetylation at CTD by p300 or PCAF regulate apoptosis and 
cell cycle arrest. Methylation of p53 at different lysine residues can activate or repress gene 
transactivation. Mutant p53 proteins show intense phosphorylation and acetylation at the sites 
known to stabilize wildtype p53 and results in accumulation of mutant p53 in the nucleus (Bode 
2004). Sumoylation and neddylation are some of the other PTMs undergone by p53 that 
contribute to p53 promoter specificity. 
 
Figure 1.3. Different PTMs of p53 and the enzymes that catalyze them. Phosphorylations 
occur at N-terminus. Acetylation in DNA binding domain (DBD), oligomerization domain (OD) 
and carboxy terminal domain (CTD). Methylation and ubiquitylation occur at the CTD. Image 
adapted from (Hafner 2019). 
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Transcription co-factor recruitment by p53 affects the activation of specific gene program like p53 
interacts with acetyltransferase p300 and activates the target gene CDKN1A. The p53 level in the 
cells change over time and so the gene expression dynamics of the p53 target genes showing 
different timing, level and pattern of induction. Overall, p53 PTMs and cofactors regulate stability, 
strength of DNA binding and target gene selection (Hafner 2019). With p53 binding to its 
response element within a promoter recruits chromatin remodeling factors, histone 
transacetylases and methyltransferases that result in histone modification and promoter opening. 
The approximate number of p53 target genes is 300 and the functional p53 binding sites are 
independent of cell type and treatment (Fischer 2017). Recent studies define p53 as only a 
transcription activator and not a direct transcription repressor.  
 
The discovery of p53 and its establishment as a tumor suppressor gene 
 
In the period between 1950 and 1970 much attention in research was grabbed by viruses and 
oncogenes. By the 1970s the researchers found that many viruses carried oncogenes. The 
Bishop and Varmus labs discovered that the RNA tumor viruses captured a cellular gene and 
reintroduced its modified version when infecting a cell whose overexpression gradually caused 
the transformation of the cell.  By then it was established that oncogenes caused cancer in 
animals and that the DNA tumor viruses acted the same way as the RNA tumor viruses. The 
oncogenes from DNA tumor viruses were different from the RNA tumor viruses and believed to 
indirectly induce excessive production of oncoproteins (Levine 2009).  
 
In the initial years of discovery of TP53, now known as a major tumor suppressor gene, was 
instead accepted as an oncogene. In the year 1979, researchers found that the small DNA tumor 
virus, the simian virus 40 (SV40) contained two antigens small t and the large T antigens and the 
large T antigen initiated and maintained the transformation of the infected cells. While 
understanding the mechanism of cellular transformation by SV40, T antigen formed a complex 
with a specific cell coded protein in SV40 transformed mouse cells with a molecular weight of 53 
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kDa. The labs of Lane and Crawford inferred that either this 53 kDa protein had the same 
antigenic determinants as the T antigen or it forms a complex with the T antigen (Lane 1979). 
Similar results from another study showed a 54 kDa protein immunoprecipitated from a SV40 
transformed mouse cell line and uninfected embryonal carcinoma cells with SV40 anti T sera. 
The immunoprecipitated proteins had identical peptide maps but completely different from peptide 
map of large T antigen. The researchers concluded that the transformation of the mouse cells 
with the SV40 virus stimulated the synthesis or stability of the 54 kDa protein, which associated 
with the large T antigen in the infected cells (Linzer 1979). In yet another study, the sera from 
BALB/c mice bearing tumors from injection of Abelson murine leukemia virus (A-MuLV) 
transformed cells reproducibly immunoprecipitated a 50 kDa protein from A-MuLV transformed 
BALB/c cells. The 50 kDa protein remained at very low levels in normal cells or cells not 
transformed by A-MuLV (Rotter 1980). As high levels of this protein presented in virus 
transformed cells (SV40 or A-MuLV) and hardly detectable in non-transformed cells, it was 
convincing that this protein is a tumor antigen and thus, a cancer-causing oncogene. This protein 
became designated as the ‘Tumor protein 53 (TP53) or simply p53’.   
 
Several observations made p53 protein look like a cellular oncogene. Normal mouse 3T3 cells 
had low levels of p53 protein which escalated to 25-50-fold with transformation by SV40. But a 
temperature sensitive mutant of SV40 large T antigen could not maintain a high level of the p53 
protein in the virus infected cells (Linzer 1979). The E1b protein from another DNA virus, 
adenovirus, associated with the 54 kDa protein (p53) in adenovirus transformed mouse cells 
(Sarnow 1982). The p53 protein was also found at high concentrations in transformed cell lines 
and in induced and spontaneously occurring mouse tumors making it a biochemical diagnostic 
marker for primary tumors (Rotter 1983). 
 
After the discovery of TP53, the study of its ‘oncogenic properties’ required cloning of the gene. 
As transformed cells contained abundant p53, it reasoned that the cells would have more p53 
mRNA and were used to prepare the first cloned cDNA instead of normal cells. The p53 protein 
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from the cloned gene cooperated with HRAS oncogene to transform the normal embryonic cells 
and these cell lines formed tumors in animals (Eliyahu 1984). In another study, the co-
transfection of murine cellular p53 gene with Ras gene into primary rat embryo fibroblasts 
converted the normal cells into tumorigenic fibroblasts (Parada 1984). When a functional p53 
gene was transfected into L12 cells (Ab MuLV transformed cells lacking p53), p53 expressing L12 
cells caused lethal tumors in mice (Wolf 1984). Gathering the results, overexpression of p53 in 
transformed cells presented TP53 as an oncogene that drove cancer progression. 
 
But studies since the 1980s completely changed the way researchers had described the TP53 
gene. There were increasing evidences that TP53 was a tumor suppressor and not an oncogene. 
These studies were an eye opener and showed TP53 into new light as a potent tumor suppressor 
gene whose wildtype version was frequently deleted in transformed cells and tumors. A study in 
the mid-1980s reported that Abelson murine leukemia virus transformed L12 cells lacked 
expression of cellular p53. The p53 genomic DNA sequence was interrupted by integration of a 
viral DNA segment (Wolf 1984). This provided one of the first evidences that the p53 protein 
could be a tumor suppressor protein rather than an oncogene. Analysis of the genomic DNA in 
the HL-60 cells (human tumor cell line) lacked the p53 gene due to deletion which contrasted with 
the previous studies where the p53 tumor antigen was found to be over-produced in the 
transformed cells (Wolf 1985). The studies implicated that the loss of functional p53 promoted 
cancer and the full-length protein is required to prevent cancer. When the DNA sequences of the 
various p53 clones were compared, none of the sequences were identical suggesting that 
different clones contained mutations in the TP53 gene. The wildtype p53 cDNA failed to transform 
the primary rat fibroblasts while mutated p53 resulted in transformation (Finlay 1988). In the 
tumors of colorectal carcinoma, p53 was lost due to allelic deletion in chromosome 17. The 
remaining allele of p53 was mutated where a single amino acid was substituted with another. 
Moreover, the expression of wildtype p53 also inhibited the transformation of primary rat embryo 
fibroblasts by E1A and Ras (Finlay 1989). By the end of 1980s, substantial evidences were found 
to highlight TP53 as a tumor suppressor gene and now called the ‘Tumor suppressor Protein 53’.  
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Somatic mutations in TP53 are abundant in cancer cell lines and the tumors. Germline mutations 
in TP53 were discovered in the Li-Fraumeni patients that predisposed patients to increased 
cancer susceptibility (Srivastava 1990). In mice models, homozygous deletion of the p53 alleles 
did not affect development but made the mice prone to spontaneous neoplasms by 6 months of 
age. The absence of TP53 predisposing mice and Li-Fraumeni syndrome patients to neoplastic 
disease undoubtedly presented TP53 as a tumor suppressor gene (Donehower 1992). Finally, by 
the year 1989, 10 years since the discovery of p53, it was defined as a tumor suppressor gene 
and shown to be either mutated or lost in the human cancer tumors. The researchers did not 
have the slightest idea how versatile this protein could be. While the wildtype p53 is a potent 
tumor suppressor, the mutant p53 exerts a dominant negative effect on wildtype p53 (if present) 
as well as can have gain-of-function (GOF) activities like oncogenes in the absence of wildtype 
p53 alleles. 
 
The structure of the p53 protein 
 
The TP53 tumor suppressor is a transcription factor and shows sequence specific DNA binding. A 
good understanding of the structure facilitates a deeper understanding of the structure-function 
relationship and how the mutations at specific locations affect the conformation of the protein and 
the resultant function of the mutant form.    
 
The p53 transcription factor is functional as a homo-tetramer and the N-terminus of a monomer 
contains an intrinsically disordered trans-activation domain (TAD) and a proline rich region. The 
central domain is folded and is the DNA binding core domain that facilitates sequence specific 
DNA binding (Fig 1.4).  A flexible linker connects this domain with a tetramerization domain that 
enables the homo-tetramer formation. At the C-terminus of the monomer protein is a regulatory 
domain. This is an unfolded region rich in basic amino acids (lysine) and non-specifically binds 
DNA (Joerger 2008).  
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The N-terminal region of the monomer is intrinsically disordered. The TAD in this region is a 
binding site for several interacting proteins of p53. For example, the transcriptional co-activators 
p300/CBP and the negative regulators MDM2/MDM4. This intrinsic disorder in TAD is often seen 
in proteins that form a part of a signaling network and promotes binding to diverse other proteins 
with high specificity. The residues undergo disorder-to-order transition on binding the interacting 
proteins or nucleic acids. The proline rich region contains five PXXP motifs that are known to 
interact with proteins that contain Src homology 3 (SH3) domains. It is likely that these poly-
prolines provide rigidity to the formed helices in the TAD regions and project the TAD away from 
the central core domain (Wells 2008). 
 
The central DNA-binding core domain is where the missense mutations in p53 concentrate. It 
contains a β-sandwich that forms the primary scaffold for DNA-binding surface. The surface has 
two structural motifs i) loop-sheet-helix motif that bind the DNA major groove. It consists of loop 
L1, β-strands and C-terminal helix. ii) L2 and L3, two large loops contact the DNA minor groove 
and are stabilized by a zinc ion. The ion is tetrahedrally coordinated by histidine at position 179 
 
 
Figure 1.4. Domains of the full length p53 protein. N-terminal transactivation domain 
(TAD), proline-rich region (PRR), central core DNA binding domain (p53C), tetramerization 
domain (TET) and the C-terminus (CT). The rainbow-colored DNA binding domain is where 
most cancer associated mutations occur. The bars represent the relative frequency of 
missense mutation at the residue. Image from (Joerger 2008). 
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and cysteines at 176, 238 and 242. The loss of zinc results in instability and structural distortion 
of the domain affecting DNA binding specificity of the p53 monomer (Fig 1.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The p53 tetramer has sequence specific DNA binding capability and the target binding sites 
consist of two decameric motifs (half-sites) of the general form RRRCWWGYYY (R=A, G; W=A, 
T; Y=C, T), separated by 0–13 base pairs. But most p53 binding sites have consecutive half sites. 
For sequence specific DNA binding two core domains bind to a half site forming a dimer. The L3 
loop contacts the DNA minor groove through Arg248 and Arg273 contacts the DNA phosphate 
backbone. The functional p53 is described as a dimer of dimers and two dimers binding to the 
half sites form a tetramer which is stabilized by base stacking and protein-protein interaction 
(Joerger 2010) (Fig 1.6). As the DNA binding domain determines the sequence specificity of p53, 
missense mutations (replacement of one amino acid with another in the protein) frequently occur 
in this domain and contain the mutation hotspots that is described in the next section. 
  
 
 
Figure 1.5. Ribbon representation of the DNA binding domain of p53. 
Amino terminus in blue and carboxyl terminus in red. The essential DNA 
contact points are shown as grey sticks. On the right, p53 zinc coordination 
sphere and the amino acids involved are in green. Images adapted from 
(Joerger 2016, Joerger 2010).  
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The full length p53 monomers form the functional tetramers through the tetramerization domain in 
the C-terminal region of p53. These tetramers are reversible in nature. The tetramerization 
domain in each monomer has a short β-strand and a α-helix linked by a sharp turn. The tetramer 
is formed from the dimerization of the dimers (Fig 1.7). Hydrophobic interactions contribute 
towards the stabilization of the p53 tetramer.  
 
The C-terminal regulatory domain is also intrinsically disordered and subjected to PTM (described 
under function and regulation of p53).  Acetylation of lysines at C-terminal increases sequence 
specific DNA binding and may modulate p53 transcription activity. This domain interacts with 
different regulatory proteins and may have a role in p53 activation, degradation and localization. 
On binding other proteins or non-specific DNA, a disorder-to-order transition occurs in the C-
terminal domain which adopts different conformations based on structural context and PTM 
patterns and hence, referred to as a ‘chameleon sequence’ (Joerger 2010). Recently, it was 
  
 
 
Figure 1.6. Core domain tetramer bound to DNA in a sequence specific manner. A 
p53 dimer binds to the palindromic half site on the DNA. Right, DNA contact residues in 
the major groove interaction. Image adapted from (Joerger 2010). 
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confirmed that the lysine rich C-terminal 
domain (CTD) governs the binding of p53 in a 
DNA sequence dependent manner and 
stabilizes the p53-DNA complexes (Laptenko 
2015). 
 
The knowledge of the quaternary structure of 
p53 is necessary to understand its function. In 
the open conformation, the core domains are 
accessible to DNA.  On binding DNA, p53 
wraps around it and the overall structure 
becomes less flexible. Four p53 core domains 
bind to the consensus sequence forming a 
tetramer. In both free and DNA bound p53, the 
N-termini remain extended and suggest their 
 
Figure 1.7. Dimerization of the p53 
dimers forming the functional tetramer. 
Shown in two separate orientations. Image 
taken from (Joerger 2008). 
 
 
 
Figure 1.8. Full length p53 in unbound state in A. and B. with bound DNA showing the 
ternary complex (homo-tetramer). DNA binding domains (blue, green), tetramerization 
domain (red) and TAD (purple). Image from (Joerger 2010). 
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involvement with different proteins and post-translational modifications (Fig 1.8). Overall, the 
intrinsically disordered N and C-terminal domains provide p53 structural and thus, functional 
plasticity needed to bind to different protein partners. 
 
 
TP53 mutations in human cancer 
 
Cancer associated somatic mutations in the TP53 gene 
 
The TP53 database of the International Agency for Research on Cancer (IARC TP53 database) 
collects information on TP53 mutations in all types of cancer from peer reviewed literature and 
available databases. The database is updated regularly, and the latest version is R19. The 
database includes information about TP53 somatic mutations in sporadic cancers, germ-line 
mutation in familial cancers, TP53 polymorphism, functional assessment of the mutant protein, 
mutation in cell lines and TP53 mouse models. The database has been helpful in analyzing tumor 
specific TP53 mutation patterns, genotype and phenotype relationship and clinical impact of 
mutant p53 proteins.  
 
The database has reported that majority of the mutations in the sporadic cancers are missense 
mutations caused by single nucleotide substitutions in TP53 that account for about 75% in total 
(Fig 1.9). The remaining 25% of the mutations include truncation (nonsense, frameshift and 
deletion) and silent mutations. These missense mutant p53 proteins are full length proteins with a 
single change in the amino acid sequence characteristic of activated oncogenes. The highest 
frequency of missense mutations in TP53 has been observed in ovarian carcinomas in contrast to 
cervical carcinomas with much less frequent mutations in TP53. Somatic mutations in TP53 are 
also found in colorectal, lung, esophagus, liver, breast, brain, bladder, leukemia and skin cancers 
(Petitjean 2007). These missense mutations primarily occur in the evolutionarily conserved 
codons of TP53, but the mutational spectrum differs among different cancer types. The mutation 
  17 
spectrum differs in the position of the hotspots (frequently mutated nucleotide), frequency of 
transitions (purine/pyrimidine substituted by purine/pyrimidine) and transversions (purine replaced 
by pyrimidine or vice versa). For example, colon tumor mutations are mainly caused by base 
transitions at CpG dinucleotides. In comparison, G to T transversions were much higher in the 
breast tumors (Hollstein 1991).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The frequent somatic missense mutations found in human cancers are the most commonly 
observed genetic alterations clustered within the evolutionarily conserved DNA binding domain of 
the p53 protein and uncommon in the amino and carboxy terminus of the protein (Fig 1.10). The 
non-sense, silent and frameshift mutations predominate in the N and C-terminal regions. Among 
the missense mutations occurring in the DNA binding domain there are a few frequent mutations 
that account for nearly 30% of all missense mutations in cancers and have been addressed as 
the ‘hotspot’ mutations and underline the importance of these sites for p53-DNA complex 
formation. The frequently mutated amino acid residues are located near the protein DNA 
interface. They occur in the L3 loop (minor groove contact), the loop-sheet-helix motif (major 
 
Figure 1.9. TP53 mutations in cancer. The different 
cancer associated somatic mutations in TP53 based on 
IARC TP53 mutation database (Release R17, November 
2013, N=28,717, http://p53.iarc.fr/). Taken from (Joerger 
2016). 
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groove contact) and the L2 loop (interacts with L3 loop). The six major hotspots include Arg248, 
Arg273, Arg175, Gly245, Arg249 and Arg282 (Fig 1.11). 
 
 
Arg248 in the L3 loop contacts the minor groove of DNA and Arg273 from the loop-sheet-helix 
motif contacts the phosphate backbone of DNA in the major groove. The rest of the hotspot 
residues stabilize the structure of DNA binding surface of p53 transcription factor. Arg175 is in the 
L2 loop and stabilizes the zinc ion binding that bridges the L2 and L3 loops. Arg249 is in the L3 
loop right next to Arg248 that contacts the DNA minor groove. Arg282 resides in the loop-sheet-
helix motif and Gly245 in the L3 loop is the only non-arginine residue important for the 
maintenance of the L3 loop conformation. These hotspot mutants can be classified into two 
groups- mutations in the residues that directly contact the DNA and cause loss of critical DNA 
contacts (DNA contact mutants) and mutation of residues that stabilize the folding of the core 
domain and may cause structural defects (structural mutants). Mutation at Arg175 is an example 
 
Figure 1.10. Evolutionarily conserved domains (purple boxes) in the DNA binding 
domain of p53 protein (pink). Vertical lines above denote missense mutations (mainly 
in the conserved regions) with the height corresponding to its frequency and below 
denote non-missense mutations (occurring throughout the protein). Adapted from 
(Greenblatt 1994). 
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of structural mutant. Other examples for 
structural mutants include Arg249, Gly245 
and Arg282. The mutations at Arg273 and 
Arg248 are referred to as the DNA contact 
mutants that abrogate important DNA 
contacts at the p53 protein-DNA interface 
but do not have any significant effect on 
the structure of DNA binding core region 
of p53 but influence the DNA binding 
affinity of p53. Thus, DNA contact mutants 
inactivate p53 by losing critical DNA 
contacts and the structural mutants 
disrupt the structural integrity of p53 core 
domain and inactivate it (Cho 1994). The 
five hotspot codons (175, 245, 248, 273 and 282) contain CpG dinucleotides and the single base 
substitutions result from G:C to A:T transitions (deamination of 5-methylcytosine) at these sites. 
Deletions and insertions may result from DNA polymerase infidelity during replication or faulty 
repair of the carcinogen-DNA adducts (Greenblatt 1994).  
 
The most common genetic aberrations in other tumor suppressor genes such as RB and APC are 
deletions or non-sense mutations in both the alleles that knock-out proteins and their loss-of-
function leads to tumorigenesis. In stark contrast, the TP53 tumor suppressor undergoes not only 
deletion but also frequent missense mutations generating a full-length mutant protein like tumor 
causing oncogenes, with eventual loss or mutation of the second wildtype allele.  
 
 
 
 
 
Figure 1.11. p53 DNA binding domain bound 
to a DNA sequence. The hopspot mutation sites 
include codons 175, 248, 273, 245, 249 and 282. 
Figure adapted from (Joerger 2016). 
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Germline mutations in TP53 gene and Li-Fraumeni syndrome 
 
The Li-Fraumeni syndrome (LFS) is an autosomal dominant disease where patients are pre-
disposed to cancer with early onset of tumors (strikingly lower than sporadic cancers) including 
sarcomas, brain tumor, breast cancer and adrenocortical carcinoma. Germline mutations in TP53 
form the primary molecular basis for LFS development. 74% of these mutations are missense 
mutations that predominantly occur in the highly conserved DNA binding domain of p53 including 
the hotspot codons (Guha 2017). The mutations also include non-sense and splice mutations 
distributed across the TP53 gene. Mutation in one allele is followed by loss of heterozygosity 
(LOH) in the other either by mutation or deletion. Thus, TP53 qualifies as a tumor suppressor 
gene whose inactivation leads to tumor development as per ‘Knudson two hit hypothesis’. This 
was proposed for genetic model of retinoblastoma development where inheritance of one 
mutated tumor suppressor RB allele was the first hit and mutation or loss of second RB allele as 
the second hit promoting retinoblastoma development (Rivlin 2011).  
 
LFS patients have increased risk of developing multiple primary tumors and the risk of developing 
cancer in patients with TP53 mutations is approximately 73% in males and abnormally high in 
females being 93% where they develop breast cancer at a very young age. The clinical 
presentation of LFS is very heterogeneous as the age of tumor onset and the subtype vary and 
suggests the involvement of other genetic factors apart from germline mutation in TP53 for 
example, mutation in BRCA1. 
 
Trp53 germline mutant heterozygous mice present a close genetic model of LFS as patients are 
heterozygous for TP53 and develop metastatic tumors providing evidence for dominant negative 
and eventual gain-of-function phenotypes of mutant TP53. In the identical genetic background 
two different missense mutations, R172H and R270H (human R175H and R273H), gave rise to 
different tumor spectra observed in humans with LFS (Olive 2004). The loss of the wildtype TP53 
allele was significantly lower in the tumors carrying missense mutation in the DBD of TP53 (Birch 
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1998). These observations ascertain that some mutants exhibit dominant negative effect over 
wildtype allele or gain-of-function properties when wildtype allele is lost. The mean age of onset 
of breast cancer is much lower in LFS families carrying a germline TP53 mutation than LFS 
families without TP53 mutation.  The Li-Fraumeni syndrome where germline mutation in TP53 
predisposes individuals to cancer underlines the importance of TP53 tumor suppressor in 
restricting cancer development. 
 
Somatic mutation burden in cancer tumors 
 
The somatic cells accumulate spontaneously occurring mutations over time. These mutations 
arise due to errors in DNA replication or when a damage in the DNA is repaired incorrectly or kept 
unrepaired. A small fraction of these spontaneous mutations provides selective advantage in 
terms of growth and survival of cells and are termed the ‘driver’ mutations that remain under 
positive selection. 1-2 % of the protein coding genes in human genome are recurrently mutated in 
cancers and are the drivers that drive the process of oncogenesis. Most mutation variants do not 
provide any selective biological advantage and are termed the ‘passenger’ mutations. There is a 
small fraction of advantageous infrequent mutations that co-appear with the major drivers and 
contribute towards tumor development. They can be addressed as the ‘co-drivers’ working as an 
accomplice to the drivers. The targeting of the pathways involving the co-drivers in addition to the 
driver pathway may enhance the effect of targeted combination therapies for cancer treatment.  
 
The advancement in the genome sequencing methods over the years has revealed the repertoire 
of somatic mutations in different cancers. The results highlight the mutational processes and the 
‘cancer genes’ (Martincorena 2015). Most of the cancer tumors carry 1000 to 20,000 somatic 
point mutations and hundreds of insertions, deletions and gene rearrangements, DNA copy 
number increase as well as reductions (Fig 1.12). The cancer cells also acquire epigenetic 
changes that manifest as changes in DNA methylation and chromatin structure. The overall 
somatic mutation prevalence differs with the cancer types. The lung carcinomas followed by 
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gastric, ovarian and colorectal cancers show highest prevalence of somatic mutations and may 
carry more than 100,000 point mutations. On the other hand, hematological cancers and most 
breast cancers show a comparatively lower prevalence of somatic mutations (Greenman 2007). 
High cell turn-over and exposure of the surface epithelia to exogenous mutagens as in colorectal, 
lung and gastric cells leads to high somatic mutation rates.   
 
The analysis of 9,423 tumor exomes using 26 computational tools has identified 299 driver genes 
and more than 3000 putative missense driver mutations (Bailey 2018). To date, this study has 
been the most comprehensive discovery of cancer genes and mutations. The mutation spectrum 
and cancer driver genes vary among different cancer types. Some driver genes are specifically 
associated with a single cancer while some have driver roles in two or more cancer types. As an 
example, TP53 gene acts as a driver in 27 cancer types and PIK3CA, KRAS and PTEN are  
 
associated with 15 or more cancer types. As evident from the sequencing of tumors, cancer is a 
disease of numerous mutations that are required for turning the benign tumors into the malignant 
form. Apart from the driver mutations, additional less prevalent mutations ‘the co-drivers’ as 
introduced before, exist that do not clonally dominate the tumor but make reservoir of genetically 
 
 
Figure 1.12. Somatic mutation burden (base substitutions and small indels) in 20 
different types of cancer. The orange bar is the median burden of all samples. Image 
adapted from (Martincorena 2015). 
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heterogeneous cells that may contribute to metastasis or drug resistance and to tumor 
heterogeneity. The immediate challenge lies in identifying these less prevalent drivers, the co-
drivers, in the sea of passenger mutations. 
 
 
TP53 mutations in breast cancer 
 
Germ-line mutation in TP53 is found in patients of Li-Fraumeni syndrome with increased risk of 
breast cancer and this established the involvement of TP53 mutations in breast cancer 
development. Somatic mutations in TP53 are also known to occur in Ductal Carcinoma In-Situ 
(DCIS), preceding stages of invasive breast cancer and the frequency of p53 mutations increase 
with the grade of DCIS tumors. These imply that TP53 mutations occur early in the process of 
breast carcinogenesis (Boressen-Dale 2003) and has been designated as one of the driver 
mutations. The frequency of TP53 mutations are found to be much higher in node-positive, large 
tumors, tumors from advanced disease and recurrent tumors than primary tumors.  
 
Breast cancer is a highly heterogeneous disease with tumors of characteristic molecular features, 
prognosis and therapy responses. Gene expression patterns obtained from cDNA microarray on 
breast tumors and normal breast tissues classified the tumors into basal type, ERBB2 or HER2 
overexpressing, normal breast like group and luminal type (with subgroups luminal A and luminal 
B) each with distinctive expression profiles (Table 1.1). Poor prognosis is associated with the 
basal-like subtype and happens to be the most aggressive of all subtypes (Sorlie 2001). 
Immunohistochemically, luminal subtype is estrogen receptor (ER+), progesterone receptor 
(PR+) and HER2 receptor positive (HER2+). HER2 overexpressing subtype has amplification of 
HER2 receptor and could be ER+ or ER-. The hormone receptor positive subtypes are treated 
with hormone therapy targeting the receptors and their downstream partners. Treatment of HER2 
amplified subtype with monoclonal antibody trastuzumab has been effective. But the basal type is 
ER-, PR- and HER2- (triple negative breast cancer or TNBC). It is more frequent in young African 
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American women and the tumors are of high grade, mitotic, aggressive, show metastatic behavior 
and relapse with distant metastasis. TNBC is highly heterogeneous and in turn consists of six 
more subtypes and the lack of any targetable receptors leaves the systemic chemotherapy as the 
only treatment option.   
 
Whole exome sequencing of DNA from tumors of different breast cancer subtypes show recurrent 
somatic mutations in PIK3CA, TP53, AKT1, GATA3 and MAP3K1 with high rate of missense 
mutations particularly in PIK3CA and TP53 (Banerji 2012). 30% of all breast cancer tumor 
subtypes carry mutations in TP53.  The distribution of TP53 mutations in the subtypes include 
26% of luminal tumors (17% luminal A, 41% luminal B), 88% of basal-like carcinomas, and almost 
50% of HER2+ tumors. There is high frequency of base substitution in luminal subtype while 
deletions and insertions are high in TP53 in basal-like tumors (Bertheau 2013). 
 
Table 1.1. Molecular features of the breast cancer subtypes. Table taken from (TCGA 
network, 2012).  
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Clinical and prognostic value of TP53 somatic mutations in breast cancer 
 
The mean age of tumor onset in patients with germline TP53 mutations (Li-Fraumeni disease 
patients) is 24 years for carriers of missense mutations compared to 29 years for patients with 
nonsense mutation in TP53. With hotspot mutations R175H or R248W, mean age of tumor onset 
was between 15 and 20 years and 39 years with deletion in the TP53 gene resulting in its loss-of-
function. This indicates severe clinical outcomes associated with hotspot missense mutations in 
TP53 with similar correlations for the somatic mutations (Hainaut 2016).   
 
TP53 mutations and p53 protein overexpression are associated with prediction of response to 
chemotherapy. Failure of neoadjuvant treatment with fluorouracil, epirubicin and 
cyclophosphamide in breast cancer patients is attributed to both presence of TP53 mutations and 
p53 overexpression captured by immunohistochemistry (IHC) (Kandioler-Eckersberger 2000). 
Mutations in p53 obtained from sequencing than IHC as the marker for mutation status has 
constantly been associated with poor prognosis in breast, colorectal, head and neck cancers and 
leukemia.   
 
TP53 mutations are found to be more prevalent in recurring tumors compared to their 
corresponding primary breast tumors (41% vs 23%) indicating the importance of p53 mutations 
for tumor progression in breast cancer (Norberg 2001). Complete sequencing of the TP53 coding 
regions from 316 breast cancer patients provided prognostic information about adjuvant systemic 
therapy and radiotherapy where the p53 mutations in the evolutionarily conserved regions (now 
known to harbor frequent or hotspot missense mutations) were associated with worse prognosis. 
Tumors that contained p53 mutations and were lymph-node positive did not benefit from adjuvant 
therapy with tamoxifen along with radiotherapy (Bergh 1995). In another study of 63 patients with 
locally advanced breast cancer and receiving doxorubicin monotherapy as the first line treatment 
showed primary resistance to doxorubicin therapy and early relapse in the breast cancer patients 
with mutation in TP53 (Aas 1996). TP53 mutations have also been linked to resistance to 
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anthracyclines and cisplatin-based chemotherapy. Investigation of the somatic mutations in TP53 
by exon sequencing in 1,794 primary breast cancer tumors with long-term follow up associated 
with aggressive phenotype like high tumor grade, large size, node positivity and low hormone 
receptors and high mortality rates. In fact, mutations in TP53 and absence of progesterone 
receptor showed worst prognosis (Olivier 2006).  TP53 mutation status in 1,420 breast tumors 
(METABRIC cohort) by sequencing revealed different clinical relevance in subtypes of breast 
cancer. Mutations in p53 conferred worst overall breast cancer specific survival and marker of 
poor prognosis in ER+ patients. TP53 mutation spectrum was different in different subtypes and 
linked to increased mortality in luminal B and HER2+ patients than luminal A and basal-like 
breast cancer patients (Silwal-Pandit 2014). 
 
The advancement in whole genome or exome sequencing, DNA copy number changes, mRNA 
and protein expression has provided a comprehensive view of TP53 mutations and their contexts 
where they appear. But one must be careful that prognostic and predictive significance of TP53 
mutations is quite variable and depends on the tumor type and the treatment and there is no 
universal clinical message deciphered from the TP53 mutation status. 
 
Other co-existing somatic mutations in breast cancer 
 
The TP53 mutations are early occurrences in breast cancer and a known clonal driver mutation 
that contributes to initiation and progression of the disease. But it exists with several other 
somatic mutations in the tumor resulting in genetic heterogeneity that complicates the treatment 
regime. The co-existing subclonal (less frequent, present in some cells not all) somatic mutations, 
the co-drivers, that drive tumorigenesis forward largely remain undiscovered. These functionally 
important driver mutations or as we introduced ‘the co-drivers’ can help to find out alternative 
direct drug targets (gene or proteins) or pathways for targeted therapies. For tackling the 
heterogeneous tumors, combination therapies would prove more beneficial than administration of 
a single drug.  
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Breast cancer is a heterogeneous disease with inter-tumor (between patients and within a 
patient) and intra-tumor (within a tumor from a patient) heterogeneity with respect to histological, 
prognostic and clinical aspects (Zardavas 2015). Intra-tumor heterogeneity has been observed at 
the spatial and temporal levels and is the consequence of tumor evolution resulting from selective 
pressure and this heterogeneity poses the biggest hurdle at developing targeted therapies for 
breast cancer. Analysis of different gene expression levels with microarray technology enabled 
the understanding of inter-tumor heterogeneity and classified breast cancer into subclasses- 
Luminal A, Luminal B, HER2 enriched and Basal like. Later, basal-like or TNBC was reported to 
be highly heterogeneous consisting of additional subtypes. With next-generation sequencing 
(NGS) of the breast tumors several genetic aberrations are found that affect the genomic 
landscape of breast cancer tumors namely, point mutations, small insertion or deletions (indels), 
amplification, chromosome or segmental duplication, translocations, inversions and fusions 
(Kalimutho 2019).  
 
NGS identified high frequency of somatic mutations in TP53, PIK3CA and GATA3 across all 
subtypes of breast cancer. The number of somatic mutations greatly vary between individual 
tumors. From whole-genome sequencing of 560 breast cancer tumors probable driver mutations, 
the highly mutated non-coding regions, genome rearrangements (tandem duplication or deletion) 
were identified that formed the somatic mutation landscape in breast cancer. TP53, PIK3CA, 
MYC, CCND1, PTEN, ERBB2, ZNF703/FGFR1 locus, GATA3, RB1 and MAP3K1 are the most 
frequently mutated genes that account for 62% of drivers. Mutations in TP53, MYC, PTEN and 
RB1 are more common in ER- breast tumors while mutations in PIK3CA, GATA3, CCND1 and 
MAP2K4 more common in ER+ breast tumors. Several other genes are mutated though at a 
much lower frequency and co-appeared with the above repertoire of frequently mutated genes 
(Nik-Zainal 2016).  Mutations in genes AKT2, ARID1B, CASP8, CDKN1B, MAP3K13, NCOR1, 
SMARCD1 and TBX3 have been considered as other driver mutations in breast cancer 
(Stephens 2012) (Fig 1.13). For the pairwise association of somatic events tumors with 
inactivating mutations in PTEN also harbored recurrent PIK3CA mutations. Co-mutation of TP53 
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and RB1 commonly occurs in TNBCs whereas CDH1 and PIK3CA in lobular carcinomas (Pereira 
2016).  
 
Other than mutations in protein-coding regions, recurrent mutations are found in the non-coding 
RNA genes and promoters of genes like FOXA1 (breast cancer oncogene) leading to its over-
expression. Other recurrent somatic mutations in AKT1 and CBFB and deletion in RUNX1 and 
MAGI3-AKT3 fusion enriched in TNBC were discovered from whole genome sequences of DNA 
from 103 breast tumors of different subtypes (Banerji 2012). From another study, deep 
sequencing of somatic mutations in 104 TNBC tumor samples identified varying clonal 
frequencies with more variation in basal subtype than non-basal TNBCs. Somatic mutations in 
TP53, PTEN and PIK3CA were clonally dominant while lower mutation frequencies were 
observed in cytoskeletal, cell shape and motility genes indicating their occurrence at a later stage 
during tumor progression (Shah 2012).   
 
 
 
 
Figure 1.13. Breast cancer tumors with copy number alterations in different genes in 
ER+ or ER- samples. Image taken from (Pereira 2016). 
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Owing to breast tumor heterogeneity, combination therapies targeting multiple driver mutations 
may prove beneficial. The sequencing results from the breast tumor subtypes emphasize the 
importance of mutation-based stratification of breast cancer patients for designing therapeutic 
strategies. 
 
The Breast Cancer Landscape 
 
Breast cancer is a world-wide problem. It is the most common cancer found in women and it has 
been estimated that in the US in 2019, about 268,600 women will be diagnosed with breast 
cancer. In general, about one in every 8 women will be diagnosed with breast cancer in her 
lifetime. It is quite interesting to know that females on active military duties have up to 40% higher 
risk of breast cancer than the general population. Though breast cancer occurs 100 times more 
frequently in women, men can also be diagnosed with the disease. The race or ethnicity also has 
an influence on breast cancer incidence and mortality rates. In the US, there is enough variation 
and the Caucasians, and the Black Americans have higher incidence rates compared to Asians 
and Latinas. But mortality rates are highest among Black women. Triple Negative Breast Cancer 
(TNBC) is more frequent in African Americans typically the Basal-like subtype than the 
Caucasians. African Americans are also known to have shorter TTP (time to progression) and 
worse DFS (disease free survival) though no specific genomic profile, high prevalence genes or 
gene expression patterns in breast cancer biology are associated with racial differences 
(Ademuyiwa 2017).   
 
Breast cancer is highly heterogeneous with major molecular subtypes luminal A, luminal B, HER2 
overexpressing and basal-like. Luminal A subtype breast tumors are most common (70%) while 
the TNBC subtype tumors account for 15%. The TNBC and the HER2 overexpressing tumors 
have the worst prognosis. The metastatic disease is the cause for the estimated 90% deaths due 
to breast cancer and is not curable. Treatments like surgery, radiation, chemotherapy, hormone 
therapy, targeted therapy and immunotherapy are known to shrink the tumors and delay the 
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metastasis process. De novo and acquired resistance are the major challenges and no targeted 
therapies have been approved for the most aggressive TNBCs. The most commonly used 
combination chemotherapies show only 7-11% improvement in survival for younger women and 
just 2-3% for women above 50 years. The non-specific chemotherapy benefits only a small 
fraction of patients as we do not know how the heterogeneity of each tumor affects response to 
therapy or the recurrence.  
 
Only very recently, the genome analysis methods are providing a comprehensive picture of 
genetic diversity in breast cancer tumors and could be used in routine clinical practice given that 
these methods are powerful, fast and reliable. Sequencing of TNBC tumors has revealed that 
copy number changes and mutation frequencies vary between and within tumors. Hence, the 
genome analysis method defines the landscape of this complex disease where there are few 
consistent and functionally characterized aberrations with hundreds of other genomic changes 
unique to individual tumor.  
 
 
Cellular and molecular mechanism of action of mutant p53  
 
The following sections provide a detailed read on how the mutant p53 protein gains oncogenic 
functions and how this phenomenon possibly shapes cancer development.  
 
Hallmarks of cancer disrupted by mutant p53 
 
Cancer progression in humans is a multistep process driven by genetic alterations that transform 
normal cells into malignant cells. These transformed cancer cells acquire certain molecular and 
biochemical capabilities that are shared by most cancer cells and these new traits dictate 
malignant growth. These cellular traits include- sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis and 
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activation of cell invasion and metastasis. These acquired capabilities comprise the ‘hallmarks of 
cancer’. Mutation in TP53 directly affects cell viability and proliferation potential, apoptosis 
(programmed cell death) resistance, cell migration and invasion. There are two emerging 
hallmarks- reprogramming cellular metabolism and evasion of immune destruction. Genomic 
instability and inflammation supporting tumors have been described as the enabling hallmarks as 
genetic alterations drive tumor progression and sustained inflammatory responses often promote 
tumors. Thus, now there are a total of ten hallmarks of cancer that define the complexity of the 
neoplastic disease (Hanahan 2011). 
 
Accumulation of mutant p53 protein in tumor cells 
 
Accumulation of p53 protein in the nucleus is strongly associated with missense mutations in 
TP53. The tumor cells accumulate high but very heterogeneous level of mutant p53 proteins 
whereas the wildtype protein is barely detectable in cells under normal conditions. The protein 
levels build up only under stressed conditions. Concordance between TP53 missense mutations 
in the DNA binding domain (DBD) determined by sequencing of cells from tumors and nuclear 
p53 mutant protein accumulation using immunohistochemistry in formalin fixed paraffin 
embedded tissue has been found in metastatic prostate cancer, invasive ductal carcinomas of 
breast, bladder cancer, colorectal adenocarcinomas, esophageal neoplasms, lung cancer and 
ovarian cancer that also strongly associates with poor prognosis. In fact, the ‘dominant negative’ 
effect or the ‘gain-of-function (GOF)’ effect of missense mutant p53 protein is attributable to its 
high concentration in the nucleus of the cancer cells and the formation of the hetero-tetramers.  
 
In normal unstressed cells p53 protein accumulation is prevented by its efficient turnover and 
under stressed conditions modulation of these degradation pathways causes stabilization and 
accumulation of p53 protein leading to the activation of the target genes. Mdm2 is an essential 
component of the p53 degradation pathway which ubiquitinates p53 promoting degradation of 
p53 by proteasomes and Mdm2 also happens to be a p53 target gene. Mdm2 directly binds p53 
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at the N-terminal disrupting the binding of other transcriptional machinery components 
maintaining a very low p53 protein level under normal conditions. Mutant p53 proteins do not 
activate the Mdm2 expression, are unusually stable and accumulate to high levels in the tumor 
cells (Ashcroft 1999). Some cancer cell lines show hyperphosphorylation or hyperacetylation of 
mutant p53 protein that affects its stability and interaction with other proteins. This may change 
DNA binding and transcriptional regulation by mutant p53. As the p53 acetylation sites are shared 
for ubiquitylation, hyperacetylation impairs ubiquitylation and degradation of mutant p53 leading 
to its accumulation in the nucleus (Bode 2004). Overexpression of Mdm2 is common in many 
tumor types deactivating p53. Stabilization of mutant p53 is also supported by loss of INK4A 
expression and interaction with heat shock proteins HSP90 and HSP70 (Brosh 2009). 
 
TP53 loss of function 
 
The tumor suppressor gene TP53 is addressed as the ‘guardian of the genome’ for the activation 
of senescence, cell-cycle arrest, apoptosis and DNA repair pathways for maintenance of genomic 
integrity under stressed conditions generated by DNA damage, oncogene activation, oxidative 
stress, hypoxia and nutrient deprivation. But after discovering TP53’s involvement in modulation 
of metabolic reprogramming, autophagy, tumor microenvironment signaling, inhibition of stem cell 
renewal and negatively regulating invasion and metastasis, TP53 has now been designated the 
title of ‘the master regulator’. For its broad range of tumor suppressive activities, without a doubt 
TP53 remains the most mutated gene across all cancer types. TP53 is inactivated either by 
missense or deletion mutations followed by loss of the remaining allele.  
 
Homozygous deletion of p53 is seen in colon carcinomas, lung cancer, brain and breast tumors. 
The missense mutations concentrate in the highly conserved DNA binding domain of p53. The 
missense mutations in TP53 occur in spontaneous tumors as well as the germline of Li-Fraumeni 
syndrome patients. The inherited mutations remain in the heterozygous state and pre-dispose an 
individual to carcinogenesis (Levine 1991). Though TP53 undergoes deletion or truncation 
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mutations, missense mutations in the DBD of the protein are the most common mutations found 
in TP53 in cancer patients. Typically, truncating or non-sense mutations, gene deletion and even 
missense mutations that abrogate binding of p53 to its consensus DNA sequences restrict the 
activation of the p53 target genes leading to its loss-of-function (LOF). Missense mutations in 
TP53 give rise to full-length mutant p53 protein that interferes with the function of the wildtype 
p53. Oligomerization of the mutant and the wildtype p53 hinders sequence specific DNA binding 
and exerts the ‘dominant negative effect’ (DN). Loss of the other remaining wildtype TP53 allele 
by mutation or deletion, enables ‘gain-of-function’ (GOF) properties to the mutant p53 with new 
functions that are independent of the wildtype p53 (Fig 1.14) (Brosh 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mice homozygous for the null TP53 allele develop normally but become susceptible to 
spontaneous tumors by 6 months since birth. These results show that the normal p53 is 
 
 
Figure 1.14. Summary for phenotypic effects of TP53 mutations. 
Adapted from (Brosh 2009). 
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dispensable for embryonic development, but its absence predisposes animals to neoplasms. 
(Donehower 1992). The p53 null homozygous mice particularly develop lymphomas and 
sarcomas. In comparison, heterozygous mice with one wildtype p53 allele rarely develop tumors 
before the age of 9 months. The homozygotes develop multiple types of cancer by 20 weeks 
including malignant lymphomas and sarcomas along with primary neoplasms of different cell-type 
of origin. The germline disruption of TP53 show variable tumor latency and tissue distribution. 
p53+/Δ serves as a model for Li-Fraumeni syndrome where the heterozygous mice develop 
sarcomas (57%), lymphomas (25%) and carcinomas. Determination of the p53 status in tumors of 
the heterozygous mice presented the complete absence of wildtype p53 allele by deletion rather 
than point mutation. The homozygous mice p53 Δ/Δ have accelerated rate of tumorigenesis 
compared to heterozygous and p53 wildtype mice (Jacks 1994). Very few female mice with p53 
null phenotype develop spontaneous mammary adenocarcinomas. Only tissue specific 
inactivation of p53 in a conditional mouse mammary tumor model developed spontaneous 
mammary tumors.  
 
Loss of p53 accentuates tumor development whereas restoration of endogenous p53 expression 
result in regression of lymphomas and sarcomas (Ventura 2007) making TP53 a perfect example 
of a tumor suppressor gene. 
 
Dominant negative effect of mutant p53 protein  
 
Acquisition of mutation in one TP53 allele can interfere with the normal function of the remaining 
wildtype (WT) TP53 allele. This phenomenon is referred to as the ‘dominant negative’ (DN) 
activity of the mutant TP53. Several possible reasons have been proposed to explain the ability of 
the dominant negative mutants to disrupt the WT allele function by 1) competition with the WT 
p53 where mutant p53 occupy the WT p53 binding sites and the co-factors 2) formation of hetero-
tetramers comprising of both WT and mutant p53 monomers  and 3) change in conformation of 
WT p53 by interaction with the mutant p53 into an inactive conformation suggestive of a prion-like 
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mechanism. Mutant p53 protein has no characteristics of an infectious protein and cannot be 
propagated, nullifying the prion like mechanism for dominant negative effect. The mechanism of 
this effect relies more on competition between mutant and wildtype p53. A higher concentration of 
mutant p53 can inhibit wildtype mediated transcription (Fig 1.15).  
 
A yeast system shows that the p53 hotspot mutants exhibit dominant negative potential and this 
potential over WT p53 is based on formation of inactive hetero-tetramers and doesn’t involve 
prion-like mechanism. Moreover, in this study the DN effect of p53 mutant R175H was dependent 
on its expression level and inhibited WT p53 in a dose-dependent manner. And inhibition of 
tetramerization abolished the dominant negative effect of the p53 mutants (Billant 2016). In an 
inducible system capable of expressing only mutant p53, only WT p53 or concurrent expression 
of both, p53 mutants R175H, R248W and R273H reduced the binding of WT p53 to its 
endogenous target genes p21, MDM2 and PIG3 reducing growth suppression, in presence of the 
mutant p53. The reduced ability of WT p53 to bind to the target genes in presence of mutant p53 
was confirmed by chromatin immunoprecipitation (ChIP) demonstrating how the mutant p53 
exhibit dominant negative effect (Willis 2004).  
 
 
Several animal models expressing a mutant and a wildtype TP53 allele demonstrated the 
dominant negative effect (DN) of mutant p53 over wildtype p53. The animals hemizygous for 
 
 
Figure 1.15. Co-dominance of wildtype and mutant p53. At higher concentration of mutant 
p53, hetero-tetramers of mutant and wild-type p53 are formed that poison the formation of 
wildtype p53 homo-tetramers. Image from (Goh 2011). 
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endogenous wildtype p53 gene expressing multiple copies of mutant p53 Val135 had accelerated 
tumor growth and different tumor spectrum than the non-transgenic mice stressing on dominant 
negative effect of the mutant. These p53+/- transgenic mice developed lymphomas, soft tissue 
sarcomas, osteosarcomas and typically lung adenocarcinomas not seen in non-transgenic mice 
(Harvey 1995).   In a conditional mouse model with heterozygous expression of mutant p53 in 
only the epithelium had increased incidence of spontaneous and UVB induced skin tumors. 
Reduced tumor latency time were observed in K14Cre;p53R270H/+ (human R273H) mice compared 
to K14Cre;p53+/+  mice. Upon UVB exposure, the tumor latency time of K14Cre;p53R270H/+ mice 
were drastically reduced pointing towards the dominant negative effect of the R270H mutant 
equivalent to human R273H mutation (Wijnhoven 2007). Heterozygous mice p53R172H/+ (human 
R175H) expressing mutant p53 to near wildtype levels had a different tumor spectrum from p53+/- 
mice. The p53R172H/+ mice contracted more carcinomas and the osteosarcomas and the 
carcinomas metastasized where the osteosarcomas in p53+/- mice rarely metastasized (Liu 2000).  
 
Mice with heterogeneous germline p53 loci p53R270H/+ and p53R172H/+ presented models for Li-
Fraumeni syndrome and formed allele specific tumor spectra different from p53+/- mice showing 
that point/missense mutant p53 had oncogenic potential than simply loss of p53 function. 
p53R270H/+ (human R273H) mice had increased tumor burden and incidence of carcinomas that 
were invasive. On the other hand, osteosarcomas were frequent in p53R172H/+ (human R175H) 
with metastasis compared to p53+/-. Mouse embryonic fibroblasts (MEFs) extracted from the 
p53R270H/+ and p53R172H/+ mice had a large fraction in the S-phase of cell cycle compared to p53+/- 
MEFs (Olive 2004). In a parallel study, osteosracomas and carcinomas in p53+/515A mice 
metastasized compared to the p53+/- heterozygous mice.  Retrovirally expressed mutant TRP53 
(TP53 in mice) in different genetic backgrounds- Trp53-/-, Trp53+/- and Eµ-Myc/Trp53+/+ 
demonstrated dominant negative effect of mutant TRP53 in driving lymphomagenesis and a role 
of gain-of-function effect (GOF) of mutant TRP53. This system recapitulated the early stages of 
tumorigenesis in humans when a heterozygous state for the TP53 exists before the loss of 
heterozygosity (LOH) at the TP53 locus and mutant TP53 driven cancers that retain a WT copy of 
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TP53. Among all the mutants R270H allowed the expression of WT TRP53 target genes and 
displayed weakest dominant negative effects (Aubrey 2018). It is likely that the dominant negative 
effect exerted by the mutant p53 depends on a number of factors like mutant conformation, 
affinity of the mutant for WT p53 targets, DNA binding site, cell type and the available co-factors. 
 
Gain of function (GOF) of neo-morphic mutant p53 
  
The cancer associated TP53 missense mutations not only abrogate the tumor suppressor 
functions of wildtype p53 but also endow the mutant proteins with new functions that actively 
contribute to the different stages of tumor progression. Hence, these ‘neo-morphic’ oncogenic 
properties acquired by the accumulation of abnormal amounts of mutant p53 protein in cell nuclei 
in absence of any wildtype p53 have been termed as the ‘gain-of-function’ (GOF). GOF has been 
studied by over-expressing a p53 mutant in a p53 null background in cells or in mice models to 
assess its impact on the cellular properties. Alternatively, by knocking-down endogenous mutant 
p53 by siRNA in tumor derived cells and monitoring the changes in cell phenotype has proven 
mutant p53 GOF (Oren 2010). Acquisition of missense mutations in TP53 in human tumors is 
generally followed by loss of heterozygosity (LOH) at the other allele indicating a selective 
advantage of losing the wildtype allele after the other TP53 allele is mutated. A strong selection 
for the mutant p53 proteins ascertains their role as tumor promoters instead of tumor 
suppressors. A pre-requisite for GOF is stabilization of mutant p53 and a recent work has shown 
that LOH is essential for mutant p53 stabilization and GOF.  
 
Mouse tumors with high frequency of p53 LOH have accelerated tumor onset compared to p53+/- 
tumors and in the tumors with low frequency of LOH, p53R248Q/+, mutant protein was not stabilized 
and hence, GOF was not observed (Alexandrova 2017). Over-expression of mutant p53 in cells 
with endogenous wildtype p53 do not qualify for GOF but dominant negative effect of the mutant. 
The biological manifestation of GOF of mutant p53 proteins in cultured cells encompass 
increased genomic instability, increased proliferation, apoptosis resistance, chemoresistance and 
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increased cell migration and invasion. Expression of mutant p53 proteins in murine fibroblast cell 
line (10)3 and human osteosarcoma cell-line SAOS-2 lacking endogenous wildtype p53 
enhanced tumor formation in nude mice and plating efficiency in agar cell culture. The gain of 
tumorigenic potential of the mutants also activated multidrug resistance in the cells (Dittmer 
1993). Missense mutant p53 proteins upregulate genes like MDR1, PCNA, EGFR, c-MYC, cyclin 
A, cdk1, cdc25C and repress the canonical WT p53 targets p21, gadd45 and PTEN.  
 
Expression of mutant p53 proteins in mouse models at the physiological levels and under 
physiological regulation cleared any doubt about the cancer associated features of mutant p53 
GOF. Mutant p53 knock-in mice with hotspot mutations R248Q and G245S showed early onset of 
different tumor types in comparison to p53 null mice. Mice with R248Q/- had expanded 
hematopoietic and mesenchymal stem cells and R248Q/R248Q mice had broadened tumor 
spectrum with enhanced Akt signaling compared to null mice (Hanel 2013). p53R270H/- and 
p53R172H/- (equivalent to human R273H and R175H) mice developed tumor spectrum specific to 
Table 1.2. Some of the mutant p53 protein interacting partners. Table from (Freed-Pastor 
2012). 
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the allele compared to p53 null mice including frequent metastatic carcinomas and endothelial 
tumors (Olive 2004). 
 
Several models for mechanism of GOF for mutant p53 proteins have been proposed. For GOF 
the different missense mutant p53 proteins interact with many other proteins to either enhance or 
inhibit the activities (Table 1.2). Some of the proposed mechanisms include 1) Specific p53 
mutant binding elements or regions in DNA but as mutant p53 loses sequence specific DNA 
binding it is unlikely that sequence specific mutant p53 response elements exist. Rather, mutant 
p53 could sense DNA in a structure specific manner (Freed-Pastor 2012). 2) Mutant p53 interacts 
with other transcription factors in a complex with co-factors and other proteins resulting in 
activation of their target genes. Mutant p53 interacts with transcription factor NF-Y upregulating 
expression of cyclin A, cyclin B1, cdk1 and cdc25C post DNA damage. Following DNA damage 
mutant p53 binds to NF-Y target promoters and recruits p300 for histone acetylation (Di Agostino 
2006). Mutant p53 enhances the expression of NF-Y, Sp1, Ets1 and VDR target genes all known 
to be repressed by the wildtype version of p53. For example, p53 mutants commonly found in 
breast cancer cell lines bind and upregulate chromatin methyltransferases MLL1 and MLL2 and 
acetyltransferase MOZ increasing genome wide histone methylation and acetylation culminating 
into uncontrolled cell proliferation. MLL1, MLL2 and MOZ are specifically upregulated in patient 
derived p53 mutated breast tumors and not in p53 wildtype or null tumors. Genetic knock-down or 
inhibition of MLL1 methyltransferase complex markedly lowered cancer cell proliferation (Zhu 
2015). 3) Mutant p53 can form aggregates with other proteins decreasing binding of transcription 
factors and co-factors to DNA. Murine p53R172H (human R175H) mutant binds to p63 and p73 
and inhibits their function as transcription factors (Lang 2004). 4) Mutant p53 interacts with 
proteins other than transcriptional regulators and either enhances or blocks the protein function 
(Muller 2013) (Fig 1.16). Generation of humanized p53 mutant knock-in (HUPKI) mouse models 
with common p53 mutants R273H, R248W and R175H showed interaction of mutant p53 with 
Mre11 (part of MRN complex) inactivating ATM dependent DNA damage response resulting in 
chromosomal translocation and disrupted G2/M checkpoint. This formed the basis for common 
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gain of function of the mutants by inducing genetic instability (Song 2007, Liu 2010). 5) Mutant 
p53 may introduce alterations in chromatin architecture by making portions of the genome 
accessible or not accessible to transcription factors creating broad changes in gene expression. 
The GOF effect of mutant p53 proteins are likely to be context specific and dependent on type of 
cancer, cell type and cellular microenvironment. The difference in the mutant p53 protein 
conformations (DNA contact vs structural described in an earlier section) could also determine 
the protein-protein interactions and binding affinities (Kim 2018). 
 
 
Figure 1.16. Proposed mechanisms for explaining GOF of mutant p53 proteins. Image 
adapted from (Muller 2013). 
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Cancer is a multistep process 
 
Cancer tumors evolve from a benign state to the malignant form by accumulation of a large 
number of mutations. Some of these mutations provide a selective advantage to the growth of 
tumor while most of them remain neutral. The advantageous mutations could be recurrent 
mutations or infrequent mutations. The molecular interactions between the frequent (clonal) and 
the infrequent (subclonal) mutations shape the molecular heterogeneity in the tumors. A difficult 
task is to recognize these less prevalent mutations from the neutral mutations and an urgent 
need.  
 
Clonal evolution in cancer 
 
In the 1950s Armitage and Doll proposed the multistage model of carcinogenesis and in 1976, 
Peter Nowell proposed the clonal evolution theory for the tumor development. Nowell’s 
hypothesis of tumor evolution described that tumor formation is initiated by a neoplastic change in 
a normal cell that acquires a selective growth advantage over the other normal cells. As time 
lapses genetic instability increases and mutations accumulate, and more cell subpopulations 
arise. Sequential selection by an evolutionary process forms a malignant tumor with high genetic 
diversity rich in genetic structural variations and point mutations (Nowell 1976). These proposals 
formed the basis for understanding the process of tumor initiation and progression to malignancy.  
The proposals have been supported by the study of progression of colorectal cancers that 
undergo histopathological changes from early adenomas to carcinomas with sequential 
acquisition of mutations and clonal expansions and breast cancers that proceed from ductal 
carcinoma in-situ (DCIS) to invasive carcinomas with increasing mutation burden and genetic 
alterations (Vogelstein 1993, Fujji 1996). In simple words a growing cancerous tumor can be 
viewed as entities evolving as per Darwinian rules. The tumors accumulate mutations and the 
selective pressure from the tumor environment select beneficial mutations that drive the 
expansion of subclones, and different subclones together form the tumor mass.  
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The clonal evolution is a dynamic process where the tumor cells constantly acquire new somatic 
mutations or aberrations in a changing microenvironment giving rise to a heterogeneous 
population of cells and a positive selection of phenotypic traits increases the adaptability of the 
tumors and their aggressiveness (Sun 2018). The chromosomal instability of the tumor cells is 
crucial for cancer evolution as it alters the mutation rate resulting in accumulation of adaptive but 
grossly genetically altered clones increasing the tumor cell population diversity.  
Genomics has proved to be a powerful method to quantitatively measure evolving clones in 
tumors in space and time. Next generation sequencing (NGS) techniques have provided a 
detailed map of the genetic landscape of different cancer types and highlight the tumor 
evolutionary patterns. These techniques no longer support the linear evolution model which 
supports that a single clone survives over time and mutations are acquired sequentially. The NGS 
data rather supports the branching evolution of the tumors as continuous mutation accumulation 
produce genetic divergence. The high genetic diversity of the tumors has prompted the existence 
of neutral evolution within tumor cell population that occurs in absence of selection. Thus, 
subclonal composition is preserved over time contributing more to tumor heterogeneity (Turajlic 
2019). The high genomic instability often results in loss, gain, translocation, rearrangement or 
fusion of chromosomes causing rapid adaptive evolution than gradualism called punctuated 
evolution. 
 
The continuous acquisition of genetic mutations in a tumor makes intratumor genetic 
heterogeneity unavoidable in cancer tumors and amplifies genomic differences among single 
cells in a tumor. Thus, each cell remains as a record for the distinct mutational events shaping the 
evolutionary history. Bulk sequencing of cells captures the highly prevalent or recurrent mutations 
but miss the low frequency variants. It also doesn’t provide any information on co-occurrence of 
the mutations. On the other hand, single cell sequencing provides very high resolution and traces 
events in each cell. Single cell sequencing resolves tumor genetic diversity, deep sequencing 
reveals population dynamics and mutation frequencies and multi-region sequencing from a tumor 
infers tumor evolution patterns (Williams 2019).    
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Taking samples from a tumor separated in space or time is the most direct and simplest approach 
to understand tumor evolution. Comparing the genome at different stages of tumor development 
exhibits the temporal sequence of events identifying the early and the late events with the clear 
picture of the mutational landscape. Whole genome and exome single cell sequencing approach 
of single normal and tumor nuclei from an ER+ and TNBC revealed that point mutations evolved 
gradually establishing large clonal diversity. In contrast, single nuclei copy number profiling 
showed that chromosomal rearrangements occurred early during tumor progression and 
remained stable throughout tumor evolution (punctuated evolution). This method of single cell 
sequencing could capture mutations occurring at low frequencies missed in bulk sequencing of 
tumor masses. They also deduced that TNBC tumors have increased mutation rate, 13 times 
more than ER+ tumors, explaining the high heterogeneity observed in the TNBC subtype 
compared to the other breast cancer subtypes (Wang 2014).  
 
Sequencing a set of genes or whole genome sequencing of locally relapsed or metastatic breast 
cancer and the primary tumors indicated that metastatic and relapsed clones disseminated late 
from the primary tumors and acquired new mutations not seen in the primary tumor. These 
metastatic drivers or drivers in the local relapses (mostly point mutants) were separate from the 
early drivers. Mutation in the less frequent cancer genes SWI/SNF, ARID1A, ARID1B were found 
only in the recurrent tumor. Sequencing of the local recurrences and distant metastasis included 
very different pathways important for designing therapies (Yates 2017).   
 
Breast cancer is not a single disease entity but has distinct subtypes with different clinical 
outcomes. The molecular subtypes luminal A, luminal B, HER2+ and basal-like each have 
subtype specific genetic alteration patterns and possibly explain the observed tumor 
heterogeneity (described in section ‘other co-existing somatic mutations in breast cancer’). The 
breast tumor initiation and progression are driven by genetic alterations and evolves into the 
malignant form.  Identification of subtype specific mutation patterns and altered molecular 
pathways is required for the successful development of targeted therapy regimes.  Application of 
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single-cell DNA and RNA sequencing accompanied by bulk exome sequencing traced the 
evolutionary trajectory of clones in TNBC tumors. TNBC tumors extracted from patients 
undergoing neoadjuvant chemotherapy showed that resistant clones pre-existed and were 
selected by chemotherapy and the transcriptional profiles of resistant signatures resulted from 
reprogramming in response to chemotherapy (Kim 2018). 
 
The somatic driver and passenger mutations in cancer 
 
Development of a cancer tumor is an example of an evolutionary process where the growing 
tumors accumulate mutations that promote genetic diversification and selection of clones in the 
tumor microenvironment result in clonal expansion and the final architecture of the tumor 
(Greaves 2012). The tumor evolution occurs through the interaction between the functionally 
advantageous somatic ‘driver’ mutations and the neutral ‘passenger’ mutations. The driver 
mutations are identified as recurrent mutations seen in multiple cancers, present in greater 
proportion of the tumor, mutation rate much higher than the normal cell background mutation rate, 
associated with clonal expansions and involved in pathways leading to oncogenesis particularly 
providing a growth advantage to the tumor. The drivers may bear missense, non-sense, 
frameshift or deletion mutations. The driver mutations could be in the gene coding regions, in 
non-coding regions, miRNAs and in the epigenome. It has been suggested that driver mutations 
provide an average fitness advantage of only 0.4% indicating that the drivers help in the tumor 
initiation stages and requires interaction with other less prevalent somatic mutations that we 
introduced as the co-drivers for tumor maintenance and spread.   
 
A central topic of debate is how many driver mutations are necessary for the onset of 
tumorigenesis. In a recent study, application of mathematical methods for cancer mutation 
network analysis from 7665 tumors and 30 cancer types identified that 27% of the tumors could 
be placed into modules linked to specific driver mutations and the rest belonged to a diffused 
network with lower specificity of driver mutations. The mean number of driver mutations needed 
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for cancer onset was suggested with a range from 1 to 5. The cancers placed in the diffused 
component had late onset and suggested presence of multiple unidentified or interchangeable 
driver mutations (Iranzo 2018). The number of driver mutations increase with increase in the 
mutation burden, but this increase is not linear. The driver genes comprise of 1-4% of all genes, 
97-98% passenger genes and less than 0.5% genes are lost in cancer (Martincorena 2017). The 
passenger mutations do not provide any positive or negative selective growth advantage to the 
tumor cells and remain in the tumor mass by chance during cell division and clonal expansion. 
 
The classical model of cancer progression describe that a handful of recurrently mutated driver 
genes promote tumor development while the passenger mutations do not participate in the 
process. Initiation of cancer therapy often gives rise to resistant tumors that relapse. It is possible 
that the existing passenger mutations under the selective pressure of therapy get converted into 
minor drivers, clonally expand and cause recurrence of tumors. These resistance mutations may 
not provide a strong proliferative advantage but offer advantage of tumor persistence (Stratton 
2009).  
 
In most cancers, few frequent driver mutations co-exist with several low-frequency mutations that 
may have biological significance and weak tumor promoting effects by themselves. The number 
of passenger mutations far exceed the number of driver mutations. Such less frequently mutated 
genes have also been termed as the ‘mini-drivers’ and several of these mutations may equal for a 
major strong driver change in the context of genome instability as observed in the cancerous 
tumors (Castro-Giner 2015). They provide small selective advantage to the tumor but may not be 
essential for cancer growth. These rare ‘candidate drivers’ genes may harbor missense or small 
indel mutations, DNA copy number variations and even gene fusions and be located at non-
coding genomic regions. The infrequently mutated genes cannot be identified using the usual 
method of frequency determination as for the strong frequently mutated driver genes (Pon 2015). 
Computational methods to identify such low-frequency drivers from sequencing data of tumors 
have considered mutation frequency, mutation clustering pattern and mutations at conserved 
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sites that have not been considered before. But an unbiased method to identify the rare genetic 
drivers is functional validation. Methods like CRISPR-Cas9 that can introduce mutations in 
untransformed cells, RNAi and drug screening on established cancer cells are valuable tools to 
assay functional consequences of different mutations (Scholl 2019).  
 
The breast cancer genomic landscape consists of few frequently mutated genes, the ‘mountains’ 
and a large number of genes mutated at a low frequency called the ‘hills’ (Wood 2007). Both the 
hills and the mountains provide fitness to the growing breast tumors (Fig 1.17). The tumor 
suppressor gene TP53 is the most frequently mutated gene in breast cancer and is an 
established driver gene. Accumulation of missense mutant p53 is recognized in early phase of 
breast cancer (in-situ ductal carcinomas) and is maintained through invasive carcinomas and 
lymph node metastases (Davidoff 1991). The PIK3CA gene is the next recurrently mutated gene.  
A key challenge is to distinguish the drivers from the passengers.  We have applied an efficient 
function-based approach to separate the rare drivers from the passenger mutations using an 
 
 
Figure 1.17. The breast cancer genome landscape. TP53 and PIK3CA are recurrently 
mutated in breast cancers and are the recognized driver genes. The tiny purple hills represent 
the less frequently mutated candidate driver genes and the white dots are the neutral 
passenger mutations. Image from (Wood 2007). 
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efficient model to introduce genetic alterations in non-transformed cells and the systematic 
analysis of the phenotype change in the cells. 
 
Cancer tumor heterogeneity 
 
Tumor heterogeneity is driven by genetic alteration due to genome instability and selection of 
advantageous genotype during tumor evolution and poses a threat for targeted therapies. Tumors 
originating from different tissues and cell types or tumors from same tissue and cell type differing 
in genomic aberration, phenotype and drug sensitivity comprise the inter-tumor heterogeneity. 
Within a tumor, distinct cell subpopulations arise by genetic variations and selection of cells with a 
phenotype advantage in the given context resulting in intra-tumor heterogeneity (Fig 1.18). These 
subpopulations may intermingle or may remain separated as clones in different regions of the 
tumor (Burrell 2013). 
 
Figure 1.18. Inter and intra-tumor heterogeneity. Tumor heterogeneity result from 
genetic and non-genetic influences and complicate therapeutic decisions. Image 
taken from (Marusyk 2012). 
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Before the widespread use of next generation sequencing (NGS) methods, first proof of presence 
of multiple subpopulation of cells with differing genotypes in a tumor came from karyotyping and 
fluorescent in-situ hybridization (FISH) that highlighted patterns of chromosomal rearrangement 
and copy number aberrations (Fisher 2013). Deep exome sequencing, whole genome, multi-
region and single cell sequencing have proved to be powerful tools to detect intra-tumor 
heterogeneity and added overflowing information about point mutations and small indels. 
Application of whole genome and targeted sequencing of breast cancer samples from multiple 
regions in tumors elucidated the subclonal diversification of the tumors. The commonly mutated 
breast cancer genes (clonal or frequent mutations) TP53, PIK3CA, PTEN, BRCA and MYC 
appeared along with subclonal mutations (mutations present in small fraction of cells in the tumor, 
co-drivers) with implication in resistance to chemotherapy (amplification of CDK6, FGFR2, 
deletion in RUNX1) and acquisition of invasive potential (Yates 2015).  
 
The phenotypic heterogeneity of a tumor is determined by increased genomic instability of the 
cancer cells that leads to higher mutation rates and acquisition of diverse mutations and 
genotypes. Apart from genetic changes epigenetic aberrations (DNA methylations, chromatin 
remodeling, post-translational modification of histones) and heterogeneous tumor 
microenvironment also affect the clonal composition of the tumors. All these factors give rise to 
tumors with distinct clonal architecture which is spatially and temporally heterogeneous (Marusyk 
2012). The heterogeneous tumors act like complex systems where the minor subpopulations 
affect tumor growth and maintain tumor heterogeneity along with the dominant clones. It is not 
easy to filter out passengers from the co-drivers but genome sequencing with functional screens 
in physiologically relevant background may identify clinically important minor subclonal mutations. 
 
Tumor heterogeneity is a major source of therapeutic resistance and is a marker for poor clinical 
outcome. The tumor evolution following the branching evolution and the clonal composition of the 
tumors changes over time during tumor progression adding to the layer of complexities. Targeted 
therapies tend to exploit the dependence of tumors on clonally dominant driver mutations. But 
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such strategies help only a fraction of patients and those who benefit, the outcome lasts for a 
limited duration and is often accompanied by relapse and such clinical outcomes could be 
explained by the presence of minor subclones or co-drivers resulting in tumor heterogeneity.  
Therapeutic decisions based on determining the dominant clone in a tumor would be ineffective if 
clinically and biologically important co-drivers are not accounted for as such subclones can select 
for drug resistance and relapse. The intra-tumor heterogeneity provides plasticity and diversity to 
the tumor to adapt under varying microenvironmental pressure. Hence, there is a need to explore 
the relevant minor or subclonal drivers, the co-drivers, and their implication in therapeutic 
outcome. The heterogeneous or polyclonal tumors can be tackled by targeting multiple pathways 
simultaneously or sequentially. Targeting trunk mutations first and then blocking the emerging 
subclones could prove to be an ideal treatment combination. However, combinatorial targeted 
therapeutic strategies are associated with high toxicity and costs and often limit the use of such 
strategies (McGranahan 2015). 
 
Breast cancer evolves from a transformed normal cell via hyperplasia, premalignant tumor, in-situ 
carcinoma to invasive carcinoma by accumulation of various genetic alterations (Beckmann 
1997). Consequentially breast cancer displays heterogeneity with inter and intra-tumor diversity 
that influences breast cancer progression and therapy resistance (Polyak 2011). Gene 
expression analysis of breast tumors have identified the major subtypes- luminal, HER2 
overexpressing and basal-like. Each subtype has different genetic constitution, risk factor, 
response to treatment, disease progression and pattern of metastasis. Luminal tumors are ER+ 
and PR+ and are treated with hormonal therapies. HER2 amplified tumors respond well to anti-
HER2 antibody trastuzumab. But there is no targeted therapy for basal-like subtype due to lack of 
the targetable receptors ER, PR and HER2 (triple negative). Systemic chemotherapy is the only 
available option and unfortunately, only 20% of tumors respond to the standard chemotherapy. 
Triple negative breast cancer (TNBC) is more complex than was thought before where gene 
expression analysis identified six more of its subtypes, each with unique molecular markers. The 
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six subtypes include basal-like (BL1 and BL2), immunomodulatory, mesenchymal (M), 
mesenchymal stem-like (MSL) and luminal androgen receptor (LAR) subtype (Mayer 2014).  
 
Owing to this heterogeneity, no single targeted therapy has been approved for treatment of 
TNBC. Single targeted therapies including platinum agents, PARP inhibitors, PI3K and MEK 
inhibitors did not bear favorable outcomes but combination of two or more agents would make a 
more rational approach to treat TNBC. The TNBC tumors contain more genetic mutations 
compared to luminal and HER2+ subtype due to high mutation rate and identification of the co-
drivers and designing targeted therapies against them could be effective in treating the TNBC 
patients.      
 
 
Hypothesis and approach 
 
Unlike the established tumor suppressor genes RB1 and APC, 80% of mutations in TP53 are 
missense mutations instead of indels, non-sense and frameshift mutations. These missense 
mutations in p53 are associated with heterogeneous phenotypes because of the gain-of-function 
(GOF) or neo-morphic activities with the recognition of missense mutant p53 as oncogenic 
proteins. For such an atypical tumor suppressor, some open questions remain that need to be 
answered. 
1. How are these p53 mutant protein variants functionally important in the context of breast 
cancer? Are the proteins functionally equal?  
2. How are these diverse mutant variants contributing to the heterogeneity of malignant 
breast tumors like TNBC? Do they have any other accomplices?   
The dissertation provides an answer to these questions that would help in achieving a better 
understanding of how the missense mutant p53 proteins drive breast tumor progression, tumor 
heterogeneity, how breast cancers become metastatic and may build a scope for developing 
targeted therapies to counteract the tumor progression. 
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We hypothesized that the TNBC tumor heterogeneity is attributed to 1) phenotypic or functional 
difference across the different TP53 missense mutations themselves as well as 2) and the 
functional crosstalk with the distinct co-driver mutations and pathways unique to each TP53 
mutant. 
 
We addressed these questions by 1) detailed phenotypic and molecular profiling of a panel of 
clinically important TP53 mutations found in breast cancer and 2) adopted a functional genomics 
approach to identify the co-driver candidates that promoted cell invasion. In the following chapters 
we describe all our approaches and the results obtained in detail. 
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CHAPTER 2 
DISTINCT NEOMORPHIC MOLECULAR AND CELLULAR FUNCTIONS OF DIFFERENT 
MISSENSE MUTANT P53  
 
 
Introduction 
 
The tumor suppressor TP53 is the most frequently mutated gene in human cancers, and, in 
different cancer types, mutations in TP53 occur at different stages of malignant transformation 
and contribute to tumor initiation, progression or metastatic spread (Rivlin 2011). Unlike other 
classical tumor suppressor genes like RB, APC and BRCA1 that are typically deleted or truncated 
in cancer, the majority of TP53 mutations occur as missense mutations, concentrated within the 
exons 4 to 9 that encode the DNA binding domain of the transcription factor. p53 functions as a 
homo-tetramer and this provides the mutant p53 protein with the privilege of dominant negative 
action over the wildtype allele when the both alleles co-exist in a heterozygous condition. 
However, loss of heterozygosity (LOH) follows TP53 mutations during cancer progression where 
the remaining allele is deleted or mutated. LOH is commonly seen in tumor suppressors. 
Following LOH, mutant p53 gains additional function, gain-of-function (GOF), oncogene like 
activities than simply loss of tumor suppressor function.  
 
The timing of p53 mutation occurrence during tumorigenesis is variable for different cancer types 
and suggests the function of p53 at different stages of cancer development. p53 mutations 
appear at a later stage in colorectal carcinomas (CRCs), prostate and bladder cancer. On the 
other hand, mutant p53 is found in human pre-malignant breast lesion, ductal carcinoma in-situ 
(DCIS) and in Barret esophagus patients that predisposes them to esophageal adenocarcinoma.  
 
Though TP53 mutations are most frequent genetic aberrations found in different cancer types, 
there is limited knowledge about the effect of the different p53 mutants on cancer-related 
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phenotypes and the underlying mechanisms. Since more than 75% of the mutations in TP53 are 
the missense mutations that cluster in the DNA binding domain of this transcription factor, a 
comprehensive study on whether and how these different missense mutations have 
heterogeneous influences on cellular phenotypes and molecular function of p53 proteins is 
needed. It can shed light on understanding the phenotypic heterogeneity observed in cancer 
tumors and finding personalized therapeutic options particularly for TNBC patients as nearly 88% 
of these tumors harbor mutation in TP53. Therefore, as the first step, we aimed to generate a 
panel of cell lines that mimic triple-negative tumors with a wide range of different p53 missense 
mutations and investigate their molecular and cellular characteristics. 
 
 
Aim 
 
Phenotypic characterization of ten most prevalent p53 missense mutant proteins found in breast 
cancer tumors expressed in non-transformed mammary epithelial cells and molecular profiling to 
elucidate their phenotypic heterogeneity. 
 
 
Approach 
 
Model system of normal breast epithelial cells to study the effect of mutant p53 
 
MCF 10 breast epithelial cells were derived from a pre-menopausal woman with fibrocystic 
disease that spontaneously immortalized into MCF 10A cells capable of attachment and growth in 
DMEM-F12 media (Tait 1990). The MCF 10A cells are the most widely used non-transformed 
mammary epithelial cell line, which are ERα negative and behave mostly like basal cells though 
they carry luminal markers. The cell line carries wild type TP53, while the p16 and p14 genes are 
absent. In 3D culture, they form an acinus like spheroid with a hollow lumen and polarized single 
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layer of cells with basement membrane on the outside. Therefore, it has been a useful tool to 
study mammary gland development, effect of microenvironment and genetic alterations on 
mammary cell transformation.  
 
TP53 missense mutations are the most frequent in the basal-like or the triple-negative breast 
cancer subtype. Hence, for studying the phenotypic effect of these mutations, the receptor 
negative (i.e., no ERα, no PR and no HER2 amplification) MCF 10A cell-line was the natural 
choice as opposed to the MCF 12A cells, which are ERα positive non-tumorigenic mammary 
epithelial cells with sensitivity to estrogen (Marchese 2012). In another breast epithelial cell line of 
the immortalized Human Mammary Epithelial Cells (HMECs) with human (h) TERT (catalytic 
subunit of telomerase) resulted in activation and overexpression of c-myc in the cells (Wang 
2000). To study the functional effect of the different missense mutant p53 occurring in breast 
cancer, we over-expressed the mutant p53 proteins in the normal-like MCF 10A and the HMEC-
hTERT cells. However, the missense mutant p53 over-expressing HMEC-hTERT cells provided 
very inconsistent results in the phenotype assays while the p53 mutant-expressing MCF 10A cells 
displayed consistent phenotypes. Therefore, we chose MCF 10A as the cell-based model system 
for this study. 
 
The phenotype assays 
 
The transformed cancer cells acquire certain molecular and biochemical capabilities that are 
shared by most cancer cells, and these new traits dictate malignant growth. The cellular traits 
include sustaining proliferative signaling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis and activation of cell invasion and 
metastasis (Hanahan 2011). These acquired capabilities comprise the ‘hallmarks of cancer’, and 
mutation in TP53 directly affects cell viability and proliferation potential, apoptosis (programmed 
cell death) resistance, cell migration and invasion among the hallmarks. Therefore, we chose to 
characterize 1) cell survival and proliferation in absence of growth factors 2) resistance to 
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apoptosis and anoikis 3) cell migration and invasion and 4) 3D morphology of mammospheres. 
Furthermore, well established assays were available for measuring these phenotypes, and the 
assays were easy to adapt to a high-throughput format. 
 
Molecular profiling of the p53 mutant MCF 10A cell lines 
 
The p53 is a transcription factor that binds to DNA elements with specific sequence motifs and 
modulate the transcription of target genes. The missense mutations on the DNA binding domain 
affect the DNA binding capacity and preference of p53. Therefore, we included the ChIP seq and 
RNA seq studies in addition to the phenotype assays to understand the molecular mechanisms 
giving rise to the phenotypic differences. ChIP seq would highlight the DNA binding targets of the 
p53 mutants that could be correlated with up and down regulation of the corresponding genes 
measured by RNA seq. Lastly, integrated bioinformatics analysis can correlate the changes in 
overall gene expression profiles with the phenotypes induced by different p53 mutants and infer 
the dysregulated pathways underlying the heterogeneous phenotypes.    
 
 
 
Method 
 
Cell culture 
 
MCF 10A cells were cultured at 37˚C in a 5% CO2 humidified incubator. DMEM/F12 media 
(ThermoFisher #11320-082) was supplemented with 5% Horse Serum (ThermoFisher #16050-
122), hEGF (10ng/ml, ThermoFisher #PHG0311), hydrocortisone (0.5µg/ml, Sigma #H0888), 
cholera toxin (100ng/ml, Sigma #C8052), and Insulin (10µg/ml, Sigma #I9278). Cells were 
routinely passaged with trypsin (0.25% in HBSS with 0.2g/ml EDTA, GE Healthcare 
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#SH30042.01) at 80-90% confluence. The cells were checked for mycoplasma infection at 
regular intervals as it is a common cell culture contaminant. 
 
Production of MCF 10A clones 
 
The MCF 10A cells over-expressing p53 mutant proteins were made using vectors procured from 
DNASU (The center for personalized diagnostics at the Biodesign Institute, ASU). The TP53 
missense mutant genes from these vectors were cloned into the pLenti4/V5-DEST Gateway 
vector (ThermoFisher Scientific #V49810). Plasmids were expanded in 500ml E. coli cultures and 
then purified using Machery-Nagel DNA Maxi-Preps. The stable cell-lines were then prepared 
through lentiviral transduction. 
 
Western blot 
 
Cells were grown to 80% confluency in six well plates (Greiner #5665-7160) and lysed using 
RIPA lysis buffer that contains 50mM Tris, 150mM NaCl, 1% IGEPAL CA-630 (Sigma #I9996), 
0.1% sodium azide (Sigma #S8032), cOmplete mini protease inhibitor (Sigma #04693124001), 
200 µM sodium fluoride (Sigma #S6776) and 200 µM of sodium orthovanadate (Sigma #450243). 
Cells were scraped, incubated on ice for 10 minutes and then centrifuged at 10,000 rpm. Lysates 
were quantified using the Pierce BCA kit (#23225). Samples were run on 4-20% TGX gels from 
BioRad (#567-1093) and blotted onto 0.45µm PVDF membrane (GE Healthcare #10600023) 
using the BioRad semi-dry transfer system. Primary antibody for p53 protein from Sigma 
(#P6874) diluted to 1:200 and secondary HRP-linked anti-mouse antibody (Cell Signaling 
Technologies #7076) diluted to 1:3000 were used to visualize p53 bands. The p53 mutant 
proteins were seen using the V5 tag Ab (CST, Catalogue no. 13202S). The western blots were 
imaged on the Fluorchem FC2 from AlphaInnotech. 
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Assay for cell viability 
 
Cells were parallelly plated in clear CellBIND 96-well plates (Corning #3300) for pictures and 
opaque white plates for chemiluminescent analysis (Perkin-Elmer #6005680) and allowed to grow 
for 24 hours in normal growth media before treatment. The following day, media was replaced 
with the restricted media with or without growth factors serum and EGF (+S+E, -S-E, +S-E and -
S+E). Human EGF (10 ng/ml, ThermoFisher #PHG0311) and horse serum (5% v/v, 
ThermoFisher #16050-122) were excluded individually or together from normal growth media and 
added to the cells. Cells were then allowed to grow for 72 hours and cell viability was analyzed by 
Cell Titer Glo (Promega # PAG7571) on the Envision plate reader (Perkin-Elmer). Results were 
calculated with respect to untreated cells, then log2 transformed. 
 
Apoptosis assay 
 
MCF 10A p53 mutant cells (4000 cells/well) were plated into both 96-well CellBIND clear plates 
(Corning #3300) for observation and Perkin-Elmer white opaque plates (#6005680). On the 
following day, cells were treated with 1µM Doxorubicin (Calbiochem #324380) using the Biomek 
NX liquid handler (Beckman Coulter) and incubated for 24 hours.  For evaluating apoptosis 
induction, cells were treated with Caspase-Glo 3/7 (Promega #G8091) per supplier protocol and 
read in the Envision plate reader (Perkin-Elmer). Results were reported as log2 fold-change 
relative to the MCF 10A TP53 WT-OE cells. 
 
Cell migration and invasion assay 
 
MCF 10A cell-lines (70-80% confluency) were trypsinized and counted using trypan blue dye. The 
invasion chambers were taken out of -20˚C, and 200 µl of serum free media was added to the 
inserts, incubated at 37˚C for at least 1hr to warm the Matrigel coat. 2.5 x 105 cells (in 200ul) in 
serum free media were seeded in the upper well of the Matrigel coated (Corning cat no. 354480 
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for invasion assay) or non-coated (Corning cat no. 354569, migration assay) cell culture insert. 
The media with serum (750ul) as the chemoattractant was placed in the lower well. The plates 
were incubated for 22 hrs. The migratory or invasive cells were first fixed with 4% 
paraformaldehyde for 2 min at RT, permeabilized by adding 500ul of 100% cold methanol (2 min 
at RT) to each well and stained with 0.5% crystal violet. A media-moistened cotton swab was 
used to remove any cells that did not migrate or invade through the membrane. Cells were 
imaged under a microscope at 4X and 10X magnification. Cells were counted in CellProfiler from 
different areas of the membrane to get a more accurate representation of cell count.   
 
Anoikis assay 
 
MCF 10A p53 mutant and control cells lines were plated into 96-well round bottom (low binding) 
plates at 150 cells/well and allowed to grow in regular growth media for 7 days. After 7 days, 
Vybrant Violet Dye (ThermoFisher Scientific #V35003) was added to the cell aggregates at a final 
concentration of 0.5µM and incubated at 37˚C for a minimum of 30 min. Then Ethidium 
Homodimer (Biotium #40014) was added to the wells at a final concentration of 0.3µM directly 
before analysis. The MetaXpress High Content Image Acquisition platform (Molecular Devices) 
was used to capture images from all the wells of the plate. A total of eight wells for each sample 
were captured and only the images of the entire cell mass was used for image analysis. Vybrant 
Violet and the Ethidium homodimer were captured in the Cy3 and Cy5 channels respectively.  
ImageXpress image analysis software (Molecular Devices) was used to identify and count the 
cells which were stained with either Vybrant Violet (blue) or Ethidium Homodimer (red). Data was 
reported as a ratio of live cells to dead cells (Cy3:Cy5) and log2 transformed. 
 
3D Culture and Analysis 
 
Before adding cells to wells, 96-well black µClear plates were pre-coated with 100µl of Matrigel 
(Corning #35428) and allowed to gel for 30 min. Cells were added on top of the Matrigel and 
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allowed to grow for nine days, with two media changes in the interim. Cells were then fixed with 
4% paraformaldehyde (Alfa-Aeser # AA43368-9M) for 15 minutes and were washed with 100mM 
Glycine-PBS solution to neutralize the paraformaldehyde and then permeabilized with 0.5% 
Triton X-100 (Sigma-Aldrich #X100) for 15 min at 37˚C. Permeabilized cells were blocked with 
10% goat serum (ThermoFisher Scientific #PCN5000) and 20ug/ml goat α-mouse IgG (Jackson 
ImmunoResearch #115-006-006) for at least 1hr. The spheroids were washed with PBS and 
plates stored at 4˚C until use. Staining of cells were done following the procedure previously 
described (Debnath 2003). Analysis was performed by employing custom Cell Profiler pipelines. 
For identification of spheroids, the β-Catenin staining was used as a mask. Intensity 
measurements were then based on the average pixel intensity over the object mask for each 
target protein. To analyze laminin localization, relative bins (concentric rings) were created 
around the center of each object. The average pixel intensity per ring was recorded and graphed, 
giving intensity measurements relative to the center of each spheroid. For nuclear localization 
(clearing of lumens) the same technique of using bins was employed, analyzing nuclear intensity 
per bin. 
 
RNA seq  
 
Total RNA extracted from the cells (Qiagen catalogue no. 74134) were used to prepare cDNA 
using Nugen’s Ovation RNA-Seq System via single primer isothermal amplification (Catalogue # 
7102-A01) automated on the Apollo 324 liquid handler from Wafergen. cDNA was sheared to 
approximately 300 bp fragments using the Covaris M220 ultrasonicator. Libraries were generated 
using Kapa Biosystem’s library preparation kit (KK8201). Fragments were end-repaired and A-
tailed, individual indexes and adapters (Bioo, catalogue #520999) were ligated on each separate 
sample. The adapter ligated molecules were cleaned using AMPure beads (Agencourt 
Bioscience/Beckman Coulter, A63883), and amplified with Kapa’s HIFI enzyme.  The library was 
then analyzed on an Agilent Bioanalyzer, and quantified by qPCR (KAPA Library Quantification 
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Kit, KK4835) before multiplex pooling and sequencing a 2x75 PE flow cell on the NextSeq500 
platform (Illumina) at the ASU’s CLAS Genomics Core facility. 
 
Raw sequencing read data quality were analyzed using FastQC (v0.10.1). STAR (V020201) 
(Dobin 2013) was used to align reads to the human genome (GRCh38.p92/hg38) to counts. 
Duplication rate was obtained, and duplicated reads were marked by PICARD (PICARD 2.18.3). 
Duplication plots were generated using R package dupRadar (Sayols 2016). As high duplication 
rates were observed (85.81% - 97.24%), gene counts after removal of duplicated reads were 
used as a reference to check whether the expression levels were overestimated due to PCR 
duplication. Next, because mitochondrial RNA occupied a large but variable portion of RNA pool 
in every sample (40 to 80% of all sequence reads), to avoid the bias in calculating the total read-
normalized transcript abundance, mitochondrial RNA data was dropped. Finally, sequencing 
counts were normalized to TPM (transcripts per million reads).  
 
To validate that the duplicated reads did not systematically impact the quantification of transcript 
levels, we repeated RNA-Seq on a subset of Y234C, Y220C, R273C, R273H and WT-OE cell 
lines and compare the overall expression profiles. Despite the much lower duplication rates 
(<60%) in the second RNA Seq, the Pearson’s correlation coefficient of RNA expression levels 
between the runs ranged from 0.7 to 0.82.   
  
ChIP seq  
 
All the MCF 10A cell lines were fixed with 1% formaldehyde in PBS and incubated for 10 min at 
RT in the petri-dish. Formaldehyde was quenched with glycine (125mM final conc.) for 5 min at 
RT. Cells were rinsed with ice cold PBS twice and scraped with 2ml of cold PBS with protease 
inhibitor (Sigma Aldrich Cat no. 04693124001). Cells were washed two more times with cold PBS 
with protease inhibitor and pellets from 20 million cells were snap frozen and stored at -80oC. 1ml 
of ChIP lysis buffer (1% SDS,10mM EDTA, 50mM Tris-HCl pH8.1) with protease inhibitors was 
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added and the cells were sonicated in the Covaris M220 ultrasonicator for 8 min. The time and 
setting for sonication would vary with the cell line and concentration. The lysates were spun at 
maximum speed at 4oC for 10 min and the DNA concentration was checked. The supernatant 
was transferred into fresh tube. 25-50ul of the lysate was incubated at 65oC overnight with 0.1M 
NaCl and run on a 2% agarose gel to check the sonication efficiency. You should get an average 
fragmentation of ~500 bp. For IP, 30ul of beads (Thermo Catalogue no. 11203D) were first 
washed with 1ml of cold BSA (5mg/ml) in PBS at RT (3 times). Then V5 antibody (CST Catalogue 
no. 13202S) was added to the beads in 1ml of PBS+ BSA. The beads with the antibody were 
incubated for 4 to 6 hrs at 4oC. The IP was performed on 50ug of total DNA and the samples 
were diluted accordingly in the dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 
mM Tris-HCl pH 8.0). The diluted chromatin was precleared with 15ul of washed beads for 1hr at 
4oC. 5% of this precleared lysate was kept as input control. PBS/BSA was aspirated from the 
antibody coated beads and precleared lysate was added to incubate O/N at 4oC on a rotating 
wheel. Next day beads were collected using the magnetic concentrator and washed 6 times with 
ChIP RIPA buffer (50mM HEPES, 1mM EDTA, 0.7% Na Deoxycholate, 1% NP-40, 0.5M LiCl pH 
7.6) at RT on a rotating platform for 10 min between every wash. Then washed twice with 1X TE 
(pH7.6) at RT. 100 ul of Elution buffer (1% SDS, 0.1M NaHCO3, 0.1M NaCl) was added to the 
beads and input samples (make up volume to 100ul). The beads were vortexed in this solution 
every few minutes for 30 minutes in total at RT and incubated at 65oC O/N for 12-14 hrs. Next 
day 1ul of proteinase K (10mg/ml) was added and incubated at 42oC for 2 hrs. The IP DNA was 
purified with QIAquick PCR purification kit. 
 
The sequencing read counts varied from 4.3 X 107 to 5.9 X 107. Quality of the reads were 
analyzed using FastQC (v0.10.1). Paired-ended reads were mapped to the reference human 
genome (GRCh38.p92/hg38) end to end using Bowtie2 (Bowtie2 2.1.0) (Langmead 2012). Non-
primary alignment, unmapped reads were removed by Samtools (Samtools v1.7) (Li 2009). 
Duplication rates were calculated by PICARD (PICARD 2.18.3) (duplication rate ranges from 18% 
to 88%). MACS2 (macs2 2.1.2.20181017) was used for peak calling using BAMPE mode under 
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the q-value cutoff 0.05 (Zhang 2008). Peaks were annotated under Ensembl genome annotation 
(GRCh38.p92/hg38) using Homer toolkit (Homer v4.9.1) (Heinz 2010), which was also been 
utilized for motif finding (Heinz 2010). Regions located between -100 and 2500 bp upstream of 
the nearest TSS were defined as the promoter region. Known and de-novo motifs were called by 
Homer toolkit. De-novo motifs comparison was done by Tomtom in MEME Suite (MEME Suite 
5.0.1) (Timothy 2009). 
 
Pathway analysis 
 
Partial Least Squares Regression models were built for each of the KEGG pathways under each 
phenotype using scikit-learn, a machine learning Python library (Pedregosawe 2011). Gene 
expression values of the cell lines were used as training vectors and the phenotype scores of the 
cell lines under each phenotype were used as targeting vectors. Leave one out cross validation 
was implied to avoid overfit. Mean value for R2 and mean squared of error (MSE) were calculated 
in the test set for evaluating the performance of the models and ranking the pathways under a 
particular phenotype. Visualized pathway maps were generated by Cytoscape (Shannon 2003) 
and module KEGGscape (Nishida 2014). 
 
GSEA 
 
Gene Set Enrichment Analysis (GSEA) was carried out using gseapy, a Python library 
(Subramanian 2005). The gene sets were obtained from ChIP Seq data using lists of gene that 
were targeted at promoter region. The ‘jump’ score of each gene was calculated using RNA 
expression score (TPM) minus the mean TPM of this gene in all the cell lines. Then genes were 
divided into two groups by the cut-off of 0, and GSEA was carried out on two groups in each cell 
line separately. 
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Flow cytometry 
 
MCF 10A p53 mutant cells were grown in 6-well plates (Greiner #5665-7160) for 24 hours and 
then treated with 1µM Doxorubicin (VWR #80058-048) for 24 hours. Staurosporine (Cell 
Signaling #9953) at 0.1µM was the positive control for the experiments. Cells were washed in 
PBS and resuspended in annexin binding (ThermoFisher # V13246) buffer and counted. Cells 
were aliquoted to 1,000,000 cells/ml in 100µl for annexin and PI binding. After transfer to 1.5ml 
microcentrifuge tubes, cells were reconstituted in 100 µl annexin binding buffer and then 5ul of 
annexin (ThermoFisher #A13199) was added and incubated at 4˚C for 15 minutes. After the 
incubation, 400µl of annexin binding buffer was added followed by propidium iodide (PI; 
ThermoFisher #P3566) to a final concentration of 1 µg/ml. The samples were kept on ice while 
analyzing on the Attune flow cytometer from Life Technologies. Compensation controls were run 
to apply compensation settings, as well as unstained controls to set FSC and SSC parameters. 
Gates were set on the negative controls. 
 
Cell migration and invasion in 96-well plates 
 
Matrigel (BD Matrigel 354230, stored at -20oC) was thawed while keeping in ice in a 4oC 
refrigerator overnight. It was diluted to 3mg/ml in ice-cold serum free media. The collagen coated 
96-well plate (Platypus tech Cat no. CMACC5.101) was removed from 4oC and allowed to 
equilibrate to RT. The underside of the plate was checked to ensure that the seeding stoppers 
were firmly sealed against the bottom of the plate. 100uL of suspended cells were added into 
each well (control & test wells) without disturbing the seeding stopper, lightly tapping the plate to 
evenly distribute the cells in each well. The seeded plate with stoppers was incubated at 37oC & 
5% CO2 for 6-8 hours to permit cell attachment. Using the stopper tool seeding stoppers were 
removed. Reference or the control wells remained with the stoppers till the end of the assay. 
Media was removed with a pipette and the well gently washed with 100uL of serum free media to 
remove any unattached cells. 50uL of the Matrigel overlay was added to each well. The plate was 
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incubated at 37oC and 5% CO2 for 1hr to permit the Matrigel polymerization. 100uL of serum 
media was a put on top of the 3D matrix. The plate was incubated at 37oC for 18-20 hours to 
permit cell invasion. For end-point analysis cell seeding stoppers were removed from the 
reference/control wells, Matrigel overlay was added and allowed to form the gel. The cells were 
stained with 5uM cell tracker green (100ul/ well, 45 min, 37oC) and 0.5uM vybrant violet dye 
(100ul/ well, 30 min, 37oC). Wells were washed with 1X PBS and fixed using 3.7% 
paraformaldehyde in 1X PBS for 15 min at RT. Images were taken with ImageXpress at different 
planes on the Z axis. 
 
Immunofluorescence 
 
This protocol was used for staining cells in a 96-well (VWR #82050-748) format and a shaker was 
used during antibody incubations to obtain uniform staining. The cells were washed with 1XPBS 
(100ul, 2 times) and fixed with 75µl of 4% paraformaldehyde (VWR #AA43368-9M) per well (15 
min at RT). Cells were washed with PBS and 75µl of Blocking Buffer (5% Goat Serum Life 
Technologies #PCN5000 with 0.32% Triton X-100 Sigma #T8787 in 1X PBS) added per well (1hr 
at RT). After PBS wash, 50ul/well of primary antibody (at recommended dilutions in Ab protocol) 
in the Antibody Buffer (1% BSA and 0.3% Triton X-100 in 1X PBS) was added  and incubated at 
RT, shaking gently at 350 RPM in an orbital shaker for 1-2 hours for same day processing or O/N 
at 4°C while shaking. Cells were washed with PBS and 50ul/well of secondary antibody in 
Antibody Buffer (at recommended dilutions in Ab protocol) was added with incubation at RT, 
shaking at 350 RPM in an orbital shaker for 1-2 hours. After final wash in 1x PBS, plates were 
wrapped in aluminum foil and stored at 4°C with 100µl 0.05% Sodium Azide (NaN3 Sigma 
#S8032) in PBS. 
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Results 
 
Generation of MCF 10A cell lines expressing 10 different clinically important mutant p53 
proteins 
 
More than 100 different missense mutations occur across the TP53 gene, and most of them 
concentrate within the DBD of the protein, thus influencing the DNA binding of p53. Although a 
limited amount of study on a few p53 missense mutants showed potential neo-morphic gain-of-
functions of the individual mutants (Freed-Pastor 2012), it was still not entirely clear if the different 
missense mutant p53 proteins are functionally equal or unique. Therefore, to address the 
question, we designed a cell line-based study to characterize the influence of a broad spectrum of 
TP53 missense mutations on molecular profiles and cellular phenotypes. To focus our study on 
clinically relevant mutations, we first selected the ten most prevalent TP53 missense mutations 
found in breast cancer patients by using the TCGA data (Fig 2.1B). Among the ten mutations, 
four mutations (R248Q, R248W, R273C, and R273H) are at the residues in direct contact with 
DNA (referred as “DNA contact mutations”), whereas the other six mutations (G245S, H179R, 
R175H, Y163C, Y220C, and Y234C) occur in other areas of the DNA binding domain thus 
affecting the structure of the domain (“Structural mutants”). Thus, in addition to the differences 
among the individual mutations, it was of interest to see whether the two types of mutations affect 
distinctively the cellular phenotypes, DNA binding properties, and overall gene expression 
profiles. As described in the Introduction, we utilized the normal mammary epithelial cell line MCF 
10A lacking ER and PR expression as a TNBC-like model system to generate cell lines stably 
expressing mutant p53 proteins. It should be noted that the cell lines express the endogenous 
wildtype p53 protein, modeling the heterozygous TP53 mutations. 
 
The missense mutant TP53 genes were cloned in the pLenti4/V5-DEST Gateway vector, 
packaged into lentiviruses, transduced to MCF 10A cells, and selected for the over-expression of 
the p53 mutant proteins. Western blots showed consistently higher p53 mutant protein levels with 
  75 
respect to MCF 10A cells with endogenous wildtype p53 protein. However, more importantly, the 
mutant protein levels were comparable to those of a panel of breast cancer cells harboring 
missense mutations in endgenous TP53 gene such as HCC70 (TP53R248Q),  MDA-MB-231 
(TP53R280K), MDA-MB-468 (TP53R273H), AU565 (TP53R175H), and SK-BR-3 (TP53 R175H) (Fig 2.2). 
 
 
 
 
Figure 2.1. The TCGA data on TP53 mutations in breast cancer. A. The frequency of 
TP53 mutations is the highest in the basal-like subtype. The mutation type includes missense 
and truncation mutations. B. The highly frequent missense mutations concentrate at the DNA 
binding domain (DBD) of transcription factor p53 and influence DNA binding. C. The amino 
acid positions of the DNA contact and the structural mutants of p53. Image adapted from 
(Joerger 2016). 
Structural DNA contact
G245S R248Q
H179R R248W
R175H R273C
Y163C R273H
Y220C
Y234C
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Characterization of cancer hallmark phenotypes of mutant p53 protein expressing MCF 
10A cells 
 
We developed high-throughput functional assays to investigate how the different missense 
mutant p53 proteins affect the cell phenotypes. These quantitative assays assessed several 
hallmarks of cancer including 1) cell viability in the complete absence of essential growth factors 
2) resistance to apoptosis 3) cell migration and invasion 4) anoikis resistance and 5) changes in 
the 3D acinar morphology and cell polarity. For an unbiased analysis of the phenotypic outcomes 
and to have a uniform genetic background for comparison among the mutants, we also 
developed MCF 10A cell line over-expressing the wildtype p53 protein (MCF 10A p53OE or WTOE).  
All the phenotype data was normalized with respect to the phenotype observed in MCF 10A 
p53OE cells. MCF 10A p53KD (endogenous p53 knocked down with shRNA) cells were also 
included in the phenotypic assays to underscore the relevance of dominant negative activity of 
the missense mutant p53 proteins over the endogenous wildtype p53. All the phenotypes were 
scored by the log2-transformed fold changes over the wildtype p53 values for cross-comparisons 
and for plotting. 
 
 
Figure 2.2. Western blot of MCF 10A p53 mutant cell lines confirming the stable 
overexpression of mutant p53 proteins. The total p53 protein level in the cells is 
comparable to the other breast cancer cell lines harboring a mutation in endogenous TP53 
(HCC70, MDA-MB 231, MDA-MB 468, AU565 and SKBR3). The mutant p53 proteins 
expressed in MCF 10A cells have a C-term V5 tag.  Band for V5 tag is seen for all the 
mutants and for wildtype p53 over-expressing (OE) cells. 
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Survival and proliferation of cells in absence of growth factors 
 
A fundamental characteristic of cancer cells is the ability to survive and sustain high tumor 
proliferation rate even in the absence of growth factors (Hanahan 2011). To find out whether 
missense p53 mutations by themselves are sufficient to induce self-sustained proliferation without 
presence of external growth factors and whether different p53 mutants affect the process at 
different degree, we tested the proliferation and viability of the ten MCF 10A mutant p53 
expressing cells in the presence or absence of growth factors. 
 
The MCF 10A cells expressing mutant p53 proteins were kept in the complete DMEM-F12 media 
supplemented with EGF (epidermal growth factor), insulin, hydrocortisone, cholera toxin and 5% 
horse serum, and switched to the minimal DMEM-F12 media with or without growth factors (i.e., 
serum and EGF). We evaluated the viability of all the ten mutant p53 cells under different growth 
conditions, with or without serum and EGF (-Serum+EGF, +Serum-EGF, and –Serum-EGF). After 
72 hours, the CellTiter-glo assay was used to determine the number of viable cells in culture after 
incubation in the different growth conditions. The luminescent signal recorded was proportional to 
the amount of ATP present that directly corresponded to the number of live cells.  
 
In general, the DNA contact mutants R248Q, R248W, R273C and R273H had higher viability 
than the structural mutants after 72 hrs of incubation in complete absence of serum and EGF (-S-
E) (Fig. 2.3A). R248Q was the most viable mutant with a viability significantly greater than the 
MCF10A p53 WT, WT-OE, as well as the p53KD cells indicating the neo-morphic activity of the 
mutant over the loss-of-function effects.  R175H and Y234C were the only structural mutants that 
showed viabilities comparable to that of the MCF10A p53KD cells under the growth factor starved 
condition. In contrast, withdrawal of EGF from the growth media significantly decreased the 
viability of all the cell lines and had a profound effect on viability of the mutant G245S (Fig 2.3C). 
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To measure proliferation, we counted the cells under the same experimental conditions with DAPI 
staining, and high nuclei counts for the R248Q and R175H cells in the absence of serum and 
EGF were observed, demonstrating an increase capability in self-sustained survival and 
proliferation without external stimuli (Fig 2.3B). In agreement, mouse embryonic fibroblasts 
(MEFs) extracted from the genetically engineered p53R172H/+ (equivalent to human R175H) mice 
were more proliferative with a larger fraction of cells in the S-phase compared to p53+/- MEF 
(Olive 2004). 
 
  
 
 
 
 
Figure 2.3. Effect of p53 mutants on cell viability. A. Viability of the MCF 10A p53 mutant 
cells in absence of growth factors- Serum and EGF (-S-E) measured by the CellTiter-glo 
assay. B. Cell counts measured by DAPI staining after 72 hrs growth in growth factor-
deprived media. C. Cell viability measured by the CellTiter-glo assay after cells were either 
grown in the presence of both serum and EGF (+S+E) or in the absence of EGF (+S-E) or 
serum (-S+E). All the data have been analyzed from 3 separate experiments and normalized 
with respect to the phenotypic data of WTOE cells, and the error bars show the SEM values.  
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Resistance to apoptosis 
 
Apoptosis, the programmed cell death is a barrier to cancer development and is triggered by 
tumor suppressor TP53. Loss of function or mutation in TP53 fails DNA damage sensing and 
hence, apoptosis induction (Aubrey 2018). Anthracyclins such as doxorubicin has been widely 
used as a primary chemotherapeutic drug and for adjuvant therapy for breast cancer to curb the 
proliferation and trigger apoptosis of the cancer cells.  To test whether different missense p53 
mutants make cells respond differently to the apoptotic stimuli, we evaluated the level of 
apoptosis in MCF 10A cells expressing p53 mutant proteins after 24 hrs of 1µM doxorubicin 
treatment by measuring the activities of caspase 3 and caspase 7 released during apoptosis, 
using a luminescent assay where luminescence was proportional to amount of caspase activity 
present. 
 
Overall, MCF 10A p53 mutant cells were more resistant to apoptosis except for the mutants 
G245S and R273H compared to the p53KD cells. In contrast to the results for the cell viability 
assay in different growth conditions, the most apoptosis-resistant mutants were the structural 
mutants R175H, Y163C, Y220C, H179R and Y234C, while the other structural mutant G245S 
was significantly more sensitive compared to the WTOE cell (Fig 2.4A, left graph). Among the DNA 
contact mutants, R248W was the most resistant to apoptosis followed by R248Q. However, 
overall, cell viability of mutant p53-expressing cells in the presence of 1µM doxorubicin (Fig 2.4A, 
right graph) was not significantly different from that of WTOE cells. Similar results were found 
when we measured the fraction of apoptotic cells with annexin V staining by flow cytometry (Fig 
2.4B). Annexin V stains the apoptotic cells by binding to phosphatidyl serine when it flips out on 
plasma membrane after cell death. 
 
The tumors derived from p53-/- embryonic fibroblasts contained less apoptotic cells, and missense 
mutations in p53 were associated with resistance to multiple doses with gamma radiation or 
doxorubicin (Lowe 1994). In another study of 63 breast cancer patients receiving doxorubicin 
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monotherapy, 18 patients had mutation in the TP53 gene, and mutations in the L2 and L3 loop 
regions in the DNA binding domain where the hotspot mutations are located, resulted in 
progressive disease during doxorubicin treatment. Specific p53 point mutation at codon 248 was 
implicated in primary resistance to doxorubicin and early relapse in breast cancer patients (Aas 
1996). In agreement, our experimental studies showed that R248W was the DNA contact mutant 
resistant to apoptosis. In another study with p53 mutant-expressing H1299 lung adenocarcinoma 
cells, p53His175 and p53His179 were found to be resistant to etoposide-induced apoptosis while 
p53His273 along with p53Trp248 had a protective effect (Blandino 1999). 
 
 
 
 
 
 
 
Figure 2.4. Resistance to apoptosis of MCF 10A p53 mutants in presence of 1µM 
doxorubicin for 24 hrs. A. Resistance to apoptosis measured by activity of caspase 3 and 
caspase 7 using the Apotox Glo kit (left graph). In a parallel cell viability assay in presence of 
1uM doxorubicin show the structural mutants to be more viable along with mutants R248Q 
and R248W that correlated well with the apoptosis assay. R273H and G245S were not viable 
in doxorubicin. All the data have been analyzed from 3 separate experiments and normalized 
with respect to the phenotypic data of WTOE cells, and the error bars show the SEM values. 
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Figure 2.4. Resistance to apoptosis of MCF 10A p53 mutants in presence of 1µM 
doxorubicin for 24 hrs. B. Flow cytometry data for apoptosis induction in mutants after 24 
hrs doxorubicin treatment and shows percentage of cells entering early apoptosis. These 
results were comparable to that found by measuring the caspase 3 and caspase 7 levels. All 
the data have been analyzed from 3 separate experiments and normalized with respect to the 
phenotypic data of WTOE cells, and the error bars show the SEM values 
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Cell migration and invasion 
 
One of the hallmarks of progression towards a metastatic phenotype is the ability of the malignant 
cells to migrate from the primary site, survive outside of their natural adhesion niche and colonize 
the secondary sites. This whole process involves several steps including migration of cells, local 
invasion in their immediate habitat, crossing the basement membrane, entering the bloodstream 
and finally invading and proliferating at a new secondary site (Powell 2014). Wildtype p53 protein 
negatively modulates cell spreading, polarization, and filopodia formation thereby inhibiting 
initiation of migration and invasion. On the contrary, mutant p53 protein enhances random cell 
migration and invasion. During the process, the adherent epithelial cells undergo transition from 
polarized epithelial cells to motile, long and spindle-like mesenchymal cells, which is known as 
the ‘epithelial-to-mesenchymal transition’ (EMT) that allows the cells to cut through the basement 
membrane and squeeze through the extracellular matrix (ECM) (Kalluri 2009). Wildtype p53 
protein suppresses EMT by repressing the transcription factors SNAIL, SLUG and TWIST which 
are the master regulators of EMT. 
 
To determine the migratory potential of the MCF 10A p53 mutant cell lines, we used a well-
established cell migration assay based on the transwell chamber also known as the Boyden 
chambers. These chambers have a membrane with pores with 8 µm diameter, allowing only the 
slender migratory cells to cross the membrane. After incubation for 22 hours, the migrated cells 
were stained with crystal violet and counted under the light microscope. The most migratory 
mutants were R248W, R273C and Y220C (Fig 2.5A). R175H and Y163C were moderately 
migratory and migrated more than the p53 null cells. The least migratory mutants included 
Y234C, G245S and R273H.  
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Figure 2.5. Migration and invasion of MCF 10A p53 mutant cells. A. Migratory potential of 
the MCF 10A p53 mutants. Mutants R248W, R273C and Y220C were the most migratory 
(highlighted in red). The least migratory mutants were G245S, Y234C and R273H. B. 
Invasion potential of the MCF 10A p53 mutants. R248W, R273C and Y220C (highlighted in 
red) were significantly more invasive than the WTKD cells. The least invasive mutants were 
G245S, H179R and Y234C. The small black dots in blank well depict the pores in the 
membrane. All the data have been analyzed from 3 separate experiments and normalized 
with respect to the phenotypic data of WTOE cells, and the error bars show the SEM values. 
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To measure cell invasion, the Boyden chamber membrane coated with Matrigel (reconstituted 
basement membrane), were used which needs to be proteolytically digested to allow invasion 
and thus, forms a perfect barrier for the non-invasive cells. The results provided a clear distinction 
between the non-invasive mutants G245S, H179R and Y234C and more invasive R248W, R273C 
and Y220C mutants. (Fig 2.5B), while R248Q and Y163C were moderately invasive. As the 
invasion process requires both cell migration and basement membrane breakdown, we compared 
the invasiveness and the migratory phenotype. The most migratory mutants R248W, R273C and 
Y220C were also invasive and crossed the Matrigel barrier. Similarly, the least migratory mutants 
Y234C and G245S proved to be non-invasive, while the mutant Y163C was moderately migratory 
and invasive. It is interesting to note that the moderately migratory mutants H179R and R175H 
failed to invade the Matrigel barrier, further demonstrating that not all cells that can migrate have 
invading potential, but cell migration is a pre-requisite for the invasion process. Lastly, it should 
be noted that even the most invasive R273C cells were far less invasive than the metastatic cells 
such as MDA MB-231 with additional mutations to TP53 mutation, implying that p53 mutation by 
itself is not sufficient to induce the full invasive capacity. 
 
To assess the EMT process during cell migration, we then performed the immunofluorescence 
staining for β-catenin (a marker for epithelial cells) and Vimentin (a marker for mesenchymal 
cells). We observed that the migratory cells, R273C and Y220C, had typical mesenchymal 
characteristics, including disorganized β-catenin (i.e., more in the cytoplasm than at the cell 
adherens junctions) and vimentin (i.e., stretched across the cells) staining (Fig 2.5C). To further 
contrast the invasiveness of cells, two of the migratory mutant R175H (moderately migratory but 
not invasive) and R248W (highly migratory and more invasive) cells were seeded on a type I 
collagen bed with a Matrigel overlay to create a 3D matrix. The cells were then allowed to invade 
the Matrigel bed and imaged at different focal planes along the Z-axis. The R248W cells were 
detected up to 600um away from the base of the well, while very few R175H mutant cells could 
invade the Matrigel overlay (Fig 2.5D) restating that a migratory phenotype may not translate into 
an invasive phenotype.  
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In previous reports, the mutant R273H has been shown to cooperate with p21 to promote Slug 
protein degradation and decreasing cell invasion (Kim 2014).  TP53 mutation, low MDM2 and 
high Slug expression correlates with poor survival and metastasis in NSCLC patients and 
expressing the p53-R248W mutant in the p53-null H1299 lung carcinoma cells decreased MDM2 
  
 
 
 
 
 
 
Figure 2.5. Migration and invasion of MCF 10A p53 mutant cells. C. EMT markers- β-
catenin and vimentin staining in the least (G245S), moderately (R175H) and most (R273C 
and Y220C) migratory p53 mutants. Cells were seeded in wells with stopper. The white line 
shows the boundary of the stopper and the yellow line the extent of migration of the least 
migratory mutant G245S. β-catenin was observed to be delocalized to the cytoplasm from the 
cell junctions in the migratory cells. The migrating R273C and Y220C mutant cells looked very 
spread like a ‘fan’ which is typical for a migratory phenotype. Vimentin staining was also very 
prominent in the migratory cells (R273C). D. Invasion potential of R175H (less invasive) and 
R248W (highly invasive) mutants in 3D Matrigel matrix. R248W mutant cells were very 
invasive and invaded till 600um along the Z-axis. Very few R175H mutant cells could invade 
only till 150um along the Z-direction. 
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protein levels and stabilized Slug to promote cell invasiveness (Wang 2009). TP53 mutants are 
known to downregulate E-cadherin expression with simultaneous upregulation of transcription 
factors Slug and Zeb-1, which are known to repress E-cadherin expression. Loss of E-cadherin 
expression is accompanied by expression of the mesenchymal marker Vimentin and 
delocalization of β-catenin to cell cytoplasm, the characteristics of EMT (Roger 2010). 
 
Moreover, we showed that different missense mutations at the same position (e.g., R248W/Q and 
R273C/H) could affect cell migration and invasion differently. Similarly, a study with lung and 
breast cancer cell lines stably expressing R273H, R273C and R273G p53 mutant proteins 
demonstrated different gene expression profiles resulting in different phenotypes, where the 
R273H- and R273C-expressing cells were more migratory than the R273G-expressing cells (Li 
2014). Overall, these findings demonstrated that a single amino acid change can have strikingly 
different effects on cellular phenotypes and hence likely the clinical outcomes. 
 
Resistance to anoikis 
 
When adherent cells are detached from extracellular matrix (ECM) attachment, an apoptotic 
process known as anoikis is initiated, and resistance to anoikis is a characteristic of transformed 
cells to enhance tumor metastasis (Gilmore 2005). Upon detachment from three-dimensional 
matrix, a p53 dependent apoptotic program is induced in fibroblast and endothelial cells, and loss 
of functional p53 protein enables cell survival without any anchorage dependency. p53 controls 
survival signal from ECM and FAK in anchorage dependent cells, and expression of dominant-
negative forms of mutant p53 protein resulted in anoikis resistance (Ilic 1998).  
 
To check the effect of different p53 missense mutant proteins on anoikis, the MCF 10A p53 
mutant cells were grown in low-binding 96-well plates for 7 days to form the cell aggregates, 
mimicking the conditions in-vivo when cells enter the bloodstream after detachment from the 
basement membrane. These cell aggregates were then stained with EtBr and Vybrant violet to 
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stain dead (i.e., EtBr-permeable) and live cells, respectively.  When the death index (dead cells/ 
live cells) was calculated, the mutants G245S and Y234C were most sensitive to anoikis (i.e., 
with higher death index) and underwent cell death in absence of attachment to any matrix (Fig 
2.6). The rest of the p53 mutants were more resistant to anoikis than the WTOE cells, whereas 
MCF 10A cells with endogenous wildtype p53 (WT) and with p53 knock-down (WTKD) were 
sensitive to anoikis compared to the MCF 10A cells over-expressing wildtype p53 (WTOE). The 
most resistant p53 mutants were R248W, R273C, R175H, H179R followed by Y220C where the 
spherical aggregates comprised mostly of live cells with a low death index in complete absence of 
any attachment to 3D matrix. The other mutants R248Q, R273H and Y163C also demonstrated 
anoikis resistance (more live cells than dead) but to a lesser extent than the most resistant 
mutants.  
 
 
 
 
Figure 2.6. Anoikis resistance of the p53 mutant MCF 10A cell lines. Cell aggregates were 
stained with Vybrant violet dye (live cells, blue) and EtBr (dead cells, red), and the death 
index (dead/ live cells) was calculated. All the data have been analyzed from 3 separate 
experiments and normalized with respect to the phenotypic data of MCF10A p53 WTOE. The 
error bars show the SEM values. 
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Supporting our results, breast cancer cells MDA-MB-468 harboring R273H mutation in TP53 was 
reported to suppress anoikis (Tan 2015). EMT is known to confer anoikis resistance and 
increases the likelihood of survival of the invasive cells that breach the basement membrane and 
enter the blood flow (Cao 2016), and we observed that the most migratory and invasive R248W, 
R273C and Y220C cells were also resistant to anoikis. However, the R273H cells were not 
invasive but resistant to anoikis, indicating an alternative mechanism of resisting anoikis in the 
absence of EMT. 
 
The 3-dimensional mammosphere morphology 
 
The MCF 10A mammary epithelial cells form spherical, growth arrested, polarized structures in 
three dimensional Matrigel matrix (ECM), the mammospheres, that resemble the glandular 
epithelial architecture of mammary acini (Debnath 2003). The mammosphere has a clear lumen 
(i.e., the absence of cells at the center of the spheroids) due to anoikis or apoptotic death of the 
centrally located cells devoid of attachment to the substratum. The resultant spheroid looks like a 
hollow ball, with a single layer of cells only at the periphery. The over-expression of wildtype p53 
does not affect this phenotype but cells without p53 (p53 null) and cells with the hotspot TP53 
mutations are known to develop non-polarized, disorganized cell clusters without a hollow lumen, 
which is either filled or partially cleared, indicating transformation of cells. Malignant tumor cells 
such as T4-2 form highly disorganized and continuously proliferating colonies in 3D Matrigel 
matrix (Kenny 2003).  
 
For high-throughput assessment of mammosphere formation in a 96-well format, we developed 
the ‘on top’ method where cells were seeded on top of a Matrigel layer rather than being 
embedded. This method allowed reduced time for acini formation (~7 to 9 days) and clearance of 
lumen as well as similar focal planes for automated confocal Z-stack imaging compared to the 
embedded method. An image analysis pipeline was also developed using the CellProfiler 
software to quantify i) the spheroid sizes ii) number of cells in the lumen (counting nuclei in the 
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lumen) or hollowness of the mammospheres iii) expression of cell polarity marker like laminin (for 
apico-basal polarity) by relative fluorescent antibody intensities.  
 
The size of the spheroids was determined by measuring the diameter of the spheroid cross-
sections and applying the formula for the area of a circle after a pixel-to-µm conversion.  
When we tested the cells expressing different missense p53 mutant proteins for mammosphere 
fomation, the MCF 10A p53 WTOE cells formed the largest spheroids with a mean area of 785 
µm2, whereas the R273H cells formed the smallest dense spheroids with a mean area of 65 µm2 
(Fig 2.7A). The MCF 10A cells with endogenous wildtype p53 and p53KD control had comparable 
mean areas of 450 µm2 and 470 µm2, respectively. All the cells expressing DNA contact mutants 
had mean spheroid areas significantly smaller than the p53OE and p53WT spheroids, with mean 
areas ranging from 65 µm2 to 266 µm2. The cells with structural mutants had spheroid areas 
comparable to that of p53WT control, with an exception of the G245S cells that had the second 
smallest spheroid (mean area157 µm2). The mean spheroid sizes for the p53 structural mutants 
were twice as large than the DNA contact mutants. It was also interesting to note that the 
spheroids derived from cells expressing the two most invasive mutants show a significant size 
difference, where the R248W and Y220C spheroids had areas of 266 µm2 and 475µm2, 
respectively. While both the mutants R248W and Y220C behave similarly in the invasion 
chambers penetrating a thin Matrigel layer, they develop different morphologies in the 3D Matrigel 
alluding to other significant changes between them. The p53 mutants R248Q, R175H and Y220C 
formed deformed spheroids of various shapes. 
 
The MCF 10A p53 WTOE cells formed the mammary acini with cleared lumen like the p53WT. All 
p53 mutants had cells at the center of the mammospheres. The mutants with most prominent 
nuclear staining indicating a filled lumen were the DNA contact mutants (Fig 2.7B). The DNA 
contact mutant R273H and the structural mutant G245S showed a substantial nuclear stain 
intensity due to the tiny and dense spheroids. The DNA contact mutants had filled lumens and 
structural mutants had partially filled lumens compared to the p53WT and p53 WTOE 
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mammospheres.  p53KD did prove to elicit the abnormal spheroid morphology with the nuclei 
staining intensity in the inner bins like p53 mutants R248W and R273C.  
 
 
Another important morphological characteristic of normal MCF 10A mammary spheroids is the 
polarization of the cells in the single peripheral layer, where the apical side orients towards the 
lumen (center of the mammosphere) and basal side away from the central lumen marked by the 
protein markers. We measured the localization of laminin (Fig 2.7C), a protein that is present on 
the basal side (outer side) of the spheroids lining the circumference of the hollow sphere. To 
quantify the formation of properly structured spheroids, we developed a method of estimating the 
‘hollowness’ of mammospheres using the CellProfiler by taking the equatorial cross-section 
pictures and measuring the staining intensity across 20 concentric rings with increasing radius, 
 
 
Figure 2.7. Morphology of the MCF 10A p53 mutant mammospheres. A. The spheroid 
sizes were measured on day 9 on the on-top culture in 3D Matrigel bed. The WTOE formed the 
largest spheroids. Some of the mutants had a mixed population of small and big spheroids 
(R248Q, G245S, H179R and R175H) but on average G245S formed smaller spheroids. All 
the data have been analyzed from 3 separate experiments and normalized with respect to the 
phenotypic data of MCF10A p53 WTOE. The error bars show the SEM values. 
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called bins, expanding outward (Fig 2.7C). In this setting, the bins 1 and 20 represent the 
innermost and outermost rings, respectively, and higher signal intensity of laminin in the inner 
bins indicates reversed polarity of cells. The intensity value data was normalized to the total 
number of pixels for each spheroid since the larger the bin, the more pixels present. 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Morphology of the MCF 10A p53 mutant mammospheres. B. DAPI staining 
showed lumen clearance of mammospheres. None of the mutants could form the normal 
hollowsphere, and DNA contact mutants formed quite dense spheres compared to the 
structural mutants. 
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The p53OE and p53WT cells demonstrated laminin staining on the outer side of the spheroids 
indicating normal cell polarity (Fig 2.7C). The p53OE cells had laminin staining not detectable until 
 
 
Figure 2.7. Morphology of the MCF 10A p53 mutant mammospheres. C. Laminin staining 
intensity profiles across the bins. The error bars represent SEM from independent 
measurements of an average of spheroids. 
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bin 13 (out of 20) that was close to the periphery, which then steadily increased until bin 20. The 
p53WT cells had no central laminin intensity inside the spheroids, while laminin staining inside the 
spheroid was detected for p53KD cells suggestive of disrupted polarity of cells. The missense 
mutant with a strong laminin intensity towards the center of the spheroid was R248Q (Fig 2.7C). 
The laminin intensity of R273H and G245S cell was constant from the spheroid center to the 
periphery because of the small and dense spheroids (the bin size is proportional to the size of the 
spheroid as a whole). Among the mutant p53 expressing cells, only the R248Q cells showed a 
consistent decrease in laminin staining intensity from the center towards the periphery indicating 
reversed polarity of cells. The two invasive mutants, R248W and Y220C, also led to a decreased 
laminin staining at the periphery. In addition, we stained the mammospheres for β-catenin to 
assess the status of EMT, and observed that the cells expressing Y220C and R248Q showed 
disrupted β-catenin staining (Fig 2.7D), indicating altered cell polarity via EMT.  
 
Earlier work has shown that knock-down of endogenous wildtype p53 in MCF 10A cells form 
mammary acini with partial clearance of the lumen and altered staining of β-catenin and laminin V 
(Zhang 2011). In agreement with our results, ectopic expression of p53 mutants G245S, R248W, 
R175H and R273H formed disrupted acini with filled lumen along with increased expression of 
mesenchymal markers like Snail, Slug and Twist and decreased levels of epithelial markers and 
staining patterns of E-cadherin, β-catenin and ZO-1. Thus, collectively with previous reports, our 
data suggest that a subset of missense mutant p53 caused change in cell polarity through EMT. 
 
Overview of phenotypic characteristics of MCF 10A cells expressing mutant p53 protein 
 
In summary, we have developed a series of high-throughput quantitative assays to assess the 
cancer hallmark phenotypes of normal mammary epithelial MCF 10A cells over-expressing the 
ten most common p53 missense mutant proteins found in breast cancer. To normalize the effect 
of protein overexpression in the context of identical genetic background, the phenotype scores for 
each mutant was calculated with respect to the phenotype of the MCF 10A cells overexpressing 
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the wildtype p53. The carefully designed and performed experiments provided a spectrum of 
mutant-specific phenotypic changes occurring across the ten p53 missense mutant protein 
expressing mammary epithelial cells and established that the different mutant proteins are 
functionally unequal (Fig 2.8). Each of them produces a ‘neo-morphic’ phenotype different from 
wildtype p53 and p53KD cells, which may reflect the heterogeneity of phenotypes observed in 
patient tumor samples. 
 
 
Based on the assessed cancer hallmark phenotypes, the highly aggressive p53 mutants were the 
two DNA contact mutants R248W and R273C and a structural mutant Y220C (Fig 2.8). These 
 
 
 
Figure 2.7. Morphology of the MCF 10A p53 mutant mammospheres. D. Matrigel Confocal 
images of equatorial cross-section of mammospheres stained with laminin, β-catenin and 
DAPI.  
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aggressive mutants were viable under growth factor deprivation (absence of EGF and serum) and 
were resistant to apoptosis under doxorubicin treatment. Apoptotic resistance of the R273C cells 
was comparable to wildtype p53KD cells whereas the R248W and Y220C cells were more 
resistant to apoptosis than R273C and p53KD cells. Cells expressing R248W, R273C and Y220C 
mutants were the most migratory and invaded the Matrigel barrier establishing themselves as the 
most invasive mutants. These invasive mutants survived without attaching to a substratum 
demonstrating anoikis resistance that correlated with their resistance to apoptosis. In 3D Matrigel 
bed, cells expressing the anoikis-resistant DNA contact mutants R248W and R273C formed very 
small and dense mammospheres unlike the large hollow spheres with a single layer of polarized 
cells formed by mammary epithelial cells with wildtype p53. Cells expressing the Y220C structural 
mutant formed mammospheres of distorted shapes with partially filled lumen, and more laminin 
staining was observed inside the spheres than on the periphery, which indicated disruption of cell 
polarity that correlated with the migratory and invasive characteristics.  
 
 
 
 
 
Figure 2.8. Heat map of the phenotypic characteristics of the ten MCF 10A cells 
over-expressing p53 missense mutants based on the hallmarks of cancer. The 
phenotype scores were calculated with respect to the results for MCF 10A wildtype p53 
over-expressing cells. 
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An exceptional missense mutant was G245S with phenotype comparable to that of the MCF 10A 
cells overexpressing wildtype p53. The G245S cells had decreased viability in the absence of 
serum and EGF and was sensitive to doxorubicin treatment undergoing apoptotic cell death. The 
G245S cells were neither migratory nor invasive and did not show anoikis resistance. 
 
Taken together, while the rest of the mutant expressing cells displayed intermediate cancer 
hallmark phenotypes, we can position G245S on one end of the spectrum as the least aggressive 
mutant and R248W, R273C and Y220C on the opposite end as the most aggressive mutants. 
Based on these distinct phenotypic patterns, we hypothesized that diverse phenotypes arose 
from neo-morphic transcriptional function of each mutant p53 protein, which then led to 
downstream changes in gene expression profile and cellular pathways. Therefore, to obtain 
genome wide molecular profiles, we next performed the RNA seq and ChIP seq, followed by 
comprehensive bioinformatics analyses. 
 
RNA seq data and pathway analysis 
 
To profile the baseline transcriptome, we performed RNA Seq on the MCF 10A cell lines 
expressing missense mutant p53 proteins as well as the cells overexpressing wildtype p53 
(p53OE). We extracted the total RNA from the cells, enriched for mRNA and sequenced on the 
Illumina HiSeq 2000 platform. Our goal was to understand the underlying molecular basis of the 
phenotypic heterogeneity of the p53 mutants.  
 
After aligning the reads using STAR (Dobin 2013), we identified an average of 24,252 genes and 
microRNAs with 20X coverage and normalized to TPM (Transcripts Per Kilobase Million) in all 
cell lines. Next, we carried out PCA (Principal Component Analysis) and pathway analysis to 
systematically analyze the genes differentially expressed among the cell lines (mutant p53 vs 
wildtype p53). For PCA, we selected the top 1,000 most variant genes across all 13 cell lines (10 
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p53 mutants and 3 controls) and performed dimension reduction to extract the fundamental 
structure of RNA expression level then mapped them onto a 2-D space (Fig 2.9D). Y234C and 
R273H were separated from the other cell lines, which indicates general differences in expression 
level. For pathway analysis, correlation between expression levels and phenotypic values across 
13 cell lines (10 p53 mutants and 3 controls) were calculated for each gene and phenotype, and 
top 500 positively or negatively correlated genes were identified. By using the ontology and 
pathway terms in DAVID and Reactome databases, pathway enrichment tests were performed by 
the Fisher’s exact. Because conventional pathway enrichment analysis are based on the counts 
of genes and don’t take gene expression or continuous variables of phenotypes into account, we 
applied model-based approaches to identify the phenotype-associated pathways, in which 
expression levels of the genes were informative in explaining the phenotypic differences such as 
cell invasiveness (Fig 2.9). We specifically used a classification method (Pathifier) and a 
regression method (Partial Least Squares regression or PLS) for pathway analysis.  
 
Pathifier (Drier 2013) performs non-linear regression to find a principal curve spanning the data 
points (i.e, cell-lines in our data) after dimensional reduction on the expression levels of a given 
set of pathway genes by the principal component analysis (PCA). Based on the relative position 
on the curve, a dysregulation score is assigned to each sample, and the scores are compared 
between pre-defined groups (e.g, cells with higher and lower invasiveness) by statistical tests 
such as a non-parametric Mann-Whitney-Wilcoxon test to determine whether the expression 
levels of the pathway genes are informative with statistical significance in classifying two groups 
of cells. When we tested the pathways in KEGG for weakly invasive cells (G245S, Y234C, 
H179R, R175H, p53-wt, p53-KD) vs. more invasive cells (R273H, Y220C, R273C, R248W, 
p53OE, Y163C, R248Q), metabolism-related pathways, cell adhesion related pathways, notch 
signaling, and axon guidance were identified as the most dysregulated pathways across the least 
to the most invasive mutant p53 expressing cells (Fig 2.9A).  
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To avoid any bias in the data, we applied PLS, a multivariate statistical regression method, which 
builds robust linear models on continuous response variables and particularly suitable for high 
dimensional data with a small sample size. With PLS, we can build models on individual 
pathways to test whether the expression levels of pathway genes (predictor variables or training 
vectors) can explain the continuous trend of phenotypes (response variable or targeting vectors) 
by measuring the coefficient of correlation of the models. From the analysis, we identified that the 
genes sets in pathways like Hippo signaling pathway (correlation = 0.71) , ECM-receptor 
interaction (correlation = 0.56), and focal adhesion (correlation = 0.52) in KEGG; ERBB4 
signaling (correlation = 0.76), and Ca2+/K+ channels (correlation = 0.67) related terms in 
Reactome can explain the trend of cell invasion observed across the ten p53 mutant cell lines. 
When the regression results were projected onto the PLS components, for the focal adhesion 
pathways, the most invasive p53 mutants (R273C, Y220C and R248W) as determined from the 
Matrigel-coated transwell invasion assay clustered together while the least invasive mutants 
H179R and Y234C clustered on the other end (Fig 2.9B). To highlight the genes that contribute 
most to the phenotypic differences, we overlaid the pathway diagram with the correlation between 
the expression levels of each gene and the phenotypic scores (Fig 2.9C). In addition, to show the 
potential direct transcriptional targets of p53 proteins, we also highlighted the known p53 target 
genes as well as the genes that we identified from our ChIP Seq data for p53 WT and mutant p53 
proteins. 
 
To select the genes for further validation, we calculated the invasion correlation scores by 
Pearson correlation between RNA expression level and invasion level among the 13 cell lines. 
We then ranked the scores to get a list of top genes who exhibit high RNA expression level in 
invasive cell lines while low in non-invasive cell lines (Appendix B). The top list of genes includes 
STAP2, CYP4B1 and PARP10 (high in invasive p53 mutants) and PLPPR2, SREBF1 and PDK2 
(high in non-invasive p53 mutants). 
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Figure 2.9. RNA seq and pathway analysis of p53 mutants. A. Pathway heatmap. Top 
ranked pathways in PLS analysis. B. PLS 3D plot. RNA expression scores of 24,252 genes 
were reduced to 2 dimensions (x and y axis). Cell lines of high/low (red/blue) invasiveness are 
separately clustered in the Focal Adhesion pathway. C. Focal adhesion pathway 
visualization. Red and blue in gene boxes indicate the high/low RNA expression level based 
on cell invasion level. Black borders imply known p53 targets. ChIP binding in MCF 10A 
p53OE, Y220C, Y234C, R273H are highlighted. D. PCA 2D plot. 1,000 genes were selected 
ranked by coefficient of variation across 13 cell lines.  
C.
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ChIP seq data 
 
The p53 protein is a sequence specific transcription factor, and to understand the DNA binding 
patterns of different missense mutant p53 proteins, we performed ChIP Seq on a set of two most 
invasive p53 mutants R273C and Y220C as well as two least invasive p53 mutants R273H and 
Y234C cells. To match the experimental conditions for RNA Seq, we used untreated cells (no 
treatment to induce high expression of p53 protein) and immunoprecipitated the C-term V5-
tagged mutant p53 proteins expressed from the genome integrated plenti4 V5-DEST cassettes 
using antibody against the V5 tag. As a positive control we included the MCF 10A p53OE cells, 
overexpressing wildtype p53 with a V5 tag, while the parental MCF 10A cells expressing 
endogenous wildtype p53 (without any V5 tag) was used as the negative control for detecting the 
ChIP Seq peaks. Unlike the conventional p53 ChIP Seq typically performed after treatment (with 
Doxorubicin) of cells that elevate the cellular p53 protein level, we used untreated cells. 
Therefore, when we examined the enrichment of known DNA binding motifs, we did not observe 
a strong over representation of the p53 binding motif in the identified peaks in the p53OE cells, in 
contrast to the studies using Doxorubicin treatment where > 30% peaks contained p53 binding 
motif (Tonelli 2017). In our dataset, 7.91% of binding sites at promoter region were identified as 
p53 binding motifs which is similar to a previous study performed with the WT p53 (Idogawa, 
2014), indicating a limited basal level of DNA binding of WT p53 in the absence of any stress. 
 
Different DNA binding capacity and preference of p53 missense mutant proteins 
 
Across the WT and 10 mutant p53 expressing cell lines, the p53 binding sites were mainly 
identified at the intergenic region (33% - 80%), and 5% - 23% of peaks were located within the 
promoter regions (+100/-2,500 bps of transcription start sites). Although no universal binding 
motifs were identified for both WT and mutant p53 proteins within the promoter regions by the de  
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novo motif discovery tool Homer at the significance level of P < 0.001, several distinct binding 
motifs were observed for the different p53 mutants, implying the ‘neo-morphic’ functional variation  
across different p53 mutations. Upon examining the enrichment level of known p53 binding motifs 
at the promoter region, it was evident that the mutant forms of p53 (especially the invasive 
R273C) showed reduced binding to the canonical p53 motifs, while the degree of reduced binding 
did not correlate to the invasiveness of cells (Fig 2.10A). Well-known targets of wildtype p53 such 
as CDKN1A were pulled down only by WT p53OE but not by the mutant p53. When we compared 
the binding motifs for all p53 mutants, R273H showed most similar binding preference as the WT 
p53OE, while R273C bound to a very small number of distinct DNA motifs from WT and other p53 
mutants (Fig 2.10B), implying general loss-of-function of DNA binding.  
 
In addition, compared to the invasive mutants of Y220C and R273C, the less invasive mutants 
R273H and Y234C presented more similar motif binding pattern as wildtype p53 protein for both 
known (Fig 2.10A) and de novo motifs (Fig 2.10B). Overall, these indicate that the missense 
mutant p53 proteins, especially the more invasive ones, had decreased affinity for canonical p53 
binding motif and altered binding preference (neo-morphic function). 
 
Further, in agreement with a previous study that suggested an alternative mode of transcriptional 
regulation of the p53-R273H mutant without direct DNA binding via interacting with a transcription 
factor ETS (Vaughan 2014), the binding motif for ETS was over-represented at promoter regions 
targeted by R273H mutant. Moreover, the most prevalent ETS binding motif, CCGGAAG, was 
found in 22% of promoter peaks with p-value < 10-7 in R273H, and this binding motif was over-
represented for all mutant p53 proteins when compared to p53OE. 
 
Taken together, these suggest that mutant p53 proteins may exert neo-morphic transcriptional 
functions both by changing DNA binding preference and via interaction with other transcriptional 
factors. 
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Figure 2.10. Results from ChIP seq. A. Figure of known p53 motif heatmap. Distinct known 
motif binding was observed in different p53 mutant cell lines. B. De-novo motif heatmap. 
Distinct de-novo motif binding were observed in different p53 mutant cell lines. The p53 
mutant cell lines lose the function of canonical sequence specific DNA binding. 
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Znf263(Zf)/K562−Znf263−ChIP−Seq(GSE31477)/Homer
ZNF467(Zf)/HEK293−ZNF467.GFP−ChIP−Seq(GSE58341)/Homer
NTM1(NAC)/col−NTM1−D AP−Seq(GSE60143)/Homer
ELF5(ETS)/T47D−ELF5−ChIP−Seq(GSE30407)/Homer
AT3G12130(C3H)/colamp−A T3G12130−D AP−Seq(GSE60143)/Homer
PABPC1(?)/MEL−P ABC1−CLIP−Seq(GSE69755)/Homer
COG1(C2C2dof)/col−COG1−D AP−Seq(GSE60143)/Homer
HDG7(HB)/col−HDG7−D AP−Seq(GSE60143)/Homer
Reverb(NR),DR2/RA W−Reverba.biotin−ChIP−Seq(GSE45914)/Homer
NTM2(NAC)/col−NTM2−D AP−Seq(GSE60143)/Homer
EMB1789(C3H)/col−EMB1789−D AP−Seq(GSE60143)/Homer
GT2(Trihelix)/colamp−GT2−D AP−Seq(GSE60143)/Homer
ANAC103(NAC)/col−ANA C103−DAP−Seq(GSE60143)/Homer
dof45(C2C2dof)/col−dof45−D AP−Seq(GSE60143)/Homer
Unknown1(NR/Ini−lik e)/Drosophila−Promoters/Homer
HLF(bZIP)/HSC−HLF .Flag−ChIP−Seq(GSE69817)/Homer
Six2(Homeobo x)/NephronProgenitor−Six2−ChIP−Seq(GSE39837)/Homer
ATHB24(ZFHD)/colamp−A THB24−D AP−Seq(GSE60143)/Homer
Sox6(HMG)/My otubes−So x6−ChIP−Seq(GSE32627)/Homer
AT3G25990(T rihelix)/colamp−A T3G25990−D AP−Seq(GSE60143)/Homer
ATHB25(ZFHD)/colamp−A THB25−D AP−Seq(GSE60143)/Homer
Atf4(bZIP)/MEF−Atf4−ChIP−Seq(GSE35681)/Homer
Lhx1(Homeobo x)/Embr yoCarcinoma−Lhx1−ChIP−Seq(GSE70957)/Homer
AT5G05550(T rihelix)/col−A T5G05550−D AP−Seq(GSE60143)/Homer
ATHB34(ZFHD)/colamp−A THB34−D AP−Seq(GSE60143)/Homer
Chop(bZIP)/MEF−Chop−ChIP−Seq(GSE35681)/Homer
SRS7(SRS)/colamp−SRS7−D AP−Seq(GSE60143)/Homer
JGL(C2H2)/col−JGL−D AP−Seq(GSE60143)/Homer
Sox3(HMG)/NPC−So x3−ChIP−Seq(GSE33059)/Homer
MYB(HTH)/ERMYB−Myb−ChIPSeq(GSE22095)/Homer
Arnt:Ahr(bHLH)/MCF7−Ar nt−ChIP−Seq(Lo_et_al.)/Homer
ERE(NR),IR3/MCF7−ERa−ChIP−Seq(Unpub lished)/Homer
CEBP:AP1(bZIP)/ThioMac−CEBPb−ChIP−Seq(GSE21512)/Homer
PPARE(NR),DR1/3T3L1−Pparg−ChIP−Seq(GSE13511)/Homer
SFP1/SacCer−Promoters/Homer
GATA3(Zf),DR8/iT reg−Gata3−ChIP−Seq(GSE20898)/Homer
LRF(Zf)/Er ythrob lasts−ZBTB7A−ChIP−Seq(GSE74977)/Homer
Zic(Zf)/Cerebellum−ZIC1.2−ChIP−Seq(GSE60731)/Homer
Hoxb4(Homeobo x)/ES−Ho xb4−ChIP−Seq(GSE34014)/Homer
ATHB33(ZFHD)/col−A THB33−DAP−Seq(GSE60143)/Homer
Lhx3(Homeobo x)/Neuron−Lhx3−ChIP−Seq(GSE31456)/Homer
Tgif1(Homeobo x)/mES−Tgif1−ChIP−Seq(GSE55404)/Homer
Rfx2(HTH)/LoV o−RFX2−ChIP−Seq(GSE49402)/Homer
AT2G15740(C2H2)/col−A T2G15740−D AP−Seq(GSE60143)/Homer
AR−halfsite(NR)/LNCaP−AR−ChIP−Seq(GSE27824)/Homer
MYB81(MYB)/col−MYB81−D AP−Seq(GSE60143)/Homer
M1BP(Zf)/S2R+−M1BP−ChIP−Seq(GSE49842)/Homer
ATHB40(HB)/col−A THB40−DAP−Seq(GSE60143)/Homer
AARE(HLH)/mES−cMyc−ChIP−Seq/Homer
CArG(MADS)/PUER−Srf−ChIP−Seq(Sulliv an_et_al.)/Homer
ATHB23(ZFHD)/col−A THB23−DAP−Seq(GSE60143)/Homer
SPDEF(ETS)/VCaP−SPDEF−ChIP−Seq(SRA014231)/Homer
MYB51(MYB)/col−MYB51−D AP−Seq(GSE60143)/Homer
SGR5(C2H2)/colamp−SGR5−D AP−Seq(GSE60143)/Homer
Unknown5/Drosophila−Promoters/Homer
CTCF(Zf)/CD4+−CTCF−ChIP−Seq(Barski_et_al.)/Homer
Elk1(ETS)/Hela−Elk1−ChIP−Seq(GSE31477)/Homer
Elk4(ETS)/Hela−Elk4−ChIP−Seq(GSE31477)/Homer
Bcl6(Zf)/Liv er−Bcl6−ChIP−Seq(GSE31578)/Homer
ATY19(MYB)/col−A TY19−DAP−Seq(GSE60143)/Homer
E2F6(E2F)/Hela−E2F6−ChIP−Seq(GSE31477)/Homer
AGL16(MADS)/col−A GL16−DAP−Seq(GSE60143)/Homer
AGL6(MADS)/col−A GL6−DAP−Seq(GSE60143)/Homer
ZNF264(Zf)/HEK293−ZNF264.GFP−ChIP−Seq(GSE58341)/Homer
MYB10(MYB)/col−MYB10−D AP−Seq(GSE60143)/Homer
MYB83(MYB)/colamp−MYB83−D AP−Seq(GSE60143)/Homer
GRE(NR),IR3/RA W264.7−GRE−ChIP−Seq(Unpub lished)/Homer
ATHB20(Homeobo x)/colamp−A THB20−DAP−Seq(GSE60143)/Homer
AGL95(ND)/col−A GL95−DAP−Seq(GSE60143)/Homer
MYB13(MYB)/col−MYB13−D AP−Seq(GSE60143)/Homer
PAX5(Paired,Homeobo x)/GM12878−P AX5−ChIP−Seq(GSE32465)/Homer
RBPJ:Ebo x(?,bHLH)/P anc1−Rbpj1−ChIP−Seq(GSE47459)/Homer
GLI3(Zf)/Limb−GLI3−ChIP−Chip(GSE11077)/Homer
ZNF415(Zf)/HEK293−ZNF415.GFP−ChIP−Seq(GSE58341)/Homer
AT1G76880(T rihelix)/col−A T1G76880−D AP−Seq(GSE60143)/Homer
ERF10(AP2EREBP)/col−ERF10−D AP−Seq(GSE60143)/Homer
EFL−1(E2F)/cElegans−L1−EFL1−ChIP−Seq(modEncode)/Homer
ZNF669(Zf)/HEK293−ZNF669.GFP−ChIP−Seq(GSE58341)/Homer
MYB3R5(MYB)/col−MYB3R5−D AP−Seq(GSE60143)/Homer
Rbpj1(?)/P anc1−Rbpj1−ChIP−Seq(GSE47459)/Homer
Stat3+il21(Stat)/CD4−Stat3−ChIP−Seq(GSE19198)/Homer
ARE(NR)/LNCAP−AR−ChIP−Seq(GSE27824)/Homer
CBF1(AP2EREBP)/colamp−CBF1−D AP−Seq(GSE60143)/Homer
WRKY27(WRKY)/colamp−WRKY27−D AP−Seq(GSE60143)/Homer
STAT1(Stat)/HelaS3−ST AT1−ChIP−Seq(GSE12782)/Homer
PHV(HB)/col−PHV−D AP−Seq(GSE60143)/Homer
Smad3(MAD)/NPC−Smad3−ChIP−Seq(GSE36673)/Homer
At1g75490(AP2EREBP)/colamp−At1g75490−D AP−Seq(GSE60143)/Homer
AT4G26030(C2H2)/col−A T4G26030−D AP−Seq(GSE60143)/Homer
E2F7(E2F)/Hela−E2F7−ChIP−Seq(GSE32673)/Homer
AT5G60130(ABI3VP1)/col−A T5G60130−D AP−Seq(GSE60143)/Homer
FOXK2(Forkhead)/U2OS−FO XK2−ChIP−Seq(E−MT AB−2204)/Homer
ATHB15(HB)/col−A THB15−DAP−Seq(GSE60143)/Homer
STOP1(C2H2)/colamp−ST OP1−DAP−Seq(GSE60143)/Homer
Rap210(AP2EREBP)/col−Rap210−D AP−Seq(GSE60143)/Homer
AtGRF6(GRF)/col−AtGRF6−D AP−Seq(GSE60143)/Homer
ZIM(C2C2gata)/col−ZIM−D AP−Seq(GSE60143)/Homer
MYB93(MYB)/colamp−MYB93−D AP−Seq(GSE60143)/Homer
AT5G59990(C2C2COlik e)/colamp−A T5G59990−D AP−Seq(GSE60143)/Homer
AIL7(AP2EREBP)/colamp−AIL7−D AP−Seq(GSE60143)/Homer
CRF4(AP2EREBP)/colamp−CRF4−D AP−Seq(GSE60143)/Homer
SpiB(ETS)/OCIL Y3−SPIB−ChIP−Seq(GSE56857)/Homer
Pitx1(Homeobo x)/Chick en−Pitx1−ChIP−Seq(GSE38910)/Homer
ANAC047(NAC)/colamp−ANA C047−DAP−Seq(GSE60143)/Homer
STAT4(Stat)/CD4−Stat4−ChIP−Seq(GSE22104)/Homer
Unknown1/Ar abidopsis−Promoters/Homer
GATA15(C2C2gata)/col−GA TA15−DAP−Seq(GSE60143)/Homer
AT5G22990(C2H2)/col−A T5G22990−D AP−Seq(GSE60143)/Homer
GRE(NR),IR3/A549−GR−ChIP−Seq(GSE32465)/Homer
SPL1(SBP)/colamp−SPL1−D AP−Seq(GSE60143)/Homer
Usf2(bHLH)/C2C12−Usf2−ChIP−Seq(GSE36030)/Homer
AGL15(MADS)/col−A GL15−DAP−Seq(GSE60143)/Homer
MYB49(MYB)/col−MYB49−D AP−Seq(GSE60143)/Homer
WRKY26(WRKY)/colamp−WRKY26−D AP−Seq(GSE60143)/Homer
Rfx6(HTH)/Min6b1−Rfx6.HA−ChIP−Seq(GSE62844)/Homer
bHLH157(bHLH)/col−bHLH157−D AP−Seq(GSE60143)/Homer
GATA19(C2C2gata)/colamp−GA TA19−DAP−Seq(GSE60143)/Homer
ZNF143|STAF(Zf)/CUTLL−ZNF143−ChIP−Seq(GSE29600)/Homer
Oct2(POU,Homeobo x)/Bcell−Oct2−ChIP−Seq(GSE21512)/Homer
caudal(Homeobo x)/Drosophila−Embr yos−ChIP−Chip(modEncode)/Homer
Trl(Zf)/S2−GA GAfactor−ChIP−Seq(GSE40646)/Homer
LMI1(HB)/colamp−LMI1−D AP−Seq(GSE60143)/Homer
DMRT6(DM)/Testis−DMR T6−ChIP−Seq(GSE60440)/Homer
Klf9(Zf)/GBM−Klf9−ChIP−Seq(GSE62211)/Homer
AT5G66940(C2C2dof)/col−A T5G66940−D AP−Seq(GSE60143)/Homer
CDX4(Homeobo x)/Zebr afishEmbr yos−Cdx4.Myc−ChIP−Seq(GSE48254)/Homer
E2F(E2F)/Hela−CellCycle−Expression/Homer
Sp5(Zf)/mES−Sp5.Flag−ChIP−Seq(GSE72989)/Homer
MYB62(MYB)/colamp−MYB62−D AP−Seq(GSE60143)/Homer
VND3(NAC)/colamp−VND3−D AP−Seq(GSE60143)/Homer
VND4(NAC)/colamp−VND4−D AP−Seq(GSE60143)/Homer
ANAC016(NAC)/col−ANA C016−DAP−Seq(GSE60143)/Homer
AT1G19040(NA C)/col−AT1G19040−D AP−Seq(GSE60143)/Homer
Cdx2(Homeobo x)/mES−Cdx2−ChIP−Seq(GSE14586)/Homer
CUC3(NAC)/col−CUC3−D AP−Seq(GSE60143)/Homer
AT1G69570(C2C2dof)/col−A T1G69570−D AP−Seq(GSE60143)/Homer
dof43(C2C2dof)/colamp−dof43−D AP−Seq(GSE60143)/Homer
WUS1(Homeobo x)/colamp−WUS1−D AP−Seq(GSE60143)/Homer
Zelda(Zf)/Embr yo−zld−ChIP−Seq(GSE65441)/Homer
dof24(C2C2dof)/col−dof24−D AP−Seq(GSE60143)/Homer
ZNF711(Zf)/SHSY5Y−ZNF711−ChIP−Seq(GSE20673)/Homer
ATHB21(HB)/colamp−A THB21−D AP−Seq(GSE60143)/Homer
Hoxc9(Homeobo x)/Ain v15−Hoxc9−ChIP−Seq(GSE21812)/Homer
BBX31(Or phan)/col−BBX31−D AP−Seq(GSE60143)/Homer
Egr1(Zf)/K562−Egr1−ChIP−Seq(GSE32465)/Homer
OBP1(C2C2dof)/col−OBP1−D AP−Seq(GSE60143)/Homer
Adof1(C2C2dof)/col−Adof1−D AP−Seq(GSE60143)/Homer
OBP3(C2C2dof)/col−OBP3−D AP−Seq(GSE60143)/Homer
AT1G47655(C2C2dof)/colamp−A T1G47655−D AP−Seq(GSE60143)/Homer
JKD(C2H2)/col−JKD−D AP−Seq(GSE60143)/Homer
At5g66730(C2H2)/colamp−At5g66730−D AP−Seq(GSE60143)/Homer
AT3G52440(C2C2dof)/colamp−A T3G52440−D AP−Seq(GSE60143)/Homer
MYB116(MYB)/colamp−MYB116−D AP−Seq(GSE60143)/Homer
AtIDD11(C2H2)/colamp−AtIDD11−D AP−Seq(GSE60143)/Homer
ZFX(Zf)/mES−Zfx−ChIP−Seq(GSE11431)/Homer
DMRT1(DM)/Testis−DMR T1−ChIP−Seq(GSE64892)/Homer
MGP(C2H2)/colamp−MGP−D AP−Seq(GSE60143)/Homer
IDD7(C2H2)/col−IDD7−D AP−Seq(GSE60143)/Homer
VND6(NAC)/col−VND6−D AP−Seq(GSE60143)/Homer
NUC(C2H2)/col−NUC−D AP−Seq(GSE60143)/Homer
IDD2(C2H2)/colamp−IDD2−D AP−Seq(GSE60143)/Homer
KAN2(G2lik e)/colamp−KAN2−D AP−Seq(GSE60143)/Homer
HSFB3(HSF)/colamp−HSFB3−D AP−Seq(GSE60143)/Homer
Gata4(Zf)/Hear t−Gata4−ChIP−Seq(GSE35151)/Homer
KLF5(Zf)/LoV o−KLF5−ChIP−Seq(GSE49402)/Homer
GATA3(Zf)/iT reg−Gata3−ChIP−Seq(GSE20898)/Homer
KLF14(Zf)/HEK293−KLF14.GFP−ChIP−Seq(GSE58341)/Homer
Atf2(bZIP)/3T3L1−Atf2−ChIP−Seq(GSE56872)/Homer
ANAC087(NAC)/col−ANA C087−DAP−Seq(GSE60143)/Homer
TGA3(bZIP)/colamp−TGA3−D AP−Seq(GSE60143)/Homer
FRS9(ND)/col−FRS9−D AP−Seq(GSE60143)/Homer
PU.1(ETS)/ThioMac−PU.1−ChIP−Seq(GSE21512)/Homer
Ets1−distal(ETS)/CD4+−P olII−ChIP−Seq(Barski_et_al.)/Homer
CEBP(bZIP)/ThioMac−CEBPb−ChIP−Seq(GSE21512)/Homer
VRN1(ABI3VP1)/col−VRN1−D AP−Seq(GSE60143)/Homer
HNF1b(Homeobo x)/PDAC−HNF1B−ChIP−Seq(GSE64557)/Homer
ZBTB33(Zf)/GM12878−ZBTB33−ChIP−Seq(GSE32465)/Homer
OCT:OCT(POU ,Homeobo x)/NPC−OCT6−ChIP−Seq(GSE43916)/Homer
Sox4(HMG)/proB−So x4−ChIP−Seq(GSE50066)/Homer
bZIP44(bZIP)/colamp−bZIP44−D AP−Seq(GSE60143)/Homer
Tbet(T−bo x)/CD8−Tbet−ChIP−Seq(GSE33802)/Homer
Eomes(T−bo x)/H9−Eomes−ChIP−Seq(GSE26097)/Homer
HAP3(CCAATHAP3)/col−HAP3−D AP−Seq(GSE60143)/Homer
AtHB32(ZFHD)/col200−AtHB32−D AP−Seq(GSE60143)/Homer
At5g29000(G2lik e)/col−At5g29000−D AP−Seq(GSE60143)/Homer
KANADI1(Myb)/Seedling−KAN1−ChIP−Seq(GSE48081)/Homer
RKD2(RWPRK)/colamp−RKD2−D AP−Seq(GSE60143)/Homer
ATHB13(Homeobo x)/col−ATHB13−DAP−Seq(GSE60143)/Homer
HY5(bZIP)/colamp−HY5−D AP−Seq(GSE60143)/Homer
KLF10(Zf)/HEK293−KLF10.GFP−ChIP−Seq(GSE58341)/Homer
PU.1:IRF8(ETS:IRF)/pDC−Irf8−ChIP−Seq(GSE66899)/Homer
ARF2(ARF)/col−ARF2−D AP−Seq(GSE60143)/Homer
IRF3(IRF)/BMDM−Irf3−ChIP−Seq(GSE67343)/Homer
ERF3(AP2EREBP)/colamp−ERF3−D AP−Seq(GSE60143)/Homer
bZIP68(bZIP)/col−bZIP68−D AP−Seq(GSE60143)/Homer
Brn2(POU,Homeobo x)/NPC−Br n2−ChIP−Seq(GSE35496)/Homer
Cux2(Homeobo x)/Liver−Cux2−ChIP−Seq(GSE35985)/Homer
NFAT:AP1(RHD ,bZIP)/J urkat−NFATC1−ChIP−Seq(Jolma_et_al.)/Homer
MafF(bZIP)/HepG2−MafF−ChIP−Seq(GSE31477)/Homer
ATHB5(HB)/colamp−A THB5−DAP−Seq(GSE60143)/Homer
SeqBias: polyC−repeat
AREB3(bZIP)/col−AREB3−D AP−Seq(GSE60143)/Homer
HOXB13(Homeobo x)/ProstateT umor−HOXB13−ChIP−Seq(GSE56288)/Homer
HAT2(Homeobo x)/colamp−HA T2−DAP−Seq(GSE60143)/Homer
E−box(bHLH)/Promoter/Homer
MYB40(MYB)/col−MYB40−D AP−Seq(GSE60143)/Homer
ZEB1(Zf)/PD AC−ZEB1−ChIP−Seq(GSE64557)/Homer
Sp1(Zf)/Promoter/Homer
RORgt(NR)/EL4−R ORgt.Flag−ChIP−Seq(GSE56019)/Homer
bHLH18(bHLH)/col−bHLH18−D AP−Seq(GSE60143)/Homer
BIM3(bHLH)/col−BIM3−D AP−Seq(GSE60143)/Homer
KLF6(Zf)/PD AC−KLF6−ChIP−Seq(GSE64557)/Homer
dHNF4(NR)/Fly−HNF4−ChIP−Seq(GSE73675)/Homer
Gata2(Zf)/K562−GA TA2−ChIP−Seq(GSE18829)/Homer
Gata1(Zf)/K562−GA TA1−ChIP−Seq(GSE18829)/Homer
BIM1(bHLH)/colamp−BIM1−D AP−Seq(GSE60143)/Homer
PRDM14(Zf)/H1−PRDM14−ChIP−Seq(GSE22767)/Homer
TFE3(bHLH)/MEF−TFE3−ChIP−Seq(GSE75757)/Homer
HSF21(HSF)/col−HSF21−D AP−Seq(GSE60143)/Homer
JunD(bZIP)/K562−J unD−ChIP−Seq/Homer
TGA5(bZIP)/col−TGA5−D AP−Seq(GSE60143)/Homer
ANAC079(NAC)/colamp−ANA C079−DAP−Seq(GSE60143)/Homer
TCP17(TCP)/col−TCP17−D AP−Seq(GSE60143)/Homer
FOXA1:AR(F orkhead,NR)/LNCAP−AR−ChIP−Seq(GSE27824)/Homer
STZ(C2H2)/colamp−STZ−D AP−Seq(GSE60143)/Homer
TEAD2(TEA)/Py2T−T ead2−ChIP−Seq(GSE55709)/Homer
HSFA6A(HSF)/col−HSF A6A−DAP−Seq(GSE60143)/Homer
PR(NR)/T47D−PR−ChIP−Seq(GSE31130)/Homer
BATF(bZIP)/Th17−BA TF−ChIP−Seq(GSE39756)/Homer
SeqBias: A/T bias
PCF/Arabidopsis−Promoters/Homer
Zfp809(Zf)/ES−Zfp809−ChIP−Seq(GSE70799)/Homer
MYB96(MYB)/colamp−MYB96−D AP−Seq(GSE60143)/Homer
HSF7(HSF)/colamp−HSF7−D AP−Seq(GSE60143)/Homer
Slug(Zf)/Mesoder m−Snai2−ChIP−Seq(GSE61475)/Homer
Bach1(bZIP)/K562−Bach1−ChIP−Seq(GSE31477)/Homer
SeqBias: G/A bias
ANAC004(NAC)/colamp−ANA C004−DAP−Seq(GSE60143)/Homer
TGA1(bZIP)/colamp−TGA1−D AP−Seq(GSE60143)/Homer
FEA4(bZIP)/Cor n−FEA4−ChIP−Seq(GSE61954)/Homer
p63(p53)/K eratinocyte−p63−ChIP−Seq(GSE17611)/Homer
AP−1(bZIP)/ThioMac−PU.1−ChIP−Seq(GSE21512)/Homer
Atf3(bZIP)/GBM−A TF3−ChIP−Seq(GSE33912)/Homer
SeqBias: T A−repeat
AT3G09735(S1F alike)/col−AT3G09735−D AP−Seq(GSE60143)/Homer
Atf7(bZIP)/3T3L1−Atf7−ChIP−Seq(GSE56872)/Homer
STAT6(Stat)/CD4−Stat6−ChIP−Seq(GSE22104)/Homer
Nr5a2(NR)/mES−Nr5a2−ChIP−Seq(GSE19019)/Homer
DEL2(E2FDP)/col−DEL2−D AP−Seq(GSE60143)/Homer
ZNF165(Zf)/WHIM12−ZNF165−ChIP−Seq(GSE65937)/Homer
X−box(HTH)/NPC−H3K4me1−ChIP−Seq(GSE16256)/Homer
ASHR1(ND)/col−ASHR1−D AP−Seq(GSE60143)/Homer
Initiator/Drosophila−Promoters/Homer
bZIP18(bZIP)/colamp−bZIP18−D AP−Seq(GSE60143)/Homer
ANAC057(NAC)/colamp−ANA C057−DAP−Seq(GSE60143)/Homer
ZNF382(Zf)/HEK293−ZNF382.GFP−ChIP−Seq(GSE58341)/Homer
AP−2alpha(AP2)/Hela−AP2alpha−ChIP−Seq(GSE31477)/Homer
VIP1(bZIP)/col−VIP1−D AP−Seq(GSE60143)/Homer
Ronin(THAP)/ES−Thap11−ChIP−Seq(GSE51522)/Homer
SND3(NAC)/col−SND3−D AP−Seq(GSE60143)/Homer
SND2(NAC)/colamp−SND2−D AP−Seq(GSE60143)/Homer
ANAC020(NAC)/col−ANA C020−DAP−Seq(GSE60143)/Homer
NAC2(NAC)/colamp−NA C2−DAP−Seq(GSE60143)/Homer
Gfi1b(Zf)/HPC7−Gfi1b−ChIP−Seq(GSE22178)/Homer
ANAC038(NAC)/col−ANA C038−DAP−Seq(GSE60143)/Homer
Nkx2.5(Homeobo x)/HL1−Nkx2.5.biotin−ChIP−Seq(GSE21529)/Homer
ATY13(MYB)/col−A TY13−DAP−Seq(GSE60143)/Homer
Brachyury(T−box)/Mesoendoder m−Brachyury−ChIP−e xo(GSE54963)/Homer
ANL2(HB)/col−ANL2−D AP−Seq(GSE60143)/Homer
EWS:ERG−fusion(ETS)/CADO_ES1−EWS:ERG−ChIP−Seq(SRA014231)/Homer
SPCH(bHLH)/Seedling−SPCH−ChIP−Seq(GSE57497)/Homer
CAMTA1(CAMTA)/col−CAMT A1−DAP−Seq(GSE60143)/Homer
ANAC058(NAC)/col−ANA C058−DAP−Seq(GSE60143)/Homer
ANAC075(NAC)/col−ANA C075−DAP−Seq(GSE60143)/Homer
Pit1(Homeobo x)/GCrat−Pit1−ChIP−Seq(GSE58009)/Homer
ANAC096(NAC)/colamp−ANA C096−DAP−Seq(GSE60143)/Homer
MafA(bZIP)/Islet−MafA−ChIP−Seq(GSE30298)/Homer
c−Myc(bHLH)/LNCAP−cMyc−ChIP−Seq(Unpub lished)/Homer
TCP3(TCP)/colamp−TCP3−D AP−Seq(GSE60143)/Homer
BMAL1(bHLH)/Liv er−Bmal1−ChIP−Seq(GSE39860)/Homer
At5g08750(C3H)/col−At5g08750−D AP−Seq(GSE60143)/Homer
ANAC028(NAC)/col−ANA C028−DAP−Seq(GSE60143)/Homer
ANAC005(NAC)/col−ANA C005−DAP−Seq(GSE60143)/Homer
FHY3(FAR1)/Ar abidopsis−FHY3−ChIP−Seq(GSE30711)/Homer
TEAD(TEA)/Fibrob last−PU.1−ChIP−Seq(Unpub lished)/Homer
SeqBias: GCW−tr iplet
HSFA6B(HSF)/colamp−HSF A6B−D AP−Seq(GSE60143)/Homer
Pit1+1bp(Homeobo x)/GCrat−Pit1−ChIP−Seq(GSE58009)/Homer
JunB(bZIP)/Dendr iticCells−J unb−ChIP−Seq(GSE36099)/Homer
At5g04390(C2H2)/col200−At5g04390−D AP−Seq(GSE60143)/Homer
At2g33710(AP2EREBP)/colamp−At2g33710−D AP−Seq(GSE60143)/Homer
CRE(bZIP)/Promoter/Homer
Pax7(Paired,Homeobo x),long/My oblast−Pax7−ChIP−Seq(GSE25064)/Homer
GAGA−repeat/Ar abidopsis−Promoters/Homer
RARg(NR)/ES−RARg−ChIP−Seq(GSE30538)/Homer
E2A(bHLH),near_PU.1/Bcell−PU.1−ChIP−Seq(GSE21512)/Homer
AT1G72740(MYBrelated)/colamp−A T1G72740−D AP−Seq(GSE60143)/Homer
PTF1(TCP)/colamp−PTF1−D AP−Seq(GSE60143)/Homer
EBF(EBF)/proBcell−EBF−ChIP−Seq(GSE21978)/Homer
HLH−1(bHLH)/cElegans−Embr yo−HLH1−ChIP−Seq(modEncode)/Homer
IBL1(bHLH)/Seedling−IBL1−ChIP−Seq(GSE51120)/Homer
GATA20(C2C2gata)/colamp−GA TA20−DAP−Seq(GSE60143)/Homer
GFY−Staf(?,Zf)/Promoter/Homer
SUT1?/SacCer−Promoters/Homer
Unknown3/Ar abidopsis−Promoters/Homer
REB1/SacCer−Promoters/Homer
NF1−halfsite(CTF)/LNCaP−NF1−ChIP−Seq(Unpub lished)/Homer
RAV1(RAV)/colamp−RA V1−DAP−Seq(GSE60143)/Homer
SeqBias: CG bias
HAT5(Homeobo x)/colamp−HA T5−DAP−Seq(GSE60143)/Homer
ETS(ETS)/Promoter/Homer
ELF1(ETS)/J urkat−ELF1−ChIP−Seq(SRA014231)/Homer
AP−2gamma(AP2)/MCF7−TF AP2C−ChIP−Seq(GSE21234)/Homer
ZNF322(Zf)/HEK293−ZNF322.GFP−ChIP−Seq(GSE58341)/Homer
MYB17(MYB)/colamp−MYB17−D AP−Seq(GSE60143)/Homer
TCP16(TCP)/colamp−TCP16−D AP−Seq(GSE60143)/Homer
SeqBias: polyA−repeat
THRb(NR)/Liv er−NR1A2−ChIP−Seq(GSE52613)/Homer
SeqBias: GA−repeat
NGA4(ABI3VP1)/col−NGA4−D AP−Seq(GSE60143)/Homer
Mef2c(MADS)/GM12878−Mef2c−ChIP−Seq(GSE32465)/Homer
Tcfcp2l1(CP2)/mES−Tcfcp2l1−ChIP−Seq(GSE11431)/Homer
PRDM9(Zf)/Testis−DMC1−ChIP−Seq(GSE35498)/Homer
ETS1(ETS)/J urkat−ETS1−ChIP−Seq(GSE17954)/Homer
Unknown2/Drosophila−Promoters/Homer
IDD4(C2H2)/col−IDD4−D AP−Seq(GSE60143)/Homer
GTL1(Trihelix)/colamp−GTL1−D AP−Seq(GSE60143)/Homer
Bach2(bZIP)/OCIL y7−Bach2−ChIP−Seq(GSE44420)/Homer
LXRE(NR),DR4/RA W−LXRb.biotin−ChIP−Seq(GSE21512)/Homer
Mef2b(MADS)/HEK293−Mef2b .V5−ChIP−Seq(GSE67450)/Homer
Jun−AP1(bZIP)/K562−cJ un−ChIP−Seq(GSE31477)/Homer
GT3a(Trihelix)/col−GT3a−D AP−Seq(GSE60143)/Homer
Atf1(bZIP)/K562−A TF1−ChIP−Seq(GSE31477)/Homer
SF1(NR)/H295R−Nr5a1−ChIP−Seq(GSE44220)/Homer
NF−E2(bZIP)/K562−NFE2−ChIP−Seq(GSE31477)/Homer
Fra2(bZIP)/Str iatum−Fr a2−ChIP−Seq(GSE43429)/Homer
Mef2a(MADS)/HL1−Mef2a.biotin−ChIP−Seq(GSE21529)/Homer
Fra1(bZIP)/BT549−Fr a1−ChIP−Seq(GSE46166)/Homer
MYB30(MYB)/colamp−MYB30−D AP−Seq(GSE60143)/Homer
MYB94(MYB)/col−MYB94−D AP−Seq(GSE60143)/Homer
Fosl2(bZIP)/3T3L1−F osl2−ChIP−Seq(GSE56872)/Homer
REM19(REM)/colamp−REM19−D AP−Seq(GSE60143)/Homer
DREF/Drosophila−Promoters/Homer
TRP2(MYBrelated)/colamp−TRP2−D AP−Seq(GSE60143)/Homer
Nr5a2(NR)/P ancreas−LRH1−ChIP−Seq(GSE34295)/Homer
ISRE(IRF)/ThioMac−LPS−Expression(GSE23622)/Homer
IRF2(IRF)/Er ythrob las−IRF2−ChIP−Seq(GSE36985)/Homer
PQM−1(?)/cElegans−L3−ChIP−Seq(modEncode)/Homer
Otx2(Homeobo x)/EpiLC−Otx2−ChIP−Seq(GSE56098)/Homer
EWS:FLI1−fusion(ETS)/SK_N_MC−EWS:FLI1−ChIP−Seq(SRA014231)/Homer
TF3A(C2H2)/col−TF3A−D AP−Seq(GSE60143)/Homer
SVP(MADS)/col−SVP−D AP−Seq(GSE60143)/Homer
NF1:FOXA1(CTF,Forkhead)/LNCAP−FO XA1−ChIP−Seq(GSE27824)/Homer
AGL63(MADS)/col−A GL63−DAP−Seq(GSE60143)/Homer
Nkx6.1(Homeobo x)/Islet−Nkx6.1−ChIP−Seq(GSE40975)/Homer
GAGA−repeat/SacCer−Promoters/Homer
Esrrb(NR)/mES−Esrrb−ChIP−Seq(GSE11431)/Homer
WRKY50(WRKY)/col−WRKY50−D AP−Seq(GSE60143)/Homer
MYB113(MYB)/col−MYB113−D AP−Seq(GSE60143)/Homer
AT1G10720(BSD)/col−A T1G10720−D AP−Seq(GSE60143)/Homer
WRKY11(WRKY)/col−WRKY11−D AP−Seq(GSE60143)/Homer
AT1G23810(Or phan)/col−A T1G23810−D AP−Seq(GSE60143)/Homer
ETS:RUNX(ETS ,Runt)/Jurkat−RUNX1−ChIP−Seq(GSE17954)/Homer
Mef2d(MADS)/Retina−Mef2d−ChIP−Seq(GSE61391)/Homer
E2F3(E2F)/MEF−E2F3−ChIP−Seq(GSE71376)/Homer
ANAC062(NAC)/colamp−ANA C062−DAP−Seq(GSE60143)/Homer
ETS:E−bo x(ETS ,bHLH)/HPC7−Scl−ChIP−Seq(GSE22178)/Homer
MITF(bHLH)/MastCells−MITF−ChIP−Seq(GSE48085)/Homer
c−Jun−CRE(bZIP)/K562−cJ un−ChIP−Seq(GSE31477)/Homer
Tbx20(T−bo x)/Hear t−Tbx20−ChIP−Seq(GSE29636)/Homer
Sox2(HMG)/mES−So x2−ChIP−Seq(GSE11431)/Homer
ELT−3(Gata)/cElegans−L1−EL T3−ChIP−Seq(modEncode)/Homer
WRKY46(WRKY)/colamp−WRKY46−D AP−Seq(GSE60143)/Homer
TOD6?/SacCer−Promoters/Homer
bZIP53(bZIP)/colamp−bZIP53−D AP−Seq(GSE60143)/Homer
SeqBias: CA−repeat
MYB63(MYB)/col−MYB63−D AP−Seq(GSE60143)/Homer
MYB70(MYB)/col−MYB70−D AP−Seq(GSE60143)/Homer
OCT:OCT−shor t(POU,Homeobo x)/NPC−OCT6−ChIP−Seq(GSE43916)/Homer
FUS3(ABI3VP1)/col−FUS3−D AP−Seq(GSE60143)/Homer
At5g08520(MYBrelated)/colamp−At5g08520−D AP−Seq(GSE60143)/Homer
CRX(Homeobo x)/Retina−Crx−ChIP−Seq(GSE20012)/Homer
SHN3(AP2EREBP)/col−SHN3−D AP−Seq(GSE60143)/Homer
HAT1(Homeobo x)/col−HAT1−DAP−Seq(GSE60143)/Homer
BPC1(BBRBPC)/colamp−BPC1−D AP−Seq(GSE60143)/Homer
RLR1?/SacCer−Promoters/Homer
AGL13(MADS)/col−A GL13−DAP−Seq(GSE60143)/Homer
MYB3R4(MYB)/col−MYB3R4−D AP−Seq(GSE60143)/Homer
AT3G10030(T rihelix)/colamp−A T3G10030−D AP−Seq(GSE60143)/Homer
AT2G33550(T rihelix)/colamp−A T2G33550−D AP−Seq(GSE60143)/Homer
NFkB−p50,p52(RHD)/Monocyte−p50−ChIP−Chip(Schreiber_et_al.)/Homer
Bapx1(Homeobo x)/VertebralCol−Bapx1−ChIP−Seq(GSE36672)/Homer
HRE(HSF)/Str iatum−HSF1−ChIP−Seq(GSE38000)/Homer
Tbr1(T−bo x)/Cor tex−Tbr1−ChIP−Seq(GSE71384)/Homer
Erra(NR)/HepG2−Err a−ChIP−Seq(GSE31477)/Homer
p73(p53)/T rachea−p73−ChIP−Seq(PRJNA310161)/Homer
Nkx2.1(Homeobo x)/LungA C−Nkx2.1−ChIP−Seq(GSE43252)/Homer
PBX1(Homeobo x)/MCF7−PBX1−ChIP−Seq(GSE28007)/Homer
HSFC1(HSF)/col−HSFC1−D AP−Seq(GSE60143)/Homer
TCP1(TCP)/col−TCP1−D AP−Seq(GSE60143)/Homer
AT5G47660(T rihelix)/colamp−A T5G47660−D AP−Seq(GSE60143)/Homer
MYB92(MYB)/colamp−MYB92−D AP−Seq(GSE60143)/Homer
ERG(ETS)/VCaP−ERG−ChIP−Seq(GSE14097)/Homer
Etv2(ETS)/ES−ER71−ChIP−Seq(GSE59402)/Homer(0.967)
Nrf2(bZIP)/L ymphob last−Nrf2−ChIP−Seq(GSE37589)/Homer
ATHB18(Homeobo x)/colamp−A THB18−DAP−Seq(GSE60143)/Homer
Nkx2.2(Homeobo x)/NPC−Nkx2.2−ChIP−Seq(GSE61673)/Homer
ETV1(ETS)/GIST48−ETV1−ChIP−Seq(GSE22441)/Homer
Pknox1(Homeobo x)/ES−Prep1−ChIP−Seq(GSE63282)/Homer
GSC(Homeobo x)/FrogEmbr yos−GSC−ChIP−Seq(DRA000576)/Homer
Pbx3(Homeobo x)/GM12878−PBX3−ChIP−Seq(GSE32465)/Homer
WRKY8(WRKY)/colamp−WRKY8−D AP−Seq(GSE60143)/Homer
ANAC094(NAC)/col−ANA C094−DAP−Seq(GSE60143)/Homer
IDD5(C2H2)/colamp−IDD5−D AP−Seq(GSE60143)/Homer
ATHB53(HB)/col−A THB53−DAP−Seq(GSE60143)/Homer
At3g11280(MYBrelated)/col−At3g11280−D AP−Seq(GSE60143)/Homer
At5g05790(MYBrelated)/col−At5g05790−D AP−Seq(GSE60143)/Homer
Fli1(ETS)/CD8−FLI−ChIP−Seq(GSE20898)/Homer
EHF(ETS)/LoV o−EHF−ChIP−Seq(GSE49402)/Homer
GABPA(ETS)/J urkat−GABP a−ChIP−Seq(GSE17954)/Homer
HRE(HSF)/HepG2−HSF1−ChIP−Seq(GSE31477)/Homer
Lhx2(Homeobo x)/HFSC−Lhx2−ChIP−Seq(GSE48068)/Homer
ANAC045(NAC)/col−ANA C045−DAP−Seq(GSE60143)/Homer
EKLF(Zf)/Er ythrocyte−Klf1−ChIP−Seq(GSE20478)/Homer
Oct4(POU,Homeobo x)/mES−Oct4−ChIP−Seq(GSE11431)/Homer
TBP3(MYBrelated)/col−TBP3−D AP−Seq(GSE60143)/Homer
PAX3:FKHR−fusion(P aired,Homeobo x)/Rh4−PAX3:FKHR−ChIP−Seq(GSE19063)/Homer
BORIS(Zf)/K562−CTCFL−ChIP−Seq(GSE32465)/Homer
GFY(?)/Promoter/Homer
Maz(Zf)/HepG2−Maz−ChIP−Seq(GSE31477)/Homer
OCT4−SOX2−TCF−NANOG(POU ,Homeobo x,HMG)/mES−Oct4−ChIP−Seq(GSE11431)/Homer
Klf4(Zf)/mES−Klf4−ChIP−Seq(GSE11431)/Homer
p53(p53)/Saos−p53−ChIP−Seq/Homer
p53(p53)/Saos−p53−ChIP−Seq(GSE15780)/Homer
ELF3(ETS)/PD AC−ELF3−ChIP−Seq(GSE64557)/Homer
EBF1(EBF)/Near−E2A−ChIP−Seq(GSE21512)/Homer
0 0.5 1 1.5
Value
0
2
0
0
6
0
0
1
0
0
0
Color Key
and Histogram
C
o
u
n
t
A.
R
27
3C
Y2
20
C
Y2
34
C
R
27
3H
W
T.
O
E
R273H;motif_25−A TATGTRTGT,BestGuess:Cf2/MA0015.1/J aspar(0.781)
R273H;motif_24−A GAGGAGGAG,BestGuess:TF3A(C2H2)/col−TF3A−D AP−Seq(GSE60143)/Homer(0.849)
R273H;motif_23−A TCCGTCCAT,BestGuess:FHL1(MacIsaac)/Y east(0.799)
R273C;motif_24−GGGAAAA TTT,BestGuess:SFP1/SacCer−Promoters/Homer(0.787)
R273C;motif_14−GTGA TGAAAC,BestGuess:Chop(bZIP)/MEF−Chop−ChIP−Seq(GSE35681)/Homer(0.801)
R273C;motif_22−STCTGCA CTG,BestGuess:PB0091.1_Zbtb3_1/J aspar(0.745)
R273C;motif_16−GCCKGYCGST ,BestGuess:Med/dmmpmm(P ollard)/fly(0.661)
R273C;motif_19−TGTGTCA CAA,BestGuess:CUP9/MA0288.1/J aspar(0.777)
R273C;motif_5−AAAAAKYTCT ,BestGuess:HNRNPC(RRM)/Homo_sapiens−RNCMPT00025−PBM/HughesRNA(0.730)
R273C;motif_4−AA GGGACCAT,BestGuess:TCP5/MA1067.1/J aspar(0.752)
R273C;motif_7−TGTTTGCTTT ,BestGuess:pha−4/MA0546.1/J aspar(0.838)
Y220C;motif_24−CTT AGCAGAC,BestGuess:RIM101/Liter ature(Harbison)/Y east(0.689)
R273H;motif_19−SCCTTT ACCA,BestGuess:PCBP1(KH)/Mus_m usculus−RNCMPT00239−PBM/HughesRNA(0.712)
R273H;motif_10−TCA TTTGGGT,BestGuess:Hr46/dmmpmm(P ollard)/fly(0.771)
R273H;motif_22−CGCCCGGGGA,BestGuess:SUT1?/SacCer−Promoters/Homer(0.759)
R273H;motif_20−A GGGCCAATA,BestGuess:NLP7(R WPRK)/col−NLP7−D AP−Seq(GSE60143)/Homer(0.680)
Y234C;motif_25−GGA GGCCTCT,BestGuess:ZFX(Zf)/mES−Zfx−ChIP−Seq(GSE11431)/Homer(0.679)
Y220C;motif_11−CTGT AGGCTT,BestGuess:SRS7(SRS)/colamp−SRS7−D AP−Seq(GSE60143)/Homer(0.652)
Y220C;motif_2−CGASA GGGCG,BestGuess:HNRNPH2(RRM)/Homo_sapiens−RNCMPT00160−PBM/HughesRNA(0.740)
R273C;motif_25−CTGCCT AAAG,BestGuess:MYB116(MYB)/colamp−MYB116−D AP−Seq(GSE60143)/Homer(0.701)
R273C;motif_17−A GCAGGCGCG,BestGuess:Slug(Zf)/Mesoder m−Snai2−ChIP−Seq(GSE61475)/Homer(0.705)
R273C;motif_13−TTCA GGATCC,BestGuess:ttk/dmmpmm(Bigf oot)/fly(0.736)
R273C;motif_2−AA TTACAGTG,BestGuess:PUM(PUF)/Drosophila_melanogaster−RNCMPT00105−PBM/HughesRNA(0.797)
R273C;motif_10−CCAA GAACGA,BestGuess:RIM101/MA0368.1/J aspar(0.697)
R273C;motif_1−GCGTTCA GCC,BestGuess:Initiator/Drosophila−Promoters/Homer(0.707)
R273C;motif_12−NCGA CCATAS,BestGuess:GLI2/MA0734.1/J aspar(0.772)
R273C;motif_15−TTTCTBGA TT,BestGuess:RLR1?/SacCer−Promoters/Homer(0.700)
R273C;motif_6−A CGGGWAACC,BestGuess:STB2(MacIsaac)/Y east(0.768)
R273C;motif_3−A TAACCCCGG,BestGuess:STB5/STB5_YPD/[](Harbison)/Y east(0.782)
WT−OE;motif_18−GTCAA GAGCT,BestGuess:vnd/dmmpmm(P ollard)/fly(0.710)
WT−OE;motif_22−CTTGA CAGCT,BestGuess:PH0170.1_Tgif2/J aspar(0.843)
Y234C;motif_24−CT ACGGAGGT,BestGuess:LIN28A(CSD)/Homo_sapiens−RNCMPT00162−PBM/HughesRNA(0.796)
R273H;motif_8−T AGCGCCCGC,BestGuess:br k/dmmpmm(Do wn)/fly(0.704)
R273H;motif_7−GA CTGACCTC,BestGuess:COUP−TFII(NR)/Ar tia−Nr2f2−ChIP−Seq(GSE46497)/Homer(0.780)
R273H;motif_14−TTMTGGA GGT,BestGuess:WIP5(C2H2)/colamp−WIP5−D AP−Seq(GSE60143)/Homer(0.722)
WT−OE;motif_3−TTGAA CTCCT,BestGuess:ct/MA0218.1/J aspar(0.770)
R273H;motif_1−RGGA GTTCWR,BestGuess:ADR1/Liter ature(Harbison)/Y east(0.644)
WT−OE;motif_21−T ACTAAAATT,BestGuess:PH0075.1_Ho xd10/Jaspar(0.791)
WT−OE;motif_8−TTTTGCAAA T,BestGuess:PB0145.1_Mafb_2/J aspar(0.810)
R273H;motif_18−GGGGAA GGGA,BestGuess:ZNF467(Zf)/HEK293−ZNF467.GFP−ChIP−Seq(GSE58341)/Homer(0.852)
R273H;motif_13−CCGA GTTCTT,BestGuess:PEND/MA0127.1/J aspar(0.643)
R273H;motif_11−GCTCA GGTGA,BestGuess:RA V1(2)(AP2/EREBP)/Ar abidopsis thaliana/AthaMap(0.803)
WT−OE;motif_15−CGT ACCACCA,BestGuess:schlank/MA0193.1/J aspar(0.756)
R273H;motif_6−GAAA TBAGGC,BestGuess:A T2G31460(REMB3)/col−A T2G31460−D AP−Seq(GSE60143)/Homer(0.708)
R273H;motif_3−GA GGGSCGGG,BestGuess:Maz(Zf)/HepG2−Maz−ChIP−Seq(GSE31477)/Homer(0.758)
WT−OE;motif_14−GTCCA GGTCG,BestGuess:WIP5(C2H2)/colamp−WIP5−D AP−Seq(GSE60143)/Homer(0.773)
R273H;motif_4−CAKGGTCA CT,BestGuess:R TG3/Liter ature(Harbison)/Y east(0.701)
R273H;motif_2−CCCTCAA CAT,BestGuess:z/dmmpmm(SeSiMCMC)/fly(0.664)
R273H;motif_9−GCT ACCCCCA,BestGuess:Klf4(Zf)/mES−Klf4−ChIP−Seq(GSE11431)/Homer(0.746)
WT−OE;motif_9−SA GCAGCCCT,BestGuess:ERF15(AP2EREBP)/colamp−ERF15−D AP−Seq(GSE60143)/Homer(0.664)
WT−OE;motif_10−GGAAAA GAVG,BestGuess:NF ATC2/MA0152.1/J aspar(0.774)
R273H;motif_5−GA GCCGCGCC ,BestGuess:RBM4(RRM,Znf)/Homo_sapiens−RNCMPT00052−PBM/HughesRNA(0.749)
WT−OE;motif_1−GA GGCAGCCT,BestGuess:GCR1/Liter ature(Harbison)/Y east(0.769)
Y234C;motif_2−GSGCKGGGA C,BestGuess:SUT1?/SacCer−Promoters/Homer(0.903)
WT−OE;motif_2−GGGGCT ACAT,BestGuess:PCF5(TCP)/Or yza sativ a/AthaMap(0.754)
Y234C;motif_22−TTTCKTGCTT ,BestGuess:NA C058/MA0938.1/J aspar(0.701)
WT−OE;motif_6−GGGCCCTRGG,BestGuess:OJ1581_H09.2/MA1031.1/J aspar(0.744)
WT−OE;motif_4−CCCA GCCCCT,BestGuess:Sp1(Zf)/Promoter/Homer(0.748)
Y234C;motif_3−CTCGGV ACCC,BestGuess:AFT2(MacIsaac)/Y east(0.697)
Y220C;motif_7−GCTCTGGGCC ,BestGuess:SKN7(MacIsaac)/Y east(0.798)
Y234C;motif_4−GGGRCAA GAG,BestGuess:FMR1(KH)/Homo_sapiens−RNCMPT00016−PBM/HughesRNA(0.718)
Y234C;motif_6−CCCCAA CTTG,BestGuess:ADR1/MA0268.1/J aspar(0.735)
Y234C;motif_1−TGRHGGCYCT ,BestGuess:ERF105(AP2EREBP)/colamp−ERF105−D AP−Seq(GSE60143)/Homer(0.660)
Y220C;motif_1−CA CCGCTAGM,BestGuess:Run/dmmpmm(P apatsenk o)/fly(0.741)
Y220C;motif_5−CTTCCCCCGG,BestGuess:NHP10/MA0344.1/J aspar(0.728)
Y220C;motif_4−T ATGGCCGTT,BestGuess:MYB(HTH)/ERMYB−Myb−ChIPSeq(GSE22095)/Homer(0.753)
Y220C;motif_3−A TCCAAGTAC,BestGuess:RBM6(RRM)/Homo_sapiens−RNCMPT00170−PBM/HughesRNA(0.714)
Y220C;motif_6−AAA CCAGGCC,BestGuess:ZNF711(Zf)/SHSY5Y−ZNF711−ChIP−Seq(GSE20673)/Homer(0.749)
Y220C;motif_12−AA GCGTTTAC,BestGuess:BARHL2/MA0635.1/J aspar(0.729)
Y234C;motif_11−AA GCGTTTAC,BestGuess:BARHL2/MA0635.1/J aspar(0.729)
Y220C;motif_15−CCAA TTCGTG,BestGuess:PH0089.1_Isx/J aspar(0.686)
Y220C;motif_13−GT AGGCACGC,BestGuess:PHD1(MacIsaac)/Y east(0.775)
Y220C;motif_9−GCA TCACAGG,BestGuess:BR UNOL6(RRM)/Homo_sapiens−RNCMPT00187−PBM/HughesRNA(0.748)
Y220C;motif_20−CGGGT AACCC,BestGuess:STB2(MacIsaac)/Y east(0.853)
R273C;motif_11−A CCTGAGATT,BestGuess:Gfi1/MA0038.1/J aspar(0.715)
R273C;motif_18−AA CTAGTTAC,BestGuess:PH0040.1_Hmbo x1/Jaspar(0.810)
R273C;motif_8−A GAAGTTGRG,BestGuess:bHLH130(bHLH)/col−bHLH130−D AP−Seq(GSE60143)/Homer(0.647)
R273C;motif_9−AA GAGCACAA,BestGuess:NCU08034(RRM)/Neurospor a_crassa−RNCMPT00209−PBM/HughesRNA(0.704)
Y220C;motif_19−GA GTCCTTTA,BestGuess:PB0203.1_Zfp691_2/J aspar(0.689)
Y234C;motif_10−GCCCTCA GTT,BestGuess:Initiator/Drosophila−Promoters/Homer(0.726)
R273H;motif_21−CCSA GGRCRT,BestGuess:ttk/dmmpmm(P ollard)/fly(0.739)
WT−OE;motif_19−CCTGGT ACCA,BestGuess:TCP2/MA1064.1/J aspar(0.717)
R273C;motif_23−CCGCCCGCTC ,BestGuess:PB0010.1_Egr1_1/J aspar(0.798)
Y234C;motif_21−GA GCGGGCGG,BestGuess:PB0010.1_Egr1_1/J aspar(0.773)
R273H;motif_12−TGCRGCAA CG,BestGuess:SOK2/SOK2_B UT14/4−SUT1(Harbison)/Y east(0.687)
Y234C;motif_20−CTGCGCGAA G,BestGuess:PB0199.1_Zfp161_2/J aspar(0.689)
Y220C;motif_22−CGA GTTTCTC ,BestGuess:SRSF10(RRM)/Homo_sapiens−RNCMPT00019−PBM/HughesRNA(0.686)
Y220C;motif_18−CGGA TCGGGG,BestGuess:ASH1(MacIsaac)/Y east(0.782)
Y220C;motif_16−CTTCCGCGCT ,BestGuess:POL011.1_XCPE1/J aspar(0.748)
Y234C;motif_18−A TCCAAGTAC,BestGuess:RBM6(RRM)/Homo_sapiens−RNCMPT00170−PBM/HughesRNA(0.700)
Y234C;motif_9−A CGTGGGCGC ,BestGuess:Egr2(Zf)/Th ymocytes−Egr2−ChIP−Seq(GSE34254)/Homer(0.745)
Y220C;motif_8−TTCCTTCCTT ,BestGuess:RBM5(Znf)/Homo_sapiens−RNCMPT00055−PBM/HughesRNA(0.773)
Y234C;motif_7−A CCTTSCGCC ,BestGuess:AtMYB84(MYB)/Ar abidopsis thaliana/AthaMap(0.676)
Y234C;motif_23−A GGAAAGATA,BestGuess:BPC1(BBRBPC)/colamp−BPC1−D AP−Seq(GSE60143)/Homer(0.753)
Y234C;motif_16−CCT AGCGGAG,BestGuess:CHA4/MA0283.1/J aspar(0.734)
R273H;motif_17−T AAGAGCATG,BestGuess:EIF−2ALPHA(S1)/Drosophila_melanogaster−RNCMPT00273−PBM/HughesRNA(0.724)
Y220C;motif_10−CA GSAAAAAT,BestGuess:CUP2/MA0287.1/J aspar(0.838)
WT−OE;motif_11−GGCTTGTGCT ,BestGuess:NCU08034(RRM)/Neurospor a_crassa−RNCMPT00209−PBM/HughesRNA(0.706)
WT−OE;motif_23−TGTTGCTT AG,BestGuess:RA V1(1)(AP2/EREBP)/Ar abidopsis thaliana/AthaMap(0.718)
Y220C;motif_23−CA GCCTGAGC,BestGuess:ZNF519(Zf)/HEK293−ZNF519.GFP−ChIP−Seq(GSE58341)/Homer(0.731)
WT−OE;motif_20−AA TCTGAGGC,BestGuess:MET32(MacIsaac)/Y east(0.733)
WT−OE;motif_16−CCGA GGACTT,BestGuess:LIN28A(CSD)/Homo_sapiens−RNCMPT00162−PBM/HughesRNA(0.651)
WT−OE;motif_7−GCCGCGA GCG,BestGuess:ERF069/MA0997.1/J aspar(0.692)
WT−OE;motif_17−CAA GCTGATC,BestGuess:PL0001.1_hlh−11/J aspar(0.734)
R273H;motif_16−A GTSCYTGSC ,BestGuess:Zfx/MA0146.2/J aspar(0.705)
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Inferring transcriptional activities of different p53 mutants by integrated analysis of ChIP 
Seq and RNA Seq 
 
The p53 can function as both a direct transcriptional activator and an indirect transcriptional 
repressor. We thus, examined how the promoter binding affected the expression of target genes 
by comparing the expression level in each cell to the average levels in other cell lines. In general, 
weakly invasive mutants targeted considerably more genes and induced broader and more 
significant expressional changes (Fig 2.11). Further, when we examined the expression changes 
in each cell line, a large fraction (66%) of genes differentially expressed by R273H (but not 
Y234C) were direct binding targets, indicating more active transcriptional function of R273H upon 
binding to its targets. In contrast, much less influence on gene expression of strongly invasive 
mutants implied alternative modes of driving aggressiveness (e.g., via protein interaction with 
ETS). Overall, our integrated analysis revealed both loss and gain of DNA binding function of 
different mutant p53 proteins, which in part explains the phenotypic heterogeneity. 
 
Though the overall trend of expression direction for each p53 mutant was not statistically 
significant in GSEA test, expressions of many target genes were differentially regulated. For 
example, we identified genes such as TFAP2A, whose promoter region was occupied by Y234C 
and displayed a 2-fold increase in RNA expression. Overexpression of this gene decreases cell 
migration and invasion (Huang 2016), which corresponded with the phenotype of Y234C as the 
least invasive p53 mutant among the ten chosen p53 missense mutants. A negative correlation 
with RNA expression level and invasion/migration level was also observed. p53-Y234C protein 
bound to promoter of CASZ1, a zinc finger transcription factor that functions as a tumor 
suppressor, and its expression level dropped to 0 in Y234C cells. Interestingly, in the TCGA data, 
breast cancer patients with CASZ1 mutation have a significantly shorter survival time (P < 0.05). 
We also identified genes such as BCKDK, whose promoter was occupied by mutants R273H and 
Y234C and displayed a 4-fold increase and 2-fold decrease in RNA expression respectively. 
BCKDK can enhance MAPK signaling pathway through direct MEK phosphorylation (Xue 2017) 
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and promotes pro-apoptotic response to genotoxic stress (Haydn 2014). Interestingly, R273H 
cells were sensitive to apoptosis while Y234C cells were insensitive to Doxorubicin treatment. 
 
In summary, the neo-morphic phenotypes of the p53 missense mutants or the phenotypic 
heterogeneity observed across the p53 mutants can be attributed to altered DNA binding by 
mutated p53 transcription factors resulting in up or down regulation of target genes (canonical 
and non-canonical) which in turn affect cellular pathways. 
 
 
 
Figure 2.11. Integrated analysis of ChIP Seq and RNA Seq. Expression of 1,263 combined 
target genes of all mutant p53 proteins in each cell were compared to average expression in 
other 9 mutant p53-expressing cells. Color coded are differentially expressed genes (DEG, P 
< 0.05), the number of direct targets of each mutant, DEGs, and target genes among the 
DEG are shown. 
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Conclusion 
 
TP53 is the most frequently mutated gene occurring in a variety of sporadic human cancers and 
its mutation in the germline causes early onset of familial cancers in Li-Fraumeni syndrome 
illuminating p53 as a major tumor suppressor protein. While the tumor suppressors are 
inactivated by deletion or truncation mutations, the most common genetic aberration in TP53 is 
the missense mutations that generate a full-length protein with a single altered amino acid at a 
crucial codon. The missense or point mutations concentrate at the DNA binding domain of the 
TP53 transcription factor and affect its DNA sequence specific binding activity.  
 
The p53 protein is active as a homo-tetramer but hetero-tetramerization of mutant with wildtype 
p53 monomers exhibits dominant negative effect over the wildtype p53. The gain-of-function 
(GOF) properties of the mutants in complete absence of wildtype allele due to loss of 
heterozygosity (LOH) at the TP53 genetic locus contributes to the oncogenic characteristics of 
this mutant tumor suppressor. Thus, both the dominant negative effect and GOF impart ‘neo-
morphic’ function to the mutant p53 protein.  
 
In cancer tumors harboring TP53 missense mutations, 60% show LOH but the rest 40% retain 
the wildtype TP53 allele showing the relevance of dominant negative mechanism of the mutants 
to inhibit wildtype p53.  Moreover, the knock-in mouse strains with p53R172H and p53R270H 
(equivalent to human hotspot missense mutations R175H and R273H) in combination with wild-
type or null TP53 allele show wide spectrum of tumors, tumor burden and metastasis compared 
to the p53+/- and p53-/- mice. The dominant negative effects vary by the allele. Carcinomas were 
common in p53R270H and osteosarcomas in p53R172H (Olive 2004).  p53R248Q mutant HUPKI 
mice had rapid tumor development, decreased survival time and different tumor spectrum in 
comparison to p53G245S and p53null mice. Both p53R248Q and p53G245S showed higher 
diversity of sarcomas, more carcinomas and germ cell tumors than p53 null mice (Hanel 2013). 
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The mice studies support that the full-length p53 missense mutant proteins are not created equal 
and are rather heterogeneous (Mello 2013).  
 
The TNBCs produce the most heterogeneous and aggressive tumors and 90% of them harbor 
mutations in the TP53 gene. More than 100 different missense mutations are reported to occur 
along the length of TP53 and it is likely that the mutant p53 proteins contribute to the tumor 
heterogeneity observed in the TNBCs. But how are these missense mutant p53 proteins different 
from one another and how do they contribute to tumor heterogeneity remains a mystery. 
 
We selected a panel of ten most prevalent missense mutations of TP53 occurring in breast tumor 
samples in the DBD of the protein. We expressed them in the non-transformed mammary 
epithelial cells, MCF 10A, to model the accumulation of mutant p53 in tumor cells and used them 
to study the phenotypic effect based on prominent hallmarks of cancer. The 10 different mutants 
produced heterogeneous phenotypes but based on the phenotype scores, some mutants were 
found to be more aggressive than the others. The DNA contact mutants R248W, R273C and the 
structural mutant Y220C were identified as the most aggressive based on their survival capacity 
in absence of critical growth factors, apoptosis and anoikis resistance, increased cell migration, 
invasion and formation of reverse polarized distorted mammospheres. In contrast, G245S mutant 
was the least aggressive with completely opposite phenotypes as compared to the aggressive 
mutants. Mutants R273H and Y234C were comparable to G245S. The rest of the p53 mutants 
formed a rainbow of phenotypes substantiating the fact that the different p53 missense mutant 
proteins are not functionally equal and these missense mutant proteins act more like oncogenes 
with ‘neo-morphic’ activities than loss-of-function tumor suppressors. We emphasize that our 
phenotypic results are reflective of the dominant negative effect of mutant p53 as the MCF 10A 
cells retain the endogenous wildtype p53. Such a system models the condition of early phase 
tumors that harbor TP53 mutations in only one allele and eventually lose the remaining allele 
(deletion or mutation) by LOH during tumor progression.    
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Our phenotypic data correlates with a patient study data. In a study of 1,794 women with primary 
breast cancer, specific missense mutations at codon 179 and R248W were associated with worse 
prognosis. Breast cancer patients with missense mutation in DBD of p53 showed reduced 
survival compared to patients without the mutations and the 10-year mortality rates for DBD and 
non-DBD mutations were 73 and 44 (per 1,000 patients) respectively. Where missense mutation 
at codon 179 and R248W had reduced survival, G245S had better survival compared to any 
other missense mutation. Other mutation hotspots in breast cancer including R175H, R248Q, 
R273H, R273C, codon 163, 249 and 282 had mortality rates like other non-missense mutations in 
p53 (Olivier 2006). Our phenotype data on the p53 mutant proteins matches with the study except 
for the results of codon 179. This can be expected as the TP53 mutations in patients appear in 
complex mutation background where thousands of other somatic mutations co-exist and the 
phenotypic outcome is the result of gene interactions. On the other hand, p53 mutations were the 
only mutations introduced in our model system.     
 
Several other reported studies support our finding of grouping the R248W, R273C and Y220C as 
the most aggressive p53 mutants. The hotspot codon 248 is frequently mutated in luminal B, 
HER2 enriched and basal-like breast tumor subtypes. The other hotspot codons 175 and 273 are 
frequently mutated in basal-like subtype which is the most aggressive breast cancer subtype 
(Silwal-Pandit 2014). Moreover, in a patient cohort with locally advanced breast cancer treated 
with Doxorubicin monotherapy, some patients showed progressive disease during the treatment 
and harbored mutations in the L3 loop of the TP53 gene (codon 273 and 248) that directly 
contacts DNA. The patients with mutations in the L2/L3 domain of p53 predicted poor survival 
and suggested the association of these specific p53 mutations with primary resistance to 
Doxorubicin therapy in breast cancer patients (Aas 1996). In a very recent study, mice with 
somatic mutation in TP53 R245W (equivalent to human R248W) produced most aggressive and 
metastatic breast tumors and R172H (human R175H) mutated tumors were less aggressive. 
Trp53R245W/+ mice developed breast tumors with 46% metastasis to lung and the liver whereas 
loss of heterozygosity (LOH) was needed for Trp53R172H/- mice to develop mammary tumors and 
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few of them disseminated to lungs. Early dissemination of mammary tumors was observed in 
R245W mice and thus, constant monitoring of human breast cancer patients harboring R248W 
mutations in primary tumors could prove beneficial. The mammary tumors from such mice models 
recapitulated the characteristics of human breast cancers making this an invaluable model to 
study the initiating event in breast cancer progression and the aggressive behavior of the TP53 
mutations (Zhang 2018).  
 
Our study is a comprehensive resource for p53 missense mutant protein functional activities and 
transcriptomics. Compared to previous conventional research on p53 mutants, our study carefully 
integrated the cellular phenotypes based on the hallmarks of cancer with RNA seq and ChIP Seq 
data. We included 10 p53 missense mutants and an elaborate set of controls, the MCF 10A cells 
with endogenous wildtype p53, 10A cells overexpressing wildtype p53 and cells with knocked-
down p53 (p53 null). To explore the underlying basis for the neo-morphic functions of missense 
mutant p53 proteins, we performed ChIP Seq on invasive mutants (R273C, Y220C) and non-
invasive mutants (Y234C, R273H) with MCF 10A p53OE as the control. We used untreated cells 
and immunoprecipitated mutant p53 with a V5-tag. We found evidence that p53 missense mutant 
protein experiences altered DNA binding. The binding affinity to consensus p53 motif was low in 
all mutant p53 expressing cell lines compared to wildtype p53OE. The altered DNA binding 
patterns of p53 mutants translated into the neo-morphic activities and the heterogeneous 
phenotypes. The RNA seq and the pathway analysis showed good correlation between the 
dysregulated pathways and the cancer related phenotypes across the mutant p53 expressing 
MCF 10A cell lines. We discovered that focal adhesion pathway was one of the highly 
dysregulated pathways in the invasive p53 mutants.  
 
We also observed a close structure-function relationship of the mutant p53 proteins. The p53 
hotspot mutant proteins in cancer preserve the overall structural scaffold but display different 
local structural changes that affect DNA binding and facilitate interactions with other proteins and 
provide the GOF properties. The mutant specific local structural changes refer to removal of DNA 
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contact point (by DNA contact mutants), conformational changes on the DNA binding surface and 
formation of surface cavities (by structural mutants). We observed that a subtle change in a single 
amino acid at a codon results in remarkable changes in the phenotype. Though the DNA contact 
mutations remove just a DNA contact residue without introducing large structural perturbations 
and preserving the architecture of the DNA-binding surface, replacement with a large 
hydrophobic side chain prevented sequence specific DNA binding. For example, R248W severely 
affects the hallmarks of cancer than R248Q and such a change could be attributed to the 
introduction of hydrophobic Tryptophan (R248W) instead of positively charged Arginine or polar 
and positively charged Glutamine (R248Q). Also, replacement of Arginine with small amino acid 
Cysteine (R273C) results in more aggressive behavior than R273H mutant where replacement 
with Histidine was comparable to Arginine. At codon 245, substitution of Glycine with Serine, 
doesn’t severely impair the structure of p53 and that is what we observe in terms of the 
phenotypes generated by the mutant G245S whose phenotypes where similar to 10A cells with 
wildtype p53. The structural changes in G245S are much smaller and the information of the L3 
loop is conserved.  
 
Introduction of bulky Histidine at codon 175 causes structural distortions and disrupts the zinc-
binding pocket of p53. Substitution of hydrophobic amino acid side chain Tyrosine with small 
Cysteine residue at Y163C, Y220C and Y234C created differential phenotypes with an 
aggressive phenotype associated with Y220C mutant that contains a large surface crevice on the 
mutant protein that perturbs the packing of the β-sandwich. The DNA contact mutant R273H has 
a subtle effect on the thermodynamic stability of the protein whereas the structural mutant R175H 
causes strong structural perturbation destabilizing the core domain. Such changes in the 
thermodynamic stability affect the DNA binding capacity of the mutant p53 (Joerger 2007). It is 
also reported that R273H has half-life similar to that of wildtype p53. Taking the structural studies 
on p53 mutant proteins into consideration, we find a good correlation between the deviation in 
structure and function (phenotypes) of the p53 missense mutant proteins though additional 
structural evidence is required to explain changes in function of mutant p53. 
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When mutant p53 proteins are over-expressed, such as the MCF 10A cells expressing mutant 
p53 in our study, formation of the mixed hetero-tetramers between mutant and wildtype p53 
drastically reduces normal transactivation by wildtype p53. Ideally due to the co-existence of wild-
type p53 with the mutant p53 in the MCF 10A cells, the phenotypes would be attributed to the 
dominant negative effect of the mutant p53 proteins but the overexpression of the p53 mutant 
proteins and the resultant phenotypes produced by them tilts more towards over-dominance or 
GOF properties of mutant p53 imparting ‘neo-morphic’ characteristics to the p53 mutant MCF 10A 
cells.  
 
As the genetic background in the MCF 10A cells overexpressing the p53 missense mutant 
proteins is identical, our data highlights the neo-morphic activities of the p53 missense mutant 
proteins generating a spectrum of phenotypes based on the hallmarks of cancer supported by 
data at the molecular level from ChIP and RNA seq. The results may explain the phenotype 
heterogeneity observed in the TNBC tumors that contain different TP53 mutations. Hence, 
identification of the exact mutation in TP53 in human TNBC patients and its correlation with 
resistance to chemotherapy and poor prognosis may inform the course of therapy and stratify 
patients for effective clinical outcome. 
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CHAPTER 3 
PTEN AS A CO-DRIVER OF MISSENSE MUTANT P53 TO DRIVE CELL INVASION: A PILOT 
STUDY 
 
 
Introduction 
 
Next generation sequencing (NGS) has identified millions of somatic mutations in the cells 
derived from cancer tumors. An important challenge is to distinguish the driver mutations in a sea 
of neutral passenger mutations that accelerate cancer development. For the identification of 
candidate driver genes frequency-based and function-based approaches have been developed.  
 
The frequency-based approach relies on candidate driver genes mutated in greater proportion of 
cancer sample than expected from the background mutation rate (Pon 2015). Whether a 
candidate driver is a tumor suppressor, or an oncogene is determined by assessing the relative 
frequency and the distribution of missense, non-sense and frameshift mutations. Recurrent 
mutations are characteristic of driver mutations. But infrequent mutations in driver genes are 
abundant in the mutational landscape of cancer tumors and present in <5% of samples. The 
frequency-based approaches often overlook the infrequently mutated genes as drivers and a 
huge sample size is needed to identify these infrequent drivers by bulk sequencing method. 
 
The function-based approach distinguishes the candidate drivers from the passengers by their 
tendency to have a selective advantage on protein function compared to the non-advantageous 
neutral passenger mutations. The functional impact of the candidate driver mutations can be 
predicted from the evolutionary conservation of the protein, its structural features and changes in 
amino acid sequence affecting the 3D structure of the protein. Other methods under this 
approach include studying different pathways, cell phenotypes and transcriptome data. Moreover, 
this approach can directly distinguish the candidate driver genes as oncogenes or tumor 
  120 
suppressors. Function-based approaches are the methods of choice to study intra and inter-
tumor heterogeneity and develop precision targeted treatments.   
 
The breast cancer tumors, specifically the TNBC tumors are highly heterogeneous and >88% of 
the samples contain mutations in the TP53 tumor suppressor establishing it as one of the driver 
genes. But it exists in a sea of co-mutated genes that include the passenger mutations and the 
infrequent drivers which we term as the ‘co-drivers’. We hypothesize that the observed 
heterogeneity in TNBC tumors is a result of functional cooperation between the neo-morphic p53 
mutants and distinct sets of co-existing somatic mutations or the co-drivers. To identify the 
possible co-drivers of different TP53 missense mutations we tried to establish a function-based 
experimental pipeline. To determine the workability of the pipeline, we performed a pilot study by 
deleting PTEN in cells expressing missense mutant p53. Deletion mutation in PTEN is a known 
co-driver of mutant TP53 where they cooperate to drive increased cell invasion.    
 
Aim  
 
Establishing an entire pipeline to identify co-drivers of missense mutant p53 by performing a pilot 
study focusing on cell invasion phenotype with the known co-driver PTEN. The pipeline required 
optimization of parameter such as gene deletion, phenotype-based enrichment of cells with 
targeted gene deletion, confirmation of gene deletion by NGS and validation of the phenotype 
change.  
 
Approach 
 
PTEN deletion is a known co-driver of mutant p53 in Triple Negative Breast Cancer (TNBC) 
 
Triple negative breast cancer (TNBC) is the most aggressive subtype that represents about 16% 
of all breast cancer tumors. These tumors lack the expression of estrogen, progesterone and 
  121 
HER2 receptors and hence, are called triple negative. RNA and deep sequencing measurements 
show that there is much variation in the clonal frequencies of somatic mutations in these tumors. 
Somatic mutations in TP53, PTEN and PIK3CA are clonally dominant, and mutations in 
cytoskeletal and motility related genes occur at lower frequencies in TNBC (Shah 2012). The 
TCGA confirms that loss of RB1 and BRCA1 along with mutations in TP53 and PIK3CA are 
TNBC or basal-like features.  
 
Concomitant deletion of PTEN and TP53 in mice increased the formation of claudin-low triple 
negative breast cancer with activated AKT signaling and mesenchymal morphology compared to 
tumors with only PTEN or TP53 mutations (Liu 2014). In another study, knock-down of both p53 
and PTEN proteins in human mammary epithelial cells (HNMECs) and MCF 10As resulted in 
metastatic tumors in mice whose gene expression profiles mimicked the profile of the 
basal/claudin-low breast cancer tumor subtypes of TNBC. The simultaneous knock-down also 
increased sphere forming ability and cell motility in vitro and led to formation of tumors in 
NOD/SCID mice that metastasized to lungs, while single deletion of either TP53 or PTEN failed to 
produce such results (Kim 2015). Thus, mutations in both TP53 and PTEN work synergistically 
towards an aggressive cellular phenotype but are not enough for full malignant transformation of 
cells as seen in patient tumor samples.  
 
We used the MCF 10A cell-lines expressing mutant p53 with either knocked-down PTEN by use 
of shRNA or deleted PTEN gene by CRISPR-Cas9 editing as the control cell-lines to develop the 
pipeline.   
 
PTEN as a tumor suppressor 
 
The PI3K pathway is a central biochemical pathway that regulates cellular processes like cell 
metabolism, survival, proliferation and migration. The pathway is triggered by signaling through 
receptor tyrosine kinases (RTKs) or G-protein coupled receptors (GPCRs), which results in the 
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activation of the PI3 kinases (PI3K). PI3K then phosphorylates phosphatidylinositol-4,5-
bisphosphate (PIP2) into the signaling molecule phosphatidylinositol-3,4,5-triphosphate (PIP3), 
which in turn triggers numerous downstream targets.  Counterposing the activation of the 
pathway, the lipid phosphatase PTEN reverses this by dephosphorylating PIP3 back into PIP2 
thereby negatively regulating the PI3K pathway (Fig 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activation of the PI3K pathway drives cell proliferation.  An important downstream effector of PIP3 
is AKT, a Ser/Thr kinase. Phosphorylation of transcription factor FOXO by AKT increases cell 
proliferation and survival. AKT directed phosphorylation of TSC2 activates mTORC1 that 
upregulates protein synthesis. AKT mediated phosphorylation of several proteins regulate cell 
cycle progression, survival and cell motility. In human cancers catalytic unit of PI3K, p110α, and 
PTEN are frequently mutated increasing the activity of the PI3K signaling pathway (Chalhoub 
2009). Activation of PI3K-AKT-mTORC1 pathway influences metabolic re-programming of cancer 
cells and sustains their growth and proliferation via macromolecule (protein, lipid, nucleotide) 
 
 
Figure 3.1. The phosphatidylinositol 3-kinase (PI3K) signaling pathway. 
Image adapted from (Chalhoub 2009). 
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biosynthesis. Not surprisingly, activating mutations of the key effectors (PI3K, AKT) behave as 
oncogenes, whereas negative regulators, such as PTEN, behave as tumor suppressors.   
 
Beyond opposing the PI3K pathway, PTEN protein activity also regulates Rho GTPases RAC1 
and CDC42, thus reducing cell motility and maintain polarity. Dephosphorylation of FAK by PTEN 
decreases migration. Hence, PTEN deficient cancer cells lose cell polarity and show increased 
cell migration, i.e., become more mesenchymal. As a tumor suppressor gene deletions and 
somatic mutations in the PTEN (Phosphatase and tensin homologue deleted on chromosome 10) 
are very common in cancers of prostate, endometrium and glioblastoma multiforme.   
 
Structure of PTEN 
 
The crystal structure of PTEN reveals a N-terminal phosphatase domain and a C-terminal C2 
domain (Lee 1999). The C2 domain is essential for phospholipid membrane binding and 
mutations in this region reduce membrane affinity and ability to suppress tumors (Fig 3.2). Most 
mutations occurring in PTEN are deletions and only a fraction of them are missense mutations. 
The missense mutation in PTEN occurs in the phosphatase domain and impairs the catalytic 
activity of PTEN protein in human cancers and Cowden syndrome. The C-terminal tail of the 
protein contains sites for phosphorylation that regulates PTEN stability, activity and its recruitment 
to the membrane (Georgescu 1999). 
 
The prior knowledge of the protein domains is helpful while designing sgRNAs for gene editing by 
CRISPR-Ca9 method as described in the following section (inactivation of PTEN: Use of the 
CRISPR-Cas9 system for gene editing). 
 
 
 
 
  124 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
The two important tumor suppressor genes PTEN and TP53 and their interdependence 
 
PTEN and TP53 remain the most commonly inactivated or mutated genes in human cancers.  
Moreover, there is a great deal of functional and regulatory interdependence between the tumor 
suppressors. Analysis of the human PTEN genomic locus show the presence of a p53 DNA 
binding element at the PTEN promoter region and this element is essential for inducible 
transactivation of PTEN by p53. PTEN mRNA and protein levels rise with the induction of 
wildtype p53 and in turn PTEN is needed for p53 mediated cell apoptosis (Stambolic 2001). 
PTEN regulates the stability of p53 in a phosphatase-dependent manner by inhibiting Akt-Mdm2 
pathway (Mayo 2002) where PTEN inhibits activation of Akt that fails to phosphorylate Mdm2 and 
restricts Mdm2 to the cytoplasm. The absence of Mdm2 in the nucleus stabilizes p53 protein 
levels by inhibiting ubiquitination of p53. In the phosphatase-independent manner PTEN forms a 
nuclear complex with p300 and keeps p53 acetylated, and the acetylated p53 forms tetramers 
and interacts with PTEN (Li 2006). 
 
Figure 3.2. The crystal structure of the PTEN tumor 
suppressor protein. Image taken from (Lee 1999). 
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Inactivation of PTEN: PTEN protein knock-down by shRNA  
 
RNA interference or RNAi is the most extensively used approach to disrupt gene function in 
mammalian cells. It is achieved by using short-interfering RNAs (siRNAs) or the short-hairpin 
RNAs (shRNAs). The dsRNA is introduced into a cell in an expression vector. Drosha/ DGCR8 
complex process primary transcripts and form pre-shRNAs in the nucleus. Pre-shRNAs are 
loaded onto Dicer/TRBP/PCT complex in the cytoplasm to get processed into mature shRNA. 
The matured shRNA is finally loaded into the RNA induced silencing complex (RISC) that 
promotes the degradation of complementary target mRNA. RNAi targets mRNA and the 
subsequently reduces target protein levels (Rao 2009, Boettcher 2015). The RNAi silencing 
machinery is present in all mammalian cells and no prior genetic manipulation of the target cell is 
required. A direct siRNA or shRNA transfection results in loss-of-function phenotype.  
 
Inactivation of PTEN: Use of the CRISPR-Cas9 system for gene editing 
 
Clustered regularly interspaced short palindromic repeats (CRISPR) is a microbial adaptive 
immune system by which the host recognizes pathogenic DNA sequences and targets them for 
cleavage. This system has been adapted for use in the eukaryotic cells for genome engineering 
using a specific 20 nt targeting sequence as the guide RNA (gRNA). Such precise editing of 
genomic loci elucidates the function of genetic elements and genetic variations. The RNA guided 
CRISPR-Cas9 system has the guide RNA that base-pairs with the target DNA and the Cas9 
endonuclease creates the double stand breaks (DSBs) after proper positioning (Fig 3.3). This 
system is easy to design, is quite specific and efficient, and can be used for high-throughput and 
multiplexed gene editing in various cell types and organisms.  
 
DSB by Cas9 at the target locus may repair under the error-prone non-homologous end joining 
(NHEJ) DNA repair or high-fidelity homology directed repair (HDR). In absence of the repair 
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template, NHEJ leaves random insertions/ deletions (indels). Indels in the exons often cause 
frameshifts that lead to premature stop codons. Multiple DSBs can result in larger deletions at the 
targeted loci (Fig 3.4). The CRISPR-Cas9 system is reconstituted in the mammalian cells by 
expressing human codon-optimized Cas9 enzyme and the gRNA components. This Cas9 
endonuclease can then be targeted specifically to any part of the genome preceding the PAM 
(Protospacer adjacent motif) sequence just by programming the 20 nt gRNA sequence with 
matching sequences (Ran 2013, Canver 2014).  This CRISPR-Cas9 system is used mostly for 
gene knock-out and for several other purposes like gene repression or activation, specific 
genomic loci imaging and purification and for genome-wide screens.  
 
 
 
 
 
 
Figure 3.3. The RNA guided Cas9 (CRISPR-Cas) system. The 20 nt 
(blue) guide RNA with the (red) scaffold targets the Cas9 endonuclease 
(yellow) to the genomic loci. The DSB occurs at the red arrows. Adapted 
from (Ran 2013). 
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The shRNA causes mRNA cleavage and degradation resulting in deletion of protein. But RNAi 
doesn’t always mirror the complete loss-of-function that results from gene mutation. RNAi is 
efficient in causing a knock-down than a knock-out. The ability to directly edit the genome and 
create gene knock-out makes the CRISPR-Cas9 a method of choice when mimicking somatic 
mutations under physiological conditions. Gene-knockout leads to complete depletion of 
functional protein.  
 
 
 
 
 
Figure 3.4. Gene deletion by the CRISPR-Cas9 system and its other uses. Figures 
adapted from www.addgene.org. 
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Method 
 
Downregulation of PTEN in MCF 10A cell lines using shRNA 
 
The PTEN shRNA containing plasmids were obtained from our internal plasmid repository 
DNASU. After plasmid purification, the lentivirus was prepared in 6-well plates as following. On 
Day 1, 1.5 million 293Lx cells were plated in each well in 2 ml media. On Day 2 a transfection 
master mix was prepared containing mix 1 and mix 2. Mix 1 of total 150 ul contained diluted 
Fugene HD in serum free DMEM media (Fugene HD ul: total ug of DNA = 6: 1). Mix 2 had 
packaging plasmids 500 ng VSVG, 2500 ng Gag-pol and 2500 ng of lentivector containing the 
shRNA in serum free DMEM media making a total of 150 ul. Mix 1 and mix 2 were combined and 
incubated at room temperature (RT) for 20 to 30 min. After incubation, 150 ul of the master mix 
was dispensed into each of 2 wells. The volume of the master mix and the concentration of the 
plasmids was increased according to the number of wells transfected. The 6-well plate was spun 
at 2250 rpm for 30 min and placed in the incubator at 37oC with 5% CO2. 1% Wescodyne was 
used for disposing biohazard waste at every step. On Day 3, 1 ml media was removed and 
replaced with 2 ml fresh media in the morning and in the evening 2.5 ml media was removed and 
replaced with 5.5 ml fresh media in each well. On Day 4, 5.5 ml media was collected in a 50 ml 
conical tube and stored at 4oC and 3.5 ml fresh media was put into the wells. On the last day, 
Day 5, 4 ml media was collected from each well in the same tube. The media was added into 
each well cautiously at a very slow speed not to disturb the 293Lx cell monolayer.  
 
For the transduction of MCF 10A p53 mutant cell lines 80,000 cells/ well were plated in a 6-well 
plate.  After 24 hours 1 ml media was removed and polybrene (8ug/ml) was added to each well 
which was followed by the addition of the lentivirus. On the next day the media in the plates was 
replaced by fresh media. The selection reagent, in this case puromycin (0.7 ug/ml), was added to 
the media on the following day and cells were selected for 72 hrs. As controls, we had un-
transduced cells with and without puromycin. The un-transduced cells in puromycin were dead by 
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72 hours whereas the un-transduced cells without puromycin remained confluent. The cells were 
selected for at least 7 to 10 days in puromycin before using them for experiments. Cells were 
passaged at regular intervals and frozen stocks were also prepared.  
 
Cell lysate preparation and western blot 
 
100,000 cells/well were plated in 6-well plates for the cell lysate preparation. Cell lysates were 
made using the RIPA lysis buffer containing 50mM Tris, 150mM NaCl, 1% IGEPAL CA-630, 0.1% 
sodium azide (Sigma #S8032), cOmplete mini protease inhibitor (Sigma #04693124001), 200 µM 
Sodium fluoride and 200 µM of Sodium orthovanadate. After addition of 500 ul lysis buffer to each 
well, cells were scraped, incubated on ice for 10 minutes and centrifuged to collect the clear cell 
lysate. Lysates were quantified using the Pierce BCA kit (cat # 23225). Samples were run on 4-
20% TGX gels from BioRad (#567-1093) and blotted onto 0.45µm PVDF membrane (GE 
Healthcare #10600023) using the BioRad semi-dry transfer system. Primary antibody for PTEN 
(CST catalogue no. 9188) and p53 (Sigma catalogue no. P6874) were diluted to 1:1000 and 
secondary HRP-linked anti-mouse or anti-rabbit antibody used to visualize the protein bands. The 
blots were imaged on the Fluorchem FC3 from AlphaInnotech. 
 
Transwell cell invasion assay 
 
Cells (70-80% confluent) were trypsinized and used for the transwell invasion assay. Before the 
experiment, the 24 well Matrigel coated invasion plate (Corning cat # 354480) was thawed with 
200 ul serum free media in each well for rehydrating the Matrigel layer at 37oC for 1 hr. 2.5 x 105 
cells in 200ul serum free media were seeded in each Matrigel coated insert. 750 ul of serum 
containing media was added to the bottom wells. The plate was incubated for 24 hrs. After 
incubation, cells were fixed with 4% paraformaldehyde for 2 min at RT, permeabilized by adding 
500ul of 100% cold methanol (20 min at RT) and stained with 0.5% crystal violet for 15 min. The 
inserts were washed with 1X PBS 3 times. A cotton swab was used to remove any non-invasive 
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cells from inside of the insert. The invasive cells were imaged under the microscope at 4X and 
10X magnification.   
 
Designing and cloning the sgRNAs for PTEN in lentiCRISPR v2 plasmid 
 
The sgRNAs targeting PTEN were designed using the online design tool from Feng Zhang’s lab 
page and from the genetic perturbation platform of the BROAD Institute (Appendix A).  
 
To clone the sgRNA sequences targeting PTEN into lentiCRISPR v2 plasmid, two oligos were 
synthesized for each sgRNA. After the vector digestion with BsmBI, the plasmids had an 
overhang that matched with that on the synthesized oligos. For the cloning of the appropriate 
sgRNAs into the lentiCRISPR v2 plasmid, the following steps were performed (Table 3.1). 
1) Digestion of lentiCRISPR v2 plasmid. The vector was either digested and dephosphorylated or 
simply digested with BsmBI restriction enzyme without dephosphorylation. 2) Gel extraction of cut 
plasmid. BsmBI digestion resulted in a 2 kb filler fragment and a larger band.  The digested 
products were checked on 1% agarose gel run for 27 min at 120 V. For cloning, only the larger 
band was extracted from the 1% GTG agarose gel (with gelstar) run for 27 min at 120 V. The 
extracted band was purified using the QIAquick gel extraction kit (cat # 28704) as per 
manufacturer’s protocol. 3) Annealing each pair of synthesized oligos. The oligo pairs were either 
annealed and phosphorylated or simply annealed without phosphorylation. For phosphorylation 
and annealing of the oligos, the thermocycler was set as 37oC for 30 min, 95oC for 5 min and then 
ramp down to 25oC at 5oC/min. For simply annealing the oligos, the setting was 95oC for 5 min 
and then ramp down to 25oC at 5oC/min. The annealed oligos were diluted (1:200) in sterile 
water. 4) Ligation reaction. The dephosphorylated cut plasmid was ligated with the 
phosphorylated oligos and the simply cut plasmid was ligated with the annealed oligos without 
phosphorylation. As a negative control we had water instead of the oligos with the digested 
vector. 
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Table 3.1. Detail of the cloning procedure.  
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5) Transformation into Stbl3 bacteria. 25 ul Stbl3 cells were mixed with 5 ul ligation reaction by 
gentle flicking. Cells were incubated on ice for 15-20 min. For transformation, cells were given 
heat shock at 42oC for 30-40 s and then immediately put on ice for 2 min. 200 ul SOC media was 
added to the cells and shaken at 250 rpm for 1 hour. All the cells were plated on agar plates with 
appropriate selection reagent and incubated at 37oC overnight for colony formation. After 16 to 18 
hours, if colonies appeared, 3 to 4 random colonies were picked for 5 ml overnight cultures. The 
agar plates were then stored at 4oC. Plasmids were extracted from the overnight cultures and 
colony PCR was performed with appropriate oligo 1 as forward and Cas9 as reverse primer with 
2 ul cells. The region of the plasmid containing the cloned sgRNAs was PCR amplified and the 
sequence checked using Sanger sequencing. 
 
Transient transfection into 293T cells 
 
On Day 1, 5X105 cells/well were plated in a 6-well plate. On day 2 transfection mix was prepared 
containing the plasmid (1.5 ug/well) and fugene (transfection reagent). In the transfection mix the 
ratio of fugene to plasmid DNA was 6:1. 100 ul of the transfection mix was dispensed in each 
well. On Day 3 media with the selection marker (puromycin 1 ug/ml) was added to the wells. Cells 
were selected for 72 hours and then used for the experiments. 
 
T7 endonuclease I assay 
 
Genomic DNA (gDNA) was extracted from the cells using the Blood and Cell culture DNA midi kit 
(Qiagen #13343) and the sgRNA target locus was PCR amplified (Table 3.2). The PCR products 
were run on 1% agarose gel to verify the size and amplification. PCR products were purified, and 
their concentrations determined. These PCR products were then set for the annealing reaction. 1 
ul of T7 endonuclease I enzyme (NEB cat # M0302) was added to 19 ul annealed PCR products 
and incubated for 15 min at 37oC. The reaction was stopped with 1.5 ul of 0.25 M EDTA. One 
may also consult the protocol provided in the NEB website. The fragmented PCR products were 
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analyzed on 10% TBE gel run in 0.5X TBE buffer for 70 min. The gel was then stained in 75 ml 
0.5X TBE buffer with 0.7 ul EtBr for 20 min.  
 
Preparation of stable MCF 10A p53 mutant cell lines expressing sgRNAs to knock-out 
PTEN 
 
Once the sgRNAs targeting PTEN were cloned into lentiCRISPR v2 plasmid and the sequence 
verified, the cloned plasmids were purified. The lentivirus was prepared and used for transduction 
of the different MCF 10A cell lines as described above. The transduced cells were selected for at 
least 10 to 14 days before using them for the experiments. Please see the method section on 
Table 3.2. Detail of PCR and annealing for T7 endonuclease assay 
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‘Generation of PTEN null MCF 10A cell-lines using shRNA’ for the detail of lentivirus generation 
and transduction of cells with the lentivirus. 
 
Extraction of invasive cells 
 
For the extraction of invasive cells, the 6-well BioCoat Matrigel invasion chamber plates (cat # 
354481) were used.  1 million cells in 2 ml were seeded in each Matrigel coated insert in serum 
free media, making a total of 6 million cells per plate. In the bottom well, 2.5 ml media with serum 
was placed. After seeding, the plates were incubated at 37oC and 5% CO2 for 24 hrs. Following 
incubation, media from both the insert and the well were removed. The inserts and the wells were 
washed with 1X PBS. Using a cotton swab the cells on top of the insert, the non-invasive cells, 
were scraped off. 1 ml of trypsin was added to the bottom well and the insert now with only the 
invasive cells was placed over it. After 15 to 20 min (if the typsinization was complete, cells would 
be completely round and floating) media containing serum was added to the well to neutralize 
trypsin. The invasive cells were collected from each well in a tube and then re-plated in a new 
sterile 6-well plate. Images were taken at each step of the process. Once the invasive cells 
started to grow, they were transferred to petri-dishes for expansion. Pellets were made for 
genomic DNA (gDNA) extraction and vials for frozen cells were also prepared. Genomic DNA 
was extracted using the Blood and Cell culture DNA midi kit from Qiagen (cat # 13343) as per the 
manufacturer’s protocol. 
 
Sequencing of the PTEN locus 
 
For sequencing of the targeted locus of PTEN, the locus was PCR amplified with suitable primers 
as per the Table 3.3, purified and submitted for MiSeq 2x150 bp run. To verify the disruption of 
the targeted gene, paired-ended sequences were aligned to the reference human genome 
(GRCh38.p92/hg38) using Bowtie2 (Bowtie2 2.1.0) (Langmead B, 2012). A deletion was called if 
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a deletion site was within ± 5bp apart from the sgRNA targeting site. Igvtools (igv_2.4.13) was 
used for data visualization (Thorvaldsdóttir 2013).  
 
Soft agar assay 
 
For the soft agar assay, the agar bed of 0.6% was made by mixing equal volumes of 2X media 
and 1.2% noble agar (autoclaved) and plating 800 ul for the base. The agar was then allowed to 
solidify. 10,000 cells/well in a 24 well plate was suspended in the soft agar with a final 
concentration of 0.3% noble agar. Each cell line was first trypsinized and then counted. To have 
10,000 cells/well with final concentration of 0.3% agar, equal volumes of 20,000 cells in 2X media 
Table 3.3. Primers to amplify PTEN locus and the PCR detail. 
 
 
 
Set Primer
1 Forward CTA CCC CTG TGC AGT TGA AAA TTC ACA TG Exon 2
Reverse CTG AAG TCC ATT AGG TAC GGT AAG CCA
2 Forward CTG TTA AGT TTG TAT GCA ACA TTT CTA AAG TTA CC Exon 5
Reverse TAC TTG TCA ATT ACA CCT CAA TAA AAC TGA AGG
3 Forward CTA CGA CCC AGT TAC CAT AGC AAT TTA GTG Exon 6
Reverse GTT CAA ATG CTT CAG AAA TAT AGT CTC CTG C
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were mixed with 0.6% soft agar (first melted and then strictly maintained at 42oC) and 1 ml of the 
solution was put over the solid agar bed. At each step the agar was allowed to solidify, and 
formation of bubbles was avoided. We plated the MDA-MB-231 cells as the positive control and 
had a well without cells as the background control. 500 ul 1X media was added on top of the soft 
agar and the media was replenished every 3 to 4 days to allow the cells to form colonies. 
Colonies in soft agar appeared in 3 to 4 weeks or longer depending upon the cell lines used. 
Once the colonies were visible, the cells were fixed with 500 ul of 10% acetic acid and 10% 
methanol in water for 15-20 min and imaged under the light microscope. 
 
Immunofluorescence 
 
This protocol was used for staining cells in a 96-well format and a shaker was used during 
antibody incubations to obtain uniform staining. The cells were washed with 1X PBS (100 ul, 2 
times) and fixed with 75 ul of 4% paraformaldehyde (VWR #AA43368-9M) per well for 15 min at 
room temperature (RT). The cells were washed with PBS and 75 ul of blocking buffer containing 
5% goat serum (Life Technologies #PCN5000) with 0.32% Triton X-100 in 1X PBS was added 
per well for 1 hour at RT. After a PBS wash, 50 ul/well of primary antibody (at recommended 
dilutions in Ab protocol from manufacturer) in antibody buffer with 1% BSA and 0.3% Triton X-100 
in 1X PBS was added and incubated at RT shaking gently at 350 rpm in an orbital shaker for 1 to 
2 hours for same day processing or overnight at 4°C while shaking. Cells were washed with 1X 
PBS and 50 ul/well of secondary antibody (at recommended dilution) in antibody buffer was 
added. The 96-well plate was incubated at RT, shaking at 350 rpm for 1 to 2 hours. After a final 
wash with 1X PBS plate was stored at 4°C with 100µl 0.05% Sodium Azide (NaN3 Sigma 
#S8032) in 1X PBS. 
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Results 
 
PTEN protein knock-down using the shRNA system increases the invasiveness of p53 
mutant cells 
 
Deletion mutation in PTEN frequently co-appears with TP53 missense mutations in invasive 
breast carcinomas (Kim 2015). We hypothesized that deletion of PTEN in the weakly invasive 
MCF 10A p53 mutant cells could enhance their invasive potential and demonstrate cooperativity 
between mutant PTEN and mutant p53.  
 
To check the effect of reduced PTEN protein levels we tested three different shRNAs (PTEN sh1, 
2, and 3) to knock-down the PTEN protein in the MCF 10A p53 mutant cells G245S, R273H and 
Y234C, which were the least invasive mutants as determined before using the transwell invasion 
assay (chapter 2) (Fig 3.5A). The MCF 10A cells overexpressing wildtype p53 protein (WT-OE) 
and the cells lacking p53 protein, the p53 null cells, were included as the controls for the 
experiment. The shRNA bearing plasmids were packaged into lentivirus, and the MCF 10A cell-
lines were transduced with these lentiviruses. The cells were selected with puromycin for 7 to 10 
days and lysates were prepared for western blots. All three cell lines expressing any of the 
shRNAs targeting PTEN showed decreased level of PTEN protein compared to cells without 
PTEN shRNA or cells expressing scrambled shRNA. Notably, the p53 null cells were produced by 
expressing p53-specific shRNA from the same vector as shRNA for PTEN. Thus, we could not 
select the PTEN shRNA-transduced cells with puromycin and no effective down-regulation of the 
PTEN protein was seen in the MCF 10A p53 null cells. We chose shRNA #3 for PTEN knock-
down to determine any changes in the invasiveness of the cells because it shut down the PTEN 
protein levels more effectively than the rest of the shRNAs.  
 
With PTEN protein knock-down there was an increase in the invasive potential of the weakly 
invasive p53 mutants G245S, R273H and Y234C (Fig 3.5B). The increase in invasiveness was  
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significantly higher for the R273H cells compared to G245S and Y234C cells. The MDA-MB-231 
cells were included as the positive control, which is a highly invasive and metastatic TNBC cell 
     
 
 
 
 
 
Figure 3.5. Shutting down the PTEN protein using shRNAs. A. Western blot showing the 
level of PTEN protein in the cells. GAPDH is the loading control. B. Transwell cell invasion 
assay results. PTEN knock-down increased the invasive potential of the weakly invasive MCF 
10A p53 missense mutant protein expressing cell lines.  
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line. The results from the invasion assay demonstrated that PTEN loss enhances the invasion of 
p53 mutant cells across the Matrigel barrier, making the loss-of-function mutation of PTEN a ‘co-
driver’ (co-existing driver mutation) of mutant p53. 
 
Generation of PTEN knock-out using the CRISPR-Cas9 system  
 
In the basal-like breast cancer (BLBC) or TNBC subtypes (chapter 1, page 29), PTEN deep 
deletions co-occur (5%) with TP53 mutations. We used the CRISPR-Cas9 gene editing system to 
knock-out the PTEN gene and mimic the somatic mutations present in tumors. We designed a 
total of 6 sgRNAs (short guide RNAs) targeting different regions of the PTEN gene (Appendix A). 
These sgRNAs were chosen based on the parameters recommended by the online CRISPR 
design tools developed by the Broad Institute. We also verified that the sgRNAs did not target 
PTENP1, the pseudogene of PTEN, with similar sequences. These sgRNAs were first cloned into 
the CRISPR-Cas9 based lentivector lentiCRISPR v2, and the sequence were verified by Sanger 
sequencing before using them for further experiments (Fig 3.6).  
 
To check the efficiency of the sgRNAs to knock-out PTEN, we transiently transfected the 293T 
cells with the sgRNA plasmids. The cells were harvested at 24, 48 and 72 hrs post transfection 
for lysate preparation and genomic DNA extraction to confirm the knock-out at the protein and 
genome levels, respectively. A reduction in the PTEN protein level was observed at 72 hrs post 
transfection with the PTEN sgRNA 4 (Fig 3.7A). The PTEN locus was amplified from the genomic 
DNA (gDNA) and digested with T7 endonuclease I to detect the genome editing efficiency by the 
sgRNAs. T7 endonuclease I detects and cleaves mismatched DNA. Amplification of the targeted 
locus followed by denaturation and slow annealing of the strands cause bulges resulting from 
mismatched DNA due to gene editing by the CRISPR-Cas9 system. These mismatches are 
recognized and then cleaved by T7 endonuclease I forming multiple DNA fragments. Multiple 
DNA fragments were seen on the 10% TBE gel from the 293T cells transfected with sgRNAs and 
none for the non-transfected 293T cells (Fig 3.7B).  
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To transduce the MCF 10A p53 mutant cells, we prepared lentivirus expressing sgRNA 4, sgRNA 
5 and sgRNA 6 cloned plasmids. We chose these 3 sgRNAs because of the importance of their 
targeting positions on the PTEN gene (Fig 3.8A). The sgRNA 4 targeted PTEN exon 2 and 
sgRNA 5 targeted exon 5. Both sgRNAs targeted the phosphatase domain of PTEN while sgRNA 
6 targeted the linker region that connects the phosphatase domain with the C2 domain. The C2 
domain positions the protein on the plasma membrane, and both the domains are essential for 
the activity of the PTEN protein. The MCF 10A cells expressing WT p53, WT-OE, G245S, R273H 
and Y234C p53 mutant cells were transduced with the PTEN sgRNA (4, 5 and 6) containing 
lentiviruses. The cells were selected for 2 weeks and then used for the experiments. 
 
 
 
Figure 3.6. Cloning of the PTEN sgRNAs into lentiCRISPR v2 plasmid. A. Colonies 
obtained on agar plates with selection reagent from Stbl3 cells transformed with the PTEN 
sgRNA cloned plasmids. B. Colony PCR C. The position of the cloned PTEN sgRNA 4 just 
preceding the gRNA scaffold. 
 
C.
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Figure 3.7. Results from the transient transfection of 293T cells with PTEN sgRNA 
cloned plasmids. A. Western blot to show PTEN protein levels. B. DNA fragments detected 
from T7 endonuclease I assay. 
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When the cell lysates from the culture were prepared to check the PTEN protein levels (Fig 3.8B), 
no reduction in the PTEN protein level was observed for any of the PTEN sgRNA-transduced 
cells which can be explained by the low efficiency of the CRISPR editing ranging between 20 and 
30%. As the knock-out could have happened in a small fraction of the cell population, we did not 
observe reduction of PTEN protein by analyzing the bulk population of cells. Therefore, we used 
the invasion assay platform to enrich the clonal population of cells with PTEN knock-out by taking 
advantage of their increased invasiveness, as shown by the PTEN shRNA knock-down (Fig 3.5).  
 
Method for enrichment of post-invasion cell population and confirmation of targeted gene 
deletion: foundation for the genome wide co-driver screen 
 
The PTEN sgRNA-transduced Y234C cells were seeded in the matrigel coated Boyden chambers 
of the transwell invasion plates (Fig 3.9A).  After the incubation period, the non-invasive cells 
were first scraped off from the top of Matrigel coated insert, and the invasive cells were detached 
with trypsin treatment. Only about 10% of cells invaded the Matrigel coated membrane. To yield 
enough nucleic acid from cells for sequencing of the PTEN locus to detect genome editing, the 
extracted invasive cells were expanded in culture for 4-5 doublings. We noted that the invasive 
cells had completely different morphology (Fig 3.9B) from the population of the pre-invasive 
Y234C PTEN sgRNA 4, 5 and 6 (denoted as PTEN C4, C5 and C6) cells.  
 
Post-invasion cells were more elongated and spindle-like, characteristic of mesenchymal cells. 
The change in morphology was most pronounced in Y234C PTEN C4 cells. In the western blot, 
there was complete absence of the PTEN protein in the post-invasion Y234C PTEN C4 cells (Fig 
3.9C), demonstrating that sgRNA 4 was effective in disrupting the PTEN gene, and we could 
enrich the true PTEN knock-out clones from the mixed population of cells using the invasion 
assay. We sequenced the PTEN locus from the genomic DNA isolated from the Y234C PTEN 
C4, C5 and C6 cells. Sequencing results confirmed a uniform deletion of 2 or 4 bases (i.e., 
frameshift deletions) at the locus targeted by sgRNA 4. The targeted locus was in the exon 2 
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(close to the N-term) of the PTEN protein, and the efficient editing by sgRNA 4 resulted in 
frameshift mutation terminating the PTEN protein production (Fig 3.9D). On the contrary, sgRNA 
5 and 6 failed to knock-out the PTEN gene. 
 
 
  
 
 
 
 
 
Figure 3.8. sgRNA targeting positions on the PTEN gene. A. sgRNA 4 and sgRNA 5 
targeted the PTEN phosphatase domain and sgRNA 6 targeted the linker region between the 
phosphatase and the C2 domain. Structure of PTEN from PDB. B. Western blot to check 
PTEN protein levels. The cell lysates were prepared after transduction of cells with PTEN 
sgRNA expressing lentivirus. The transduced population was a mixed population where a 
very small fraction of cells lost PTEN due to CRISPR editing. Thus, in the bulk population of 
cells there was no reduction in PTEN protein level.  
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Figure 3.9. PTEN gene knock-out by CRISPR-Cas9 editing. A. Extraction of only the 
invasive cells that managed to breach the Matrigel coated inserts. C4, C5, C6 correspond to 
PTEN sgRNA 4, sgRNA 5 and sgRNA 6. B. Expansion and morphology of the invasive cells 
in 6-well plate. C. Western blot to check the PTEN protein levels. sgRNA 4 effectively knock-
out PTEN gene. D. Sequencing results of the PTEN locus. The red arrow shows the position 
of the deleted base pairs. Uniform deletion of 2 to 4 bp resulted in frameshift mutation and 
subsequent deletion of the PTEN gene and the protein with sgRNA 4. 
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PTEN sgRNA 5 caused a non-uniform deletion of 2 to 22 bases at the exon 5, and sgRNA 6 
resulted in non-uniform deletion of 4 bases at exon 6. This explained the presence of PTEN 
protein band and indicated a mixed population of Y234C PTEN C5 and C6 cells post-invasion. 
Ideally the cells expressing PTEN should not be present in the invasive fraction of cells. But it 
could be possible that such cells invaded along with the PTEN knock-out cells (Yamaguchi 2005, 
Weaver 2006), or there could be non-specific targeting by sgRNA 5 and 6 in the genome that 
directly or indirectly promoted the invasion of the cells. Off-target effects have been observed 
while using the CRISPR-Cas9 system for gene editing.  
 
Immunofluorescent staining of the parental Y234C cells and the post-invasion Y234C PTEN C4, 
C5 and C6 cells with beta-catenin and vimentin showed different localization patterns of the 
proteins (Fig 3.10A). Beta-catenin is part of the cell adherens junction and is normally located at 
the cell-cell junction of the epithelial cells. For Y234C cells and the Y234C PTEN C6-inv (post-
invasion or invasive Y234C cells transduced with PTEN gRNA 6) cells beta-catenin was located 
at cell-cell junctions (typical for epithelial cells), while the protein was delocalized from the cell-cell 
junctions and present  in the cytoplasm in the Y234C PTEN C4-inv and C5-inv cells as typically 
seen in migratory or invasive cells. Vimentin, a mesenchymal marker more abundant in invasive 
cells, was observed throughout the Y234C PTEN C4-inv cells. Overall, the morphology, beta-
catenin and vimentin staining patterns indicated that PTEN knockout in Y234C cells led to more 
mesenchymal phenotype and invasive behavior, which was especially apparent in the Y234C 
PTEN C4-inv cells.  
 
The post-invasion Y234C PTEN C4 cells were also capable of anchorage independent growth 
and formed colonies in the soft agar (Fig 3.10B). While the post-invasion Y234C PTEN C5 cells 
failed to form colonies, a fraction of the post-invasion PTEN C6 cells formed colonies, which 
possibly had PTEN knocked-out.  From the results, we chose the most effective sgRNA 4 to 
knock-out PTEN in the other p53 mutant cell lines. 
 
  148 
 
 
 
 
 
 
 
 
Figure 3.10. Results from immunofluorescence and soft agar assay. A. 
Immunofluoresence study showing localization of beta-catenin and vimentin in the post-
invasion or invasive (inv) cells. Beta-catenin was in the cytoplasm than cell-cell junction for 
PTEN C4-inv cells indicating mesenchymal phenotype. B. Anchorage independent growth of 
post-invasion Y234C PTEN cells. 
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PTEN knock-out increases invasiveness of p53 mutant cells 
 
Two other weakly invasive G245S and R273H cells were first transduced with PTEN sgRNA 4 
lentivirus and then selected with puromycin for 2 weeks. As performed above for Y234C cells, the 
invasive population of cells were enriched by using the invasion chambers and confirmed for the 
reduced level of PTEN proteins (Fig. 3.11B). When we tested and compared the panel of cell 
lines transduced with PTEN sgRNA C4, the post-invasion or invasive MCF 10A p53 WT, WT-OE, 
G245S, R273H and Y234C cells were capable of colony formation in soft agar (Fig 3.11A). 
 
 
  
Figure 3.11. Soft agar assay to show transformation of cells. A. Colony formation in soft 
agar by cells expressing mutant p53 and knocked-out PTEN. B. Western blot to check the 
PTEN protein level in p53 mutant cells. 
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Like the results obtained with PTEN knock-down by shRNA (Fig 3.5), the effect of PTEN loss in 
R273H cells was most prominent among all the mutants. These cells were most invasive in the 
Boyden chamber/ transwell assay and formed huge spheres in the soft agar compared to G245S 
and Y234C mutants. 
 
 
Conclusion 
 
Loss of function of the tumor suppressor PTEN is frequently accompanied by the loss of function 
of TP53 gene in the most aggressive subtype of basal-like breast cancer that lacks the detectable 
expression of ER, PR and HER2 receptors. The concurrent downregulation of these two tumor 
suppressor genes leads to increased cell invasion and anchorage independent growth in vitro 
and tumor formation in vivo. We sought to find out the effect of PTEN loss in the context of 
different TP53 missense mutations, and the results recapitulated the previous findings but 
provided additional knowledge on the phenotypic heterogeneity among the cells with different p53 
mutants and PTEN deletion. 
 
We intended to setup a function-based approach to identify the distinct co-drivers of mutant p53 
and required a positive control to set the conditions for the genome wide screen for the co-
drivers. Deletion in PTEN is known to cooperate with mutant p53 in exacerbating cancer-related 
phenotypes such as cell proliferation and invasion. Hence, we chose to delete PTEN by CRISPR-
Cas9 method in the MCF 10A mutant p53 expressing cells and observe the changes in cell 
invasion phenotype. This entire experimental setup was designed to establish a pipeline to 
identify co-drivers of mutant p53 by targeted gene deletions using a genome wide CRISPR based 
plasmid library and resulting change in cellular phenotypes. Using deletion in PTEN as a control, 
the known co-driver of mutant p53, we could perform phenotype-based enrichment of cells with 
targeted gene deletion, confirmation of gene deletion by NGS and validate the change in the 
observed phenotype of increased cell invasion. 
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PTEN protein knock-down using shRNAs in the weakly invasive MCF 10A mammary epithelial 
cells expressing p53 missense mutant proteins (G245S, R273H and Y234C) caused an increase 
in cell invasion compared to the cells with only p53 mutation. Particularly, invasion of the R273H 
cells was most influenced by the PTEN knock-down. Reduction in PTEN protein levels in MCF 
10A cells with wildtype p53 also invaded more than the MCF 10A cells without PTEN knock-
down.  
 
As shRNA-based partial knock-down of PTEN proteins cannot recapitulate the complete loss of 
PTEN function via homozygous deletion observed in breast cancer patients, we utilized the 
powerful gene editing technology of CRISPR-Cas9 system. Among all the designed sgRNAs 
targeting different parts of the PTEN gene, the sgRNA targeting a region close to the N-terminus 
was found to be the most efficient in knocking-out PTEN. Targeting at this locus caused uniform 
deletion of 2 or 4 bps resulting in frameshift mutations and consequent ablation of the gene 
function. As the efficiency of gene editing by the CRISPR system is relatively low, we developed 
a phenotype selection-based strategy to enrich the cells with loss-of-function PTEN deletion, in 
which the invasive population of PTEN sgRNA-transduced cells were isolated after the invasion 
assay, followed by confirmation of gene deletion by the sequencing of the locus. The invasive 
cells expressing different p53 mutants with PTEN deletion presented a spindle-like morphology, 
characteristics of mesenchymal cells such as cytoplasmic β-catenin and vimentin staining, and 
capability of anchorage independent growth in soft agar. Consistent to the shRNA-based results, 
anchorage independent growth in R273H PTEN null cells was most prominent than the mutants 
G245S and Y234C. 
 
These results collectively showed that simultaneous down-modulation of both PTEN and TP53 
synergize to promote aggressive cellular behavior but to different extents in the context of 
different TP53 mutations. As mutant TP53 is a known driver of breast cancer, and both PTEN and 
TP53 mutations co-exist in basal type tumors, PTEN can be called a “co-driver” of mutant TP53. 
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In addition, the cell enrichment method that we developed for gene editing could be applied for 
screening for any given phenotype and to find the genotype that caused it.  
 
In the next step with the defined parameters obtained from the PTEN deletion screen, we set up 
the genome wide screen for the discovery of co-drivers of different mutant p53 based on the 
cooperativity of the mutations in enhancing cell invasion.  
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CHAPTER 4 
A FUNCTIONAL GENOMIC SCREEN IDENTIFIED DISTINCT INVASION PROMOTING ‘CO-
DRIVERS’ OF DIFFERENT MISSENSE MUTANTS OF TP53  
 
 
Introduction 
 
As mentioned in chapter 3, there are two broadly used methods to differentiate the driver genes 
from the passengers. They are the frequency-based and the function-based approach. There are 
two major limitations associated with the frequency-based approach. This approach is not 
efficient in identifying the non-prevalent driver mutations, the co-drivers, as these mutations are 
not frequent or non-recurrent unlike the clonal drivers and hence, difficult to differentiate from the 
background mutation frequency. Due to the low frequency of the co-drivers in a given sample, a 
very large number of samples (tumors or cells) need to be sequenced to identify the possible co-
drivers which is not cost effective. In contrast, the function-based approach to identify co-drivers 
is an efficient method as the co-drivers can be differentiated from the non-functional passengers 
based on a functional advantage making this approach more reliable than the frequency-based 
approach.  Choosing the function-based method, we designed a genome wide screen to identify 
the possible ‘co-drivers’ of missense mutant p53. In the previous chapter (chapter 3) we 
described about a CRISPR based screening pipeline that could deliver gRNA/Cas9 into the 
MCF10A cells, isolate/enrich invasive cell populations, and validate the gene deletion by using 
PTEN as a control, which is a known co-driver of missense mutant p53 frequently observed in 
invasive breast carcinomas. This established pipeline can be used for a genome wide functional 
screen for the discovery of unknown possible co-drivers of missense mutant p53. 
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Aim 
 
To identify the co-drivers of missense mutant p53 and to examine if each mutant p53 required a 
unique set of co-drivers to promote invasion. We designed a functional genomics screen to test 
the impact of deletion of every human gene on cell invasion in the cells expressing different 
mutant p53 proteins. 
 
 
Approach 
 
For the co-driver screens, we chose to utilize CRISPR-based approach, since shRNA-based 
method does not result in complete loss of function of the genes. CRISPR-based gene editing 
works at the level of DNA and directly recapitulates the effect of genetic alterations. The shRNAs 
degrade the mRNAs and work at the gene transcription level that eventually show reduced 
protein. In such a case, there could be partial deletion of protein that may render the results 
inconclusive.  Gene knock-out by CRISPR-Cas9 system results in complete deletion of the 
protein. A genome wide CRISPR based screen that perturbs all the human protein coding genes 
to identify the possible co-drivers of mutant p53 promoting cell invasion is a more systemic and 
effective method than screening for selected individual genes. Though expression libraries can be 
used for such a purpose but in classical molecular biology, gene deletion is the method of choice 
to determine the function of a gene. Hence, we chose a gene knock-out library (commercially 
available at Addgene from Feng Zhang’s lab) for screening of the co-drivers of mutant p53 that 
enhance cell invasion. 
 
Genetic screens with CRISPR based pooled libraries 
 
Genetic screens have become essential biological tools for unbiased functional genomics or 
phenotype screening, and the CRISPR-Cas9 system for genome editing is a very powerful tool 
  156 
for the screening because of its easy programmability (i.e., easy to design sgRNAs for targeting 
genes) and flexibility (i.e., a variety of engineered Cas9 enzymes for many types of gene 
manipulation). The use of CRISPR system has diversified and is not just limited to gene knock 
outs. This technique has been adopted for transcriptional repression (CRISPRi) with 90-99% 
repression with limited off-target effects and transcriptional activation (CRISPRa) with 
endonuclease dead Cas9 with gene expression modulation of over 1000-fold range (Gilbert 
2014).  The other applications also include the use of CRISPR-Cas9 for genetic sequence 
replacement or insertion, histone modification, DNA methylation and imaging of specific genomic 
loci.  Therefore, the pooled libraries of single guide RNAs (sgRNAs) have enabled a wide range 
of different types of genome wide screening for coding genes, gene regulatory elements and non-
coding genome features in given biological contexts. Such pooled sgRNA libraries are easy and 
inexpensive to synthesize, can be cloned into pooled plasmid library, and used for virus 
production and then cell screening in vitro or in vivo (Shalem 2015).  
 
The pooled libraries generally contain multiple sgRNAs targeting one gene and produce very 
reliable distinct phenotypes and have been used for both positive and negative selection of 
phenotypes. The CRISPR-Cas9 genetic screens have successfully identified and characterized 
genes conferring resistance to treatments (Shalem 2014), enhancer elements (Korkmaz 2016) 
and long non-coding RNAs (Zhu 2016) in the human genome.  For the pooled screens, virus 
transduction needs to be at low multiplicity of infection (LMOI) and NGS is needed for the screen 
read-out. Transduction of cells at low MOI ensures that each cell receives a single sgRNA thus, 
manipulation of one gene. This allows NGS of pooled cells or cell populations. In a typical screen, 
comparison of results between a reference cell pool (control) and the experimental cell pool (with 
treatment) identifies the genotype (sgRNAs) resulting in the selected phenotype.    
 
The animal models of cancer closely mimic the human disease and direct in-vivo CRISPR 
screens in the small animals (like mice) have identified the causative mutations driving cancer in 
the tissue microenvironment and understanding the clinical transformation of cancer. For 
  157 
example, in a genome wide CRISPR screen in mouse model for lung tumor metastasis showed 
effect of distinct mutations on primary tumor growth, late stage primary tumors and lung 
metastases (Chen 2015). Such a method can also be used to test the gene-phenotype 
relationships during cancer evolution.  Direct delivery of sgRNAs in adeno-associated virus (AAV) 
vector in the lungs caused disruption of TP53 and LKB1 and point mutations in KRAS (knock-in 
mutation) leading to adenocarcinomas (Platt 2014). CRISPR-mediated genome editing has 
unraveled the combinations of mutations that influence tumor growth pattern, tendency to 
metastasize and resistance to therapy (Chow 2018).  
 
Genome-scale CRISPR knock-out (GeCKO) v2.0 pooled libraries 
 
We chose a commercially available CRISPR-based library, the GeCKO v2.0, for the genome-
wide screen of the co-drivers of different missense mutant p53. This GeCKO v2.0 library was 
developed in the Zhang lab (Shalem 2014) and commercially available at Addgene. The library 
contains type II CRISPR nuclease system for genome editing in mammalian cells in a pooled 
library targeting the early consecutive exons and comprises of a total of 122,417 unique sgRNAs 
targeting the entire human genes. Each plasmid in this library is the lentiCRISPRv2 backbone 
vector and contains a 20 bp gene-specific sgRNA (single gRNA) for gene knock-out. To reduce 
the library complexity, the GeCKO library is split into two half-libraries A and B, and each has 3 
sgRNAs per gene, making a total of 6 sgRNAs per gene. Both the half-libraries also contain 1000 
control sgRNAs without any sequence homology to human genome. Library A targets miRNAs 
with 4 sgRNAs per miRNA. The lentiCRISPRv2 vector produces a very high viral titer, and the 
sgRNAs were designed to minimize off-target effects, making this library ideal for phenotype 
screening. 
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Library coverage for efficient screening 
 
Before the screening for the co-drivers, it was essential to ensure the full representation of the 
library during its amplification, lentivirus production and during the transduction of the cells. A 
critical parameter to consider in performing any genome wide screen is whether the experimental 
design such as the number of cells and virus particles will be enough to test evenly every gene 
and identify the hits. In this study, we targeted for a 250x coverage per sgRNA, i.e., one sgRNA 
was represented in an average of 250 cells and tested for invasion promoting activity during the 
genome wide screening process. As the transduction of cells was carried out at a low MOI 
(multiplicity of infection) of around 0.3, we calculated the number of cells required based on the 
estimated transduction efficiency of 20 to 40% (Table 4.1). We also estimated the number of viral 
particles (virus particles/ no. of cells equated to 0.3 (the chosen MOI)) needed for the low MOI 
transduction and scaled up the lentiviral library production process accordingly. 
  
PCR amplification of genome integrated sgRNA cassette 
 
In order to find out which gene deletions cause the phenotypic changes after phenotype selection 
we designed a PCR-based strategy by taking advantage of the fact that every sgRNA containing 
plasmid share common DNA sequences except the sgRNA sequences. Therefore, the genome-
integrated sgRNA cassettes can be amplified with the universal primer pair and sequenced by 
next-generation sequencing (NGS), from which each sequence read can be mapped to each 
Table 4.1. Calculation to maintain 250-fold library representation. 
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sgRNA/gene and counted. This method was preferred over the whole-genome sequencing, since 
it is less time consuming and cost effective. The method simplifies the analysis of results from the 
screen. Comparison of sgRNAs in the reference (pre-invasion) cell pool and the experimental 
(post-invasion) yields the enriched sgRNAs corresponding to the genes whose deletion or loss of 
function resulted in increased cell invasion of the p53 mutant cells. The genomic region 
containing the integrated sgRNA was amplified from genomic DNA using a two-step PCR method 
to derive short amplicons (300 bp) that can be sequenced directly. A 700 bp region was first 
amplified using a primer set (primer set 2, PCR 1) with primers specific to the lentiCRISPR v2 
plasmid and a defined PCR program. Using the purified PCR 1 product as the template, PCR 2 
was performed to get a 300 bp amplicon (Fig 4.1). This 300 bp amplicon was sequenced, and the 
read counts for each sgRNA was normalized against the total number of reads for each sample to 
CPM (counts per million reads). Lastly, by selecting the sgRNAs with the largest ratio of CPM in 
post-selection population over the ones in pre-selection population, we could identify potential co-
driver genes. 
 
 
Figure 4.1. PCR amplification to capture genome integrated sgRNA. The region 
containing the sgRNA was amplified from genomic DNA by a 2 step PCR. The 300 bp 
amplicon was then sequenced. 
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The genome wide ‘co-driver’ screen design 
 
Leveraging the optimized invasion assay condition in Chapter 3, we designed a screening 
protocol that allows enrichment of the cells with increased invasion after sgRNA library 
transduction (Fig 4.2). The library-transduced cells (i.e., pre-selection or reference pool) were 
plated in the invasion chambers with a Matrigel-coated membrane and formed the pre-invasion 
reference cell pool. After incubation, the non-invasive cells were scraped off from inside the 
chambers. The invasive cells that crossed the Matrigel-coated membrane (i.e., post-selection or 
invasive population) were isolated by adding trypsin in the bottom well. sgRNA cassettes were 
then PCR-amplified from each pool (reference and post-invasion) and sequenced, and the fold 
enrichment of sgRNAs in the invasive pool over the reference pool were calculated. The enriched  
 
 
Figure 4.2. Method for screening the co-drivers of missense mutant p53 that promote 
cell invasion. The library transduced cells (p53 mut+ 1 sgRNA) were used for the invasion 
assay and only the invasive cells were extracted. Genomic DNA was obtained from the pre 
and post-invasive cells and the region containing the sgRNA was PCR amplified. The 
amplicon was then sequenced from the pre and post-invasive cells and enrichment of 
sgRNAs in the invasive pool determined. 
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sgRNAs in the invasive cells represented the possible co-drivers of different missense mutant 
p53. The top enriched sgRNAs were individually cloned into the lentiCRISPR v2 plasmid (the 
backbone vector of GeCKO v2.0 library) and transduced into the cells, and the increased cell 
invasion capacity in cooperation with mutant p53 was validated.   
 
For the screening of unique co-drivers of missense mutant p53, we chose two cell lines with 
contrasting phenotypes, the least invasive Y234C and the most invasive R273C cells. We also 
included the MCF 10A p53 WT-OE (wildtype p53 overexpressing) cells as the control. 
 
 
 
Method 
 
Amplification and sequencing of the GeCKO v2.0 plasmid library 
 
GeCKO v2.0 library obtained from Addgene was diluted to 50 ng/ul (water or TE buffer). 2 ul of 
the library was added to 25 ul of electrocompetent Lucigen Endura cells and electroporated into 
the cells. Cells were recovered with 975 ul of recovery media and then transferred to 1 ml more of 
recovery media. A total of four electroporations were done and the tubes rotated at 250 rpm for 1 
hr at 37oC. All electroporated cells were pooled (total 8 ml) and mixed well. 10 ul was added to 1 
ml of recovery media and 20 ul of cells were plated. This 40,000-fold dilution of full transformation 
gave an estimate of the transformation efficiency and ensured full library representation. The 8 ml 
of transformation was distributed to 4 bioassay plates using a cell spreader and incubated for 14 
hrs at 32oC. The number of colonies on the diluted plate were counted and multiplied by 40,000 
to get the total number of colonies. The total number of colonies were more than 3 million and 
thus, we proceeded with the next steps. 10 ml of LB was put onto each bioassay plate and the 
colonies were scraped using the cell spreader. The liquid with the scraped colonies were 
collected in a tube and this step repeated with another 5- or 10-ml LB. The bacteria were 
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centrifuged, and the bacterial pellet was weighed. Several maxi-preps were performed to extract 
the amplified plasmid library (each maxi-prep column can hold 0.45 gm of the bacterial pellet). 
This plasmid library was sequenced to verify the representation using the primers in Table 4.2.   
 
 
 
 
 
 
 
 
 
Preparation and sequencing of the lentiviral library 
 
Lentivirus from the plasmid library was prepared in 6-well plates. On Day 1, 1.5 million 293Lx 
cells were plated in each well in 2 ml media. On Day 2, a transfection master mix was prepared 
containing mix 1 and mix 2. Mix 1 of total 150 ul had diluted Fugene HD in serum free DMEM 
media (Fugene HD ul: total ug of DNA = 6:1). Mix 2 had packaging plasmids 500 ng VSVG, 2500 
ng Gag-pol and 2500 ng of lentivector in serum free DMEM media making a total of 150 ul. Mix 1 
and mix 2 were combined and incubated at room temperature (RT) for 20 to 30 min. After the 
incubation, 150 ul of the master mix was dispensed into 2 wells each. The volume of the master 
mix and hence the concentration of the plasmids were increased according to the number of wells 
transfected. The 6-well plate was spun at 2250 rpm for 30 min and then placed in the incubator at 
37oC. 1% Westcodyne was used for disposing biohazard waste. On Day 3, 1 ml media was 
removed and replaced with 2 ml fresh media in the morning and in the evening 2.5 ml media was 
removed and replaced with 5.5 ml fresh media in each well. On Day 4, 5.5 ml media was 
collected in a 50 ml tube and stored at 4oC and 3.5 ml fresh media was put into each well. Finally, 
on Day 5, 4 ml media was collected from each well in the same tube. The lentivirus was 
Table 4.2. Primer pair used for checking GeCKO v2 library 
representation. 
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concentrated using the Lenti-X concentrator (Clontech). 1 volume of concentrator was mixed with 
3 volumes of virus containing media and mixed by gentle inversion. The mixture was incubated 
overnight at 4oC and centrifuged at 1500xg for 45 min at 4oC. The off-white virus pellet was 
resuspended with a low volume of media, immediately aliquoted and stored at -80oC. The 
packaged plasmid from the virus was extracted using the QIAamp MinElute virus spin kit (Cat. 
No. 57704) as per the manufacturer’s protocol. The PCR amplicons were sequenced to check the 
library representation in the lentivirus.  
 
MOI determination 
 
For determining the conditions for maintaining low MOI (multiplicity of infection) during 
transduction of MCF 10A p53 mutants Y234C and R273C cells with the lentiviral libraries A and 
B, different cell concentrations, virus volumes, selection reagent concentration and selection 
duration were established. 35,000 cells/well were plated in each well of 6-well plate in 2 ml on 
Day 1. On Day 2, cells were transduced with different volumes of lentivirus libraries A and B. 1 ml 
media was removed and polybrene at final concentration of 8ug/ml per well was added before 
addition of the virus. The virus was removed, and fresh media added on Day 3. Selection reagent 
(puromycin 0.7 ug/ml) was added to the cells on Day 4 and selected for 72 hrs. The un-
transduced cells with or without puromycin were included as controls. The un-transduced cells 
with puromycin were dead (floating cells) by 72 hrs. At the end of 72 hrs, %transduction was 
calculated as: (total no. of transduced cells/ total no. of untransduced cells) *100. %transduced or 
%survival corresponding to 20%-40% ensured low MOI of 0.3 to 0.5 for transduction.    
 
Transduction of MCF 10A p53 mutant cells with the lentivirus library 
 
For the transduction of MCF 10A p53 mutant Y234C and R273C cell-lines, a total of 66 million 
and 58 million cells were transduced with the CRISPR half-library A and B respectively per cell-
line at MOI=0.3. Such cell numbers were transduced in order to maintain a 250-fold 
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representation of each of the half-libraries. The 66 and 58 million cells were split into two batches 
for the ease of handling.  On Day 1, cells were plated in the large cell culture T225 flasks. On Day 
2, lentivirus libraries A and B were added after the addition of polybrene and on Day 3, the media 
in the flasks was replaced by fresh media. Puromycin (0.7 ug/ml) was added to the media on Day 
4 and cells selected for 72 hrs. The cells from the T225 flasks were combined and transferred to 
petri-dishes and selected for at least 14 days in puromycin before using them for the invasion 
assay. Cells were passaged at regular intervals where half of the cells were propagated and the 
rest frozen as stocks. 
 
Isolation and expansion of the invasive cells 
 
For the extraction of invasive cells, the 6-well BioCoat Matrigel invasion chamber plates (cat # 
354481) were used.  1 million cells were seeded in each Matrigel coated insert in serum free 
media (2ml), making a total of 12 million cells (2 plates). In the bottom well 2.5 ml media with 
serum was placed. After seeding, the plates were incubated at 37oC and 5% CO2 for 30 hrs for 
Y234C cells and 18 hrs for R273C cells. Following incubation, media from both the insert and the 
well were removed. The inserts and the wells were washed with 1X PBS. Using a cotton swab the 
cells on top of the insert, the non-invasive cells, were scraped off. 500 ul of trypsin was added to 
the bottom well and the insert now with only the invasive cells was placed on it. After 15 to 20 min 
(if the typsinization was complete, cells were completely round and floating) media containing 
serum was added to the bottom well to neutralize trypsin. The post-invasion or invasive cells were 
collected from each well in a tube and then re-plated in a new sterile 6-well plate. Once the 
invasive cells started to grow, they were transferred to petri-dishes. Pellets were generated for 
genomic DNA (gDNA) extraction and frozen vials of cells were also prepared. Genomic DNA from 
5 or 12 million pre-invasion and post-invasion cells were extracted using the Blood and Cell 
culture DNA midi kit from Qiagen (cat # 13343) as per the manufacturer’s protocol. 
 
 
  165 
Sequencing of pre and post-invasion cells 
 
The genomic region containing the sgRNA was amplified from genomic DNA of the cells using a 
two-step PCR method. A 700 bp region was first amplified using the following primer set 2 and 
PCR (PCR 1) program. PCR 1 product was purified. Using the purified PCR 1 product as the 
template, PCR 2 was performed to get a 300 bp amplicon. The amplicon size was verified on 1% 
agarose gel. This 300 bp amplicon was then sequenced (2X150 bp) to determine the enriched 
sgRNAs in the post-invasion pool of cells (Table 4.3).  
 
We performed the genome wide screen for targeted loss of function of genes in MCF 10A p53 
mutant Y234C and R273C expressing cells including the p53 WT-OE cell lines as the control. 
Sample was sequenced using the Illumina MiSeq platform. sgRNA sequences were extracted by 
trimming forward and reverse primer using Cutadapt, then matched to GeCKO v2.0 library for 
direct hit (Martin 2011). For each gene, reads from pre and post invasion samples were 
normalized to count per million (CPM). Post-invasion CPM was divided by pre-invasion CPM for 
calculation of enrichment scores. Two replicate experiments were performed with WT-OE; three 
with Y234C and four with R273C. We ranked the maximum enrichment score for the sgRNAs in 
the post-invasion cell pool to select the top hit genes.  
 
Cloning of individual sgRNA into vector 
 
To clone the target sgRNA sequences into lentiCRISPRv2 plasmid, two oligos were synthesized 
for each sgRNA (Appendix C). After the vector digestion with BsmBI, the plasmids bear an 
overhang that matches with that on the synthesized oligos. For the cloning of the individual 
sgRNAs into the lentiCRISPRv2 plasmid, the following steps were performed (Table 4.4). 
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Table 4.3. Specification of 2-step PCR. PCR 1 with primer set 2 was followed 
by PCR 2 with primer set 4 to obtain 300bp amplicon for NGS. 
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Table 4.4. Detail for cloning of individual sgRNA. 
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1) Digestion of lentiCRISPRv2 plasmid. The vector was either digested and dephosphorylated or 
simply digested. 2) Gel extraction of cut plasmid. BsmBI digestion resulted in a 2 kb filler 
fragment and a larger band.  The digested products were checked on 1% agarose gel run for 27 
min at 120 V. For cloning, only the larger band was extracted from the 1% GTG agarose gel run 
for 27 min at 120 V. The extracted band was purified using the QIAquick gel extraction kit as per 
manufacturer’s protocol. 3) Annealing each pair of oligos. The oligo pairs were either annealed 
and phosphorylated or simply annealed.  For phosphorylation and annealing of the oligos, the 
thermocycler was set as 37oC for 30 min, 95oC for 5 min and then ramp down to 25oC at 5oC/min. 
For simply annealing the oligos, the setting was 95oC for 5 min and then ramp down to 25oC at 
5oC/min. The annealed oligos were diluted (1:200) in sterile water. 4) Ligation reaction. The 
dephosphorylated cut plasmid was ligated with the phosphorylated oligos and the simply cut 
plasmid was ligated with the annealed oligos without phosphorylation. As a negative control we 
used water instead of the oligos with the digested vector. 5) Transformation into Stbl3 bacteria. 
25 ul Stbl3 cells were mixed with 5 ul ligation reaction by gentle flicking. Cells were incubated on 
ice for 15-20 min. For transformation, cells were given heat shock at 42oC for 30-40 s and then 
immediately put on ice for 2 min. 200 ul of SOC media was added to the cells and shaken at 250 
rpm for 1 hour. All the cells were plated on agar plates with appropriate selection reagent and 
incubated at 37oC overnight. After 16 to 18 hrs if colonies appeared, 3 to 4 random colonies were 
picked for 5 ml overnight cultures. The agar plates were then stored at 4oC. Plasmids were 
extracted from the overnight cultures and colony PCR was performed. The region of the plasmid 
containing the cloned sgRNAs was PCR amplified and the sequence checked with Sanger 
sequencing. 
 
Transduction of MCF 10A p53 mutant cells 
 
Lentivirus packaged with cloned sgRNA for GCNT1, FGD6, ADAM15, PACS1 and SDF4 were 
prepared in 6-well plates. 1.5 million 293Lx cells were plated in each well in 2 ml media. A 
transfection master mix was prepared the next day containing mix 1 and mix 2. Mix 1 of total 150 
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ul had diluted Fugene HD in serum free DMEM media (Fugene HD ul: total ug of DNA = 6:1). Mix 
2 had packaging plasmids 500 ng VSVG, 2500 ng Gag-pol and 2500 ng of lentivector with the 
appropriate cloned sgRNA in serum free DMEM media making a total of 150 ul. Mix 1 and mix 2 
were combined and incubated at room temperature (RT) for 20 to 30 min. After the incubation, 
150 ul of the master mix was dispensed into 2 wells each. The 6-well plate was spun at 2250 rpm 
for 30 min and then placed in the incubator at 37oC. On the following day, 1 ml media was 
removed and replaced with 2 ml fresh media in the morning and in the evening 2.5 ml media was 
removed and replaced with 5.5 ml fresh media in each well. The next day 5.5 ml media was 
collected in a 50 ml tube and stored at 4oC and 3.5 ml fresh media was put. Finally, on the last 
day 4 ml media was collected from each well in the same tube. The lentivirus was concentrated 
using the Lenti-X concentrator (Clontech).  
 
MCF 10A p53 mutant Y234C cells were transduced with lentiviruses with sgRNA for GCNT1, 
FGD6, ADAM15 and R273C cells with lentiviruses containing sgRNA for PACS1 and SDF4. For 
transduction 75,000 cells/well in 2 ml media were plated in 6-well sterile plates. On the following 
day, 1 ml media was removed from each well and desired amount of lentivirus was added after 
the addition of polybrene. Next day media was replaced by fresh media. Puromycin (0.7 ug/ml) 
was added to the media on the following day and cells selected for 72 hrs. The cells were 
transferred to petri-dishes and selected for at least 14 days in puromycin before further use. Cells 
were passaged at regular intervals and frozen stocks were also made. 
 
T7 endonuclease assay and MiSeq of the gene locus 
 
Genomic DNA (gDNA) was extracted from the cells and the sgRNA target locus was PCR 
amplified. gDNA from MCF 10A Y234C and R273C cells (not transduced with the library) were 
used as negative controls and water as no template control (NTC). Detail of the PCR (Table 4.5): 
The PCR products were run on 1% agarose gel to verify the size and amplification. The PCR 
products were then purified, and their concentrations determined. The PCR products were then 
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set for the annealing reaction. 1 ul of T7 endonuclease I enzyme (NEB cat # M0302) was added 
to 19 ul annealed PCR products and incubated for 15 min at 37oC. The reaction was stopped with 
1.5 ul of 0.25 M EDTA. One may also consult the protocol provided in the NEB website. The 
fragmented PCR products were analyzed on 10% TBE gel run in 0.5X TBE buffer for 70 min at 
120V. The gel was then stained in 75 ml 0.5X TBE buffer with 0.7 ul EtBr for 20 min.  
 
For sequencing of the targeted locus, the locus was PCR amplified as per the Table 4.6, purified 
and submitted for MiSeq 2x150 bp run. Paired-ended sequences were aligned to the reference 
human genome (GRCh38.p92/hg38) using Bowtie2 (Bowtie2 2.1.0) (Langmead B, 2012). A 
deletion was called if a deletion site was within ± 5bp apart from the sgRNA targeting site. 
Igvtools (igv_2.4.13) was used for data visualization (Helga 2013). 
 
 
 
Table 4.5. PCR and annealing step for T7 endonuclease assay. 
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Western blot 
 
Cells were grown in 6-well plates for the cell lysate preparation. Cell lysates were made using the 
RIPA lysis buffer containing 50mM Tris, 150mM NaCl, 1% IGEPAL CA-630, 0.1% sodium azide 
(Sigma #S8032), cOmplete mini protease inhibitor (Sigma #04693124001), 200 µM sodium 
fluoride and 200 µM of sodium orthovanadate. Cells when confluent were scraped, incubated on 
ice for 10 minutes and centrifuged at 10,000 rpm for 10 min to collect the clear lysate. Lysates 
were quantified using the Pierce BCA kit (cat # 23225). Samples were run on 4-20% TGX gels 
from BioRad (#567-1093) and blotted onto 0.45µm PVDF membrane (GE Healthcare #10600023) 
using the BioRad semi-dry transfer system. Primary antibody for GCNT1 (Thermo PA5-12146), 
FGD6 (Thermo PA5-48123), ADAM15 (Sigma Aldrich HPA011633), PACS1 (Invitrogen PA5-
72865) and SDF4 were diluted to 1:500 and secondary HRP-linked anti-mouse (1:5000) or anti-
rabbit (1:3000) antibody used to visualize the protein bands. The blots were imaged on the 
Fluorchem FC3 from AlphaInnotech.   
 
 
 
Table 4.6. PCR amplification of target locus for MiSeq. 
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Cell invasion assay in 24 well plates 
 
Cells (70-80% confluent) were trypsinized and used for the transwell invasion assay (24 well). 
Before the experiment, the Matrigel coated invasion plate (Corning cat # 354480) was thawed 
with 200 ul serum free media in each well for rehydrating the matrigel layer at 37oC for 1 hr. 
2.5x105 cells in 200ul serum free media were seeded in the Matrigel coated insert. 750 ul of 
serum containing media was added to the bottom wells. For the Y234C cells with the co-drivers, 
the invasion plates were incubated for 24 hrs and for R273C cells with co-drivers incubation time 
was 18 hrs. After incubation, cells were fixed with 4% paraformaldehyde for 2 min at RT, 
permeabilized by adding 500ul of 100% cold methanol (20 min at RT) and stained with 0.5% 
crystal violet dye (15 min at RT). A cotton swab was used to remove any non-invasive cells. The 
invasive cells were imaged under a microscope at 4X and 10X magnification.  
 
 
 
Results 
 
Representation of GeCKO v2.0 plasmid and lentiviral library  
 
The chapter 3 showed the proof-of-principle for ‘co-driver’ of missense mutant p53 where known 
deletion of PTEN by CRISPR-Cas9 increased invasive potential of the weakly invasive MCF 10A 
p53 mutant G245S, R273H and Y234C cells. To scale up the pipeline for a genome wide screen 
for the co-drivers of missense mutant p53, a CRISPR based library, GeCKO v2.0, was purchased 
from Addgene. Functional genomic screening for the co-drivers enabled identification of the 
perturbagen (sgRNA targeting a gene in this case) that generated the invasive phenotype.   
 
The GeCKO v2.0 library was transformed, expanded, and purified to have sufficient concentration 
and amount of the plasmid DNA to prepare the lentivirus library with complete coverage of all 
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sgRNAs. The library representation was verified using NGS at each stage, after amplification of 
the plasmid library and after preparation of the lentivirus library. The 300 bp amplicon obtained 
from PCR amplification of plasmid half-library A and B was purified and sequenced (Table 4.7). 
For both the half-libraries A and B the representation in terms of the total number of sgRNAs was 
99.8% and 99.7%, respectively. This ensured the presence of sgRNAs in half-libraries A and B 
targeting 99% of all human protein-coding genes. Using this plasmid library, the lentiviral library 
was generated. The two half-libraries A and B were always kept separate and never pooled. 
From the sequencing of the lentivirus half-libraries A and B, 83% and 91% of sgRNAs, 
respectively, were packed in the lentivirus library. But, collectively, the two lentiviral libraries 
contained sgRNAs targeting more than 99% of the human genes (Fig 4.3). These showed that 
the library representation and the sgRNA diversity were maintained during both GeCKO v2.0 
library amplification and lentivirus production. 
 
 
 
Table 4.7. Coverage of plasmid half libraries A and B from NGS. Below is the primer pair 
used to obtain the amplicon for NGS. 
 
 
 
 
 
Total genes Found in NGS % representation Total gRNA Found in NGS % representation
Half-library A 20915 20669 98.8 63950 63807 99.8
Half-library B 19050 18834 98.9 56869 56694 99.7
Set 3 Forward GGCTTTATATATCTTGTGGAAAGG
U6 promoter close to 
the cut site
Set 3 Reverse GACATCACTTTCCCAGTTTACC
EF-1 alpha core 
promoter
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Transduction of cells with lentiviral GeCKO v2.0 library at low MOI 
 
After the lentivirus library preparation, the optimal conditions for transduction of the MCF 10A p53 
mutant cells were established. The conditions were carefully worked out to ensure that a given 
cell was infected by a single virus particle and thus, only one sgRNA integrated into the genome. 
This ensured that the p53 mutant cells had only one additional mutation (1 sgRNA integration per 
cell). 
 
Multiplicity of infection (MOI) is the ratio of number of virus particles and number of host cells in 
an infection. MOI was determined and adjusted by changing the concentration of the virus and 
the cells. To allow transduction of only one sgRNA per cell, MOIs between 0.3 and 0.5 were 
considered, which corresponded to the percent survival or the percent transduction between 20% 
and 40%. The cell concentration and the lentivirus volumes were thus adjusted to yield 20% to 
40% survival of transduced cells after transduction with the GeCKO v2.0 library and puromycin 
selection (Fig 4.4). In order to maintain a 250-fold coverage for each sgRNA, 66 million and 58 
million cells were separately transduced with the lentiviral half-library A and B, respectively. The  
 
 
Figure 4.3. Coverage of the genes by the lentivirus 
library determined by NGS. 
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Figure 4.4. Cells transduced at low MOI. A. Low MOI of 0.3 for transduction corresponded 
to 20-40% cell survival after selection. Untransduced cells without or with the selection 
reagent were included as the controls. B. Independent transduction to ensure complete 
coverage by the library for co-driver screening. 
 
Untransduced +puroUntransduced -puro
Transduced lib A
+puro
Transduced lib B
+puro
WT-OE
Y234C
R273C
A.
Lib A or B: 66 million/ cell-line per half-lib
Batch 1 - Lib A
Plate 1 Plate 2 Plate 3 Plate 4
Transduction with 
lentivirus library
Transduction with 
lentivirus library
Transduction with 
lentivirus library
Transduction with 
lentivirus library
Combined cells
Transfer to regular petri-dishes (10)
Growth and selection 
in puromycin for 14 
days
Pass cells (about 4 
times), generally pass ½ 
cells and freeze rest ½ 
cells
B.
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cells were selected with puromycin for 2 weeks before using them for phenotypic selection by the 
invasion assay. 
 
A pilot study revealed at least 3 independent screens were needed to test all genes as 
possible co-drivers of missense mutant p53 
 
Although, we calculated the mathematical cell number required to achieve 250x coverage of 
every sgRNA, the actual coverage might be influenced by various biological and technical factors. 
Thus, to further ensure a complete coverage of genes during the screen, we then examined how 
many independent batches of transduced cells were needed to test and screen all human genes.  
One of the major biological factors that can affect the coverage is the fraction of genes critical for 
cell survival, such as housekeeping genes, or cell proliferation. Around 30% of the human 
protein-coding genes are considered essential, and sgRNAs that ablate the function of the 
essential genes are thus, unlikely to be detected in the transduced cells after puromycin 
selection. In addition, due to the technical factors, a small fraction of sgRNAs might be lost during 
the packaging into the lentivirus or during transduction of cells. Therefore, aiming to find the 
optimal experimental setup that can maximize the number of protein-coding genes to be 
screened, multiple rounds of independent transduction, puromycin selection, and sequencing 
were performed on 3 cell lines (WT-OE, Y234C, and R273C), and individual and cumulative 
empirical coverages of the replicates were calculated.  
 
As shown in Fig 4.5 the first batch of transduced WT-OE cells (Fig 4.5A, “run 1”) had only a small 
fraction of sgRNAs (~23,300 or 21% of all 110,819 sgRNAs for protein-coding genes in Lib A and 
B combined), but, when mapped to the genes, the sgRNAs covered 87% of all protein-coding 
genes (18,262 out of 20,700) with 1.27 sgRNAs/gene ratio. In Y234C and R273C cells, we 
observed the gene coverage of 83% and 57% with the sgRNA/gene ratio of 2.12 and 1.44, 
respectively. When we calculated the cumulative coverage over the multiple batches of 
transduced cells, combinations of 2 or 3 batches could cover 90% of all protein-coding genes with  
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Figure 4.5. sgRNA counts and gene coverage from separate NGS runs of library 
transduced pre-invasion cell pool (reference pool). A. 2 sequencing runs of WT-OE-libA 
and libB cells. B. 3 sequencing runs of Y234C-libA and libB cells. C. 4 sequencing runs of 
R273C-libA and libB cells. Although all the sgRNAs were not fully covered in the reference 
pool, there was full coverage of all the 20,000 genes targeted by the sgRNAs. At least 3 
independent screens were needed for screening all genes for the co-drivers.  
A.
Screened gene count LibA sgRNA count LibB sgRNA count
Screened gene count LibA sgRNA count LibB sgRNA countB.
Screened gene count LibA sgRNA count LibB sgRNA countC.
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the sgRNA/gene ratio greater than 2.0. Although different p53 mutant-expressing cells showed 
different library transduction efficiency likely due to distinct set of essential genes and different 
cellular states, these results demonstrated that three independent screens were sufficient to 
perturb the majority of protein-coding genes with 2 or more sgRNAs and test the phenotypic 
influence for identification of invasion promoting co-drivers of missense mutant p53. 
 
Screening for co-drivers of missense mutant p53 that drive cell invasion 
 
We screened a total of 48 million (combining from all 3 batches) library transduced Y234C cells 
(24 million from Y234C-libA and 24 million of Y234C-libB) for co-drivers promoting cell invasion. 
For library transduced R273C cells, a total of 96 million cells (48 million cells from R273C-libA 
and R273C-libB each) were screened for co-drivers. WT-OE-libA and libB cells were used as the 
control. 
 
The library transduced cells of weakly invasive p53 mutant Y234C (Y234C-libA and Y234C-libB) 
were incubated for 30 hrs while the library transduced cells of more invasive p53 mutant R273C 
(R273C-libA and R273C-libB) were incubated in the Matrigel coated transwell invasion chambers 
for 18 hrs. The library transduced cells demonstrated increased cell invasion compared to the 
non-transduced Y234C and R273C cells indicating that the gene deletion by sgRNA enhanced 
cell invasion (Fig 4.6). 
 
To identify the co-drivers of missense mutant p53 that enhanced cell invasion, the invasive cells 
that managed to cross the matrigel barrier were extracted. As only 10 to 15% of transduced cells 
invaded, the number of extracted invasive cells were too low to proceed with genomic DNA 
extraction for NGS. Hence, the extracted invasive cells were plated into new sterile 6-well plates 
and grown for 5 to 7 days. Genomic DNA (gDNA) was then isolated from 5 to 12 million post-
invasion cell population.  
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We used the MCF 10A p53 WT-OE-libA and WT-OE-libB cells as the controls to filter out the co-
driver candidates that are common to the WT p53 protein. After the amplified sgRNA cassettes 
were sequenced, counted, and normalized to CPM (counts per million reads), to assess the 
relative enrichment of sgRNAs before and after invasion-based selection, post-invasion CPM was 
then divided by pre-invasion CPM to calculate the enrichment scores. Among the replicate 
screens, we selected the maximum enrichment score for each sgRNA in the post-invasion cell 
pool to identify the top hit genes. 
 
The post-invasion cell population of WT-OE cells had a limited number of highly abundant (i.e., 
CPM >1,000 or >0.1% of total reads) sgRNAs (Fig 4.7), and only a few (N=3) genes showed the 
fold enrichments greater than 1,000 folds over the pre-invasion population (Fig 4.8). In contrast, 
in the invasive pool of Y234C cells, many selected sgRNAs were abundant above 1,000 CPM up 
to 30,000 CPM (or >3% of total reads) (Fig 4.8), including sgRNA for PTEN and several known 
cancer related genes such EPHB2.  Similarly, in the post-invasion cell pool of R273C-libA and 
R273C-libB, several highly abundant sgRNAs were detected compared to that of control cells, 
most notably for the PACS1 sgRNA that occupied up to 80% of total reads (Fig 4.8). Many known 
  
Figure 4.6. End point determination for invasion assay for screening of co-drivers. For 
the invasion assay 1 million cells were seeded in each insert per cell-line. Cells were then 
stained with crystal violet. LibA and libB transduced cells (for both Y234C and R273C) 
resulted in increased invasion of cells. 
Blank MDA-MB 231 Y234C Y234C-libA Y234C-libB R273C R273C-libA R273C-libB
18 hrs
30 hrs
Weakly invasive p53 mutant Y234C Highly invasive p53 mutant R273C
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cancer genes (FUS, EGLN1) were also enriched in the R273C-libA and libB post-invasion cell 
pool. In addition, compared to WT-OE and Y234C post-invasion cell pool, the fold enrichments of 
sgRNAs in R273C post-invasion cell pool was much larger by an order of magnitude (Fig 4.8). 
Interestingly, the set of enriched sgRNAs were cunique to each p53 missense mutant Y234C and 
R273C as well as the wildtype p53.  
 
 
 
 
 
  
 
Figure 4.7. The normalized read counts of sgRNAs in pre- and post-invasion 
(invasive) cell pools. The X and Y axes depict the CPM values of sgRNAs in the pre-
invasion and post-invasion cell pools, respectively. 
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Analysis of the top co-driver candidates 
 
Known p53 related genes such as CDKN1A and PIK3CA were largely enriched in Y234C (463- 
and 79-fold enriched, respectively), but such pattern was not observed in R273C cells. There was 
no correlation in enrichment scores between Y234C and R273C cells, and top enriched genes 
were entirely unique to each cell, indicating that a distinct set of co-drivers is needed for cell 
invasion. To select the top hits from the screens for functional validation, we ranked the hits 
based on several criteria. The top hits were first selected based on the number of times the 
candidate sgRNAs identified as hits (>1,000-fold enrichment) in the screenings. For example, all 
 
 
Figure 4.8. Fold enrichments of sgRNAs in invasive populations of WT-OE, Y234C and 
R273C cells over the reference populations. Genes marked with grey are known tumor 
suppressors among top 100 enriched genes. Black are the ones chose for validation. It is to 
be noted that the scales are not the same.  
WT-OE Y234C R273C
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the selected top hits showed up at least two or more times in the independent screens. We then 
examined the targeting site of the sgRNA in the gene (i.e., if sgRNA targets the N-term or an 
important functional domain of a protein), co-occurrence of somatic mutations with TP53 
mutations in patients or other experimental data sets, and its relevance to the process of cell 
invasion, migration and cytoskeletal organization. We also included the data from RNA seq of the 
p53 mutant cells for correlation between gene expression and the invasive phenotype.  For 
example, the GO term enrichment analysis showed that apoptosis and proliferation related genes 
were significantly enriched among the top 100 genes from the Y234C and R273C screens. As 
mentioned above, the total number of extracted invasive cells were very low for any downstream 
processing and thus, cells were expanded for a few days, which might lead to enrichment of 
sgRNAs for apoptosis and cell proliferation related genes. Thus, we carefully chose the target 
genes likely to be associated with the process of cell invasion. Finally, though there are a total of 
6 sgRNAs (3 sgRNAs in libA and 3 in libB) in the library targeting each gene, we chose to validate 
the only sgRNA sequence that appeared enriched in the multiple screens. 
 
For functional validation, we chose three top hits GCNT1, FGD6 and ADAM15 for Y234C and 
PACS1 and SDF4 for R273C from the integrated analysis. These results implied that the 
acquisition of aggressive phenotype required different sets of co-driver mutations for different p53 
missense mutations. 
 
GCNT1 is the glucosaminyl (N-acetyl) transferase 1 and forms Gal beta 1-3 GalNAc and the core 
2 O-glycan branch. It has a role in sphingolipid metabolism and cell adhesion. GCNT1 is highly 
expressed in prostate, endometrial cancer and colorectal cancer but is downregulated in breast 
cancer (Hagisawa 2005, Miyamoto 2013, St Hill 2009, Solatycka 2012). The enriched sgRNA in 
the screens targeted the N-terminus of the protein, which could effectively knock-out the gene. 
FGD6 is the FYVE, RhoGEF and PH domain containing 6 gene. The RhoGEF domain mediates 
the GDP-to-GTP exchange of the Rho/Rac/Cdc42 GTPases involved in the cell migration 
process. The PH or the Plecstrin homology domain is generally a part of cytoskeletal and signal 
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transduction proteins, binds to phosphoinositide lipids, and thus functions in membrane targeting. 
FGD6 has a proposed role in chemotaxis of cells, actin cytoskeleton organization, filopodium 
assembly, regulation of GTPase activity and cell shape (NCBI database). The selected sgRNA 
targeted the region close to the RhoGEF domain, which thus, likely would result in a non-
functional protein. The other target ADAM15 is a metallopeptidase, a transmembrane 
glycoprotein involved in cell adhesion. It has a zinc binding metalloprotease domain, a disintegrin 
like domain and an EGF like domain. It interacts with integrin and Src family protein tyrosine 
kinases indicating its potential function in cell-cell adhesion and signaling. It is known to be 
upregulated in aggressive prostate cancer and bladder cancer (Burdelski 2017, Hiles 2016), but 
not much is known about its role in breast cancer. Interestingly, the enriched sgRNA targeted the 
C-terminal end of the ADAM15 protein instead of the catalytic zinc-binding metalloprotease 
domain or the N-term (Fig 4.9A).  
 
The sgRNA targeting PACS1 was highly enriched and appeared repeatedly in the post-invasion 
cell pool of library transduced R273C. PACS1, the phosphofurin acidic cluster sorting protein 1, 
has a putative role in the trans-Golgi network. In humans, it is suggested to be a regulator of 
BAX/BAK oligomerization and downregulation of MHC-1 molecules to trans-Golgi network 
promoting escape from immune surveillance (Brascchio 2017). Though PACS1 does not have a 
suggested direct role in the process of cell invasion, we chose to validate it as it was the most 
highly enriched in the post-invasion cell population. Its possible role in protein sorting may 
indirectly help the process of cell motility by recycling of integrins and other cell adhesion proteins 
(Wan 1998). The sgRNA targeted the N-terminus of the PACS1 protein (exon 3 of 24 exons). The 
other hit, SDF4, is the stromal cell derived factor 4. It is a calcium binding protein that may 
regulate calcium dependent cellular activities and localizes to the Golgi lumen. It has a role in 
controlling cell proliferation and the secretory cargo (Crevenna 2016). SDF4 is expressed in 
mammary tissues and cells, and its reduced level has been associated with poor clinical outcome 
in breast cancer (Kang 2009).  The selected gRNA targeted a region close to the calcium binding 
EF hand motif of the protein and may affect the calcium binding activity (Fig 4.9B). 
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It is striking to see a list of completely different enriched sgRNAs obtained from the screening of 
Y234C and R273C library transduced cells for increased cell invasion. The presence of uniquely 
different sgRNAs in the post-invasion pool of the Y234C and R273C library transduced cells 
demonstrated the context dependency of the mutations and their collaboration with separate ‘co-
drivers’ to drive the process of cell invasion. 
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Validation of the co-driver candidates 
 
The highly enriched sgRNAs targeting GCNT1, FGD6 and ADAM15 as obtained from the post-
invasion cell pool of Y234C cells and the ones targeting PACS1 and SDF4 obtained from post-
invasion cell population of R273C cells were cloned individually into the lentiCRISPRv2 plasmid 
(backbone of the GeCKO v2.0 plasmid library). The individual sgRNAs were synthesized as 
  
 
Figure 4.9. The sgRNA target sites on top hits from the two screens. A. The top 3 
selected genes from Y234C library transduced post-invasion cell pool. The red vertical line is 
the position at which the sgRNA targeted in each gene. B. The top 2 selected genes from 
R273C library transduced post-invasion cell pool. The red vertical line is the position at which 
the sgRNA targeted in each gene. 
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oligos, annealed and ligated with the cut lentiCRISPRv2 plasmid, which were then transformed 
into Stbl3 bacteria and plated. The cloning of the individual sgRNAs was verified by colony PCR 
and confirmed with Sanger sequencing. The sequence verified plasmids were used to prepare 
the lentivirus and transduce the corresponding MCF 10A p53 mutants Y234C and R273C cells. 
All the transduced cells were selected with puromycin for 2 weeks before further characterization. 
 
As observed before (chapter 3), the efficiency of genome editing by CRISPR system is low, and 
the sgRNA transduced cells thus, represented a mixed population of cells with and without gene 
editing. To isolate the true CRISPR edited cells, we used the invasion assay to enrich the cells 
with phenotype-changing deletion. We did two consecutive rounds of invasion assay to isolate the 
true CRISPR edited clones, and cell lysates were prepared from the pre-invasion and post-
invasion cell population of Y234C-GCNT1, Y234C-FGD6 and Y234C-ADAM15. A decrease in the 
protein level of GCNT1, FGD6 and ADAM15 was observed in the western blots in the post-
invasion cell compared to pre-invasion cell population (Fig 4.10A). 
 
To detect the efficiency of the gene editing by the CRISPR-Cas9 system, the T7 endonuclease I 
assay was performed, which recognizes and cleaves mismatched DNA. The respective sgRNA 
targeting loci were first PCR amplified from the genomic DNA. These PCR amplicons were 
rehybridized slowly and annealed products were digested with T7 endonuclease I enzyme. The 
presence of DNA fragments on 10% TBE gel indicated gene editing made by the CRISPR-Cas9 
system (Fig 4.10B). To confirm gene editing at the genomic loci, the individual gene locus was 
PCR-amplified and sequenced by NGS (Fig 4.10C). The sequencing results showed that 98% of 
the cells carried indels at the GCNT1 locus, 39% at FGD6 locus and just 4.8% at the ADAM15 
locus which might be due to distant deletion from the target site. CRISPR editing by small indels 
at the extreme C-term may result in inefficient transcription or unstable mRNAs with no protein 
subsequently. 
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Figure 4.10. Validation of selected co-drivers from Y234C screen. A. Western blot to 
check the protein levels. Gene knock-out by CRISPR-Cas9 was observed in post-invasion 
sgRNA expressing Y234C cells. B. Multiple DNA bands obtained from T7 endonuclease I 
assay indicating gene editing by CRISPR-Cas9. 
50 kDaGCNT1
100 kDaADAM15
150 kDaFGD6
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Figure 4.10. Validation of selected co-drivers from Y234C screen. C. NGS of the targeted 
gene loci show deletion of base pairs. At ADAM15 loci deletion could be at a distant target 
site. D. Disruption of GCNT1, FGD6 and ADAM15 increased the invasive capacity of weakly 
invasive Y234C cells. MDA-MB-231 cells were the positive control and Y234C LCv2 were the 
empty vector control. 
 
ADAM15GCNT1 FGD6C.
MDA MB 231Blank Y234C Y234C LCv2 
Y234C-GCNT1 Y234C-FGD6 Y234C-ADAM15
10x
D.
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Increased invasiveness of the isolated true CRISPR-Cas9 edited cells were confirmed with 
transwell invasion assay incubated for 24 hrs. The knock-out of GCNT1, FGD6 and ADAM15 in 
p53 mutant Y234C cells demonstrated increased invasion validating the results obtained from the 
invasion screening of the Y234C-libA and Y234C-libB cells (Fig 4.10D). The MDA-MB-231 cells 
and Y234C cells transduced with empty lentiCRISPRv2 plasmid with no sgRNA insert (Y234C 
LCv2) were used as the positive and negative controls, respectively. The Y234C LCv2 cells were 
not invasive, showing that constitutive expression of the Cas9 enzyme does not affect the 
invasion of the cells. These results demonstrated that the loss-of-function mutation of GCNT1, 
FGD6, and ADAM15 drive increased invasion of mammary epithelial cells expressing p53-Y234C 
mutant protein. 
 
Similarly, the R273C cell lines expressing the highly enriched sgRNAs targeting PACS1 and 
SDF4 obtained from post-invasion cell pool of R273C-libA and libB were also generated, and the 
invasive population was selected and tested for gene deletion, protein levels, and invasiveness. A 
significant decrease in the level of PACS1 protein was observed in both the pre and post-invasion 
fraction of R273C-PACS1 cells compared to R273C cells (Fig 4.11A). Several commercial 
antibodies for SDF4 were tried but did not work for Western blots. We also confirmed the deletion 
at the genomic loci of PACS1 and SDF4 by T7 endonuclease I assay (Fig 4.11B) and NGS (Fig 
4.11C. Further, by using the same experimental setup for validating the top this for Y234C cells, 
we showed that the R273C LCv2 cells were slightly more invasive than the R273C cells but less 
than R273C sgRNA for PACS1 and SDF4 expressing cells. These individual validations showed 
that p53 missense mutant R273C collaborates with loss-of-function mutations in PACS1 and 
SDF4 to further drive cell invasion of mammary epithelial cells. 
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Figure 4.11. Validation of selected co-drivers from R273C screen. A. Western blot to 
check the protein levels. Gene knock-out by CRISPR-Cas9 was observed in post-invasion 
PACS1 sgRNA expressing R273C cells. Antibody for SDF4 did not work. B. Multiple DNA 
bands obtained from T7 endonuclease I assay indicating gene editing by CRISPR-Cas9. 
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Figure 4.11. Validation of selected co-drivers from R273C screen. C. NGS of the targeted 
gene loci show deletion of base pairs. D. Disruption of PACS1 and SDF4 increased the 
invasive capacity of R273C cells. MDA-MB-231 cells were the positive control and R273C 
LCv2 were the empty vector control. 
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Conclusion 
 
We established an efficient functional genomics pipeline to identify unique co-drivers of missense 
mutant p53 through a genome wide screen. Using this approach, we demonstrated that each 
missense mutant p53 cooperates with different co-drivers to enhance invasive cell phenotype.  
 
The CRISPR-Cas9 based GeCKO v2 library provided an effective method to perturb every 
protein coding gene in humans for identification of possible co-driver mutations. We carefully 
designed the screening condition to target a 250X coverage for the library during screening for 
the co-drivers to ensure authenticity of the data. A well-defined method of isolating the post-
invasion cell population and determining the highly enriched sgRNAs targeting specific genes in 
the post-invasion cell pool compared to pre-invasion or reference pool provided a competent way 
to capture the functionally relevant co-drivers for each p53 missense mutation. We used two MCF 
10A cell-lines expressing p53 mutants Y234C and R273C with different invasiveness for the co-
driver screen, and p53 WT-OE cells were included as a control. Screening of Y234C and R273C 
cells yielded different sets of enriched sgRNAs in the post-invasion cell pool that also differed in 
the order of magnitude of enrichment while no significant enrichment of sgRNAs was observed in 
the control p53 WT-OE post-invasion cell pool. These results further substantiated the fact that 
different set of mutant drivers and co-drivers collaborate in driving cancer tumor progression.   
 
The top hits from the co-driver screen were carefully selected based on the number of times the 
candidate sgRNAs reappeared in independent screens, the targeting site of the sgRNA in the 
gene, any mutation co-occurrence with TP53 mutations in patients and functional relevance to 
cell invasion, migration and cytoskeletal organization. Integrated analysis yielded GCNTI, FGD6 
and ADAM15 as unique co-drivers of p53 Y234C while PACS1 and SDF4 were the co-driver 
candidates of p53 R273C enhancing the invasive potential of the cells. Individual validation of the 
co-driver candidates by generating stable cell lines with sgRNAs verified the results obtained from 
the genome-wide screen for increased cell invasion.  
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Our screening method captured the unique functionally relevant co-drivers of individual p53 
missense mutants and explained how different combinations of drivers and co-driver mutations 
can contribute to inter or intratumor heterogeneity in cancer. Since we utilized the deletion-
inducing sgRNA/Cas9 library in the current study, we could screen only for tumor suppressor-like 
co-drivers. However, our pipeline can be readily applicable for searching oncogene-like co-drivers 
just by using gene expression-activating libraries, for example. 
 
We have observed that different p53 missense mutations produce differential phenotypes and 
can produce further functional and phenotypic alterations in the presence of other co-driver 
mutations. Our results from the co-driver screen show enrichment of different sets of co-drivers 
for two different p53 mutants highlighting the heterogeneity brought in by such unique 
combinations of mutations. Such a study can pave the way towards understanding of molecular 
heterogeneity observed in TNBC where TP53 missense mutations are highly prevalent, and the 
information on co-driver combinations can be useful for designing alternative personalized 
targeted therapies for patients harboring a specific TP53 mutation.    
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CHAPTER 5  
MOUSE MODEL-BASED SCREENING OF CO-DRIVERS OF MUTANT P53 FOR TUMOR 
GROWTH AND METASTASIS  
  
 
Introduction 
 
Cancer progression in-vivo is a multi-step clonal evolution and requires multiple mutations for 
tumor growth, invasion and metastasis. After establishing the in-vitro pipeline for identification of 
the co-drivers of mutant p53 that drive cell invasion (chapter 4), we defined an in-vivo mouse 
xenograft transplantation model to screen for the co-drivers of missense mutant p53 for tumor 
growth and subsequent metastasis.  
 
The process of tumorigenesis is a rather complex process. A succession of several independent 
steps is needed for the successful completion of the tumorigenesis process. Transfection with at 
least two oncogenes was required for the transformation of rat embryonic fibroblasts. Co-
transfection with ras and myc or ras and the gene for polyoma large T-antigen made cells 
tumorigenic that showed growth in soft agar and formed subcutaneous tumors in nude mice in 3 
weeks (Land 1983).  Similarly, mutation in p53 alone is not enough to drive tumorigenesis.  
Combinations of mutant p53 or deletion of TP53 with other cancer genes are required.  The p53 
cDNA derived from a murine B-cell lymphoma (mutant p53) transfected alone in Rat-1 fibroblast 
cell-line could not induce foci formation in 2D cell cultures. But co-transfection with a ras 
oncogene transformed the cell readily. Injection of the Ras and mutant p53 expressing rat 
fibroblast cells formed aggressively growing tumors in the nude mice (Parada 1984). Transgenic 
mice with p53 loss and expression of specific oncoproteins such as c-Myc and Ras or with knock-
out of tumor suppressors like Rb, Nf1 or BRCA1 show accelerated rate of tumor development 
compared to the individual genetic lesions. These double or compound mutants have shortened 
latency, increased penetrance of tumorigenesis and develop novel tumor types (Attardi 2005).  
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In contrast to the primary rodent cells, normal human epithelial and fibroblast cells required 
additional expression of hTERT (telomerase catalytic subunit) that immortalized the cells and two 
oncogenes SV40 large T oncoprotein and H-ras for tumorigenic conversion (Hahn 1999). The 
primary human mammary epithelial cells (HMECs) with the same combination of genetic 
elements formed poorly differentiated subcutaneous or mammary carcinomas in mice with 
average latency of 7.5 weeks. The transformed primary HMECs when mixed with matrigel or 
primary human mammary fibroblasts increased tumor formation and decreased latency period 
highlighting the importance of stromal microenvironment on tumor formation (Elenbaas 2000).  
 
c-Myc is more frequently amplified in ER-, PR- or the basal subtype of breast cancer that also 
harbors frequent mutations in TP53 and higher expression of MYC correlates with poorer clinical 
outcome (Liao 2000).The basal like or the tripe negative breast tumors have very high mutation 
rates and harbor more mutations than the luminal subtype tumors. HER2, EGFR and MYC are 
commonly amplified oncogenes in breast cancer and co-amplification of MYC/HER2 is associated 
with high grade and shortened survival (Al-Kuraya 2004). For most of the basal tumors, the 
partnering mutated genes other than the commonly known EGFR and MYC, of p53 mutants 
remain elusive. The TNBC cell-lines that harbor TP53 mutations (deletion or missense mutations) 
also overexpress EGFR or MYC (Chavez 2010) for example the MDA-MB-468, MDA-MB-436 and 
HCC1395 cell-lines. On the other hand, in patient derived tumor samples there could be other 
unknown less prevalent partnering genes of mutant p53 driving tumor development.   
 
 
 
Aim 
 
To test if p53 mutation with co-driver combinations are sufficient to support tumor growth in-vivo 
and perform in-vivo screens for identification of additional co-drivers.  
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The mutations in TP53 alone are neither enough to promote transformation of cells nor tumor 
formation. Deletion of PTEN in p53 mutant expressing cells form colonies in soft agar 
demonstrating the transformation of the cells (Kim 2015). Many somatic gene mutations co-occur 
with mutation in TP53 in cancer tumors and collaborate with mutant p53 to drive tumor initiation 
and subsequent metastasis but which combination of co-mutations or the co-drivers partner with 
mutant p53 largely remain unknown.  
 
 
 
Approach 
 
Xenograft mouse model and method for cell injection  
 
Breast cancer tumor growth and metastasis can be modeled in different ways. For the 
identification of co-drivers of mutant p53 that support tumor growth, we chose the cell line 
xenograft transplantation mouse model. Implantation of the cell lines orthotopically (into 
mammary fat pads of mice) or ecto-topically (subcutaneously) into immunocompromised mice 
can form primary tumors followed by metastasis resembling multiple stages of malignant breast 
cancer development in patients. The immunodeficient mice such as NOD/SCID, NOG or NSG 
show high rate of cell engraftment and lead to tumor growth and metastasis (Ito 2012).  
 
Injection of cells into the mammary gland provide a favorable microenvironment to model breast 
cancer development. This method is simple, less time consuming than developing genetically 
altered mice and allows implantation of multiple gene manipulated cell lines. The xenograft model 
can rapidly analyze the tumorigenic and metastatic potential of experimental cells, response to a 
therapeutic regime and resembles the heterogeneity of human tumor cells. 
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Testing invasion promoting co-drivers of mutant p53 for tumor growth in-vivo 
 
We speculated that MCF 10A cells expressing mutant p53 with PTEN deletion that formed 
colonies in soft agar demonstrating cell transformation could form tumors in mice. We 
hypothesized that the post-invasion cell population from the CRISPR based screening of co-
drivers of mutant p53 (with different combination of co-drivers and mutant p53, described in 
chapter 4) could form tumors and may metastasize as the cells were already proliferative and 
invasive. If these injected cells formed tumors in mice, the parallel sequencing of the primary 
tumors and the metastasized tumors would reveal the specific set of gene mutations collaborating 
with mutant p53 and responsible for the metastatic spread of tumors in the given cellular context.  
 
For this in-vivo study, we required an appropriate xenograft mouse model and first started with 
optimization of the conditions needed to establish such a model. Once the parameters were set, 
different experimental cell lines (p53 mutation with co-drivers) were injected into the mice and 
were observed for the appearance of tumors. 
 
Addition of oncogenes for the in-vivo screens 
 
We used the GeCKO v2 CRISPR based library, a gene knock-out library, to identify the possible 
co-drivers of mutant p53 driving cell invasion. The resultant mutated co-drivers obtained from the 
cell invasion screen yielded only the tumor suppressor genes as the possible co-drivers in the 
context of different p53 missense mutations. The tumor cells harbor both mutated tumor 
suppressors and oncogenes. Our experimental cell lines as described above have a combination 
of at least two mutated tumor suppressor genes (mutant p53 + co-driver gene knock-out) which 
may not form tumors in the immune-compromised NOD/SCID mice. The TNBC cell lines known 
to be tumorigenic and metastatic, harboring a mutation in TP53 or TP53 and PTEN, contain 
amplification of either MYC or EGFR that are the oncogenes (for example, MDA-MB-468 and 
HCC1395). If the experimental cell-lines expressing mutant p53 with co-driver combinations could 
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not form tumors, over-expression of an oncogene EGFR or MYC in the cells may induce tumor 
growth.  
 
 
Method 
 
Maintaining mice breeding colonies 
 
To conduct all the mice experiments, maintenance of breeding colonies was essential. The 
NOD/SCID mice were bred at 2 or 3 months of age as they get non-productive by the age of 6 
months. The number of mice bred were dependent on the total number needed for an experiment 
at a given time. The approximate litter size for NOD/SCID mice is 8 to 10 and so, the breeding 
pairs were carefully set to get the required number of females for the experiments and extra to 
retain as breeders to maintain the line. Breeding was done in compliance with the ASU Mouse 
Breeding Cage Density Guideline. The male was removed upon confirmation of pregnancy and 
the pups were weaned by 21 days. 
 
Cell injection methods 
 
For each experiment the cells were harvested by trypsin treatment (0.25% trypsin) and then 
suspended in media with Matrigel (1:1) and kept on ice throughout the following procedures. The 
NOD/SCID female mice were injected with the appropriate concentration of cells either 
subcutaneously on the flank, directly in the mammary fat pad or through the tail vein.  
 
Cell injection directly into mammary fat pads 
 
We chose to proceed with our experiments using the mammary fat pad injections. The mice 
surgeries were carried out by a certified veterinarian from Department of animal care and 
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technologies, ASU. To establish the xenograft mouse breast cancer model, 5 to 8 weeks old 
female NOD/SCID mice were injected with the experimental cell lines. Mice have 10 mammary 
glands, 5 on each side, located ventro-laterally. They can be distinguished as the thoracic glands, 
1 to 3, and inguinal glands, 4 and 5. The inguinal gland 4 is most easily accessible and hence, 
commonly used for clearing and transplantation experiments. Before cells were transplanted, it 
was necessary to completely remove the endogenous epithelial tissue from the mammary pad. 
Each mouse was anesthetized with ketamine, laid on one side and the skin were shaved and 
prepared aseptically. A 5 mm incision was made by small scissors around the 4th nipple. The skin 
and the nipple were removed together with a region containing the closest part of the fat pad and 
the mammary anlage. A pocket under the skin was opened in a cranial direction with the blades 
of the scissor so that the mammary fat pad was seen. 100 ul of suspended cells in Matrigel were 
injected in the fat pads within 40 min of harvesting. It was made sure that the inoculum remained 
inside the fat pad and did not leak into the subcutaneous space. The incision was closed with 
suture (4-0 nylon) or surgical glue and each mouse was monitored and kept warm while 
recovering from anesthesia.   
 
Imaging of mice and end point criteria 
 
NOD/SCID mice are immune compromised and were kept in sterile cages. Each mouse was 
marked with picric acid to determine the cell lines they were injected with. To determine the 
timeline of tumor onset and metastasis, in-vivo imaging of the cells was performed using the 
RGD-IR dye (LI-COR 926-09889) that binds to the integrin receptor (specific to transformed cells) 
in the XPearl Impulse Imaging System routinely used at ASU. The IR (infrared) dye has low non-
specific binding to cellular components and high signal-to-noise ratio. This in-vivo imaging system 
is specifically designed for small animal imaging and utilizes near infrared (NIR) probes for 
imaging which have very low background for auto-fluorescence in whole animals. Hence, this 
imaging system allows sensitive detection of NIR labeled antigens/ adjuvants injected into the 
animals with good signal to noise ratio. The mice were shaved with electric clippers over the 
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injection area (1.5 cm X 1.5 cm) to image the tumor by reducing the background effect caused by 
animal fur. The mice were always anesthetized with isoflurane at 1 to 2.5% inhalation for the 
Retro-Orbital (RO) injection (following the IACUC SIG for Retro-Orbital injection of mice) with 30ul 
dye during imaging.  Once primary tumors appeared, the mice were monitored every other day. 
Once the primary tumor size measured 1.5 cm in diameter, tumors were measured daily, and 
mice were euthanized before the tumors measured 2 cm in diameter. Metastasis at this stage 
was tracked through weekly dye injections and imaging. Mice with metastasis often showed 
hunched posture, ruffled fur, non-mobility, labored respiration (dyspnea) and loss of body weight. 
These mice were immediately euthanized and the primary tumor as well as the organs with 
metastasized cells were kept in formalin solution. Mice were euthanized with CO2 inhalation 
followed by cervical dislocation at the end of each experiment or when required. 
 
 
Results 
 
The pilot project to establish the xenograft mouse model 
 
In a pilot project we tried to optimize the parameters to establish a xenograft mouse model to 
study the tumorigenic and metastatic (if tumorigenic) potential of cell lines bearing different 
combinations of mutations (p53 mutation and co-drivers) using the immunocompromised female 
NOD/SCID mice. These mice have impaired B and T cell lymphocyte development and deficient 
in natural killer cells. This leads to the high acceptance of the engraftments (cells or tissues from 
other species) in these mice. We optimized the injection route, cell concentration injected into the 
mice, volume of cells per injection and mice imaging technique using the metastatic TNBC cell 
line MDA-MB-231 as the control. The cells harbor missense mutation in TP53 along with 
numerous other somatic mutations and form tumors in NOD/SCID mice that metastasize to the 
lungs and liver. The results from the pilot experiment is shown in the Table 5.1. 
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Visible and measurable tumors in the flank and the mammary fat pad were observed for the 
control TNBC cell line MDA-MB-231 after 4 weeks following cell injection. Metastasis was 
observed between 6 to 10 weeks as the health of the mice rapidly deteriorated (loss of body 
weight and immobility). Tumors with subcutaneous injection in the flank with a million cells grew 
very rapidly and hence, the number of cells were reduced to 200,000 for the highly proliferative 
MDA-MB-231 cell line to allow the monitoring of metastasis for up to 10 weeks. The tail vein 
injections resulted in the spread of tumors across the body and the mice died by 6 weeks after 
cell injection. Tumors from the primary site (flank or mammary fat pads) spread mainly to the 
lungs and the liver, the usual sites for breast cancer metastasis in mice.  
 
We tested the tumorigenicity of most of our experimental cell-lines through subcutaneous flank 
injections as they are easy to perform and tumors (when and if they appear) are easy to monitor. 
Though the primary tumors and metastasis appeared for MDA-MB-231 cells through both the 
subcutaneous and mammary fat pad injections, we chose to use the orthotopic mammary fat pad 
injections for our experimental cell lines as it is more relevant for studying breast cancer tumor 
formation and metastasis. This xenograft mouse model was used to test the tumorigenic ability 
and possible metastasis of our experimental cell lines with combination of p53 mutation and co-
drivers and at least 2 mice were used per condition in each experiment as replicates. 
Table 5.1. Pilot project to establish the xenograft mouse model. 
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Testing the growth of the cells in-vivo with defined co-driver of p53 mutation (invasive 
MCF 10A p53 mutant cell-lines and 10A p53 mutant PTENnull cells)   
 
We first started the in-vivo experiments by injecting invasive MCF 10A p53 mutant R248W, 
R273C and Y220C cell lines that were found to be the most aggressive p53 mutants determined 
from the in-vitro cell assays (described in chapter 2, page 93). The cells were injected 
subcutaneously in the flank of the female NOD/SCID mice. None of the cell lines formed tumors 
in mice by 14 weeks after the injections. Such a result was expected as TP53 mutations alone 
cannot transform cells in-vitro and form tumors in-vivo.  
 
In the next set of experiments, the MCF 10A p53 mutant Y234C cells with PTEN deletion (PTEN 
knocked out using CRISPR-Cas9 system as known co-driver of mutant p53) with high invasion 
phenotype were injected subcutaneously (Y234C PTEN-C4 and Y234C PTEN-C5) and observed 
for 10 weeks. The p53 mutant Y234C cells were very weakly invasive but the Y234C cells also 
harboring a deletion mutation in PTEN could invade the matrigel barrier efficiently and showed 
anchorage independent growth in soft agar. But these cells did not form any tumors in mice. We 
expected the cells to be tumorigenic as MCF 10A TP53null PTENnull cells form tumors and 
metastasize in a NOD/SCID mouse xenograft model. The tumors appeared in mice by 4 weeks 
and formed huge primary tumors and metastasized to lungs by 8 weeks after injection into the 
mammary fat pads as reported by Kim et.al, (2015). No tumors formed by the Y234C-PTEN null 
cells by week 13. The MDA-MB-231 control cells formed tumors by the 4th week and the mice 
were euthanized by week 8 due to metastasis of the cells to the lungs (Fig 5.1, Table 5.2).  
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Figure 5.1. Results for mice injections with aggressive MCF 10A p53 mutants and 
mutant p53 PTENnull cells. A. The highly aggressive p53 mutants and Y234C PTEN C4 and 
Y234C PTEN C5 (with sgRNAs 4 and sgRNA 5 targeting PTEN gene) were not tumorigenic. 
MDA-MB-231 cells were positive controls and formed tumors by week 4. By 8 weeks cells 
metastasized (red line) and the mice were euthanized. B. Localization of the Li-Cor dye at the 
growing tumor site (subcutaneous, flank) seen in mice injected with MDA-MB-231 cells 24 hrs 
post dye injection. 
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In-vivo screen with CRISPR library transduced MCF 10A p53 mutant cells 
transduced at LMOI  
We set up a genome wide screen for the identification of biologically important but less 
frequent driver mutations, the co-drivers, cooperating with the recurrent TP53 mutations 
in the context of mammary epithelial cells for increased cell invasion (described in 
chapter 4). For the screening, MCF 10A p53 mutants Y234C and R273C cells were 
transduced with the GeCKO v2 library (CRISPR-Cas9 based with sgRNAs targeting 
every protein coding gene in humans) at low multiplicity of infection (LMOI) and used for 
cell invasion assay to identify the co-drivers promoting invasive phenotype. As control 
for the screening, we included the MCF 10A p53 WT-OE cells that over-expressed 
wildtype p53.  
Only the invasive cells that managed to cut through the Matrigel barrier were isolated. 
The post-invasion cell population showed enrichment of different sgRNAs compared to 
the pre-invasion cell pool. We hypothesized that the post-invasion cell pool with 
Table 5.2. Mice injection detail with the aggressive MCF 10A p53 mutants and MCF 10A 
cells expressing mutant p53 with deletion in PTEN. 
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different co-driver combinations (TP53 mutation with an additional mutation) could form 
tumors when injected into mice. We injected the isolated post-invasion CRISPR library 
transduced cell population (transduced at low MOI) in the mice for the next set of 
experiments.  
The post-invasion (invasive) library transduced cells (WT-OE libA, WT-OE libB, Y234C 
libA and Y234C libB) cells were injected in the flank of female NOD/SCID mice 
subcutaneously and monitored for tumor formation. These cells did not form any tumors 
by week 20. MDA-MB-231 positive control cells formed tumors and metastasis by 8 
weeks as observed in the previous experiments (Fig 5.2, Table 5.3). 
 
 
 
Table 5.3. Mice injections with MCF 10A cells transduced with GeCKO v2 library at low 
MOI. 
 
 
 
  208 
 
 
 
 
 
 
 
 
 
 
 
 
 
In-vivo screen with CRISPR library transduced MCF 10A p53 mutant cells 
transduced at HMOI 
From the previous results we observed that the post-invasion MCF 10A Y234C library 
transduced cells (at low MOI), Y234C libA and Y234C libB, could not form any tumors 
in mice. A combination of two mutations (p53 mutation and a co-driver) were not 
enough to drive tumor formation. Moreover, Y234C is a weakly invasive p53 missense 
mutant. We anticipated that transduction of the most aggressive MCF 10A p53 mutant 
 
 
 
Figure 5.2. Mice injections with MCF 10A p53 mutant cells 
transduced with GeCKO v2 library at low MOI. None of the cells 
were tumorigenic. MDA-MB-231 cells were positive controls and 
formed tumors by 4 weeks. By the week 8 cells metastasized (red line) 
and the mice were eventually euthanized.  
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R273C cells (determined by cell-based assays, chapter 2) with GeCKO v2 library (low 
MOI) would result in different co-driver combinations with enhanced possibility of tumor 
formation in-vivo.  
We injected the post-invasion R273C libA and R273C libB cell population (transduced 
at low MOI) in the mammary fat pads of the female NOD/SCID mice. We speculated 
that with an aggressive p53 mutation, R273C, the new mutation combinations would 
generate tumors compared to less aggressive Y234C p53 mutant. But no tumors were 
observed by week 16 since the injections (Y234C library transduced cells were 
observed for 20 weeks).  
As the library transduced cells at LMOI (only one additional sgRNA in cells with p53 
mutation) failed to form any tumors, it was clear that only two mutations were not 
enough to turn cells tumorigenic in the given context. Hence, we decided to transduce 
the highly aggressive MCF 10A p53 mutant R273C cells with the GeCKO v2 (CRISPR-
Cas9 based) library at high multiplicity of infection conditions (HMOI, MOI > 4). This 
ensured that the transduced cells acquired more than two sgRNAs or mutations at a 
time in addition to the p53 mutation increasing the probability of tumor formation. The 
library transduced (at high MOI or HMOI) R273C libA (HMOI) and R273C libB (HMOI) 
cell populations both pre-invasion and post-invasion were orthotopically injected into the 
mammary fat pad of the female NOD/SCID mice. But even with a combination of at 
least three or more than three mutations, no tumors were seen after 20 weeks of cell 
injection. R273C cells were used as the negative controls (they do not form tumors) and 
the MDA-MB-231 cells as the positive that formed metastasis by 8 to 9 weeks (Fig 5.3, 
Table 5.4). 
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Introduction of an oncogene in the experimental MCF 10A mammary epithelial 
cells with combination of mutant tumor suppressor genes 
The GeCKO v2 CRISPR based library is a gene knock-out library and the resultant 
mutant co-drivers obtained from the cell invasion screen yielded only the tumor 
suppressor genes as the possible co-drivers in the context of different p53 missense 
 
 
Figure 5.3. Mice injections with MCF 10A p53 mutant R273C 
transduced with GeCKO v2 library at low and high MOI (HMOI). 
Inv refers to invasive or post-invasion cells. None of the cells were 
tumorigenic. MCF 10A R273C cells were the negative control and 
MDA-MB-231 cells the positive control and formed tumors by week 
4. By the 8 weeks cells metastasized (red line) and the mice were 
euthanized by 10 weeks.  
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mutations. But the tumor cells harbor both mutated tumor suppressors and oncogenes. 
Our experimental cell lines as described above have a combination of at least two  
 
mutated tumor suppressor genes (due to the use of knock-out CRISPR library) which 
proved to be insufficient to form tumors in the immune-compromised NOD/SCID mice. 
The TNBC cell lines known to be tumorigenic and metastatic with a mutation in TP53 or 
TP53 and PTEN also contain amplification of the oncogene either MYC or EGFR (for 
example, MDA-MB-468 and HCC1395). We thought of introducing an oncogene, either 
MYC or EGFR, in our experimental cell lines to boost the probability of tumor formation. 
Table 5.4. Mice injections with MCF 10A p53 mutant R273C cells transduced with 
GeCKO v2 library at low (LMOI) and high MOI (HMOI). 
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We first tested the protein level of EGFR and MYC in the MCF 10A cells with 
endogenous wildtype p53, p53 WT-OE and R273C cells including the MDA-MB-231 
control cells using western blot (Fig 5.4A). EGFR protein level in R273C cells and MDA-
MB-231 cells were comparable. There was no detectable MYC in the R273C cells. We 
generated a set of cell lines (Table 5.5, with different combinations of tumor 
suppressors and oncogenes) over-expressing (OE) EGFR or MYC in addition to the 
p53 and PTEN mutations (Fig 5.4B). Another set of cell-lines included the R273C over-
expressing EGFR or MYC followed by transduction with the GeCKO v2 libA and libB at 
high MOI (Fig 5.4C). The cells (with various mutation combinations) were then injected 
into the mammary fat pads of female NOD/SCID mice.  
EGFR and MYC were over-expressed using mammalian expression vector pLenti6.3 
that adds a V5 tag at the C-term end of the protein. The over-expressed EGFR was a 
truncated version while MYC was overexpressed with a V5 tag (Fig 5.5B). The mice 
transplanted with cells over-expressing MYC would likely form tumors than the EGFR 
expressing cells. The cells forming primary tumors and eventual metastasis can then be 
utilized to screen for the specific mutated gene combinations driving tissue-specific 
breast cancer metastasis. 
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Figure 5.4. Western blot images to check level of EGFR, MYC and Cas9. A. Western blot 
to check levels of endogenous EGFR and MYC. B. Expression levels of EGFR, MYC and 
PTEN in the different mutation combination cells generated for mice injections. PTEN was 
first knocked out using sgRNA in p53 mutant R273C cells. Afterwards MYC or EGFR was 
over-expressed in the cells. C. R273C cells were first transduced to over-express MYC or 
EGFR and then transduced with the CRISPR based GeCKO v2 half libA and B. Only the 
library transduced cells expressed Cas9. Beta-actin was the loading control. OE over-
expression, KO knock-out. 
 
Cas9
75 kDa
50 kDa
25 kDa
100 kDa
β-actin
Table 5.5. Cell-lines generated with over-expression of EGFR and MYC. OE over-
expression, HMOI high multiplicity of infection and del deletion.  
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Interestingly, one out of the two mice injected with R273C MYC libB and R273C EGFR 
libA cells formed huge primary tumors (1.5 cm in diameter) by week 9. The tumors were 
massive, and the mice were euthanized. During necropsy, no metastasis was observed 
in the mice and the primary tumors were collected. The primary tumors were cut into 
tiny sections and stored at -80OC for subsequent processing for single cell sequencing. 
As the cells contain multiple mutations, bulk sequencing would not be appropriate to 
decipher the mutation combinations that formed the tumors. Single cell sequencing of at 
least 1000 cells (from different sections of the tumor) would reveal the mutations that 
generated tumors in the mice. We intend to repeat the experiment with the cells that 
formed the tumors in mice with a larger set (6 mice instead of 2) to confirm the results. 
The positive control cells MDA-MB-231 formed tumors by week 5 that metastasized by 
week 8. The results showed that combination of oncogenes and mutated tumor 
suppressors drive tumor formation. 
 
Conclusion 
From the CRISPR based screen for ‘co-drivers’ of missense mutant p53, we identified 
important co-driver gene candidates specific to different p53 mutant background that 
enhanced invasion potential of cells (described in chapter 4). Cell migration and 
invasion sets the initiating stages for the metastatic cascade. Once we extracted the 
post-invasion cell population, we wondered if these invasive cells could initiate tumor 
formation when transplanted into immune-compromised NOD/SCID mice. After 
establishing the parameters for a xenograft NOD/SCID mouse model for tumor 
formation and metastasis (cell concentration, injection route and timeline) we tested 
several experimental cell lines with different combinations of mutations for tumor 
growth. We used the metastatic TNBC cell line MDA-MB-231 as the positive control for 
  216 
all our experiments that rapidly formed tumors by 4 to 5 weeks and metastasis by 8-10 
weeks in the lungs and the liver in the NOD/SCID mice. These cells are very aggressive 
and so, we generated the MCF 10A cells harboring PTEN deletion and over-expression 
of EGFR or MYC in addition to p53 mutation as the new control cells. Combination of 
MYC and mutant p53 transform cells for anchorage independent growth in soft agar. 
MCF 10A cells with these mutation combinations would provide a better control for the 
in-vivo experiments. 
The highly aggressive MCF 10A p53 mutant R273C, R248W and Y220C cells injected 
subcutaneously in the flank did not form any tumors in the NOD/SCID mice. This result 
was expected as mutation in p53 alone cannot form colonies in soft agar to show 
anchorage independent growth for cellular transformation. We generated cell lines with 
PTEN knock-out in weakly invasive p53 mutant Y234C that resulted in increased 
invasive potential of the cells. But no tumors were observed for the mice injected with 
Y234C PTEN KO cells. Such a result was unexpected as cells with downmodulation of 
both p53 and PTEN are tumorigenic when transplanted in mice within 8 to 10 weeks of 
injection. An explanation could be that PTEN deletion is frequent in TNBC subtype of 
breast cancer which is the most aggressive of all breast cancer subtypes and harbors 
either deletion mutation or other hotspot missense mutations in TP53. Y234C is not a 
hotspot TP53 missense mutation and from our phenotypic assays based on the 
hallmarks of cancer (chapter 2), Y234C is a much less aggressive mutant. Hence, a 
combination of Y234C and PTEN knock-out might not be strong enough to turn cells 
tumorigenic though such double mutant cells formed colonies in the soft agar assay and 
demonstrated increased cell invasion compared to just Y234C mutation.  
After the isolation of the post-invasion cell population of Y234C libA and Y234C libB 
transduced at low multiplicity of infection (LMOI), we transplanted the cells (p53 
mutation with combination of different co-drivers) subcutaneously into the flank of the 
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NOD/SCID female mice anticipating that these invasive cells would most likely form 
tumors. None of the mice developed tumors by week 20. From such results it was clear 
that two mutations in a cell were not enough to form tumors in this context. In this in-
vivo system cell invasiveness was not enough for tumor formation (or progression to 
metastasis) and that in-vitro invasion assays cannot be surrogates for the tumorigenic 
or metastasis process. 
The post-invasion cell population of GeCKO v2 library transduced R273C cells was 
injected into the mice to see if a strongly invasive p53 mutant like R273C could drive 
rapid cell transformation and tumor formation. No tumors were observed in this case.  In 
order to develop cells carrying multiple mutations (at least three mutations including p53 
mutation), we transduced the MCF 10A p53 mutant R273C cells with the GeCKO v2 
library at high MOI (HMOI>4) such that majority of the cell fraction received multiple 
sgRNAs and subsequently multiple mutations in addition to  p53 R273C. Both pre and 
post-invasion R273C libA and libB HMOI cell populations were injected orthotopically 
into the mammary fat pads of the female NOD/SCID mice. In such a case also, tumors 
did not develop by week 16.  
One must keep in mind that we have generated the cell lines with multiple mutations 
using a CRISPR based knock-out library. Hence, the mutated genes would all be 
possible tumor suppressors and not oncogenes. Cancer is a multistep process and 
requires the interplay between loss-of-function of tumor suppressors and gain-of-
function of oncogenes. Amplification of known oncogenes like EGFR or MYC is 
observed in the aggressive TNBC tumors. The metastatic TNBC cell-lines such as 
MDA-MB-468 and MDA-MB-436 that harbor mutations in TP53 also contain 
amplification of EGFR and MYC respectively. Previous work by Robert Weinberg’s 
group have shown that oncogenes are essential to cause transformation of cells and 
that the double mutant mice with loss of p53 function and transgenic for MYC show 
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early onset of tumors. We thus, generated cell-lines with combination of mutations in 
tumor suppressors and overexpression of EGFR or MYC that would possibly turn cells 
tumorigenic. Large primary tumors were observed in the NOD/SCID mice injected with 
R273C MYC libB and R273C EGFR libB by week 9 but the tumor cells did not 
metastasize. Single-cell sequencing from these tumors will illuminate the gene mutation 
combinations that led to tumor formation.  
Though cells with a combination of mutations in tumor suppressors and the 
overexpression of an oncogene turned tumorigenic, accumulation of more mutations 
are required for these tumorigenic cells to metastasize. The human cells need 
accumulation of more genetic events for neoplasm formation than the murine cells. The 
tumorigenic conversion of normal mouse fibroblasts required disruption of two signaling 
pathways but for human fibroblasts six pathways needed to be disrupted (Rangarajan 
2004). The requirement for tumorigenic transformation of human cells is cell-type 
dependent. While the human mammary cells needed activation of PI3K, Raf and Ral-
GEF, the immortalized human fibroblasts required the activation of only Raf and Ral-
GEF. This work reflected the complex multistep tumorigenesis process in two different 
species, mice and humans (Rangarajan 2004).  
Though we are using a mouse xenograft model and injecting the experimental cells in 
high concentration with Matrigel into the orthotopic mammary fat pads of the female 
NOD/SCID mice, the total number of cells bearing the genetic lesions is very small. The 
timeline for observation of the xenograft bearing mice could also affect the results and it 
is possible that our experimental mice have very long periods of tumor latency.  
For studying the process of metastasis, tumorigenicity of the cells is a pre-requisite. 
Once the cells undergo tumorigenic transformation followed by metastasis, this in-vivo 
system could provide valuable information on the specific gene combinations driving the 
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complex process of tumor metastasis. The extraction of primary tumors and metastatic 
tumors from specific organs and their sequencing can elucidate the process of tumor 
evolution in cancer, the genes involved in tissue tropism during metastasis and address 
the controversial topic of whether metastasis is an early or a late event in breast cancer.   
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CHAPTER 6 
SUMMARY AND FUTURE DIRECTIONS  
 
This dissertation sheds light on the dominant negative ‘neo-morphic’ activity of the ten missense 
mutations in TP53 prevalent in breast tumors and other collaborating somatic co-driver mutations 
in tumor suppressor genes that drive cell invasion and aggressiveness in the context of breast 
epithelial cells.  
 
 
Summary of the results 
 
Many missense mutations occur in the TP53 tumor suppressor gene concentrating in the DNA 
binding domain (DBD) of the protein. We hypothesized that the different missense mutations in 
the DBD affect the sequence specific binding of the mutant p53 transcription factor and hence, 
the transcriptional activity and the downstream pathways resulting in different phenotypes. In 
chapter 2, we described the detailed molecular profiling of the ten different p53 missense mutant 
proteins over-expressed in the non-transformed MCF 10A mammary epithelial cells that revealed 
‘neo-morphic’ activities of the mutant proteins based on the hallmarks of cancer. These important 
hallmarks included ability to survive and proliferate under growth factor starvation, resistance to 
cell apoptosis and anoikis, cell migration and invasion through Matrigel matrix and cell polarity 
change in mammospheres formed in 3D matrigel matrix (Chapter 2, Fig 2.8). The p53 mutants 
R248W, R273C and Y220C clustered as the most aggressive mutants whereas mutants G245S, 
R273H and Y234C were found to be least aggressive. All the mutants demonstrated a spectrum 
of phenotypes.  
 
The integrated analysis of ChIP seq showed distinct promoter binding profiles of the different p53 
mutants as transcription factors and RNA seq highlighted the activated pathways such as the 
focal adhesion pathway as one of the dysregulated pathways in the invasive mutants (Chapter 2, 
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Fig 2.9). We saw a good correlation between the observed phenotypes and the enriched 
pathways. Enrichment and model-based pathway analysis revealed the key biological pathways 
associated with metabolism, axon guidance and focal adhesion pathways during invasion of cells 
(Chapter 2, Fig 2.9). These results implied that non-canonical transcriptional activity may 
contribute to the phenotypic heterogeneity seen in the TP53 mutated breast tumors. The 
thorough phenotypic comparison of the MCF 10A cells expressing different missense mutant p53 
proteins provide information on how the TP53 mutations differentially impact cancer phenotypes. 
 
The mutations in TP53 are early events in breast cancer progression. They may contribute to the 
breast tumor initiation but are not enough to drive breast cancer progression. Several other 
somatic mutations co-appear with mutation in TP53 that are less prevalent but biologically 
significant and contribute to progression of breast cancer. We introduced the term ‘co-drivers’ of 
mutant p53 proteins that work in synergy or in addition to mutant p53 to drive the process of 
tumorigenesis. In chapter 3, we demonstrated that the deletion of another tumor suppressor gene 
PTEN acts as the co-driver of the missense mutant TP53 to drive breast epithelial cell invasion 
(Chapter 3, Fig 3.5). Homozygous deletion of PTEN is known to co-occur with TP53 mutations in 
basal-like breast cancer. Shut-down of the PTEN protein using shRNA and knocking out the 
PTEN gene using the CRISPR-Cas9 system in the weakly invasive MCF 10A p53 mutant cells 
(G245S, R273H and Y234C) resulted in increased cell invasion. The combination of PTEN 
deletion and missense mutant p53 also transformed the cells through anchorage independent 
growth as seen in the soft agar assays (Chapter 3, Fig 3.11). This study provided the proof-of-
principle for the somatically mutated ‘co-driver’ genes of missense mutant TP53 that work in 
synergy to drive increased cell invasion or aggressiveness in mammary epithelial cells. The MCF 
10A cells with mutant p53 and deletion of PTEN as the co-driver served as a positive control for 
the functional genomic pipeline that we set up for the screening of the possible co-drivers of 
missense mutant p53 on a genome wide scale. 
  
  223 
Powerful tools like Next Generation Sequencing (NGS) has uncovered the mutational landscape 
of cancer tumors. These somatic mutations include a few recurrently mutated drivers, many less-
frequently mutated co-drivers and most passenger mutations. Separation of these biologically 
relevant co-drivers from the neutral passenger mutations is a daunting task.  Chapter 4 discussed 
a CRISPR based functional genomic approach used effectively for screening a phenotype and 
discovering the genotype that caused it. As most of the somatic mutations co-existing with TP53 
mutation are likely to be non-functional passenger mutations, this functional screen sieved out the 
possible functionally relevant ‘co-drivers’ of mutant TP53.  We screened the weakly invasive MCF 
10A p53 Y234C and the highly invasive p53 R273C cells with the genome wide  GeCKO v2 
lentivirus library for increased cell invasion and found some known ‘cancer related genes’ such as 
BCL2, PTEN, EPHB2 and a number of lesser known genes with plausible role in promoting 
breast cancer aggressiveness as our top hits from the screening. The two different TP53 contexts 
enriched different set of sgRNAs in the post-invasion cell population. From each screen, different 
‘co-driver’ genes appeared in the p53 Y234C and p53 R273C cells to drive cell invasiveness 
(Chapter 4, Fig 4.8). The top hits chosen from the p53 Y234C cell screening were GCNT1, FGD6 
and ADAM15 while PACS1 and SDF4 were the most enriched hits in the p53 R273C screen. 
These mutation combinations are likely to affect breast cancer tumor heterogeneity.  
 
We were curious to know if the post-invasion cell population of Y234C and R273C cells with 
combination of co-drivers could evolve in an in-vivo system and generate tumors. We anticipated 
that the cell population could drive tumorigenesis in mice as the cells injected were already 
invasive. From chapter 2 to chapter 4, we had all the experimental results from in-vitro (cell-
based) studies. In chapter 5 we presented all the results from the in-vivo study, where we 
established a mouse xenograft model to observe tumor formation and metastasis (if primary 
tumors formed). We observed that the post-invasion cell population of 10A Y234C and R273C 
cells with one co-driver (transduction with low MOI) or with more than two additional co-drivers 
(transduction with high MOI) could not form tumors in the immunodeficient NOD/SCID mice 
(Chapter 5, Fig 5.3). The results implied that more than three or four mutations are required to 
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make cells tumorigenic in this context and a combination of mutations in both tumor suppressor 
genes and oncogenes may promote tumor formation instead of mutations only in tumor 
suppressors (GeCKO v2 is a knock-out library). For the tumors to metastasize, accumulation of 
more mutations is required as seen in the metastatic breast cancer cell-lines for example, MDA-
MB-231 (positive control) that harbors 5-6 driver mutations. Breast tumors from patients harboring 
TP53 mutation also contain hundreds of other somatic mutations. We over-expressed the known 
oncogenes, EGFR or MYC, commonly observed in TNBC cell-lines, in library transduced MCF 
10A p53 mutant R273C (at high MOI) cell-lines and injected into the mammary fat pads of the 
NOD/SCID mice. As an appropriate positive control, we also generated R273C cells with PTEN 
deletion and over-expression of either EGFR or MYC. We expect to see tumors with the 
combination of mutant tumor suppressor and overexpressed oncogenes in addition to different 
co-drivers. Large primary tumors formed in the mice injected with R273C library transduced (at 
high MOI) and overexpressing either EGFR or MYC MCF 10A cells by the 9th week. The mice did 
not show metastasis. We would be performing single cell sequencing to reveal the mutation 
combinations resulting in tumorigenesis.  
 
In summary, we performed an extensive molecular phenotyping of the MCF 10A cells expressing 
the ten most frequent missense TP53 mutations occurring in breast cancer based on five 
hallmarks of cancer that revealed heterogeneous neo-morphic phenotypes of missense mutant 
p53 proteins. The ChIP and RNA seq studies provided a deeper knowledge of the transcriptomics 
of the mutant proteins and the resultant pathways shaping the phenotype. To our knowledge, this 
is the first study to present an extensive comparative study on phenotypes imparted by a total of 
ten p53 missense mutations and a spectrum of phenotypes generated by these mutants. The 
functional genomics approach to differentiate between the non-functional passenger mutations 
and the relevant functional drivers proved to be an efficient method to identify the co-drivers of 
mutant p53 in different cellular contexts.  Overall, we found that p53 mutations alone are 
insufficient to promote transformation of normal-like MCF 10A mammary epithelial cells. Other 
genes (tumor suppressors or oncogenes) bearing somatic mutations and designated as the ‘co-
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drivers’ collaborate with the driver mutant TP53 to accelerate breast cancer progression. And 
even a larger number of mutations are required for the cells to achieve full malignancy as 
deduced from the in-vivo studies. 
 
 
Impact of the study 
 
TP53 mutations are most frequent (88%) in the TNBC which is the most aggressive breast cancer 
subtype. Our results from the molecular profiling of the missense mutant p53 proteins 
demonstrate their neo-morphic activities and shed light on the phenotypic heterogeneity observed 
in TNBC tumors harboring different TP53 mutations.  
 
The elucidation of different unique co-drivers for different missense mutant p53 can be 
informative for developing potential personalized drug target genes and pathways for TNBC 
patients with specific TP53 mutation. 
 
A function-based pipeline as opposed to predictive computational methods makes an efficient 
pipeline to screen for the biologically relevant co-drivers. This method can be applied to screen 
for other cell phenotypes (proliferation, apoptosis resistance, drug resistance) and different 
cancer context. 
 
 
Limitations of the study  
 
The phenotypic effects of missense mutant p53 proteins have been studied in only one normal-
like non-transformed mammary epithelial cell line MCF 10A. Another breast epithelial cell line, the 
non-transformed HMECs immortalized with expression of hTERT gene gave very inconsistent 
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phenotypic results with the expression of missense mutant p53 proteins. Hence, we chose the 
MCF 10A cells for our study which provided consistent results throughout the experiments.  
 
In the MCF 10A cells the mutant p53 proteins have been over-expressed using a lentiviral 
expression vector and there is no manipulation at the genome level which does not truly model 
the conditions found in the breast tumors.  
 
For the co-driver screening purpose, we have only used a CRISPR based gene knock-out library 
(GeCKO v2) and thus, considered only other tumor suppressor genes as the ‘co-drivers’ of the 
missense mutant TP53.  
 
Future directions 
Validation of the co-drivers as drug targets 
Direct targeting of the co-drivers would not be possible here as we used a knock-out 
library for the screening. The dysregulated pathways for example, genes participating in 
the focal adhesion pathway can be targeted by available drugs or gene editing to 
abrogate cell invasion. 
Mice models with specific combination of TP53 mutations and unique combination of 
co-drivers forming primary tumors and eventual metastasis can serve as pre-clinical 
models for developing alternative targeted therapies in the context of otherwise difficult 
to target mutant p53.  
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Study of how different co-drivers promote invasion 
RNA sequencing of the post-invasion MCF 10A p53 Y234C and p53 R273C cells with 
co-driver combinations can determine the altered transcriptome of the cells and 
molecular pathways that promote cell invasion in the different TP53 mutation 
background (for example, p53 Y234C GCNT1-/- or p53 R273C PACS1-/- cells).  
Screening of oncogenes as co-drivers of missense mutant p53  
The p53 mutant MCF 10A cells can be screened with CRISPR based activation or 
repression libraries (commercially available) or with a custom-made library containing 
small gRNAs (sgRNAs) for activation and repression of genes in a given library. This 
would help in determining the combinations of oncogenes or oncogenes and mutated 
tumor suppressors genes as co-drivers that collaborate with mutant p53 to drive cell 
invasion or any other hallmarks of cancer.  
Transduction of the p53 mutant cells at high multiplicity of infection (HMOI) 
The screening for co-driver sgRNA combinations by using conventional approaches 
require multiple rounds of successive clonal expansion and screens (i.e., “stepwise 
clonal screen”) that can be time consuming and cannot accommodate the complexity of 
all possible gene combinations as found in tumors (Fig 6.1). The stepwise screen may 
also suffer from a low discovery rate and a new selection marker is needed at each 
screening step. Moreover, mutations that work singly may differ from mutations that 
work in combinations. 
Multiple mutations can be introduced in the p53 mutant MCF 10A cells by transducing 
the cells at high MOI instead of maintaining the transduction conditions at low MOI as 
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done for the screening of mutant p53 co-drivers (chapter 4). In this way the cells can 
acquire two or more mutations (sgRNAs) at a time in addition to the mutant p53. Such 
mutation combinations contributing to increased cell invasion can be decoded by single 
cell sequencing. A “pooled shotgun screen” with transduction maintained at high MOI 
(MOI=4 or 5), the assessment of co-existing perturbations in each invasive or 
metastatic cell can be made. Since there is no technology available for supporting such 
screens, we are developing a novel high-throughput amplicon droplet sequencing 
platform in collaboration with Dr. Nikkhah, a microfluidics engineer at ASU. Unlike 
conventional droplet sequencing method developed for reading whole genome or 
transcriptome information from a single cell, this amplicon-targeted platform can PCR-
amplify and quantify multiple perturbagens in a single cell, specifically for genome wide 
co-driver screens. 
 
 
 
 
Figure 6.1. Stepwise clonal screen and the pooled shotgun screen. 
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Genetically altered mouse model for tumor formation and metastasis 
Determination of co-driver mutation combinations from the single cell sequencing 
results and generating genetically manipulated mice with such mutation combinations 
can determine the tumor spectrum and their consequent metastatic capabilities. Such a 
model could help to study genomic evolution of the tumors over time and act as a pre-
clinical model to discover the druggable targets or pathways to contain the tumor 
growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  230 
REFERENCES 
 
Aas, Turid, Anne-Lise Børresen, Stephanie Geisler, Birgitte Smith-Sørensen, Hilde 
Johnsen, Jan E. Varhaug, Lars A. Akslen, and Per E. Lønning. "Specific P53 mutations 
are associated with de novo resistance to doxorubicin in breast cancer patients." Nature 
medicine 2, no. 7 (1996): 811. 
Ademuyiwa, Foluso O., Yu Tao, Jingqin Luo, Katherine Weilbaecher, and Cynthia X. Ma. 
"Differences in the mutational landscape of triple-negative breast cancer in African Americans 
and Caucasians." Breast cancer research and treatment 161, no. 3 (2017): 491-499. 
 
Alexandrova, Evguenia M., Safia A. Mirza, Sulan Xu, Ramona Schulz-Heddergott, 
Natalia D. Marchenko, and Ute M. Moll. "p53 loss-of-heterozygosity is a necessary 
prerequisite for mutant p53 stabilization and gain-of-function in vivo." Cell death & 
disease 8, no. 3 (2017): e2661. 
Al-Kuraya, Khawla, Peter Schraml, Joachim Torhorst, Coya Tapia, Boriana Zaharieva, 
Hedvika Novotny, Hanspeter Spichtin et al. "Prognostic relevance of gene 
amplifications and coamplifications in breast cancer." Cancer research 64, no. 23 
(2004): 8534-8540. 
Ashcroft, Margaret, and Karen H. Vousden. "Regulation of p53 stability." Oncogene 18, 
no. 53 (1999): 7637. 
Attardi, Laura D., and Lawrence A. Donehower. "Probing p53 biological functions 
through the use of genetically engineered mouse models." Mutation 
Research/Fundamental and Molecular Mechanisms of Mutagenesis 576, no. 1-2 
(2005): 4-21. 
Aubrey, Brandon J., Ana Janic, Yunshun Chen, Catherine Chang, Elizabeth C. 
Lieschke, Sarah T. Diepstraten, Andrew J. Kueh et al. "Mutant TRP53 exerts a target 
gene-selective dominant-negative effect to drive tumor development." Genes & 
development 32, no. 21-22 (2018): 1420-1429. 
Bailey, Matthew H., Collin Tokheim, Eduard Porta-Pardo, Sohini Sengupta, Denis Bertrand, Amila 
Weerasinghe, Antonio Colaprico et al. "Comprehensive characterization of cancer driver genes 
and mutations." Cell 173, no. 2 (2018): 371-385. 
 
Bailey, Timothy L., Mikael Boden, Fabian A. Buske, Martin Frith, Charles E. Grant, Luca 
Clementi, Jingyuan Ren, Wilfred W. Li, and William S. Noble. "MEME SUITE: tools for 
motif discovery and searching." Nucleic acids research 37, no. suppl_2 (2009): W202-
W208. 
  231 
Baker, Suzanne J., Eric R. Fearon, Janice M. Nigro, A. C. Preisinger, J. M. Jessup, D. H. 
Ledbetter, D. F. Barker, Y. Nakamura, R. White, and B. Vogelstein. "Chromosome 17 deletions 
and p53 gene mutations in colorectal carcinomas." Science 244, no. 4901 (1989): 217-221. 
 
Banerji, Shantanu, Kristian Cibulskis, Claudia Rangel-Escareno, Kristin K. Brown, Scott L. Carter, 
Abbie M. Frederick, Michael S. Lawrence et al. "Sequence analysis of mutations and 
translocations across breast cancer subtypes." Nature 486, no. 7403 (2012): 405. 
 
Beckerman, Rachel, and Carol Prives. "Transcriptional regulation by p53." Cold Spring Harbor 
perspectives in biology2, no. 8 (2010): a000935. 
 
Beckmann, M. W., Dieter Niederacher, Hans-Georg Schnürch, Barry A. Gusterson, and 
Hans Georg Bender. "Multistep carcinogenesis of breast cancer and tumour 
heterogeneity." Journal of molecular medicine 75, no. 6 (1997): 429-439. 
Bergh, Jonas, Torbjörn Norberg, Sigrid Sjögren, Anders Lindgren, and Lars Holmberg. "Complete 
sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly 
in relation to adjuvant systemic therapy and radiotherapy." Nature medicine 1, no. 10 (1995): 
1029. 
 
Bertheau, Philippe, Jacqueline Lehmann-Che, Mariana Varna, Anne Dumay, Brigitte Poirot, 
Raphaël Porcher, Elisabeth Turpin et al. "p53 in breast cancer subtypes and new insights into 
response to chemotherapy." The Breast 22 (2013): S27-S29. 
 
Bianchini, Giampaolo, Justin M. Balko, Ingrid A. Mayer, Melinda E. Sanders, and Luca Gianni. 
"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease." Nature 
reviews Clinical oncology 13, no. 11 (2016): 674. 
 
Bieging, Kathryn T., Stephano Spano Mello, and Laura D. Attardi. "Unravelling mechanisms of 
p53-mediated tumour suppression." Nature Reviews Cancer 14, no. 5 (2014): 359. 
 
Billant, Olivier, Alice Léon, Solenn Le Guellec, Gaëlle Friocourt, Marc Blondel, and 
Cécile Voisset. "The dominant-negative interplay between p53, p63 and p73: A family 
affair." Oncotarget 7, no. 43 (2016): 69549. 
Birch, Jillian M., Valerie Blair, Anna M. Kelsey, D. Gareth Evans, Martin Harris, Karen J. Tricker, 
and Jennifer M. Varley. "Cancer phenotype correlates with constitutional TP53 genotype in 
families with the Li–Fraumeni syndrome." Oncogene 17, no. 9 (1998): 1061. 
 
Blandino, Giovanni, Arnold J. Levine, and Moshe Oren. "Mutant p53 gain of function: 
differential effects of different p53 mutants on resistance of cultured cells to 
chemotherapy." Oncogene 18, no. 2 (1999): 477. 
  232 
Bode, Ann M., and Zigang Dong. "Post-translational modification of p53 in 
tumorigenesis." Nature Reviews Cancer4, no. 10 (2004): 793. 
Boettcher, Michael, and Michael T. McManus. "Choosing the right tool for the job: RNAi, TALEN, 
or CRISPR." Molecular cell58, no. 4 (2015): 575-585. 
Børresen‐Dale, Anne‐Lise. "TP53 and breast cancer." Human mutation 21, no. 3 (2003): 292-
300. 
 
Brasacchio, Daniella, Amber E. Alsop, Tahereh Noori, Mariam Lufti, Sweta Iyer, Kaylene J. 
Simpson, Phillip I. Bird, Ruth M. Kluck, Ricky W. Johnstone, and Joseph A. Trapani. "Epigenetic 
control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK 
oligomerization." Cell death and differentiation 24, no. 6 (2017): 961. 
 
Brosh, Ran, and Varda Rotter. "When mutants gain new powers: news from the mutant 
p53 field." Nature reviews cancer 9, no. 10 (2009): 701. 
Burdelski, Christoph, Michael Fitzner, Claudia Hube-Magg, Martina Kluth, Asmus Heumann, 
Ronald Simon, Till Krech et al. "Overexpression of the A Disintegrin and Metalloproteinase 
ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers." Neoplasia 19, 
no. 4 (2017): 279-287. 
 
Burrell, Rebecca A., Nicholas McGranahan, Jiri Bartek, and Charles Swanton. "The 
causes and consequences of genetic heterogeneity in cancer evolution." Nature 501, 
no. 7467 (2013): 338. 
Cancer Genome Atlas Network. "Comprehensive molecular portraits of human breast 
tumours." Nature 490, no. 7418 (2012): 61. 
 
Canver, Matthew C., Daniel E. Bauer, Abhishek Dass, Yvette Y. Yien, Jacky Chung, Takeshi 
Masuda, Takahiro Maeda, Barry H. Paw, and Stuart H. Orkin. "Characterization of genomic 
deletion efficiency mediated by clustered regularly interspaced palindromic repeats 
(CRISPR)/Cas9 nuclease system in mammalian cells." Journal of Biological Chemistry289, no. 
31 (2014): 21312-21324. 
 
Cao, Zheng, Theodore Livas, and Natasha Kyprianou. "Anoikis and EMT: Lethal" 
liaisons" during cancer progression." Critical Reviews™ in Oncogenesis 21, no. 3-4 
(2016). 
Carey, Lisa, Eric Winer, Giuseppe Viale, David Cameron, and Luca Gianni. "Triple-negative 
breast cancer: disease entity or title of convenience?." Nature reviews Clinical oncology 7, no. 12 
(2010): 683. 
 
 
  233 
Castro-Giner, Francesc, Peter Ratcliffe, and Ian Tomlinson. "The mini-driver model of 
polygenic cancer evolution." Nature Reviews Cancer 15, no. 11 (2015): 680. 
Chalhoub, Nader, and Suzanne J. Baker. "PTEN and the PI3-kinase pathway in cancer." Annual 
Review of Pathological Mechanical Disease 4 (2009): 127-150. 
 
Chavez, Kathryn J., Sireesha V. Garimella, and Stanley Lipkowitz. "Triple negative 
breast cancer cell lines: one tool in the search for better treatment of triple negative 
breast cancer." Breast disease 32, no. 1-2 (2010): 35. 
Chen, Sidi, Neville E. Sanjana, Kaijie Zheng, Ophir Shalem, Kyungheon Lee, Xi Shi, David A. 
Scott et al. "Genome-wide CRISPR screen in a mouse model of tumor growth and 
metastasis." Cell 160, no. 6 (2015): 1246-1260. 
 
Cho, Yunje, Svetlana Gorina, Philip D. Jeffrey, and Nikola P. Pavletich. "Crystal structure of a p53 
tumor suppressor-DNA complex: understanding tumorigenic mutations." Science 265, no. 5170 
(1994): 346-355. 
 
Chow, Ryan D., and Sidi Chen. "Cancer CRISPR screens in vivo." Trends in cancer 4, no. 5 
(2018): 349-358. 
 
Crevenna, Alvaro H., Birgit Blank, Andreas Maiser, Derya Emin, Jens Prescher, Gisela Beck, 
Christine Kienzle et al. "Secretory cargo sorting by Ca2+-dependent Cab45 oligomerization at the 
trans-Golgi network." J Cell Biol 213, no. 3 (2016): 305-314. 
 
Davidoff, Andrew M., Billie-Jo M. Kerns, J. Dirk Iglehart, and Jeffrey R. Marks. 
"Maintenance of p53 alterations throughout breast cancer progression." Cancer 
Research 51, no. 10 (1991): 2605-2610. 
De Vries, Annemieke, Elsa R. Flores, Barbara Miranda, Harn-Mei Hsieh, Conny Th M. 
van Oostrom, Julien Sage, and Tyler Jacks. "Targeted point mutations of p53 lead to 
dominant-negative inhibition of wild-type p53 function." Proceedings of the National 
Academy of Sciences 99, no. 5 (2002): 2948-2953. 
Debnath, Jayanta, Senthil K. Muthuswamy, and Joan S. Brugge. "Morphogenesis and 
oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional 
basement membrane cultures." Methods 30, no. 3 (2003): 256-268. 
Derksen, Patrick WB, Xiaoling Liu, Francis Saridin, Hanneke van der Gulden, John 
Zevenhoven, Bastiaan Evers, Judy R. van Beijnum et al. "Somatic inactivation of E-
cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through 
induction of anoikis resistance and angiogenesis." Cancer cell 10, no. 5 (2006): 437-
449. 
  234 
Di Agostino, Silvia, Sabrina Strano, Velia Emiliozzi, Valentina Zerbini, Marcella 
Mottolese, Ada Sacchi, Giovanni Blandino, and Giulia Piaggio. "Gain of function of 
mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional 
mechanism of cell cycle regulation." Cancer cell 10, no. 3 (2006): 191-202. 
Dittmer, Dirk, Sibani Pati, Gerard Zambetti, Shelley Chu, Angelika K. Teresky, Mary 
Moore, Cathy Finlay, and Arnold J. Levine. "Gain of function mutations in p53." Nature 
genetics 4, no. 1 (1993): 42. 
Dobin, Alexander, Carrie A. Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, 
Sonali Jha, Philippe Batut, Mark Chaisson, and Thomas R. Gingeras. "STAR: ultrafast 
universal RNA-seq aligner." Bioinformatics 29, no. 1 (2013): 15-21. 
Donehower, Lawrence A., Michele Harvey, Betty L. Slagle, Mark J. McArthur, Charles 
A. Montgomery Jr, Janet S. Butel, and Allan Bradley. "Mice deficient for p53 are 
developmentally normal but susceptible to spontaneous tumours." Nature 356, no. 6366 
(1992): 215.   
Elenbaas, Brian, Lisa Spirio, Frederick Koerner, Mark D. Fleming, Drazen B. Zimonjic, 
Joana Liu Donaher, Nicholas C. Popescu, William C. Hahn, and Robert A. Weinberg. 
"Human breast cancer cells generated by oncogenic transformation of primary 
mammary epithelial cells." Genes & development 15, no. 1 (2001): 50-65. 
Eliyahu, Daniel, Avraham Raz, Peter Gruss, David Givol, and Moshe Oren. "Participation of p53 
cellular tumour antigen in transformation of normal embryonic cells." Nature 312, no. 5995 
(1984): 646. 
 
Finlay, C. A., P. W. Hinds, T. H. Tan, D. Eliyahu, M. Oren, and A. J. Levine. "Activating mutations 
for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an 
altered half-life." Molecular and cellular biology 8, no. 2 (1988): 531-539. 
 
Finlay, Cathy A., Philip W. Hinds, and Arnold J. Levine. "The p53 proto-oncogene can act as a 
suppressor of transformation." Cell 57, no. 7 (1989): 1083-1093. 
 
Fischer, M. "Census and evaluation of p53 target genes." Oncogene 36, no. 28 (2017): 3943. 
 
Fisher, R., L. Pusztai, and C. Swanton. "Cancer heterogeneity: implications for targeted 
therapeutics." British journal of cancer108, no. 3 (2013): 479. 
Freed-Pastor, William A., and Carol Prives. "Mutant p53: one name, many 
proteins." Genes & development 26, no. 12 (2012): 1268-1286. 
  235 
Fujii, Hiroaki, Carla Marsh, Paul Cairns, David Sidransky, and Edward Gabrielson. 
"Genetic divergence in the clonal evolution of breast cancer." Cancer Research 56, no. 
7 (1996): 1493-1497. 
Gao, Ruli, Alexander Davis, Thomas O. McDonald, Emi Sei, Xiuqing Shi, Yong Wang, 
Pei-Ching Tsai et al. "Punctuated copy number evolution and clonal stasis in triple-
negative breast cancer." Nature genetics 48, no. 10 (2016): 1119. 
Georgescu, Maria-Magdalena, Kathrin H. Kirsch, Tsuyoshi Akagi, Tomoyuki Shishido, and 
Hidesaburo Hanafusa. "The tumor-suppressor activity of PTEN is regulated by its carboxyl-
terminal region." Proceedings of the National Academy of Sciences 96, no. 18 (1999): 10182-
10187. 
 
Gilbert, Luke A., Max A. Horlbeck, Britt Adamson, Jacqueline E. Villalta, Yuwen Chen, Evan H. 
Whitehead, Carla Guimaraes et al. "Genome-scale CRISPR-mediated control of gene repression 
and activation." Cell 159, no. 3 (2014): 647-661. 
 
Gilmore, A. P. "Anoikis." (2005): 1473. 
Goh, Amanda M., Cynthia R. Coffill, and David P. Lane. "The role of mutant p53 in 
human cancer." The Journal of pathology223, no. 2 (2011): 116-126. 
Gottlieb, Eyal, and Karen H. Vousden. "p53 regulation of metabolic pathways." Cold Spring 
Harbor perspectives in biology 2, no. 4 (2010): a001040. 
 
Gray, Joe, and Brian Druker. "Genomics: the breast cancer landscape." Nature 486, no. 7403 
(2012): 328. 
 
Greaves, Mel, and Carlo C. Maley. "Clonal evolution in cancer." Nature 481, no. 7381 
(2012): 306. 
Greenblatt, M. S., William P. Bennett, M. Hollstein, and C. C. Harris. "Mutations in the p53 tumor 
suppressor gene: clues to cancer etiology and molecular pathogenesis." Cancer research 54, no. 
18 (1994): 4855-4878. 
 
Greenman, Christopher, Philip Stephens, Raffaella Smith, Gillian L. Dalgliesh, Christopher 
Hunter, Graham Bignell, Helen Davies et al. "Patterns of somatic mutation in human cancer 
genomes." Nature 446, no. 7132 (2007): 153. 
 
Guha, Tanya, and David Malkin. "Inherited TP53 mutations and the Li–Fraumeni syndrome." Cold 
Spring Harbor perspectives in medicine 7, no. 4 (2017): a026187. 
 
  236 
Hafner, Antonina, Martha L. Bulyk, Ashwini Jambhekar, and Galit Lahav. "The multiple 
mechanisms that regulate p53 activity and cell fate." Nature reviews. Molecular cell 
biology(2019). 
 
Hagisawa, Shigeru, Chikara Ohyama, Toshiko Takahashi, Mareyuki Endoh, Takuya Moriya, Jun 
Nakayama, Yoichi Arai, and Minoru Fukuda. "Expression of core 2 β1, 6-N-
acetylglucosaminyltransferase facilitates prostate cancer progression." Glycobiology 15, no. 10 
(2005): 1016-1024. 
 
Hahn, William C., Christopher M. Counter, Ante S. Lundberg, Roderick L. 
Beijersbergen, Mary W. Brooks, and Robert A. Weinberg. "Creation of human tumour 
cells with defined genetic elements." Nature 400, no. 6743 (1999): 464. 
Hainaut, Pierre, and Gerd P. Pfeifer. "Somatic TP53 mutations in the era of genome 
sequencing." Cold Spring Harbor Perspectives in Medicine 6, no. 11 (2016): a026179. 
Hanahan, Douglas, and Robert A. Weinberg. "Hallmarks of cancer: the next 
generation." cell 144, no. 5 (2011): 646-674. 
Hanel, W., N. Marchenko, S. Xu, S. Xiaofeng Yu, W. Weng, and U. Moll. "Two hot spot 
mutant p53 mouse models display differential gain of function in tumorigenesis." Cell 
death and differentiation 20, no. 7 (2013): 898. 
Harvey, Michele, Hannes Vogel, Danna Morris, Allan Bradley, Alan Bernstein, and 
Lawrence A. Donehower. "A mutant p53 transgene accelerates tumour development in 
heterozygous but not nullizygous p53–deficient mice." Nature genetics 9, no. 3 (1995): 
305. 
Heinz, Sven, Christopher Benner, Nathanael Spann, Eric Bertolino, Yin C. Lin, Peter 
Laslo, Jason X. Cheng, Cornelis Murre, Harinder Singh, and Christopher K. Glass. 
"Simple combinations of lineage-determining transcription factors prime cis-regulatory 
elements required for macrophage and B cell identities." Molecular cell 38, no. 4 (2010): 
576-589. 
Hiles, Guadalupe Lorenzatti, Amanda Bucheit, John R. Rubin, Alexandra Hayward, Angelica L. 
Cates, Kathleen C. Day, Layla El-Sawy et al. "ADAM15 is functionally associated with the 
metastatic progression of human bladder cancer." PloS one 11, no. 3 (2016): e0150138. 
 
Hollestelle, Antoinette, Jord HA Nagel, Marcel Smid, Suzanne Lam, Fons Elstrodt, Marijke 
Wasielewski, Ser Sue Ng et al. "Distinct gene mutation profiles among luminal-type and basal-
type breast cancer cell lines." Breast cancer research and treatment 121, no. 1 (2010): 53-64. 
 
Hollstein, Monica, David Sidransky, Bert Vogelstein, and Curtıs C. Harris. "p53 mutations in 
human cancers." Science253, no. 5015 (1991): 49-53. 
 
  237 
Huang, Wenhuan, Cheng Chen, Zhongheng Liang, Junlu Qiu, Xinxin Li, Xiang Hu, Shuanglin 
Xiang, Xiaofeng Ding, and Jian Zhang. "AP-2α inhibits hepatocellular carcinoma cell growth and 
migration." International journal of oncology 48, no. 3 (2016): 1125-1134. 
 
Ikeda, Osamu, Yuichi Sekine, Akihiro Mizushima, Misa Nakasuji, Yuto Miyasaka, 
Chikako Yamamoto, Ryuta Muromoto et al. "Interactions of STAP-2 with Brk and 
STAT3 participate in cell growth of human breast cancer cells." Journal of Biological 
Chemistry 285, no. 49 (2010): 38093-38103. 
Ilić, Duško, Eduardo AC Almeida, David D. Schlaepfer, Paul Dazin, Shinichi Aizawa, 
and Caroline H. Damsky. "Extracellular matrix survival signals transduced by focal 
adhesion kinase suppress p53-mediated apoptosis." The Journal of cell biology 143, 
no. 2 (1998): 547-560. 
Iranzo, Jaime, Iñigo Martincorena, and Eugene V. Koonin. "Cancer-mutation network 
and the number and specificity of driver mutations." Proceedings of the National 
Academy of Sciences 115, no. 26 (2018): E6010-E6019. 
Ito, Ryoji, Takeshi Takahashi, Ikumi Katano, and Mamoru Ito. "Current advances in 
humanized mouse models." Cellular & molecular immunology 9, no. 3 (2012): 208. 
Jacks, Tyler, Lee Remington, Bart O. Williams, Earlene M. Schmitt, Schlomit Halachmi, 
Roderick T. Bronson, and Robert A. Weinberg. "Tumor spectrum analysis in p53-mutant 
mice." Current biology 4, no. 1 (1994): 1-7. 
Jiang, Le, Ning Kon, Tongyuan Li, Shang-Jui Wang, Tao Su, Hanina Hibshoosh, Richard Baer, 
and Wei Gu. "Ferroptosis as a p53-mediated activity during tumour suppression." Nature520, no. 
7545 (2015): 57. 
 
Joerger, A. C., and A. R. Fersht. "Structure–function–rescue: the diverse nature of 
common p53 cancer mutants." Oncogene 26, no. 15 (2007): 2226. 
Joerger, Andreas C., and Alan R. Fersht. "Structural biology of the tumor suppressor p53." Annu. 
Rev. Biochem. 77 (2008): 557-582. 
 
Joerger, Andreas C., and Alan R. Fersht. "The p53 pathway: origins, inactivation in cancer, and 
emerging therapeutic approaches." Annual review of biochemistry 85 (2016): 375-404. 
 
Joerger, Andreas C., and Alan R. Fersht. "The tumor suppressor p53: from structures to drug 
discovery." Cold Spring Harbor perspectives in biology 2, no. 6 (2010): a000919. 
 
Kaiser, Alyssa M., and Laura D. Attardi. "Deconstructing networks of p53-mediated tumor 
suppression in vivo." Cell death and differentiation 25, no. 1 (2018): 93. 
 
  238 
Kalimutho, Murugan, Katia Nones, Sriganesh Srihari, Pascal HG Duijf, Nicola Waddell, and Kum 
Kum Khanna. "Patterns of genomic instability in breast cancer." Trends in pharmacological 
sciences (2019). 
 
Kalluri, Raghu, and Robert A. Weinberg. "The basics of epithelial-mesenchymal 
transition." The Journal of clinical investigation 119, no. 6 (2009): 1420-1428.   
Kandioler-Eckersberger, Daniela, Carmen Ludwig, Margarethe Rudas, Sonja Kappel, Elisabeth 
Janschek, Catharina Wenzel, Hermine Schlagbauer-Wadl et al. "TP53 mutation and p53 
overexpression for prediction of response to neoadjuvant treatment in breast cancer 
patients." Clinical Cancer Research6, no. 1 (2000): 50-56. 
 
Kang, Hua, Astrid Escudero-Esparza, Anthony Douglas-Jones, Robert E. Mansel, and Wen G. 
Jiang. "Transcript analyses of stromal cell derived factors (SDFs): SDF-2, SDF-4 and SDF-5 
reveal a different pattern of expression and prognostic association in human breast 
cancer." International journal of oncology 35, no. 1 (2009): 205-211. 
 
Kenny, Paraic A., and Mina J. Bissell. "Tumor reversion: correction of malignant 
behavior by microenvironmental cues." International journal of cancer 107, no. 5 (2003): 
688-695. 
Kim, Charissa, Ruli Gao, Emi Sei, Rachel Brandt, Johan Hartman, Thomas Hatschek, 
Nicola Crosetto, Theodoros Foukakis, and Nicholas E. Navin. "Chemoresistance 
evolution in triple-negative breast cancer delineated by single-cell 
sequencing." Cell 173, no. 4 (2018): 879-893. 
Kim, Gwangil, Maria Ouzounova, Ahmed A. Quraishi, April Davis, Nader Tawakkol, 
Shawn G. Clouthier, Fayaz Malik et al. "SOCS3-mediated regulation of inflammatory 
cytokines in PTEN and p53 inactivated triple negative breast cancer 
model." Oncogene 34, no. 6 (2015): 671. 
Kim, Jongdoo, Seunghee Bae, Sungkwan An, Jong Kuk Park, Eun Mi Kim, Sang‐Gu 
Hwang, Wun‐Jae Kim, and Hong‐Duck Um. "Cooperative actions of p21WAF1 and p53 
induce Slug protein degradation and suppress cell invasion." EMBO reports 15, no. 10 
(2014): 1062-1068. 
Kim, Michael P., and Guillermina Lozano. "Mutant p53 partners in crime." Cell death 
and differentiation 25, no. 1 (2018): 161. 
Klebanov, Nikolai, Mykyta Artomov, William B. Goggins, Emma Daly, Mark J. Daly, and 
Hensin Tsao. "Burden of unique and low prevalence somatic mutations correlates with 
cancer survival." Scientific reports 9, no. 1 (2019): 4848. 
Korkmaz, Gozde, Rui Lopes, Alejandro P. Ugalde, Ekaterina Nevedomskaya, Ruiqi Han, Ksenia 
Myacheva, Wilbert Zwart, Ran Elkon, and Reuven Agami. "Functional genetic screens for 
  239 
enhancer elements in the human genome using CRISPR-Cas9." Nature biotechnology 34, no. 2 
(2016): 192. 
 
Korkmaz, Gozde, Rui Lopes, Alejandro P. Ugalde, Ekaterina Nevedomskaya, Ruiqi 
Han, Ksenia Myacheva, Wilbert Zwart, Ran Elkon, and Reuven Agami. "Functional 
genetic screens for enhancer elements in the human genome using CRISPR-
Cas9." Nature biotechnology 34, no. 2 (2016): 192. 
Kuperwasser, Charlotte, Gregory D. Hurlbut, Frances S. Kittrell, Ellen S. Dickinson, Rudy 
Laucirica, Daniel Medina, Stephen P. Naber, and D. Joseph Jerry. "Development of spontaneous 
mammary tumors in BALB/c p53 heterozygous mice: a model for Li-Fraumeni syndrome." The 
American journal of pathology 157, no. 6 (2000): 2151-2159. 
 
Land, Hartmut, Luis F. Parada, and Robert A. Weinberg. "Tumorigenic conversion of 
primary embryo fibroblasts requires at least two cooperating oncogenes." Nature 304, 
no. 5927 (1983): 596. 
Lane, David P., and Lionel V. Crawford. "T antigen is bound to a host protein in SY40-
transformed cells." Nature 278, no. 5701 (1979): 261. 
 
Lang, Gene A., Tomoo Iwakuma, Young-Ah Suh, Geng Liu, V. Ashutosh Rao, John M. 
Parant, Yasmine A. Valentin-Vega et al. "Gain of function of a p53 hot spot mutation in 
a mouse model of Li-Fraumeni syndrome." Cell 119, no. 6 (2004): 861-872. 
Langmead, Ben, and Steven L. Salzberg. "Fast gapped-read alignment with Bowtie 
2." Nature methods 9, no. 4 (2012): 357. 
Laptenko, O., and C. Prives. "Transcriptional regulation by p53: one protein, many 
possibilities." Cell death and differentiation 13, no. 6 (2006): 951. 
 
Laptenko, Oleg, Idit Shiff, Will Freed-Pastor, Andrew Zupnick, Melissa Mattia, Ella Freulich, Inbal 
Shamir et al. "The p53 C terminus controls site-specific DNA binding and promotes structural 
changes within the central DNA binding domain." Molecular cell 57, no. 6 (2015): 1034-1046. 
 
Lee, Jie-Oh, Haijuan Yang, Maria-Magdalena Georgescu, Antonio Di Cristofano, Tomohiko 
Maehama, Yigong Shi, Jack E. Dixon, Pier Pandolfi, and Nikola P. Pavletich. "Crystal structure of 
the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and 
membrane association." Cell 99, no. 3 (1999): 323-334. 
 
Lee, Yu-Ru, Ming Chen, and Pier Paolo Pandolfi. "The functions and regulation of the PTEN 
tumour suppressor: new modes and prospects." Nature Reviews Molecular Cell Biology(2018): 1. 
Levine, Arnold J., and Moshe Oren. "The first 30 years of p53: growing ever more 
complex." Nature reviews cancer 9, no. 10 (2009): 749. 
 
  240 
Levine, Arnold J., Jamil Momand, and Cathy A. Finlay. "The p53 tumour suppressor 
gene." nature 351, no. 6326 (1991): 453. 
Li, Andrew G., Landon G. Piluso, Xin Cai, Gang Wei, William R. Sellers, and Xuan Liu. 
"Mechanistic insights into maintenance of high p53 acetylation by PTEN." Molecular cell23, no. 4 
(2006): 575-587. 
 
Li, Heng, Bob Handsaker, Alec Wysoker, Tim Fennell, Jue Ruan, Nils Homer, Gabor 
Marth, Goncalo Abecasis, and Richard Durbin. "The sequence alignment/map format 
and SAMtools." Bioinformatics 25, no. 16 (2009): 2078-2079. 
Li, Jie, Lixin Yang, Shikha Gaur, Keqiang Zhang, Xiwei Wu, Yate‐Ching Yuan, Hongzhi 
Li, Shuya Hu, Yaguang Weng, and Yun Yen. "Mutants TP 53 p. R273H and p. R273C 
but not p. R273G Enhance Cancer Cell Malignancy." Human mutation35, no. 5 (2014): 
575-584. 
Liao, D. J., and R. B. Dickson. "c-Myc in breast cancer." Endocrine-related cancer 7, no. 
3 (2000): 143-164. 
Linzer, Daniel IH, and Arnold J. Levine. "Characterization of a 54K dalton cellular SV40 tumor 
antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells." Cell 17, 
no. 1 (1979): 43-52. 
 
Linzer, Daniel IH, Warren Maltzman, and Arnold J. Levine. "The SV40 A gene product is required 
for the production of a 54,000 MW cellular tumor antigen." Virology 98, no. 2 (1979): 308-318. 
 
Liu, D. P., Hoseok Song, and Yang Xu. "A common gain of function of p53 cancer 
mutants in inducing genetic instability." Oncogene 29, no. 7 (2010): 949. 
Liu, Geng, Timothy J. McDonnell, Roberto Montes de Oca Luna, Mini Kapoor, Betsy 
Mims, Adel K. El-Naggar, and Guillermina Lozano. "High metastatic potential in mice 
inheriting a targeted p53 missense mutation." Proceedings of the National Academy of 
Sciences 97, no. 8 (2000): 4174-4179. 
Liu, Jeff C., Veronique Voisin, Sharon Wang, Dong‐Yu Wang, Robert A. Jones, Alessandro Datti, 
David Uehling et al. "Combined deletion of Pten and p53 in mammary epithelium accelerates 
triple‐negative breast cancer with dependency on eEF2K." EMBO molecular medicine 6, no. 12 
(2014): 1542-1560. 
 
Liu, Xiaoling, Henne Holstege, Hanneke van der Gulden, Marcelle Treur-Mulder, John 
Zevenhoven, Arno Velds, Ron M. Kerkhoven et al. "Somatic loss of BRCA1 and p53 in 
mice induces mammary tumors with features of human BRCA1-mutated basal-like 
breast cancer." Proceedings of the National Academy of Sciences 104, no. 29 (2007): 
12111-12116. 
  241 
Lowe, Scott W., Stephan Bodis, Andrea McClatchey, Lee Remington, H. Earl Ruley, 
David E. Fisher, David E. Housman, and Tyler Jacks. "p53 status and the efficacy of 
cancer therapy in vivo." Science 266, no. 5186 (1994): 807-810. 
Marchese, Stephanie, and Elisabete Silva. "Disruption of 3D MCF-12A breast cell 
cultures by estrogens–an in vitro model for ER-mediated changes indicative of 
hormonal carcinogenesis." PloS one 7, no. 10 (2012): e45767. 
Martincorena, Iñigo, and Peter J. Campbell. "Somatic mutation in cancer and normal 
cells." Science 349, no. 6255 (2015): 1483-1489. 
 
Martincorena, Iñigo, Keiran M. Raine, Moritz Gerstung, Kevin J. Dawson, Kerstin 
Haase, Peter Van Loo, Helen Davies, Michael R. Stratton, and Peter J. Campbell. 
"Universal patterns of selection in cancer and somatic tissues." Cell 171, no. 5 (2017): 
1029-1041. 
Marusyk, Andriy, Vanessa Almendro, and Kornelia Polyak. "Intra-tumour heterogeneity: 
a looking glass for cancer?." Nature Reviews Cancer 12, no. 5 (2012): 323. 
Masciari, Serena, Deborah A. Dillon, Michelle Rath, Mark Robson, Jeffrey N. Weitzel, Judith 
Balmana, Stephen B. Gruber et al. "Breast cancer phenotype in women with TP53 germline 
mutations: a Li-Fraumeni syndrome consortium effort." Breast cancer research and 
treatment 133, no. 3 (2012): 1125-1130. 
 
Mayer, Ingrid A., Vandana G. Abramson, Brian D. Lehmann, and Jennifer A. Pietenpol. 
"New strategies for triple-negative breast cancer—deciphering the 
heterogeneity." Clinical cancer research 20, no. 4 (2014): 782-790. 
Mayo, Lindsey D., and David B. Donner. "The PTEN, Mdm2, p53 tumor suppressor–oncoprotein 
network." Trends in biochemical sciences 27, no. 9 (2002): 462-467. 
McGranahan, Nicholas, and Charles Swanton. "Biological and therapeutic impact of 
intratumor heterogeneity in cancer evolution." Cancer cell 27, no. 1 (2015): 15-26. 
Mello, Stephano S., and Laura D. Attardi. "Deciphering p53 signaling in tumor 
suppression." Current opinion in cell biology51 (2018): 65-72. 
 
Mello, Stephano Spano, and Laura D. Attardi. "Not all p53 gain-of-function mutants are 
created equal." (2013): 855. 
Miyamoto, Tsutomu, Akihisa Suzuki, Ryoichi Asaka, Kaori Ishikawa, Yasushi Yamada, Hisanori 
Kobara, Jun Nakayama, and Tanri Shiozawa. "Immunohistochemical expression of core 2 β1, 6‐
N‐acetylglucosaminyl transferase 1 (C 2 G n T 1) in endometrioid‐type endometrial carcinoma: a 
novel potential prognostic factor." Histopathology 62, no. 7 (2013): 986-993. 
Muller, Patricia AJ, and Karen H. Vousden. "p53 mutations in cancer." Nature cell 
biology 15, no. 1 (2013): 2. 
  242 
Muller, Patricia AJ, Karen H. Vousden, and Jim C. Norman. "p53 and its mutants in tumor cell 
migration and invasion." The Journal of cell biology 192, no. 2 (2011): 209-218. 
 
Nik-Zainal, Serena, Helen Davies, Johan Staaf, Manasa Ramakrishna, Dominik Glodzik, Xueqing 
Zou, Inigo Martincorena et al. "Landscape of somatic mutations in 560 breast cancer whole-
genome sequences." Nature 534, no. 7605 (2016): 47. 
 
Nishida, Kozo, Keiichiro Ono, Shigehiko Kanaya, and Koichi Takahashi. "KEGGscape: 
a Cytoscape app for pathway data integration." F1000Research 3 (2014). 
Norberg, Torbjörn, Sigrid Klaar, Gunilla Kärf, Hans Nordgren, Lars Holmberg, and Jonas Bergh. 
"Increased p53 mutation frequency during tumor progression—results from a breast cancer 
cohort." Cancer research 61, no. 22 (2001): 8317-8321. 
 
Nowell, Peter C. "The clonal evolution of tumor cell populations." Science 194, no. 4260 
(1976): 23-28. 
Olive, Kenneth P., David A. Tuveson, Zachary C. Ruhe, Bob Yin, Nicholas A. Willis, 
Roderick T. Bronson, Denise Crowley, and Tyler Jacks. "Mutant p53 gain of function in 
two mouse models of Li-Fraumeni syndrome." Cell 119, no. 6 (2004): 847-860. 
Olivier, Magali, Anita Langer, Patrizia Carrieri, Jonas Bergh, Sigrid Klaar, Jorunn 
Eyfjord, Charles Theillet et al. "The clinical value of somatic TP53 gene mutations in 
1,794 patients with breast cancer." Clinical cancer research 12, no. 4 (2006): 1157-
1167. 
Olivier, Magali, David E. Goldgar, Nayanta Sodha, Hiroko Ohgaki, Paul Kleihues, Pierre Hainaut, 
and Rosalind A. Eeles. "Li-Fraumeni and related syndromes: correlation between tumor type, 
family structure, and TP53 genotype." Cancer research 63, no. 20 (2003): 6643-6650. 
 
Oren, Moshe, and Varda Rotter. "Mutant p53 gain-of-function in cancer." Cold Spring 
Harbor perspectives in biology 2, no. 2 (2010): a001107. 
Parada, Luis F., Hartmut Land, Robert A. Weinberg, David Wolf, and Varda Rotter. 
"Cooperation between gene encoding p53 tumour antigen and ras in cellular 
transformation." Nature312, no. 5995 (1984): 649. 
Pereira, Bernard, Suet-Feung Chin, Oscar M. Rueda, Hans-Kristian Moen Vollan, Elena 
Provenzano, Helen A. Bardwell, Michelle Pugh et al. "The somatic mutation profiles of 2,433 
breast cancers refine their genomic and transcriptomic landscapes." Nature communications 7 
(2016): 11479. 
 
 
Petitjean, Audrey, Ewy Mathe, Shunsuke Kato, Chikashi Ishioka, Sean V. Tavtigian, Pierre 
Hainaut, and Magali Olivier. "Impact of mutant p53 functional properties on TP53 mutation 
  243 
patterns and tumor phenotype: lessons from recent developments in the IARC TP53 
database." Human mutation28, no. 6 (2007): 622-629. 
 
Platt, Randall J., Sidi Chen, Yang Zhou, Michael J. Yim, Lukasz Swiech, Hannah R. Kempton, 
James E. Dahlman et al. "CRISPR-Cas9 knockin mice for genome editing and cancer 
modeling." Cell 159, no. 2 (2014): 440-455. 
 
Polyak, Kornelia. "Heterogeneity in breast cancer." The Journal of clinical 
investigation 121, no. 10 (2011): 3786-3788. 
Pon, Julia R., and Marco A. Marra. "Driver and passenger mutations in cancer." Annual Review of 
Pathology: Mechanisms of Disease 10 (2015): 25-50. 
 
Powell, Emily, David Piwnica-Worms, and Helen Piwnica-Worms. "Contribution of p53 
to metastasis." Cancer discovery4, no. 4 (2014): 405-414. 
Ran, F. Ann, Patrick D. Hsu, Jason Wright, Vineeta Agarwala, David A. Scott, and Feng Zhang. 
"Genome engineering using the CRISPR-Cas9 system." Nature protocols 8, no. 11 (2013): 2281. 
 
Rangarajan, Annapoorni, Sue J. Hong, Annie Gifford, and Robert A. Weinberg. "Species-and cell 
type-specific requirements for cellular transformation." Cancer cell 6, no. 2 (2004): 171-183. 
 
Rao, Donald D., John S. Vorhies, Neil Senzer, and John Nemunaitis. "siRNA vs. shRNA: 
similarities and differences." Advanced drug delivery reviews 61, no. 9 (2009): 746-759. 
 
Rheinbay, Esther, Prasanna Parasuraman, Jonna Grimsby, Grace Tiao, Jesse M. Engreitz, 
Jaegil Kim, Michael S. Lawrence et al. "Recurrent and functional regulatory mutations in breast 
cancer." Nature 547, no. 7661 (2017): 55. 
 
Rivlin, Noa, Ran Brosh, Moshe Oren, and Varda Rotter. "Mutations in the p53 tumor 
suppressor gene: important milestones at the various steps of tumorigenesis." Genes & 
cancer 2, no. 4 (2011): 466-474. 
Roger, Lauréline, Laurent Jullien, Véronique Gire, and Pierre Roux. "Gain of oncogenic 
function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion 
in colon cancer cells." J Cell Sci 123, no. 8 (2010): 1295-1305. 
Rotter, Varda, Owen N. Witte, Robert Coffman, and David Baltimore. "Abelson murine leukemia 
virus-induced tumors elicit antibodies against a host cell protein, P50." Journal of virology 36, no. 
2 (1980): 547-555. 
 
 
 
  244 
Rotter, Varda. "p53, a transformation-related cellular-encoded protein, can be used as a 
biochemical marker for the detection of primary mouse tumor cells." Proceedings of the National 
Academy of Sciences 80, no. 9 (1983): 2613-2617. 
 
Sansal, Isabelle, and William R. Sellers. "The biology and clinical relevance of the PTEN tumor 
suppressor pathway." Journal of clinical oncology 22, no. 14 (2004): 2954-2963. 
 
Santoro, Angela, Thalia Vlachou, Lucilla Luzi, Giorgio Melloni, Luca Mazzarella, Errico 
D’Elia, Xieraili Aobuli et al. "p53 Loss in Breast Cancer Leads to Myc Activation, 
Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic 
Value." Cell reports 26, no. 3 (2019): 624-638. 
Sarnow, Peter, Ye Shih Ho, Jim Williams, and Arnold J. Levine. "Adenovirus E1b-58kd tumor 
antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular 
protein in transformed cells." Cell 28, no. 2 (1982): 387-394. 
 
Sayols, Sergi, Denise Scherzinger, and Holger Klein. "dupRadar: a Bioconductor 
package for the assessment of PCR artifacts in RNA-Seq data." BMC bioinformatics 17, 
no. 1 (2016): 428. 
Scholl, Claudia, and Stefan Fröhling. "Exploiting rare driver mutations for precision 
cancer medicine." Current opinion in genetics & development 54 (2019): 1-6. 
Sekine, Yuichi, Osamu Ikeda, Satoshi Tsuji, Chikako Yamamoto, Ryuta Muromoto, 
Asuka Nanbo, Kenji Oritani, Akihiko Yoshimura, and Tadashi Matsuda. "Signal-
transducing adaptor protein-2 regulates stromal cell-derived factor-1α-induced 
chemotaxis in T cells." The Journal of Immunology183, no. 12 (2009): 7966-7974. 
Shah, Sohrab P., Andrew Roth, Rodrigo Goya, Arusha Oloumi, Gavin Ha, Yongjun Zhao, Gulisa 
Turashvili et al. "The clonal and mutational evolution spectrum of primary triple-negative breast 
cancers." Nature 486, no. 7403 (2012): 395. 
 
Shalem, Ophir, Neville E. Sanjana, and Feng Zhang. "High-throughput functional genomics using 
CRISPR–Cas9." Nature Reviews Genetics 16, no. 5 (2015): 299. 
 
Shalem, Ophir, Neville E. Sanjana, Ella Hartenian, Xi Shi, David A. Scott, Tarjei S. Mikkelsen, 
Dirk Heckl et al. "Genome-scale CRISPR-Cas9 knockout screening in human cells." Science 343, 
no. 6166 (2014): 84-87. 
 
Shannon, Paul, Andrew Markiel, Owen Ozier, Nitin S. Baliga, Jonathan T. Wang, Daniel 
Ramage, Nada Amin, Benno Schwikowski, and Trey Ideker. "Cytoscape: a software 
environment for integrated models of biomolecular interaction networks." Genome 
research 13, no. 11 (2003): 2498-2504. 
  245 
Silwal-Pandit, Laxmi, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, 
Steven McKinney, Tomo Osako, David A. Quigley et al. "TP53 mutation spectrum in 
breast cancer is subtype specific and has distinct prognostic relevance." Clinical Cancer 
Research 20, no. 13 (2014): 3569-3580. 
Solatycka, Alicja, Tomasz Owczarek, Friedrich Piller, Véronique Piller, Bartosz Pula, Lukasz 
Wojciech, Marzena Podhorska-Okolow, Piotr Dziegiel, and Maciej Ugorski. "MUC1 in human and 
murine mammary carcinoma cells decreases the expression of core 2 β1, 6-N-
acetylglucosaminyltransferase and β-galactoside α2, 3-sialyltransferase." Glycobiology 22, no. 8 
(2012): 1042-1054. 
 
Song, Hoseok, Monica Hollstein, and Yang Xu. "p53 gain-of-function cancer mutants 
induce genetic instability by inactivating ATM." Nature cell biology 9, no. 5 (2007): 573. 
Sørlie, Therese, Charles M. Perou, Robert Tibshirani, Turid Aas, Stephanie Geisler, Hilde 
Johnsen, Trevor Hastie et al. "Gene expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications." Proceedings of the National Academy of Sciences 98, no. 
19 (2001): 10869-10874. 
 
Srivastava, Shiv, Zhiqiang Zou, Kathleen Pirollo, William Blattner, and Esther H. Chang. "Germ-
line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni 
syndrome." Nature 348, no. 6303 (1990): 747. 
 
St Hill, Catherine A., Mariya Farooqui, Gregory Mitcheltree, H. Evin Gulbahce, Jose Jessurun, 
Qing Cao, and Bruce Walcheck. "The high affinity selectin glycan ligand C2-O-sLe x and mRNA 
transcripts of the core 2 β-1, 6-N-acetylglusaminyltransferase (C2GnT1) gene are highly 
expressed in human colorectal adenocarcinomas." BMC cancer 9, no. 1 (2009): 79. 
 
Stambolic, V., D. MacPherson, D. Sas, Y. Lin, B. Snow, Y. Jang, S. Benchimol, and T. W. Mak. 
"Regulation of PTEN transcription by p53." Molecular cell 8, no. 2 (2001): 317-325. 
 
Stephens, Philip J., Patrick S. Tarpey, Helen Davies, Peter Van Loo, Chris Greenman, David C. 
Wedge, Serena Nik-Zainal et al. "The landscape of cancer genes and mutational processes in 
breast cancer." Nature 486, no. 7403 (2012): 400. 
 
Stratton, Michael R., Peter J. Campbell, and P. Andrew Futreal. "The cancer 
genome." Nature 458, no. 7239 (2009): 719. 
Subramanian, Aravind, Pablo Tamayo, Vamsi K. Mootha, Sayan Mukherjee, Benjamin 
L. Ebert, Michael A. Gillette, Amanda Paulovich et al. "Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression 
profiles." Proceedings of the National Academy of Sciences 102, no. 43 (2005): 15545-
15550. 
  246 
Sullivan, Kelly D., Matthew D. Galbraith, Zdenek Andrysik, and Joaquin M. Espinosa. 
"Mechanisms of transcriptional regulation by p53." Cell death and differentiation 25, no. 1 (2018): 
133. 
 
Sun, Ruping, Zheng Hu, and Christina Curtis. "Big Bang tumor growth and clonal 
evolution." Cold Spring Harbor perspectives in medicine 8, no. 5 (2018): a028381. 
Tait, Larry, Herbert D. Soule, and Jose Russo. "Ultrastructural and 
immunocytochemical characterization of an immortalized human breast epithelial cell 
line, MCF-10." Cancer research50, no. 18 (1990): 6087-6094. 
Tan, B. S., K. H. Tiong, H. L. Choo, F. Fei-Lei Chung, L. W. Hii, S. H. Tan, I. KS Yap et 
al. "Mutant p53-R273H mediates cancer cell survival and anoikis resistance through 
AKT-dependent suppression of BCL2-modifying factor (BMF)." Cell death & disease 6, 
no. 7 (2015): e1826. 
Tidow, Henning, Roberto Melero, Efstratios Mylonas, Stefan MV Freund, J. Guenter Grossmann, 
José María Carazo, Dmitri I. Svergun, Mikel Valle, and Alan R. Fersht. "Quaternary structures of 
tumor suppressor p53 and a specific p53–DNA complex." Proceedings of the National Academy 
of Sciences104, no. 30 (2007): 12324-12329. 
 
Turajlic, Samra, Andrea Sottoriva, Trevor Graham, and Charles Swanton. "Resolving 
genetic heterogeneity in cancer." Nature Reviews Genetics (2019): 1. 
Vaughan, Catherine A., Swati P. Deb, Sumitra Deb, and Brad Windle. "Preferred binding of gain-
of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to 
multiple binding sites." Oncotarget 5, no. 2 (2014): 417. 
 
Ventura, Andrea, David G. Kirsch, Margaret E. McLaughlin, David A. Tuveson, Jan 
Grimm, Laura Lintault, Jamie Newman, Elizabeth E. Reczek, Ralph Weissleder, and 
Tyler Jacks. "Restoration of p53 function leads to tumour regression in 
vivo." Nature 445, no. 7128 (2007): 661. 
Vogelstein, Bert, and Kenneth W. Kinzler. "The multistep nature of cancer." Trends in 
genetics 9, no. 4 (1993): 138-141. 
Wan, Lei, Sean S. Molloy, Laurel Thomas, Gseping Liu, Yang Xiang, Sheree Lynn Rybak, and 
Gary Thomas. "PACS-1 defines a novel gene family of cytosolic sorting proteins required for 
trans-Golgi network localization." Cell 94, no. 2 (1998): 205-216. 
 
Wang, Jing, Gregory J. Hannon, and David H. Beach. "Cell biology: risky 
immortalization by telomerase." Nature 405, no. 6788 (2000): 755. 
  247 
Wang, Shu-Ping, Wen-Lung Wang, Yih-Leong Chang, Chen-Tu Wu, Yu-Chih Chao, 
Shih-Han Kao, Ang Yuan et al. "p53 controls cancer cell invasion by inducing the 
MDM2-mediated degradation of Slug." Nature cell biology 11, no. 6 (2009): 694. 
Wang, Yong, Jill Waters, Marco L. Leung, Anna Unruh, Whijae Roh, Xiuqing Shi, Ken 
Chen et al. "Clonal evolution in breast cancer revealed by single nucleus genome 
sequencing." Nature 512, no. 7513 (2014): 155. 
Weaver, Alissa M. "Invadopodia: specialized cell structures for cancer invasion." Clinical & 
experimental metastasis 23, no. 2 (2006): 97-105. 
 
Wells, Mark, Henning Tidow, Trevor J. Rutherford, Phineus Markwick, Malene Ringkjobing 
Jensen, Efstratios Mylonas, Dmitri I. Svergun, Martin Blackledge, and Alan R. Fersht. "Structure 
of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation 
domain." Proceedings of the National academy of Sciences 105, no. 15 (2008): 5762-5767. 
 
Whyte, Peter, Karen J. Buchkovich, Jonathan M. Horowitz, Stephen H. Friend, Margaret 
Raybuck, Robert A. Weinberg, and Ed Harlow. "Association between an oncogene and an anti-
oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product." Nature 334, 
no. 6178 (1988): 124. 
 
Wijnhoven, Susan WP, Ewoud N. Speksnijder, Xiaoling Liu, Edwin Zwart, Rudolf B. 
Beems, Esther M. Hoogervorst, Mirjam M. Schaap et al. "Dominant-negative but not 
gain-of-function effects of a p53. R270H mutation in mouse epithelium tissue after DNA 
damage." Cancer research 67, no. 10 (2007): 4648-4656. 
Williams, Marc J., Andrea Sottoriva, and Trevor A. Graham. "Measuring Clonal 
Evolution in Cancer with Genomics." Annual review of genomics and human 
genetics 20 (2019). 
Willis, Amy, Eun Joo Jung, Therese Wakefield, and Xinbin Chen. "Mutant p53 exerts a 
dominant negative effect by preventing wild-type p53 from binding to the promoter of its 
target genes." Oncogene 23, no. 13 (2004): 2330. 
Wolf, D. A. V. I. D., and V. A. R. D. A. Rotter. "Inactivation of p53 gene expression by an insertion 
of Moloney murine leukemia virus-like DNA sequences." Molecular and cellular biology 4, no. 7 
(1984): 1402-1410. 
 
Wolf, David, and Varda Rotter. "Major deletions in the gene encoding the p53 tumor antigen 
cause lack of p53 expression in HL-60 cells." Proceedings of the National Academy of 
Sciences 82, no. 3 (1985): 790-794. 
 
Wolf, David, Nicholas Harris, and Varda Rotter. "Reconstitution of p53 expression in a 
nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene." Cell 38, no. 
1 (1984): 119-126. 
  248 
 
Wood, Laura D., D. Williams Parsons, Siân Jones, Jimmy Lin, Tobias Sjöblom, 
Rebecca J. Leary, Dong Shen et al. "The genomic landscapes of human breast and 
colorectal cancers." Science 318, no. 5853 (2007): 1108-1113. 
Yamaguchi, Hideki, Jeffrey Wyckoff, and John Condeelis. "Cell migration in tumors." Current 
opinion in cell biology 17, no. 5 (2005): 559-564.  
 
Yates, Lucy R., Moritz Gerstung, Stian Knappskog, Christine Desmedt, Gunes 
Gundem, Peter Van Loo, Turid Aas et al. "Subclonal diversification of primary breast 
cancer revealed by multiregion sequencing." Nature medicine 21, no. 7 (2015): 751. 
Yates, Lucy R., Stian Knappskog, David Wedge, James HR Farmery, Santiago 
Gonzalez, Inigo Martincorena, Ludmil B. Alexandrov et al. "Genomic evolution of breast 
cancer metastasis and relapse." Cancer Cell 32, no. 2 (2017): 169-184. 
Yusuf, Rita, and Krystyna Frenkel. "Morphologic transformation of human breast 
epithelial cells MCF-10A: dependence on an oxidative microenvironment and 
estrogen/epidermal growth factor receptors." Cancer Cell International 10, no. 1 (2010): 
30. 
Zardavas, Dimitrios, Alexandre Irrthum, Charles Swanton, and Martine Piccart. "Clinical 
management of breast cancer heterogeneity." Nature reviews Clinical oncology 12, no. 7 (2015): 
381. 
 
Zhang, Yanhong, Wensheng Yan, and Xinbin Chen. "Mutant p53 disrupts MCF-10A cell 
polarity in three-dimensional culture via epithelial-to-mesenchymal transitions." Journal 
of Biological Chemistry 286, no. 18 (2011): 16218-16228. 
Zhang, Yong, Tao Liu, Clifford A. Meyer, Jérôme Eeckhoute, David S. Johnson, Bradley 
E. Bernstein, Chad Nusbaum et al. "Model-based analysis of ChIP-Seq 
(MACS)." Genome biology 9, no. 9 (2008): R137. 
Zhang, Yun, Shunbin Xiong, Bin Liu, Vinod Pant, Francis Celii, Gilda Chau, Ana C. 
Elizondo-Fraire et al. "Somatic Trp53 mutations differentially drive breast cancer and 
evolution of metastases." Nature communications 9, no. 1 (2018): 3953. 
Zhao, Yahui, Xiaoding Hu, Li Wei, Dan Song, Juanjuan Wang, Lifang You, Hexige 
Saiyin et al. "PARP10 suppresses tumor metastasis through regulation of Aurora A 
activity." Oncogene(2018): 1. 
Zheng, Tongsen, Jiabei Wang, Yuhan Zhao, Cen Zhang, Meihua Lin, Xiaowen Wang, 
Haiyang Yu, Lianxin Liu, Zhaohui Feng, and Wenwei Hu. "Spliced MDM2 isoforms 
  249 
promote mutant p53 accumulation and gain-of-function in tumorigenesis." Nature 
communications 4 (2013): 2996. 
Zhu, Jiajun, Morgan A. Sammons, Greg Donahue, Zhixun Dou, Masoud Vedadi, 
Matthäus Getlik, Dalia Barsyte-Lovejoy et al. "Gain-of-function p53 mutants co-opt 
chromatin pathways to drive cancer growth." Nature 525, no. 7568 (2015): 206. 
Zhu, Shiyou, Wei Li, Jingze Liu, Chen-Hao Chen, Qi Liao, Ping Xu, Han Xu et al. "Genome-scale 
deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR–Cas9 
library." Nature biotechnology 34, no. 12 (2016): 1279. 
 
Zilfou, Jack T., and Scott W. Lowe. "Tumor suppressive functions of p53." Cold Spring Harbor 
perspectives in biology1, no. 5 (2009): a001883. 
 
 
 
  250 
APPENDIX A 
GUIDE RNA TARGETING PTEN GENE  
  251 
  
 
Na
me
 
Sp
ac
er 
se
qu
en
ce
Str
an
d
Tra
ns
cri
pt
Am
ino
 ac
id 
cu
t p
os
itio
n
% 
pe
pt
ide
An
no
tat
ion
Sco
re
An
aly
sis
 
fro
m 
Br
oa
d 
ins
tit
ut
e
gR
NA
 1
GG
TG
GG
TT
AT
GG
TC
TT
CA
AA
an
tis
en
se
EN
ST
00
00
03
71
95
3
91
22
.58
CD
S
0.5
5
ma
tch
 in
 PT
EN
P1
gR
NA
 2
AT
AT
CA
CC
AC
AC
AC
AG
GT
AA
an
tis
en
se
24
8
61
.54
0.7
8
ma
tch
 in
 PT
EN
P1
PT
EN
 ex
on
 5
gR
NA
 3
AG
AG
GC
CC
TA
GA
TT
TC
TA
TG
se
ns
e
0.7
1
ma
tch
 in
 PT
EN
P1
Of
f-t
arg
et 
sit
e
An
aly
sis
 fr
om
 CR
ISP
R d
es
ign
sgR
NA
 se
qu
en
ce
Gu
ide
 qu
ali
ty
Gu
ide
 sc
or
e
UC
SC
 ge
ne
 
Lo
cu
s
Sco
re
PT
EN
 ex
on
 2
gR
NA
 4
TT
AT
CC
AA
AC
AT
TA
TT
GC
TA
mi
d
41
NR
_0
23
91
7
ch
r9:
-33
67
65
38
10
0
no
 m
atc
he
s in
 PT
EN
P1
PT
EN
 ex
on
 5
gR
NA
 5
AT
GT
GC
AT
AT
TT
AT
TA
CA
TC
hig
h
54
NR
_0
23
91
7
ch
r9:
-33
67
62
18
5.4
no
 m
atc
he
s in
 PT
EN
P1
PT
EN
 ex
on
 6
gR
NA
 6
CT
AC
CT
GT
TA
AA
GA
AT
CA
TC
hig
h
66
NR
_0
23
91
7
ch
r9:
-33
67
60
86
4.2
no
 m
atc
he
s in
 PT
EN
P1
  252 
APPENDIX B 
SELECTED GENES FROM RNA SEQ OF TP53 MUTANTS FOR VALIDATION 
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Gene
Av. expression level in 
3 (Y234C, H179R, 
G245S) most non-
invasive cell lines 
(TPM)
Av expression level in 3 
(R248W, Y220C, 
R273C) most invasive 
cell lines (TPM)
Correlation between 
invasion level and RNA 
expression level 
STAP2 0 14 0.63
CYP4B1 0 12 0.44
PARP10 0 2.8 0.59
PLPPR2 13 1.5 -0.39
SREBF1 24 4 -0.87
PDK2 12 2 -0.48
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APPENDIX C 
SELECTED GUIDE RNAS FOR INDIVIDUAL VALIDATION 
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Cell line screened Gene Selected sgRNA for individual validation 
      
Y234C FGD6 GATGATTTCCTCCTCATCAG 
      
  GCNT1 TAGTCGTCAGGTGTCCACCG 
      
  ADAM15 TGCCCATCGGGTGACCTGCC 
      
R273C PACS1 GAGATCGTCCTTCCAGCTAG 
      
  SDF4 CGAGTTCATCTCCCTGCCCG 
 
